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Learning and memory systems within the brain are believed to be the result of 
molecular events that occur at the synapse. These molecular events control synaptic 
efficacy – the modulation of the underlying molecular architecture of the synapse to 
influence the strength or weakness of connections between pre- and postsynaptic neurons. 
Deficits in any of these molecular processes results in neuronal dysfunction. The 
Mammalian/Mechanistic Target of Rapamycin Complex (mTORC1) is a protein complex 
within the brain composed of the serine/threonine kinase mTOR and other interacting 
proteins. Dysregulation of mTOR disrupts the many processes under its control such as 
local dendritic translation at the synapse. Since mTOR is at the core of many important 
signaling pathways, aberrant mTOR activity results in neuronal disease. The network of 
interactions between these molecular components is vast, forming an interconnected 
system that is dynamic and directed. In order to better understand the mechanistic nature 
of these interactions, the application of high-throughput technologies must be employed. 
Here we utilize multiple bioinformatics approaches combined with high-throughput 
technologies to clarify the role of mTOR in local dendritic translation. Using mass 
spectrometry, we provide the first evidence that mTOR bidirectionally controls the 
 vii 
expression of over 700 proteins in the cortex, many of which are known to be associated 
with diseases in which mTOR is overactive (Chapter 2). Our investigations reveal a novel 
role PARK7 in tuberous sclerosis complex. Furthermore, we use and develop multiple 
bioinformatics tools to further delineate the nature of the RNA-binding properties of 
PARK7 and alternative avenues for drug discovery (Chapter 3). Finally, we provide 
evidence that the Fragile-X Mental Retardation protein sequesters a population of mRNAs 
involved in trans-synaptic signaling that mTOR translates to remodel the synapse, 
providing a mechanistic basis for the action of rapidly-acting antidepressants (Chapter 4). 
Collectively, our work stresses the importance of applying high-throughput technologies 
to answer long-standing questions in the field of local dendritic translation. Our findings 
provide new avenues of investigation and research to better understand neuronal disease 
and synaptic plasticity. 
 viii 
Table of Contents 
List of Tables ......................................................................................................... xi 
List of Figures ....................................................................................................... xii 
Chapter 1: Introduction ............................................................................................1 
Local Translation and Dendritic RNA Transport ...........................................1 
mTOR and the Control of Local Translation ..................................................3 
Using high-throughput assays to understand the molecular basis of memory9 
Experimental design of high-throughput assays ...........................................10 
Rationale for extracting cell-specific and subcellular RNA populations......12 
What isolating regulatory factors can tell you about synaptic efficacy ........17 
High-Throughput Assays ..............................................................................28 
Combined transcriptomics and proteomics ...................................................41 
From statistical models to scientific models: experimental validation and 
visualization of identified proteins and RNA ......................................50 
How high throughput assays may answer long-standing questions in the field of 
learning and memory by identifying novel proteins involved in synaptic 
plasticity ...............................................................................................64 
Motivation for studies ...................................................................................66 
Chapter 2: Rapid repression of mTORC1 shifts the regional expression of disease-
related protein ensembles, .............................................................................70 
Introduction ...................................................................................................70 




Supplemental Tables ...................................................................................102 
Chapter 3: Bioinformatic approaches identify PARK7 as a novel protein aberrantly 
expressed in Tuberous Sclerosis Complex, .................................................104 
Introduction .................................................................................................104 




Supplemental Tables ...................................................................................126 
Chapter 4: mTOR mediates trans-synaptic signaling required for synapse formation 
and rapid antidepression efficacy requiring Fragile X Mental Retardation 
Protein .........................................................................................................127 
Introduction .................................................................................................127 




Supplemental Tables ...................................................................................168 
Chapter 5: Conclusion..........................................................................................170 
Appendix A: Rapid antidepressants and the homeostatic theory of depression ..174 
Engaging homeostatic mechanisms with pharmacological intervention to treat 
Major Depressive Disorder ................................................................174 
NMDAR antagonism leads to homeostatic plasticity .................................180 
Mammalian Target of Rapamycin (mTOR) serves as a thermostat in NMDAR 
antagonist-induced homeostatic response ..........................................182 
Rapid antidepressant efficacy requires distinct stages of neuronal protein 
synthesis .............................................................................................184 
NMDAR antagonists induce structural homeostasis that correlates with 
antidepressant efficacy .......................................................................188 
Evidence for alternative ways of inducing homeostatic plasticity to remedy 
depression ..........................................................................................190 
Perspectives and Open Questions ...............................................................193 
Conclusion ..................................................................................................198 
Appendix B: FMRP Regulates an Ethanol-dependent Shift in GABABR Function and 
Expression with Rapid Antidepressant Properties, .....................................200 
Introduction .................................................................................................200 




Appendix C: Code for Chapters 2 and 3 ..............................................................235 
Code for Data Processing............................................................................235 
Code for Figure 2.2 .....................................................................................239 
Code for Figure 2.3 .....................................................................................243 
Code for Figure 3.6 .....................................................................................245 
Code for Supplemental Figures ..................................................................249 
Code for Supplemental Tables ....................................................................256 
Appendix D: Code for Chapter 4 .........................................................................262 
Ubuntu Install Shell Script ..........................................................................262 
QC, trimming, alignment, and counts .........................................................266 
Post-processing QC .....................................................................................271 
Count normalization....................................................................................278 
Data filtering ...............................................................................................284 
Motif Analysis ............................................................................................299 
Clustering Analysis .....................................................................................308 
Shiny App for Park7 Binding Motif Identification .....................................326 
Appendix E: Prior Publications ...........................................................................334 
Biblography..........................................................................................................335 
 xi 
List of Tables 
Table 1.1: Comparison of techniques to isolate RNA-associated populations ......19 
Table 1.2:  RNAseq preprocessing and analysis tools currently in common use ..36 
Table 1.3: Summary of methods for identifying protein-protein interactions .......45 
Table 1.4: Visualization and detection techniques for RNA and protein downsream of 
high-throughput experiments ............................................................52 
Table 2.1: Summary of network statistics............................................................102 
Table 2.2: Unique GO Terms in Lysates by Experimental Treatment ................103 
Table 3.1: Network statistics for PPI networks ...................................................126 
Table 4.1: Statistics for motif analysis .................................................................153 
Table 4.2: RNA mass recovered and RIN values for RNA immunoprecipitation of 
FMRP targets ..................................................................................168 
Table 4.3: RIP-seq library and alignment data ....................................................169 
Table A.1: Homeostatic response to NMDAR antagonism .................................178 
 xii 
List of Figures 
Figure 1.1: NMDA receptor-mediated activation of mTORC1 ...............................4 
Figure 1.2: Workflow for High-Throughput Projects in the Brain ........................11 
Figure 1.3: Utilizing subcellular fractionation to isolate neuronal compartments .14 
Figure 1.4: General RNAseq pipeline for differential gene expression analysis ...31 
Figure 1.5: Workflow for experimental follow-up ................................................56 
Figure 1.6: Approaches to functional validation of high-throughput experiments 65 
Figure 2.1: Rapamycin reduces mTORC1 activity and rapidly alters translation and 
synaptic function ...............................................................................83 
Figure 2.2: Proteins in postsynaptic region rapidly and bidirectionally respond to 
mTORC1 repression .........................................................................86 
Figure 2.3: mTORC1 inhibition swiftly alters the expression of epilepsy, Alzheimer’s 
disease (AD) and autism spectrum disorder (ASD) proteomes in a 
region-specific fashion ......................................................................89 
Figure 2.4: mTORC1 suppression oppositely alters the appearance of new SNAP-25 
and GAP-43 ......................................................................................93 
Figure 2.5: Rapid mTORC1 repression bidirectionally modifies subcellular 
expression of SNAP-25 and GAP-43 ...............................................96 
Figure 2.6: Quantitation of standard errors in spectral counts measurements across 
treatments for Lysates .....................................................................100 
Figure 2.7: Quantitation of standard errors in spectral counts measurements across 
treatments for PSD and Soluble (SOL) fractions ............................101 
 xiii 
Figure 3.1: Protein-protein interaction (PPI) network analysis determines Parkinson 
protein 7 (PARK7) as a candidate molecule that may give rise to 
pathologies common in epilepsy, AD and ASD .............................112 
Figure 3.2: mTORC1 activity regulates PARK7 protein expression in PSD and 
protein synthesis in dendrites ..........................................................115 
Figure 3.3: PARK7 protein expression is elevated in dendrites and colocalizes with 
the PSD in Tsc1 knockout neurons .................................................117 
Figure 3.4:  Identification of PARK7 binding motifs and calculation of motif 
frequency.........................................................................................120 
Figure 3.5:  PARK7 binding target for disease-associated mTOR MS/MS data and 
CMap PubChem footprint clustering ..............................................122 
Figure 4.1: Workflow for RIP-seq experiment and analysis ...............................144 
Figure 4.2: Quality control of count data from RIP-seq libraries ........................146 
Figure 4.3: Filtration of dataset using FMRP consensus data set targets and 
background from RIP-seq KO libraries ..........................................148 
Figure 4.4: Differential gene expression analysis of RIP-seq libraries ...............151 
Figure 4.5: Motif analysis and clustering analysis for RIP-seq libraries .............156 
Figure 4.6:  Identification and clustering of trans-synaptic signaling genes .......158 
Figure 4.7: Model for mTOR-mediated synaptic remodeling through FMRP targets
.........................................................................................................161 
Figure 4.8: GO enrichment of biological process terms for MDD genes and FMRP 
consensus genes ..............................................................................164 
Figure 4.9: RIP-seq quality control ......................................................................165 
Figure 4.10: Hierarchical clustering of overlapped GO terms derived from DAVID 
GO biological process function annotation chart............................166 
 xiv 
Figure 4.11: Within-sum-of-squares (WSS) estimation for number of cluster used in 
clustering algorithms .......................................................................167 
Figure A.1: Model for rapid antidepressant activation of homeostatic mechanisms175 
Figure A.2: Cartoon describing molecular pathways triggered by NMDAR 
antagonists.......................................................................................185 
Figure A.3: Protein expression regulated by mTORC1 activity overlap with 
depression .......................................................................................195 
Figure B.1: Ethanol elicits a lasting antidepressant-like effect on behavior........213 
Figure B.2: Acute ethanol increases dendritic GABABRs in hippocampus ........216 
Figure B.3: GABABR1 and GABABR2 mRNAs are FMRP targets ....................219 
Figure B.4: FMRP and AUD share target mRNAs and ethanol decreases FMRP221 
Figure B.5: Fmr1 KO prevents ethanol-induced altered GABABR expression...223 
Figure B.6: New GABABR2 protein and surface expression requires FMRP .....226 
Figure B.7: GABABR plasticity and signaling is absent in Fmr1 KO mice ........229 
Figure B.8: Ethanol’s antidepressant effect requires GABABR activation..........231 
Figure C.1: Average S.E.M. of the normalized spectral counts across all genes within 
each fraction ....................................................................................252 
Figure C.2: Probability distribution of standard errors across all genes within each 
fraction ............................................................................................253 
Figure C.3: Correlation matrix of all replicates in all fractions ...........................256 
Figure D.1: Count correlations between RIP-seq libraries ..................................275 
Figure D.2: Global Jaccard index for low count filter .........................................279 
 1 
Chapter 1: Introduction1 
LOCAL TRANSLATION AND DENDRITIC RNA TRANSPORT 
Long-term memory formation relies on the modulation of synaptic efficacy - the 
strengthening or weakening of connections between a presynaptic and postsynaptic cell. 
Such changes are dependent on the alteration of the underlying neuronal architecture of the 
synapse through protein synthesis in the dendrites. Many of these changes are controlled 
by locally synthesized protein kinases that alter ion channel densities and conductivities to 
change the strength of connections between neurons (Martin et al., 2000; Giese, 2012; 
Papoutsi et al., 2012; Stewart and Popov, 2012). In order for the changes made at the 
synapse to be long-lasting and consolidated, proteins must be synthesized rapidly at the 
base of a region of the neuron called the dendritic spine Thus, constitutive and activity 
regulated mRNA trafficking in neuronal cells allows localized protein synthesis in specific 
compartments or areas of the neuron far from the soma such as axons, dendrites, and spines 
(Jung and Holt, 2011). Consequently, many RNA transcripts coding for proteins that 
induce changes in synaptic efficacy are localized in dendrites and ready for rapid 
expression through local mRNA translation. 
Historically, all mRNAs were thought to be exclusively translated in the soma. This 
dogmatic view was questioned when observations in a series of electron microscopy (EM) 
studies revealed the presence of polyribosomes in dendrites, specifically at the base of 
dendritic spines of the dentate gryus (Bodian, 1965; 1972; Peters et al., 1976). It was not 
until 1983 that Steward and Levy provided the first quantitative evidence of synapse-
associated polyribosome complexes and their localization (Steward and Levy, 1982). 
Steward and Levy hypothesized that synapse-associated polyribosome complexes may be 
                                                 
1 Parts of this chapter are published in Namjoshi, S. and Raab-Graham, K.F. (2017). Screening the 
Molecular Framework Underlying Local Dendritic mRNA Translation. Front. Mol. Neurosci. 10(45). doi: 
10.3389/fnmol.2017.00045. I wrote the manuscript and created all figures and tables. 
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necessary for the expression of proteins that constitute the synapse due to their proximity 
to dendritic spines. Their hypothesis was confirmed through numerous studies in the two 
decades that followed demonstrating the requirement for local protein synthesis in 
processes related to synaptic plasticity and learning. Some of these early studies 
demonstrated correlations between polyribosome numbers and synaptogenesis suggesting 
that the synapse-associated polyribosome complexes were the source of the proteins found 
in the postsynaptic density (PSD) (Steward and Falk, 1985; 1986; Palacios-Pru et al., 
1988). This was followed by a number of key studies that identified select mRNA 
transcripts that were localized and translated in the dendritic spines (Steward et al., 1996; 
Steward and Schuman, 2001). Among these was the important discovery that BDNF-
induced synaptic potentiation required local protein synthesis (Kang and Schuman, 1996). 
Dendritic mRNA transport relies on complex formation of RNA granules. RNA 
granules contain RNA-binding proteins (RBPs) - which bind to sequestered mRNAs to 
inhibit their translation - as well as some translation factors, ribosomes, and other proteins 
that control translation (Kiebler and Bassell, 2006). Upon synaptic activation, select 
repressed mRNAs localized to the synapse are translated where the ribosome within the 
RNA granule can initiate rapid translation into the required protein product (Kim et al., 
2013b; Pimentel and Boccaccio, 2014). Notably, RBPs play a vital role in learning in 
memory. The absence of an RBP resulting from incorrect localization or dysfunction due 
to mutations may lead to aberrant translation or repression of specific mRNAs under its 
control resulting in a neurological disorder (Sephton and Yu, 2015). Furthermore, the 
activity of protein kinases, such as mammalian target of rapamycin (mTOR), is coupled to 
translation to facilitate processes related to learning and memory. Disruption of these 
processes can lead to neuronal dysfunction (Giese and Mizuno, 2013; Lipton and Sahin, 
2014). Many animal disease models that reproduce both symptoms and genetic alterations 
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seen in humans show dysregulated local mRNA translation (Pei and Hugon, 2008; Zang et 
al., 2009; Sharma et al., 2010; Ricciardi et al., 2011; Devi and Ohno, 2013; Ma et al., 2013). 
 
MTOR AND THE CONTROL OF LOCAL TRANSLATION 
 Long-lasting changes to synaptic plasticity require N-methyl-D-aspartate 
glutamate receptor (NMDAR) activation (Graber et al., 2013b). The resulting signaling 
cascade activates mammalian/mechanistic target of rapamycin (mTOR) via the PI3K-TSC 
pathway (outlined below, see Figure 1.1). The local translation process is largely mediated 
by the mammalian/mechanistic target of rapamycin (mTOR). mTOR is a 289-kDa 
serine/threonine protein kinase that plays a central role in the regulation and balance of a 
large number of biological processes including the regulation of dendritic protein synthesis. 
Essentially a master regulator cell growth, mTOR responds to a large variety of upstream 
signals and processes including stress (low energy, oxygen depletion, DNA damage), 
nutrient sensing/availability, and response to growth factors (Betz and Hall, 2013). Many 
processes are modulated downstream of mTOR signaling, most notably the control of 
protein synthesis/homeostasis, but also lipid synthesis, autophagy, hormone regulation, and 
synaptic plasticity involved in learning/memory circuitry. Due to its central role in many 
cellular processes it is not surprising that mTOR is also involved in crosstalk with 
numerous other pathways including PI3K/Ras (via TSC1/2), growth factors (IGF1, Akt, 
Erk), energy (AMPK), oxygen sensing (REDD1), and DNA damage pathways (Laplante 
and Sabatini, 2009; Wang and Proud, 2011). Due to the vast number of signals mTOR 
responds to and the processes it modulates, a greater understanding of the protein and 
functional landscape altered by mTOR activity is vital for determining the causes of a 
number of diseases associated with mTOR dysfunction.  
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Figure 1.1: NMDA receptor-mediated activation of mTORC1 
Glutamate or glycine binding to NMDA receptors on the post-synaptic side of the neuron triggers 
a signaling cascade that activates mTORC1. Signaling through PI3K and PDK1/2 activates Akt. 
Akt blocks the tuberous sclerosis complex (TSC1/2) complex, an important intersection point for 
pathway crosstalk. mTORC1 is typically activated through the binding of small GTP-binding 
protein Ras homolog enriched in brain (RHEB). RHEB's GDP/GTP states are controlled by 
TSC1/2, a RHEB GTPase-activating protein and heterodimer. When it activates RHEB, in its 
GTP-bound state, RHEB is able to activate mTOR. mTORC1 has five known components. These 
include the catalytic mTOR subunit, regulatory-associated protein of mammalian target of 
rapamycin (RAPTOR), mammalian lethal with Sec13 protein 8 (mLST8), proline-rich Akt 
substrate 40 kDa (PRAS40), and DEP-domain containing mTOR-interacting protein (DEPTOR). 
mTORC1 then regulates S6K and 4E-BP2 which regulate translation in specific contexts. 
mTORC2 enters this pathway through the activation of Akt. Although mTORC1 and mTORC2 
share a number of proteins in common, they respond to a different set of cellular signals. Once 
inside the cell, rapamycin binds to FK506-binding protein of 12 kDa (FKBP12). This complex 
then interacts with the rapamycin binding domain (FRB) of mTOR and inhibits mTORC1 
function and activities in various processes.
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mTOR's ability to respond to various signals and carry out its functions is 
dependent on the formation of two different protein complexes referred to as mTORC1 
(mTOR complex 1) and mTORC2 (mTOR complex 2). We will focus on mTORC1 for the 
purpose of this introduction. mTORC1 has five known components. These include the 
catalytic mTOR subunit, regulatory-associated protein of mammalian target of rapamycin 
(RAPTOR), mammalian lethal with Sec13 protein 8 (mLST8), proline-rich Akt substrate 
40 kDa (PRAS40), and DEP-domain containing mTOR-interacting protein (DEPTOR) 
(Vander Haar et al., 2007; Peterson et al., 2009). The specific roles of the proteins in each 
complex has not been well-characterized. In the case of mTORC1, Raptor may regulate 
complex assembly by recruiting mTOR substrates while PRAS40/DEPTOR has been 
observed to negatively regulate mTORC1 when its activity levels decline (Hara et al., 2002; 
Kim et al., 2002). Although mTORC1 and mTORC2 share a number of proteins in 
common, they respond to a different set of cellular signals and activate different 
downstream targets. 
 
mTORC1 activation and rapamycin inhibition 
Typically, “activation” of mTORC1 is measured by its downstream output. 
mTORC1 is known to play an important role in the regulation of translation and so 
mTORC1 activation is usually measured through levels of S6 kinase 1 (S6K1), its 
substrates, or 4EBP1 – a translation initiation factor. mTORC1 is typically activated 
through the binding of small GTP-binding protein Ras homolog enriched in brain (RHEB). 
RHEB's GDP/GTP states are controlled by the tuber sclerosis complex (TSC), a RHEB 
GTPase-activating protein and heterodimer consisting of TSC1 and TSC2. When it 
activates RHEB, in its GTP-bound state, RHEB is able to activate mTOR (Huang and 
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Manning, 2008). The direct mechanism of mTOR activation by RHEB is unclear however, 
it may be through direct binding (Long et al., 2005) or through the RHEB promoted 
activation of phospholipase D1 (PLD1) activation (Sun et al., 2008). TSC1/2 respond to a 
number of different upstream signals including stress signals such as oxygen levels and 
energy levels (Hardie, 2007). Reduced energy levels (measured by levels of ATP and ADP) 
triggers AMPK activation which in turn leads to phosphorylation of TSC2 and subsequent 
mTOR activation (Inoki et al., 2003). TSC1/2 is the control point of mTOR signaling as 
crosstalk from other pathways are integrated at this point; for example, TSC1/2 interacts 
with various pathways including GSK3, AMPK, PTEN/PDK1/AKT (p53/DNA damage 
repair pathways), IKKβ signaling (inflammatory mediator/cytokine pathways) (Stambolic 
et al., 2001; Feng et al., 2005; Inoki et al., 2006; Lee et al., 2007). Much of what is known 
of mTORC1 was elucidated through the usage of a potent inhibitor, rapaymcin. Once inside 
the cell, rapamycin binds to FK506-binding protein of 12 kDa (FKBP12). This complex 
then interacts with the rapamycin binding domain (FRB) of mTOR and inhibits mTORC1 
function and activities in various processes (Ballou and Lin, 2008). 
 
mTORC1 and translation 
Under normal translation conditions, eIF4E binding protein 1 (4E-BP1) is 
responsible for binding to multiple RNA-binding proteins to prevent the initiation of 5’-
cap-dependent translation. These proteins include a number of other eukaryotic initiation 
factors necessary for stable mRNA translation. In particular, cap-dependent translation is 
vital for the translation of 5’-untranslated regions (UTRs) that exist on transcripts with high 
G-C content (usually the mark of extensive secondary structures). In this case eIF4F (one 
of the initiation factors recruited by eIF4E) is needed for helicase activity to promote stable 
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binding between the transcript and the ribosome. Thus, alteration of the activity of 4E-BP1 
can have downstream effects that may alter the degree to which certain mRNA transcripts 
are translated (Livingstone et al., 2010). Under conditions favorable for cell growth, mTOR 
phosphorylates p70 S6 kinase and 4E-BP1 (Beretta et al., 1996; Gingras et al., 1998). 
Phosphorylation of 4E-BP1 at four sites activates translation by removing 4E-BP1 contact 
with the translation initiation factors.  
 
Learning, memory, and local translation 
Translation in neuronal cells is localized to specific compartments known as RNA 
granules. This localization is necessary for proteins that need to be expressed in specific 
compartments or areas of the neuron far from the soma such as axons and dendrites. The 
production of proteins localized at the synapse are important in the control of the strength 
and type of signal in synaptic transmission. The consequences of the type of signal and the 
downstream signaling pathways triggered result in numerous alterations to learning, 
memory, and the general cognitive landscape (Sutton and Schuman, 2006; Cajigas et al., 
2010). The removal of 4EBP2 in the hippocampus results in an increase in excitatory 
transmission which produces mice with autistic phenotypes (Gkogkas et al., 2013). To this 
end, alteration of the local translation machinery can have significant effects and 
dysregulation of normal functioning can lead to disease states. 
Long-term memory formation relies on neuronal plasticity to 1) strengthen existing 
synaptic connections, 2) create new synapses, and 3) regulation of transcription and local 
translation to modulate ion channel density and conductivity. Thus, long-term memory 
formation is highly reliant on protein synthesis; to this end, rapamycin treatment has been 
shown to inhibit long-term memory formation in multiple different contexts (Parsons et al., 
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2006; Bekinschtein et al., 2007; Blundell et al., 2008; Gafford et al., 2011; Jobim et al., 
2012). S6K1 (vertebrate isoform of S6 kinase, and mTORC1 target) is also important for 
long-term memory formation as mice with S6K knockouts demonstrate an inability to form 
memories via early-LTP (Antion et al., 2008b). Additionally, learning processes have been 
demonstrated to increase S6 activity via mTORC1. These same mice are also impaired in 
spatial learning. Long-lasting changes to synaptic plasticity seen in memory formation can 
be induced through N-methyl-D-aspartate glutamate receptor activation (NMDAR). The 
resulting signaling cascade activates mTOR via the PI3K-mediated route. In this way, 
NMDAR activation results in the alteration of the protein architecture of the postsynaptic 
density (PSD) through mTOR-mediated control on local translation in the dendrite. 
 
mTORC1 and the K+ channel Kv1.1 
One specific mechanistic example of the effects of local translation by mTOR can 
be seen in the regulation of the mRNA transcript for the potassium channel Kv1.1. Kv1.1 
is a voltage-gated ion channel that is typically localized in the axons. Kv1.1, like other 
potassium channels, is responsible for conducting neuronal excitability. Indeed, removal 
of Kv1.1 in mice results in the development of spontaneous seizures. We previously 
demonstrated that levels of Kv1.1 at the synapse are altered in an mTOR-dependent manner 
(Raab-Graham et al., 2006). Treating neurons with rapamycin or inhibiting NMDARs 
increased dendritic Kv1.1 expression in the hippocampus. We showed that Kv1.1 is 
localized to the dendrites through a local translation assay that uses Kaede, a 
photoconvertible fluorescent protein (Chudakov et al., 2010). This suggested that 
activation of the synapse through NMDARs could have an effect on protein translation in 
the synapse – in this case a reduction in the synthesis of Kv1.1 in an mTOR-dependent 
 9 
manner. We identified the mechanism of this reduction by identifying a binding site for the 
microRNA miR-129 which binds to Kv1.1 mRNA when mTOR is on to repress translation 
(Sosanya et al., 2013). When mTOR is off, the miR-129 binding site is instead occupied 
by HuD, an RNA-binding protein that regulates microRNA binding (Kundu et al., 2012). 
HuD has been shown to have a number of high-affinity targets such as PSD95 and 
CaMKIIα (Lee et al., 2005; Gong et al., 2006). When these targets are degraded, the free 
HuD pool increases allowing miR-129 to be displaced by HuD which in turn promotes the 
active translation of Kv1.1. Herein, we present evidence that Kv1.1 is not the only 
mTORC1 target that is actively repressed (Chapter 2). 
 
USING HIGH-THROUGHPUT ASSAYS TO UNDERSTAND THE MOLECULAR BASIS OF 
MEMORY 
In order to gain a more in depth view of the underpinnings of synaptic plasticity 
both in normal and diseased states many laboratories are initiating unbiased screens to 
identify (1) the mRNA transcripts localized to synaptic compartments, (2) the mRNA 
transcripts actively translated by the ribosome under specific cellular conditions, and (3) 
the protein kinases, RBPs, and microRNAs that control the timing and expression of locally 
translated mRNA. Importantly, researchers are combining classic techniques utilized since 
the 1950’s that have been extended and improved upon with highly specialized high-
throughput methods to answer these questions and provide further insights into the 
molecular basis of neuronal function and neurological disease. 
The remainder of this introduction we will focus on the application of these 
specialized techniques in revealing the complex array of cell signaling and regulatory 
networks in neurons that govern the processes of local translation and long-term 
potentiation (LTP) in dendritic spines. First, we will consider experiment design and model 
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organisms. These techniques have revealed the complex array of cell signaling and 
regulatory networks that govern local translation and synaptic plasticity in dendrites.  We 
provide a general workflow for large-scale sequencing or proteomics projects highlighting 
general considerations and caveats at each stage (Figure 1.2). Then, we outline potential 
methods and strategies to validate findings of these large-scale projects in normal and 
disease rodent models. 
 
EXPERIMENTAL DESIGN OF HIGH-THROUGHPUT ASSAYS 
Large-scale, high-throughput projects that analyze distributions of RNA and 
protein are generally costly and time-consuming. Thus, careful consideration must be taken 
at the design stage and each of the following stages to determine the best approach and 
methodology needed to answer the question of interest (Figure 1.2). After determining any 
drug or behavioral approaches to the experimental design, the next important consideration 
is model organism of choice. The majority of research in learning in memory has been 
dominated by rat, mouse, or human studies but this is by no means the only option (Manger 
et al., 2008). Typically, rats have been used for cognitive assays because of their large size, 
low cost, and versatility (Dudchenko, 2004). However, mice have numerous transgenic 
lines available are easily to manipulate genetically making them a useful model in 
molecular biology for the study of disease. Furthermore, classic experimental design 
principles such as randomization are extremely important for high-throughput experiments 
(Auer and Doerge, 2010; Cui, 2010; Fang and Cui, 2011; Williams et al., 2014). 
Randomization is vital for lowering noise and ensuring that other unknown variables are 
not biasing the observed results. The large number of steps involved in high-throughput 


































Figure 1.2: Workflow for High-Throughput Projects in the Brain 
High-throughput experiments in the brain consist of 6 general stages. 1. The experiment is carefully 
designed with attention to replicates, statistical power, cost, and animal model. 2. Lysates are 
extracted from a brain region (in vivo) or cell culture (in vitro) with any subcellular fractionation 
to study a specific neuronal compartment. 3. Experiments such as CLIP or Co-IPs are performed 
to analyze specific interactions between RNA and protein or protein and protein. 4. RNA or proteins 
are identified through high-throughput methodology and preprocessed to determine molecular 
counts. 5. Analysis is performed on the data to determine new patterns and connections based on 
the aims of the experiment. 6. Any conclusions from 5. are validated in animal disease models or 
through various protein or RNA visualization/quantification assays.
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behavior and drug injections. In addition, drug treatments, tissue preparation, and 
molecular extraction should be performed on the same day for each set of replicates by the 
same researcher if possible to minimize variability. Replication is also extremely 
important, particularly for RNAseq experiments and tools such as Scotty 
(http://scotty.genetics.utah.edu) have been created to aid in the determination of replicate 
number (Busby et al., 2013; Hart et al., 2013). Due to high variability common in these 
projects - especially in the case of RNA immunoprecipitations - more biological replicates 
are extremely important to lowering error. The number of replicates needed for an 
experiment will vary depending on the type of experiment and ultimately need to be 
balanced with cost and depth of sequencing but should not be less than three and adding 
more replicates may gave more statistical power than sequencing deeper (Ching et al., 
2014; Liu et al., 2014). To perform a power analysis to determine the number of replicates 
needed you need a rough estimate of the effect size which in turn depends on the depth of 
sequencing. Thus, there is a tradeoff between replicates, depth of sequencing, and cost that 
must be considered during the design phase (Wang et al., 2011; Liu et al., 2013; Vijay et 
al., 2013). 
 
RATIONALE FOR EXTRACTING CELL-SPECIFIC AND SUBCELLULAR RNA POPULATIONS 
Approaches utilized to isolate synaptic mRNAs are vast. Biochemical isolation of 
synapses via centrifugation or filtration (Figure 1.3) and microdissection of dendritic fields 
in brain slices have provided a rich source of dendritic/synaptic mRNAs. More recently, 
the development of technology allowing single-cell RNAseq has allowed researchers to 
classify cell transcriptome dynamics and determine cell-type diversity (Darmanis et al., 
2015; Dueck et al., 2015; Dueck et al., 2016). These single-cell technologies offer 
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promising opportunities for the field of learning in memory, especially when combined 
with disease models, electrophysiology, and behavioral studies (Harbom et al., 2016). 
These data, collectively, will provide powerful models guiding investigators to test 
translation of specific mRNAs in a cell and site-specific manner.  
 
Utilizing centrifugation, filtration, and density sucrose gradients to isolate dendrites 
As early as 1956, researchers have been optimizing biochemical techniques to study 
synapses in isolation. In 1980, Cheung and colleagues were the first to show that the 
synaptosome (pre- and postsynaptic nerve endings) fraction contains polyribosomes, 
making it a promising candidate for the study of synaptic protein synthesis (Verity et al., 
1980). The synaptosome (S) preparation combines centrifugation and sucrose gradient 
fractionation to create a cell fraction containing a sealed presynaptic structure attached to 
part of the postsynaptic membrane (Hebb and Smallman, 1956; Whittaker et al., 1964). 
The attached postsynaptic structure varies in size and may even contain the entire 
(unsealed) dendritic spine. However, the S preparation was seen to be insufficient for 
properly studying signal transduction and other events that took place in the postsynaptic 
cell. For this reason, the synaptoneurosome (SN) preparation was developed which 
includes both the sealed presynaptic structure and sealed postsynaptic compartment 
isolated through a series of filtration steps and low-speed centrifugation (Hollingsworth et 
al., 1985). This preparation is now commonly used to study and identify components of 
the postsynaptic membrane (Figure 1.3). Some of the earliest attempts to characterize 
proteins of the postsynaptic membranes required methods to further subfractionate the 
above synaptic fractions (including a slightly modified SN, referred to as 
synaptodendrosome (SD)) (Rao and Steward, 1991b; 1993).  For example, the synaptic
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Figure 1.3: Utilizing subcellular fractionation to isolate neuronal compartments 
A. Various methods have been developed to isolate neuronal compartments from intact neurons to 
study their processes in detail. Depicted here are five different subcompartments and their contents. 
Synaptosomes contain an enclosed presynaptic sac with a portion of the postsynaptic membrane 
(varies in size), the postsynaptic density, and some of the postsynaptic molecules. 
Synaptoneurosomes, the most common preparation, consists of an enclosed presynaptic and 
postsynaptic sac containing many of the molecules involved in synaptic signaling and plasticity. 
Synaptodendrosomes produce a structure similar to synaptoneurosomes but the content of the 
posysnaptic sac is not as representative of the intact neuron as the synaptoneurosome. Further 
centrifugation and application of detergents allows isolation of the synaptic plasma membrane (pre- 
and postsynaptic membranes with associated ion channels and structural components) and the 
postsynaptic density. B. Typical protocol for extraction synaptoneurosomes modified from Quinlan 
et al. 1999. Buffer B composition: 20 mM HEPES, pH 7.4, 5 mM EDTA, pH 8.0, protease inhibitor 




plasma membrane (SPM) subfraction, containing the proteins embedded in the plasma 
membrane around the synapse, can be purified from the synaptic fractions (Blackstone et 
al., 1992; Bermejo et al., 2014). The SPM fraction can be further fractionated to obtain the 
PSD subfraction, the large scaffolded complex of proteins found clustered at the edge of 
the postsynaptic membrane (Carlin et al., 1980; Villasana et al., 2006). Rao and Steward 
isolated SPMs by subjecting S to further gradient fractionation combined with the detergent 
Triton X-100 and demonstrated that protein synthesis was occurring in this region (Rao 
and Steward, 1991a). Expanding on this early finding by Rao and Steward, Niere et al. 
subjected the PSD fraction, isolated in a similar manner, to mass spectrometry to show that 
75% of the PSD changes in composition upon inhibiting the protein synthesis pathway 
mTOR for only one hour in vivo (Niere et al., 2016). Thus, combining classic biochemical 
subcellular techniques with big data approaches has vastly expanded our knowledge in how 
dynamic protein synthesis occurs in the PSD. 
 
Limitations to biochemical synapse isolation and potential strategic measures 
utilized to overcome these limitations. 
Though subcellular fractionation is still commonly employed to study molecular 
events at the postsynapse, there are limitations. The S, SN, and SD preparations are 
considered impure since they cannot successfully remove glial fragments (Chicurel et al., 
1990; Rao and Steward, 1991b; 1993). Hollingsworth and colleagues noted “unidentifiable 
debris” when they analyzed the preparation by EM which suggests that there may be 
foreign protein and RNA carryover from membrane fragments or other fractions not 
normally associated with axons or dendrites (Hollingsworth et al., 1985). An additional 
concern is the presence of somatic contaminants. EM provides the most rigorous check, 
however one might quickly screen for somatic contamination by examining a sample of 
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the synaptic preparation versus the total homogenate with a nuclear stain such as DAPI or 
western blotting for a nuclear protein such as NeuN (Sosanya et al., 2013). Moreover, after 
large scale screens one may subtract possible contaminants bioinfomatically. To determine 
axonal or dendritically expressed transcripts, Schuman and colleagues sequenced RNA 
isolated from the stratum radiatum and lacunosum moleculare of the rat hippocampus and 
subtracted transcripts enriched in glia, interneurons, nucleus, mitochondria, and blood 
vessels based on cell type-specific transcriptome data from previous publications and 
online databases (Cajigas et al., 2012). While this technique may eliminate candidates that 
are expressed both in glia and neurons, it does allow one to follow up putative dendritic 
mRNAs with more certainty. In spite of these limitations, these preparations have provided 
the basis for many studies that have moved the field forward. 
 
Alternative approaches to isolating dendrites 
Eberwine and colleagues were the first to isolate dendrites from neuronal cell 
bodies in hippocampal cell cultures. A micropipette was used to microdissect the dendrite 
in which RNA was isolated. Differential display and microarray analysis of mRNA isolated 
in this manner, provided the first large-scale analyses of the mRNA present in the dendrite 
(Miyashiro et al., 1994; Eberwine et al., 2001; Miyashiro et al., 2003). Considering the 
limitations of these early assays, remarkably the authors estimated that ~400 mRNAs reside 
in the dendrites (Eberwine et al., 2001). 
Since then, less labor-intensive methods have been developed. One clever 
technique capitalized on the fact that neuronal and glial cell bodies are typically at least 10 
µm in size. By plating hippocampal neurons onto PET membranes with 3 µm pores 
neuronal processes are separated from neuronal cell bodies and glia. Thus, neuronal 
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processes can be isolated by scrapping the bottom of the filter (Torre and Steward, 1992; 
Poon et al., 2006). Additionally, laser capture microdissection of neurites has also been 
employed successfully to catalog the mRNAs present in dendrites (Kye et al., 2007). More 
recently, Eberwine and colleagues have refined this method to isolate a single neuron from 
cell culture including dendrites (Lovatt et al., 2015). These techniques offer promising 
alternatives to complement the standard subcellular fractionation methodologies. Through 
mRNA amplification technologies, it is now possible to perform cell and compartment-
specific identification of synaptic mRNAs. 
 
WHAT ISOLATING REGULATORY FACTORS CAN TELL YOU ABOUT SYNAPTIC EFFICACY 
Isolation of RNA-Binding proteins (RBPs) and RNA populations 
RNA-binding proteins (RBPs) and all types of RNAs are believed to play a vital 
role in learning and memory by controlling transcript localization and availability at the 
dendrite (Sephton et al., 2011; Aksoy-Aksel et al., 2014; Lenzken et al., 2014; Smalheiser, 
2014; Zhou et al., 2014). In the past decade, a number of important high-throughput 
techniques have been developed concurrently with specialized deep sequencing technology 
that has allowed researchers to elucidate the RNA populations bound to RBPs or ribosomes 
on an unprecedented scale. However, these techniques are very difficult to perform and 
must be optimized considerably. In the following sections, we will outline the basics 
principles of these techniques and compare their advantages and disadvantages (Table 1.1). 
We will also consider a number of in vitro selection-based techniques that are easier to 
perform and may reveal information to complement other assays. 
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RNA immunoprecipitation sequencing/microarray (RIP-SEQ/RIP-CHIP) 
The RNA immunoprecipitation (RIP) has been used previously to identify targets 
of RBPs involved in neurological dysfunction (Buckanovich and Darnell, 1997; Napoli et 
al., 2008; van der Brug et al., 2008; Fernandez et al., 2015). High-throughput RIP-SEQ 
serves as a useful tool in determining RNA populations bound to proteins involved in local 
translation. RIP, similar to the protein-based immunoprecipitation procedure, has been 
optimized in order to preserve the RNA-protein complex during the lysing step such as 
gentle-freeze thawing (Keene et al., 2006; Oeffinger et al., 2007; Jain et al., 2011; Dahm 
et al., 2012). Other modifications in RIP protocols are to ensure that free RNAs released 
during lysis do not bind non-specifically to the beads or the RBP, a phenomenon that has 
been observed previously and contributes to the high background of some RIP experiments 
(Mili and Steitz, 2004). Following some of the procedures outlined by Jain and colleagues, 
it is possible to achieve minimal or negligible levels of background binding (Jain et al., 
2011). While crosslinking with formaldehyde to bind the protein-protein or protein-RNA 
structures together may help in ensuring complex isolation, in some cases it may not lower 
the level of background binding (Penalva et al., 2004). Finally, like many other high-
throughput techniques, there are limitations including epitope accessibility to the antibody, 
as well nonspecific binding inherent with antibody-based procedures. Importantly, RIP is 
not able to reveal precise binding sites like other crosslinking techniques discussed below; 
however, it can reveal the full-length transcript of RNAs bound to the protein of interest in 
vivo.  
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 Table 1.1: Comparison of techniques to isolate RNA-associated populations 




Recover full length-RNA High background, antibody-based 
(Keene et al., 2006; Oeffinger 
et al., 2007; Jain et al., 2011; 
Dahm et al., 2012) 
RNA-Protein 
interactions through CLIP-SEQ 
HITS-CLIP High resolution 
Difficult, low cross-linking efficiency, 
cross-linking artifacts, antibody-based, 
RT-PCR mispriming, cannot 
distinguish between single protein 
binding and protein complex binding 
(Licatalosi et al., 2008; 
Darnell, 2010; Kishore et al., 
2011; Zhang and Darnell, 
2011; Gillen et al., 2016) 
PAR-CLIP 
Very high resolution, high cross-
linking efficiency 
Difficult, expensive, 4-SU toxic, high 
background, antibody-based, low 
alignment % 
(Hafner et al., 2010; Spitzer et 
al., 2014) 
iCLIP/iCLAP 
Very high resolution, RT-PCR does 
not stall at crosslink site 
Very difficult to perform 
(Konig et al., 2010; Wang et 
al., 2010b; Sugimoto et al., 
2012; Huppertz et al., 2014) 
CRAC Affinity purification-based, less 
background 
Difficult, tag may interfere with protein 
function 
(Granneman et al., 2009; 
Bohnsack et al., 2012) 
PIP-SEQ 
Does not use UV cross-linking, 
identifies non-Poly(A) transcripts 
Difficult, very new method (Silverman et al., 2014) 
RNA Structure 
CLASH-SEQ 
Identification of RNA-RNA duplexes 
Use of two adaptors results in 
ambiguity, ligation reaction inefficient 
(Kudla et al., 2011) 
HiCLIP Improves upon CLASH-SEQ, can 
identify long RNAs 
Difficult, very new method (Sugimoto et al., 2015) 
Ribosome-based 
RIBO-SEQ 
Greatly improves on past footprinting 
techniques, high-throughput 
Lysis preparation may change 
ribosomal distribution, stalled 
ribosome may bias results 
(Esposito et al., 2010; Masek 
et al., 2011; Gandin et al., 
2014) 
TRAP-SEQ Easier to perform than RIBO-SEQ Lacks RIBO-SEQ specificity (Jiao and Meyerowitz, 2010) 
In vitro binding 
SELEX 
Quick, easier to perform than 
alternative in vivo methods 
High affinity motif bias, identifies non-
physiological interactions (Darmostuk et al., 2015) 
RNAcompete 
Quick, easier to perform than 
alternative in vivo methods 
RNA secondary structures may affect 
binding assay, identifies non-
physiological interactions 
(Ray et al., 2009) 




(Campbell et al., 2012) 
RNA Bind-n-Seq Greatly improves on other in vitro 
methods, compliments CLIP-based 
assays 
Identifies non-physiological 
interactions (Lambert et al., 2014) 
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Crosslinking-based techniques to identify RBP-bound RNAs 
HITS-CLIP 
Cross-linking and immunoprecipitation (CLIP) was originally developed by the 
Darnell Lab to study interactions between the neuronal protein Nova and its target RNAs 
(Ule et al., 2003; Ule et al., 2005). When combined with high-throughput sequencing, the 
modified protocol is referred to as HITS-CLIP (Licatalosi et al., 2008; Darnell, 2010). The 
HITS-CLIP technique allows researchers to perform mapping of RBP binding sites on 
RNA in a high-throughput manner. The procedure has now been expanded and modified 
to a number of variants which we will detail below.  Modifications have also been made to 
the HITS-CLIP procedure that now allow up to single-nucleotide resolution of RBP 
binding sites which could aid in the discovery of RNA-binding motifs utilized in local 
translation (Kishore et al., 2011; Zhang and Darnell, 2011). While HITS-CLIP allows for 
fine resolution of RNA-protein interaction sites, the crosslinking procedure can introduce 
artifacts and during reverse transcription mispriming events can occur (Kishore et al., 
2011). Notably, recent improvements have been made to the procedure to minimize 
mispriming artifacts through the use of two specialized primers during the reverse 
transcription step (Gillen et al., 2016). One of the biggest limitations to HITS-CLIP is the 
low cross-linking efficiency, which has been reported to be ~5% (Darnell, 2010). HITS-
CLIP and its derivatives have already been utilized to identify RBP binding sites for 
proteins involved in local translation, to determine microRNA bindings sites, and identify 
RNA targets for proteins involved in neurological and developmental dysfunction (van der 
Brug et al., 2008; Darnell et al., 2011; Ascano et al., 2012b; Ince-Dunn et al., 2012; Lagier-
Tourenne et al., 2012; Wagnon et al., 2012; Boudreau et al., 2014; Weyn-Vanhentenryck 
et al., 2014; Scheckel et al., 2016). 
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The first step in the HITS-CLIP procedure is to use UV light is used to crosslink 
RNA and protein interacting within the cell population of interest. Next, cells are lysed and 
an RNase is used to shorten the crosslinked RNA-protein complexes in the cell lysate. The 
complexes are then immunoprecipitated and a radiolabeled adaptor (a nucleotide sequence 
used in high-throughput sequencing) is added to the 3’ end. After elution from beads the 
protein-RNA complex is isolated by SDS-PAGE and transferred to a nitrocellulose 
membrane. The RNA of interest is then isolated from the membrane by proteinase K 
treatment and an adapter is added to the 5’ end. The isolated RNA can then be prepared for 
high-throughput sequencing. HITS-CLIP allows for fine resolution of RNA-protein 
interaction sites however, the crosslinking procedure can introduce artifacts and 
mispriming events can occur during reverse transcription (Kishore et al., 2011). Recently, 
improvements have been made to the HITS-CLIP procedure to address mispriming 
artifacts (Gillen et al., 2016). HITS-CLIP also suffers from low cross-linking efficiency - 
a maximum of 5% (Darnell, 2010). 
 
PAR-CLIP and iPAR-CLIP 
Photoactivatable-ribonucleoside-enchanced crosslinking and immuniprecipitation 
(PAR-CLIP) was introduced in 2010 to address issues of low crosslinking efficiency in 
HITS-CLIP and issues of noncrosslinked background RNA in samples (Hafner et al., 2010; 
Spitzer et al., 2014). A photoreactive nucleoside analog of uridine (4-SU) and guanosine 
(6-SG) are added to cultured cells which increases crosslinking efficiency. 4-SU causes a 
thymidine to cytidine transition during the reverse transcriptase reaction thus indicating the 
exact crosslink sites. 4-SU was not originally believed to be toxic to cells at concentrations 
used in PAR-CLIP but recent evidence suggests it may inhibit processing of 47S rRNA 
and affect the experimental results (Burger et al., 2013). PAR-CLIP has been limited to use 
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in cell culture as its toxicity in animal tissue is not yet known but an in vivo approach called 
iPAR-CLIP has been developed, with the “i” standing for in vivo (Jungkamp et al., 2011). 
Furthermore, PAR-CLIP was quantitatively shown to have reproducible levels of 
background signals thus necessitating the use of empirically determination of background 
as an extra step in analysis (Friedersdorf and Keene, 2014). PAR-CLIP also suffers from 
other issues as aligned reads can be as low as 20% of total reads (Hafner et al., 2012). 
Importantly, PAR-CLIP has been used to understand the binding of RBPs whose 
dysregulation has been shown to play a role in neuronal diseases (Ascano et al., 2012a). 
Some example incude Rbfox3 which was find to have a unique function in the regulation 
of pri-mRNA (Kim et al., 2014), the first identification of two FMRP binding motif 
sequences (Ascano et al., 2012b), and the first report to identify all the targets of the FET 
protein family (FUS, EWSR1, and TAF15) (Hoell et al., 2011). Thus, PAR-CLIP has 
moved the field forward by determining binding motifs/targets for RBPs allowing 
investigators to answer question on how RBPs contribute to coordinated translation with 
synaptic plasticity.  
 
iCLIP, iCLAP, and CRAC 
Individual-nucleotide resolution CLIP (iCLIP) was developed in response to the 
data showing that the reverse transcription reactions truncate at the crosslink sites in HITS-
CLIP and PAR-CLIP (Konig et al., 2010; Sugimoto et al., 2012; Huppertz et al., 2014). 
The iCLIP method adds a circular PCR amplification step that allows researchers to 
determine the sequence of cDNAs that would normally be truncated in other CLIP 
methods. The method is similar to HITS-CLIP in execution. Immunoprecipitated RNA-
protein complexes are treated with proteinase K; crosslinked proteins will not be affected 
and stick to the binding site. During cDNA synthesis, truncation will occur at the crosslink 
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site. The cDNA is then circularized, linearized, and PCR amplified to determine the region 
of the protein binding site at the crosslink. While iCLIP does resolve some of the issues 
that other CLIP methods face it is technically challenging and has extra steps to handle 
RNA which is already in limited quantities. Additionally, the extra manipulation at the 
PCR amplification stage could bias the final results. iCLIP has another variation known as 
Individual-nucleotide resolution crosslinking and affinity purification (iCLAP) which uses 
a two-step affinity purification. This technique may be an option if antibodies are not 
available and may lower background (Wang et al., 2010b). Finally, another technique 
involving affinity purification is cross-linking and analysis of cDNAs (CRAC). This 
technique requires RBPs to be tagged with a protein A and hexahistidine for IgG 
purification followed by nickel-affinity purification (Granneman et al., 2009; Bohnsack et 
al., 2012). This technique has been used to uncover spliceosomal RNA-protein interactions 
and may prove to be a useful method for cleanly isolating a protein within a complex. Thus, 
each technique has been optimized to overcome specific limitation, to provide researcher 
with a tool kit to address their specific question (Table 1.1). 
 
PIP-SEQ, HiCLIP, and CLASH-SEQ 
Protein interaction profile sequencing (PIP-SEQ) is another more recent high-
throughput method that can map RNA-protein interactions in an unbiased, transcriptome-
wide manner, rather than selectively with specific RBPs (Silverman et al., 2014). 
Furthermore, RNA secondary structures are an important regulatory mechanism in post-
translational control. Indeed, RNA secondary structure has already been observed as a 
control mechanism in long-term memory formation as well as a 3’UTR recognition 
sequence for localization to the dendrite (Martin and Ephrussi, 2009). HiCLIP and 
CLASH-SEQ are two related methods that can be used to map RNA secondary structures 
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(Kudla et al., 2011). CLASH-SEQ is a high-throughput method that allows for the 
transcriptome-wide level identification of secondary structures via analysis of RNA 
duplexes. HiCLIP improves upon the biases and limitations of CLASH-SEQ by adding 
another adapter that allows identification of RNA-RNA duplexes with greater precision 
(Sugimoto et al., 2015). Collectively, these techniques are providing answer to long-sought 
after question regarding how secondary structure may ecncode dendritic targeting and 
translational regulation signal that investigators have struggled with for several years. 
 
RNA Interactome Capture 
Another crosslinking method that differs from the CLIP-based methods has 
recently been developed. RNA interactome capture can be used to survey the full repertoire 
of both protein and RNA interacting physiologically within cells (Castello et al., 2013; 
2016). UV irradiation is used to crosslink RBPs to polyadenylated RNAs which are then 
isolated using oligo(dT) magnetic beads. Next, RNA and protein are separated and 
analyzed by RNAseq and mass spectrometry respectively. Like all crosslinking methods, 
it is limited by crosslinking efficiency. Furthermore, it will not be able to isolate RBPs 
bound to nonpolyadenylated RNA. Thus, for the first time, investigators can isolate 
protein-RNA interactions as a network, providing insight into how RBPs work in concert 
to regulate mRNA translation of plasticity-related proteins. 
 
Ribosomal/Translation-Based methods 
RIBO-SEQ/ARTSEQ and Polysome Profiling 
The analysis of global mRNA levels within a cell population is commonly used to 
measure gene expression. However, this may not be a sufficient metric as mRNA levels do 
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not necessarily correlate to protein expression levels due to an extra layer of translational 
control at the level of the ribosome. Therefore, ribosome-specific RNA methods have been 
developed to better understand the dynamics and control of mRNA translation. Translation 
serves as a rapid mechanism by which the cell can finely control the amount of protein to 
be expressed from a particular mRNA in both the spatial and temporal dimensions. Such 
regulation of translation serves a major function in both memory formation and synaptic 
plasticity thus necessitating the need for methods able to profile mRNAs under active 
translation (Costa-Mattioli et al., 2009; Buffington et al., 2014). One approach to 
identifying mRNAs under active translation is polysome-profiling in which ribosomes with 
high translation efficiency are selectively isolated by polysome gradient fractionation, 
followed by RNA isolation and high-throughput sequencing or microarray (Esposito et al., 
2010; Masek et al., 2011; Gandin et al., 2014). Ribosome profiling sequencing (RIBO-
SEQ or active mRNA translation sequencing, ARTSEQ) is a genome-wide approach used 
to identify mRNA being actively translated by the ribosome without consideration of 
translational efficiency. In this context, translational efficiency is defined as the mean 
ribosomal footprint counts for a given mRNA, a quantitative measure of the degree of 
ribosomal occupancy (Ingolia et al., 2009; Ingolia et al., 2012).  All ribosomes in active 
translation are isolated and the associated untranslated mRNA is then removed and 
digested. Then, the rRNA is depleted from the samples and the actively translated mRNA 
is reverse transcribed and sequenced. The fragments of RNA protected from digestion are 
then mapped to a reference genome thereby providing the location of the ribosome on 
various mRNA at nucleotide-scale. Since ribosome profiling uses a footprinting approach, 
it is able to reveal the precise binding sites of the ribosomes across the mRNA and provide 
quantitative measures of expression. These features are not possible with the traditional 
polysome profiling approach. Due to the high sensitivity of RNA sequencing approaches, 
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these methods can provide detailed information about mRNA undergoing translation, thus 
allowing researchers to better understand how the synapse is actively changing in the 
context of learning and memory. 
 
TRAP/TRAP-SEQ and RiboTag 
Translating ribosome affinity purification (TRAP) is another method for mapping 
actively translated mRNAs using EGFP-tagged ribosomal protein L10 (RPL10). The 
technique is performed in transgenic mice containing Bacterial Artificial Chromosomes 
(BACs) (Heiman et al., 2008). The technique was later extended for use in RNAseq in a 
method known as TRAP sequencing (TRAP-SEQ) which uses His and FLAG epitope-
tagged ribosomal protein L18 (RPL18) to immunopurify translating ribosomes (Jiao and 
Meyerowitz, 2010). However, because this assay captures whole ribosomes (both 
polysomes and monosomes) the translational state of the mRNA of interest will not be as 
high-resolution as that obtained from ribosomal profiling or polysome profiling. A recent 
study has attempted to modify the TRAP-SEQ method in such a way that it is possible to 
extract ribosome-bound mRNA specifically from dendrites (Ainsley et al., 2014). RiboTag 
is another recently developed method for a mouse transgenic line in which the ribosomal 
protein L22 (RPL22) gene has been tagged with an HA tag before the stop codon. This 
mouse can then be crossed with a mouse line contained cell type-specific Cre-recombinase 
thus creating HA-tagged ribosomes in the cell-type of choice. Immunoprecipitation will 
recover ribosome-bound mRNA in the chosen cell type (Sanz et al., 2009). This method 
circumvents the need for the BAC required in TRAP-SEQ. Similar to the HA-tagging and 
TRAP technology described above, another method has been recently developed that 
allows ribosomes to be GFP-tagged, but only immunoprecipitated from cells that project 
to a specified brain region (Ekstrand et al., 2014). Thus, TRAP-SEQ provides extensive 
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information about mRNA populations undergoing translation and with the modification of 
circuit-specific GFP-tagged ribosomes it’s now possible to examine coordinated mRNA 
translation between specific brain regions. 
 
In vitro binding assays 
RNA-SELEX, RNAcompete, SEQRS, and RNA Bind-n-Seq 
In vitro binding assays provide a means for surveying the RNA-binding preference 
of RBPs. While some of the results may be non-physiological, they are useful for motif 
identification and can complement other antibody-based methods as a means separating 
falsely-identified RNA targets. Systematic evolution of Ligands by EXponentional 
Enrichment (SELEX) was developed in the 1990s as a way of assessing the binding affinity 
of proteins to a pool of random oligonucleotides. The oligonucleotide library is incubated 
with the target protein of interest. Candidate oligonucleotides that bind the protein are 
reverse-transcribed, amplified, and used to seed a new round of selection with the protein 
of interest. After several rounds, the RNA is sequenced. These RNA molecules represent 
sequences with high-affinity to the protein of interest. SELEX is useful for determing novel 
RNA-protein interactions as well RBP motif discovery. Many improvements have been 
made to SELEX over the years and RNA SELEX now exists in a high-throughput form, 
giving researchers the ability to assess possible RNA sequences that can bind to a given 
molecular target (Darmostuk et al., 2015). Other attempts to assess RBP binding preference 
include RNAcompete (Ray et al., 2009). Here, a custom-made microarray is used to 
produce a pool of RNAs (29-38 nucleotides in length) which are either unstructured or 
contain stem-loops. These RNA molecules are then made double-stranded through primer 
extension on the array. After release from the array, GST-tagged RBPs are incubated with 
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the RNA pool. The RNA bound to the RBP is then removed, extracted, labeled, and 
hybridized to a microarray for high-throughput analysis. SEQRS is another method that 
builds upon older forms of in vitro selection such as RNA SELEX. DNA oligonucleotides 
with a random 20 nucleotide sequence are transcribed to RNA and then incubated with a 
recombinant protein of interest. The RNAs are then extracted, converted to cDNA, and 
sequenced (Campbell et al., 2012). RNA Bind-n-Seq was recently developed with an aim 
to improve upon the above methods as well as provide a method that was not as 
challenging, time-consuming, or biased as CLIP (Lambert et al., 2014). The method used 
a random pool of RNAs which are incubated with a purified RBP present at different 
concentrations. The RBPs are pulled-down using streptavidin magnetic beads, the RNA is 
extracted, converted to cDNA, and sequenced. The authors suggest that this method be 
used in tandem with CLIP-based techniques to filter out false positives.  
 
HIGH-THROUGHPUT ASSAYS 
Following isolation of the samples of interest, the samples must be processed and 
then submitted for high-throughput analysis. For RNA samples, the newest technology 
available is generally referred to as RNAseq. In the last decade, RNAseq has replaced 
microarray technology primarily because it is believed to be more accurate, more sensitive, 
and has a broader dynamic range (Marioni et al., 2008; Fu et al., 2009; Zhou et al., 2014). 
However, RNAseq is still a very new technology. For this reason, it is more expensive and 
the analysis pipelines are not completely standardized. RNAseq pipelines also require in-
depth bioinformatics analysis though many sequencing facilities offer analysis services. 
Like microarrays, mass spectrometry is an older technique with a more standard analysis 
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pipeline that has been reviewed in detail elsewhere (Slonim and Yanai, 2009; Lavallee-
Adam et al., 2015).  
 
RNA-Sequencing (RNAseq) 
Next-generation sequencing technology (NGS) represents the latest technologies 
used in high-throughput sequencing. A number of different platforms are available 
including Illumina, Ion Torrent (Fischer), Roche 454 (Roche), and SOLiD (Life 
Technologies). Various approaches to sequencing have been developed and improvements 
have been made over the years (Goodwin et al., 2016). Here we will focus on solid-phase 
bridge amplification technology pioneered by Illumina. The Illumina platform is currently 
the most widely used and the company’s HiSeq 2000 boasts the lowest sequencing cost per 
Gb and a low error rate (Loman et al., 2012; Quail et al., 2012). However, for greater 
sensitivity and a lower error rate (which may be of use for SNP analysis, for example), the 
RSII platform (Pacific Biosciences) may be preferred. The entire RNAseq pipeline is 
summarized in Figure 1.4. 
 
Quality control 
Before sequencing begins, RNA obtained from cell samples are used to generate a cDNA 
library (Head et al., 2014). A common pitfall is degraded or impure RNA. Low quality 
RNA generates very noisy data whose sequences can be difficult or impossible to 
reconstruct during the data preprocessing stages. Furthermore, sequencing degraded RNA 
leads to high variability and can impact interpretation and differential gene expression 
(DGE) analysis leading to the possibility of overfitting in classification analysis 
downstream. There are a few technologies available for RNA quality and quantity 
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assessment prior to library preparation. Measuring quantity: A UV light-based Nanodrop 
(Thermo Fischer Inc.) may be used but it is not as sensitive as dye-based fluorescence 
methods of nucleic acid detection, particularly in the low range. The Qubit 3.0 Fluorometer 
(Thermo Fischer Inc.) provides accurate quantity assessment at low concentrations (as low 
as 250 pg/uL using the RNA high-sensitivity kit), even if the RNA is degraded, and is the 
preferred instrument for quick quantitative assessment. Measuring quality: The RNA 
integrity number (RIN) is a statistical measure of RNA integrity that has been developed 
to assess RNA quality in a particular sample (Schroeder et al., 2006). RIN values range 
from 1-10 and typically a RIN of 7-10 is recommended for library construction unless the 
RNA was derived from rare tissue and obtaining higher quality RNA is costly or 
impossible. However, it appears possible to construct libraries and analyze data from 
moderately degraded RNA (RIN = 4-6) using appropriate statistical corrections (Gallego 
Romero et al., 2014; Sigurgeirsson et al., 2014; Cieslik et al., 2015). The Agilent 
Bioanalyzer 2100 (Agilent Technologies) and the Agilent Tape Station (Agilent 
Technologies) both utilize microcapillary based electrophoresis to analyze RNA quantity 
as well report an accompanying RIN value. As an alternative to using RIN, qPCR may also 
be used for quality assessment if potential transcripts are already known (Vermeulen et al., 
2011). For RNA-protein interaction studies, qPCR can used to assess the validity of target 
samples by using primers for known RNA targets of the immunoprecipitated RNP. This 
method does not assess the entire extracted RNA sample but can be a useful tool to 
demonstrate the success or relative quality of the RNA isolation assay. 
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Figure 1.4: General RNAseq pipeline for differential gene expression analysis 
Extracted mRNA typically undergoes rRNA depletion or Poly(A) selection to remove the rRNA 
population from the sample. After fragmentation and library preparation, the sequencing begins. 
After sequencing, the reads must be checked for quality control and low-quality reads are trimmed 
or discarded. Next, the reads are aligned to a genome and successfully annotated libraries can 
undergo visualization and further quality control. Reads are then counted for each gene and 
normalized so they can be compared. Finally, the gene-reads can be analyzed by a number of 
methods to discovery new interactions and patterns in the data. 
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rRNA removal 
After RNA quality control, the samples typically undergo a selection stage for the 
removal of ribosomal RNA (rRNA). Since RNAseq will provide sequences for the most 
abundant RNAs in the sample, rRNAs must be removed since they comprise > 90% of the 
RNA isolated from a cell population. There are two major strategies to approach this issue 
and recent work suggest that both methods introduce biases in sequence coverage (Lahens 
et al., 2014). However, both of these methods are currently in wide use and since no 
alternatives exist, efforts are ongoing to decrease bias (van Dijk et al., 2014). Since mature, 
processed mRNAs contain a poly(A) sequence, oligo(dT) beads can be used to select for 
only mature mRNAs in a technique called poly(A) selection, effectively removing the 
rRNA from the sample. While cheaper and of higher sensitivity compared to the alternative 
choice, the rRNA depletion technique, it will not pick out non-coding RNAs and may 
detect less genes overall (Cui et al., 2010; Zhao et al., 2014). There are still concerns of 
3’end bias for poly(A) selection sequences but recent studies suggest that this may be 
overcome with appropriate statistical corrections (Roberts et al., 2011). rRNA depletion 
utilizes beads consisting of sequences complimentary to rRNA. When RNA samples are 
introduced to the beads, the rRNA attaches to the beads allowing the remaining RNAs to 
be recovered. Currently, this method is more expensive and does not remove all rRNA (Cui 
et al., 2010). However, it is necessary for sequencing non-coding RNA. 
 
High throughput sequencing 
Following rRNA depletion, the RNA is sheared into small fragments and converted 
to cDNA by reverse transcription. Unique DNA linkers are ligated onto the 3’ and 5’ ends 
of the isolated oligonucleotide. Special capture sites are then added on to the 3’ and 5’ ends 
of the molecule which allows them to be anchored onto a solid support surface during the 
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sequencing steps. PCR amplification is often performed at this stage depending on the 
amount of RNA available. RNA sequencing is often multiplexed so multiple experiments 
can be run simultaneously. This is accomplished by attaching a barcode between the 3’ 
linker and the 3’end capture site. These unique barcodes can be used to differentiate 
between multiple sets of samples run simultaneously (either one barcode, single index, or 
two, dual index). The samples are then loaded into the sequencer where they are washed 
over the surface of a small, thin surface known as a flow cell and separated into single-
stranded DNA (ssDNA). The samples attach to the flow cell via the ligated capture sites. 
Since there are capture sites on both sides, the molecule can bend over to attach to the flow 
cell at both ends. A polymerase and dNTPs are introduced and to amplify the DNA which 
is separated again into ssDNA. This process is repeated several times within an area of the 
flow cell to form a cluster of replicated molecules. The flow cell is then exposed to a 
polymerase and fluorescent dNTPs. The dNTPs are added one at a time to a cluster which 
fluoresces a different color depending on the incorporated base until the full sequence has 
been determined. The Illumina technology allows sequencing from just one side (single-
read, SR) or from both ends (paired-end, PE). Paired-end runs, which increase the accuracy 
of genome mapping, are typically more expensive and more useful for difficult, repetitive 
genomic sequences or providing information about spice junctions and alternative splicing 
transcripts (Williams et al., 2014). PE is not required for differential gene expression 
analysis but may provide greater coverage during the genomic alignment stage. Each 
machine offers a maximum achievable number of output sequence reads per lane of a flow 
cell (with a total of eight lanes per flow cell). Therefore, the number of samples loaded per 
lane must be divided by the total number of possible reads to determine the number of 
reads each sample may receive (the HiSeq 4000 typically delivers 300-400 million total 
reads per lane). A standardized number of reads required per sample to successfully map 
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to the genome, determine gene expression differences, or other experimental parameters 
has not yet been determined and must be considered on an experiment-to-experiment basis. 
Though the ENCODE consortium has released guidelines for standardized RNAseq 
practices they are now out-of-date given the pace the field is moving. However, some 
general guidelines and standards are available (Williams et al., 2014; Conesa et al., 2016).  
 
Data preparation pipeline 
There is no one standard analysis pipeline for RNAseq projects as they will vary 
given the data. Here we present a basic overview of some considerations and software for 
the DGE analysis process and other downstream analysis (Oshlack et al., 2010; Rapaport 
et al., 2013; Williams et al., 2014; Finotello and Di Camillo, 2015; Conesa et al., 2016). 
Also, note that CLIP studies may require specialized experimental design and analysis 
using specific software (Wang et al., 2015; Zhang et al., 2015). A selected list of currently 
popular tools for RNAseq data processing and analysis is shown in Table 1.2. 
The first major consideration before beginning RNAseq analysis is that the process 
requires a considerable amount of computing power. The amount of power needed will 
vary depending on the size and type of experiment. As a general minimum guideline: Large 
disc space (1-5 TB, solid-state preferred), RAM (at least 8-32+ GB, higher is preferred), 
and a multi-core CPU (4 preferred, and 2.6+ GHz clock speed) are essential for fast 
computation; the processing can easily take days on a slower machine and will thus be 
unavailable for any other use during this time. GPU computing has not currently been 
optimized for RNAseq. Some desktop computers and laptop builds may be suitable for 
small-scale analysis but typically workstations or specialized computational facilities 
(available at many universities) are preferred. Analysis may be performed using 
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R/Bioconductor packages (https://www.bioconductor.org), specialized software with 
graphical interfaces (e.g. Galaxy - (Afgan et al., 2016)), programming and scripting 
languages (e.g. R, Matlab, Python, Ruby, Perl, Java etc.), and terminal commands on a 
UNIX-based operating system. Analysis and preprocessing is possible on Windows 
operating systems but may be difficult to set up because a number of bioinformatics tools 
have been developed for a terminal/command line interface that is not normally compatible 
with the Windows environment. A Linux setup is the most convenient for analysis but it is 
possible to set up some tools on Windows usage the Cygwin terminal.  
RNAseq preprocessing and analysis roughly falls into the following pipeline:  
(i) Process reads obtained from sequencer: The sequencer will return the 
sequencing data in the form of FASTA files. Illumina sequencers perform their own 
QC checks by default but to determine if the sequences need further processing, the 
files should be analyzed by a QC tool such as FastQC (Andrews, 2010), ShortRead 
(Morgan et al., 2009), or RNAseq specific tools RSeQC (DeLuca et al., 2012; Wang 
et al., 2012a) and RNA-SeQC. These tools return a series of graphs and metrics that 
can be used to evaluate whether or not any data cleaning is necessary. Each FASTA 
file lists sequences accompanied by a base quality score (Q score) indicating the 
probability of an incorrect base assignment for that position in the sequence. The 
average Q value can be detected using a QC tool. A good sequencing read will have 
a mean Q value over 30. However, many sequences will just have a drop in Q value 
toward the 3’ end of the sequence and may need trimming by a few bases if they 
are extremely poor quality. Although trimming reads might be necessary in some 
special cases, there has been recent work to suggest that overtrimming can affect 
differential gene expression estimates at later analysis stages (Williams et al., 
2016). Finally, the adapter sequence might need to be removed if it was detected  
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Table 1.2:  RNAseq preprocessing and analysis tools currently in common use 
Tool Type Tool Name Reference 
Quality Control 
FastQC (Andrews, 2010) 
RNA-SeQC (DeLuca et al., 2012) 
RSeQC (Wang et al., 2012a) 
ShortRead (Morgan et al., 2009) 
Trimming, Demultiplexing 
FASTX-Toolkit http://hannonlab.cshl.edu/fastx_toolkit 
Stacks (Catchen et al., 2011) 
Trimmomatic (Bolger et al., 2014) 
TrimGalore http://www.bioinformatics.babraham.ac.uk/projects/trim_galore/ 
General Aligners, Psuedoaligners, 
De novo Annotators 
Bowtie2 (Langmead and Salzberg, 2012) 
Kallisto (Bray et al., 2016) 
Novalign http://www.novocraft.com 
SOAP2 (Li et al., 2009b) 
STAR (Dobin et al., 2013) 
Tophat2 (Kim et al., 2013a) 
Post-Alignment Processing, QC, 
Counting, and Visualization 
htseq-count (Anders et al., 2013) 
IGV (Thorvaldsdottir et al., 2013) 
RNA-SeQC (DeLuca et al., 2012) 
RSeQC (Wang et al., 2012a) 
Rsubread (Liao et al., 2013) 
SAMtools (Li et al., 2009a) 
Differential Expression Analysis 
edgeR (Robinson et al., 2010) 
DESeq2 (Anders et al., 2013) 
baySeq (Hardcastle and Kelly, 2010) 
Cuffdiff2 (Trapnell et al., 2013) 
DEGseq (Wang et al., 2010a) 
EBSeq (Leng et al., 2013; Leng et al., 2015) 
voom (Law et al., 2014) 
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during sequencing. Trimming, filtering, and demultiplexing can be accomplished 
with the command line or a tool like the FASTX-Toolkit 
(http://hannonlab.cshl.edu/fastx_toolkit) or Stacks (Catchen et al., 2011). For a 
more thorough review of QC metrics see (Li et al., 2015)). 
 
(ii) Align reads to reference genome: Aligners generally fall into two basic 
categories - those that emphasize speed or those that emphasize sensitivity. Fast 
aligners include STAR (Dobin et al., 2013), Bowtie2 (Langmead and Salzberg, 
2012), and SOAP2 (Li et al., 2009b). More sensitive aligners include Novalign 
(http://www.novocraft.com) and SHRiMP2 (David et al., 2011). TopHat2 (Kim et 
al., 2013a), is one of the most widely used alignment tools though it has been 
replaced by HISAT (Kim et al., 2015) which is more accurate and faster. A step-
by-step guide to Tophat2 usage can be found in (Anders et al., 2013). For a 
comparative list of aligners see (Fonseca et al., 2012; Engstrom et al., 2013; 
Baruzzo et al., 2017). The output of aligned reads is usually stored in either SAM 
or BAM file formats which can be processed with SAMtools (Li et al., 2009a). The 
SAM format is a readable formatted file that can be examined visually. The BAM 
format is a compressed SAM file that can be processed much more quickly.  
 
(iii) Generate BAM statistics, visualize aligned reads:  At this stage, it is important 
to determine the percentage of mapped reads (generally greater than 75% for a 
successful alignment). Duplicate reads may be identified but the general consensus 
is that filtering out these reads can bias downstream DGE analysis. The percent of 
rRNA reads present is also an important metric. Theoretically, the rRNA removal 
step in library preparation should have removed it but this step is not 100% 
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efficient.  All of the above statistics can be generated either using SAMtools, 
RSeQC, or RNA-SeQC. The next step is visualization of the alignment. Although 
SAM files are readable, it is much easier to use a genome visualization tool to 
confirm the success and quality of the alignment. There are many tools available 
for this purpose such as IGV (Thorvaldsdottir et al., 2013). SAMtools can be used 
to convert SAM files into position/index-sorted BAM files so they can be 
visualized. Visualization should be used to confirm the success of the alignment 
such as correct mapping over the exon-exon junctions. As a final QC check, if 
certain transcripts are already known to have differential expression, the genome 
visualizer may be used to confirm that these expression differences are seen in the 
aligned RNA samples. 
 
(iv) Obtain raw read counts and normalize: Now that the RNA has been aligned to 
the genome, raw read counts can be generated for each transcript. HTSeq can be 
used for this purpose using the htseq-count tool (Anders et al., 2015). In the 
R/Bioconductor environment, the Genomic Features and Genomic Alignment 
packages can be used (Lawrence et al., 2013). Typically, the next stages of analysis 
will be the comparison of differentially expressed genes. The issue is that raw 
counts cannot be compared to each other, either within the same library or 
comparing samples between different libraries, without subsequent normalization. 
This is because of an inherent bias in the sequencing process that results from either 
the depth of sequencing or the length of a transcript. If two transcripts actually have 
equal expression but the second transcript was sequenced to a greater depth, the 
raw counts would indicate that the second transcript has a greater differential 
expression when in reality they are the same. If two transcripts have equal 
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expression but the second one is longer than the other, higher raw counts would 
also be reported when in reality the counts of both transcripts should be the same. 
To overcome this issue, a number of different normalization strategies have been 
developed (Dillies et al., 2013; Zyprych-Walczak et al., 2015; Lin et al., 2016). One 
of the first strategies employed to overcome this issue a normalization called 
RPKM - reads per kilobase transcript per million reads (Mortazavi et al., 2008). 
FPKM was introduced later for paired-end data and employs the same principle 
except that it accounts for the fact that two reads will be mapped to a fragment. 
RPKM is still the most widely used method despite the fact that it does not take 
into account transcript length resulting in a bias in the variance of gene expression 
estimates (Oshlack and Wakefield, 2009). RPKM and FPKM were later expanded 
to other methods that divide raw counts by either the median, quantiles (Law et al., 
2014), total counts, or upper quantile (see review cited above for a comparison). 
Two alternative methods employed by the R packages DESeq2 (Love et al., 2014) 
and edgeR (Robinson et al., 2010) take different approaches entirely based on the 
assumption that most genes are not differentially expressed. 
 
Downstream data analysis 
In order to compare normalized counts between different groups of genes the 
distribution of the data must be determined. Since counts from RNAseq data are discrete 
rather than continuous (even after a transformation) only specific distributions can be used 
to model the data. The negative binomial model is currently popular because it corrects for 
errors that result from modeling with the Poisson distribution and is used by both the 
DESeq2 and EdgeR packages. There are a number of other software options available for 
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DGE analysis that use different types of modeling and no clear consensus on what approach 
is the best (Rapaport et al., 2013; Soneson and Delorenzi, 2013; Seyednasrollah et al., 
2015). Sonenson and Delornzi have provided a detailed analysis of the different methods 
and their performance depending on the features of the data (sample size, degree of 
differential expression etc.). It would be prudent to choose the method of choice based on 
this information and even try a few different methods to see how different the generated 
differential expression values are for each gene. 
In addition to DGE analysis, there are a number of options available to further 
analyse the data. Here we briefly list a few approaches. After obtaining the list of protein 
and RNA, the data may be subjected to gene ontology (GO) clustering to find broad 
associations in the data. There are a number of GO clustering software available but 
DAVID is among the simplest to use (Huang da et al., 2009a; 2009b). Given a specific list 
of genes, DAVID will associate the data with specific gene ontologies in the hierarchy and 
cluster the most representative terms. The full GO ontology as well as smaller version are 
available. DAVID also includes annotation for pathways, protein domains, and protein 
interactions providing a convenient means get a broad representation of the data. GOseq is 
another alternative which takes into account the transcript length bias mentioned above 
(Young et al., 2010). 
Network analysis can be extremely helpful in visualizing complex data. Cytoscape 
and its associated plug-ins give the user a high amount of customization and flexibility to 
visual map connections between genes associated in different pathways, molecular 
interaction networks, and disease databases (Shannon et al., 2003). Some plugins also 
allow input of gene expression data as an extra visual dimension to the data. For example, 
the Enrichment Map plugin from the Bader Lab allows the user to take GO clustered data 
from DAVID and visualize it as a network. Enrichment Map helps to simplify data 
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produced by DAVID in a visual format for easier interpretation (Merico et al., 2010; 
Merico et al., 2011). This network-based approach is especially useful for modeling 
interaction networks of proteomics data and has been used to characterize molecular 
networks in synaptic plasticity (Pocklington et al., 2006). 
Clustering (K-means, hierarchical clustering etc.) is also used to classify gene 
expression data. Clustering will group a set of genes into categories based on the similarity 
of their expression levels. Used in tandem with a heatmap, expression changes can be 
visualized on a color scale while simultaneously grouped by similarity in expression level 
changes (D'Haeseleer, 2005). The Genesis software2 provides an easy way to perform 
various clustering methods. Many clustering strategies assume the data is normally 
distributed which is not usually the case for RNAseq data. One option is to apply a 
transformation to the data so that the counts are more normally distributed and then apply 
the method (Zwiener et al., 2014). Alternatively, there are a few methods that have been 
recently developed that apply clustering strategies to either Poisson or negative binomial 
distributions which much more closely approximate RNAseq data (Witten, 2011; Si et al., 
2014). Principal components analysis (PCA), support vector machines (SVM) and other 
tools for dimensionality reduction and classification analysis can also be applied to 
RNAseq data (Tan et al., 2014). 
 
COMBINED TRANSCRIPTOMICS AND PROTEOMICS 
The overall goal of RNA sequence identification and bioinformatics analysis on 
synaptic fractions is to determine how the synapse is remodeled under dynamic 
physiological and disease conditions. Since expression of proteins with coordinated 
                                                 
2 http://genome.tugraz.at/genesisclient/genesisclient_faq.shtml 
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functions can rapidly change the efficacy of a synapse, proteomics analysis is thus a critical 
counterpart to RNA sequencing experiments (Martin and Zukin, 2006; Zukin et al., 2009; 
Fernandez-Moya et al., 2014; Rosenberg et al., 2014). The increased sensitivity and 
accuracy of high-throughput methods have now made it feasible to conduct RNASeq 
studies and follow up by mass spectrometry. While the application of Omics to synaptic 
data is slowly growing (Collins et al., 2006; Fernandez et al., 2009; Geschwind and 
Konopka, 2009; Fritzsche et al., 2013; Ch'ng et al., 2015; Hussain and Bashir, 2015; Broek 
et al., 2016; Kenney et al., 2016; Loos et al., 2016; Niere et al., 2016) few studies 
combining multiple Omics have been performed in a synaptic context (Valor and Grant, 
2007; Kitchen et al., 2014). To date, combined approaches have been used to determine 
differences in neuronal cell types (Sharma et al., 2015), the effects of oxidative stress in 
synaptosomes (Flynn et al., 2012), the age-specific differences in brains of old and young 
rats (Ori et al., 2015), differences in stages of embryonic development (Hartl et al., 2008), 
cell type-specific proteins enriched in the brain over other tissues (Sjostedt et al., 2015), 
and the molecular dynamics of Rett Syndrome (Li et al., 2016). One of the most important 
findings from the combined omics approach is the confirmation that protein and RNA 
levels from the same tissue or single-cell do not always correlate (Maier et al., 2009; 
Olivares-Hernandez et al., 2011; Haider and Pal, 2013). Therefore, such an integrated 
approach will allow more accurate modeling of the dynamic molecular interplay that 
underlies synaptic function such as post-transcriptional regulation by non-coding RNA as 
well as proteomic regulation through post-translational modifications. In the next few 
sections, we review a number of possible assays to be used for isolating protein populations 
as well as de novo protein synthesis assays. 
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Isolation of proteins populations  
Proteins play a vital role in synaptic plasticity as they are part of the molecular 
substructure that underlies neuronal circuitry. Many events in local translation are mediated 
by proteins, particularly kinases, that are able to fine-tune the timing and specific 
expression of mRNAs through the regulation of ribosome and other localized events in the 
dendrite (Giese and Mizuno, 2013; Katche et al., 2013; Rosenberg et al., 2014; Santini et 
al., 2014). As many of these proteins interact with each other in specific ways to affect 
synaptic efficacy by altering the molecular composition of the dendritic spine, particularly 
in response to cellular signaling events at the postsynaptic membrane or nuclear signals, it 
is vital to understand these interactions in greater detail. Proteomic characterization of 
synaptic plasticity is ongoing and some recent studies have used system biology 
approaches to analyze the resulting data (Collins et al., 2006; Fernandez et al., 2009; Niere 
et al., 2016). In this section, we will consider a number of techniques that may be used to 
isolate protein populations before high-throughput analysis via mass spectrometry (Table 
1.3).  
 
Co-Immunoprecipitation (Co-IP) and pull-downs 
The Co-IP is a method for determining protein-protein interactions; while an 
immunoprecipitation (IP) is intended to isolate a single molecule of interest, a Co-IP is able 
to isolate the entire complex (”prey”) the protein of interest (”bait”) is bound to (Free et 
al., 2009). Thus, specific modifications must be made to the general IP procedure to ensure 
the bait and prey interaction is not lost during the procedure. Similar to the RIP procedure, 
the lysates are combined with an antibody specific to a protein of interest and a scaffold 
(usually a magnetic or agarose bead) which has affinity to the antibody. Collecting the 
bead-antibody-protein complex allows one to selectively isolate the protein from the lysate 
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attached to any other proteins that it was bound to in vivo. The protein bound to the protein 
of interest can then be collected. This procedure is easier to perform than RIPs as proteins 
are less prone to degradation than RNA. However, it is still limited by antibody availability 
and non-specific binding issues inherent to antibody-based methodology and other 
technical limitations (Markham et al., 2007). Pull-downs have the same goal as the Co-IP 
but do not use an antibody for the isolation of the bait and prey (Free et al., 2009). Instead, 
the bait protein is isolated either through a bioengineered molecular tag or through some 
kind of covalent attachment to the bead. Though this method does not require an antibody 
it is still limited by the ability to engineer and express the bait containing the tag in 
molecularly accessible position. Following isolation by either method, the samples can then 
be prepared for mass spectrometry analysis to identify the prey proteins. Recently, an 
alternative beads-free method has been developed in which protein are isolated in wells of 
a microplate coated in either protein A or G (Mikula et al., 2015). The authors note that 
this method allows multiple IP reactions to be performed simultaneously allowing better 
control of experiment variability, can be less costly than traditional IP methods, can be 
automated using robotics, and can be adapted to thermocyclers for protein denaturation 
steps. The drawback to these methods is that they fail to catch weak or transient protein-
protein interactions due to the stringent bead washing steps. This issue may be mitigated 
by formaldehyde crosslinking (see below). 
 
Labeling methods 
Label transfer protein interaction analysis utilizes a crosslinking reagent to join the 
bait and prey proteins. A new variation of this technique which does not rely on covalent  
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 Table 1.3: Summary of methods for identifying protein-protein interactions 




Single molecule (IP) or complex 
(Co-IP) 
Antibody-based, non-specific 
binding, difficult to detect 
proteins with low expression, 
cannot identify transient 
interactions 
(Markham et al., 2007; 
Sutherland et al., 2008; Free et 
al., 2009; Mikula et al., 2015) 
Pull-down 
Tag-based, does not require 
antibody 
Tag may be difficult to engineer 
and may alter protein function, 
difficult to detect proteins with 




Label transfer protein interaction 
Isolation of transient protein-
protein interactions, interaction 
within physiological context 
Difficult to balance dissociation 
timing with label transfer 
molecule; alternative approach 
in Liu et al. 2009 
(Liu et al., 2007) 
BioID 
Overcomes difficulties in Co-IP 
and pull-downs 
Best suited for culture work, 
fusion protein may interfere 
with protein interactions, biotin 
may alter properties of 
protein/interacting partners 
(Roux et al., 2012) 
Crosslinking 
methods 
Analysis of oligo(dT)-purified 
mRNPs 
Can observe dynamic changes in 
RNA-protein interactions 
Cannot identify non-Poly(A) 
proteins or microRNAs 
(Baltz et al., 2012) 
In vitro 
binding 
Modified phage display 
Compliment to other protein-
protein interactions methods 
Technically challenging, will 
pick up non-physiological 
interactions 
(Di Niro et al., 2010) 
RNA bait quantitative proteomics  
Compliment to other protein-
protein interactions methods, 
Will pick up non-physiological 
interactions 
(Butter et al., 2009) 
Size-exclusion quantitative 
proteomics 
Identify transient interactions, 
does not require any tags 
Will pick up non-physiological 
interactions 
(Kirkwood et al., 2013) 
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modification of the bait protein has also been developed (Liu et al., 2007). The crosslinker 
is labeled, for example, with biotin or a fluorescent marker.  Next, the crosslink is cleaved 
leaving the labeled end attached to the prey proteins. The biotin-labeled prey proteins can 
then be isolated and analyzed by mass spectrometry. A major advantage of this technique 
is its ability to isolate transient protein-protein interactions. Another approach called BioID 
utilizes a biotin-ligase-fused bait protein to isolate interacting prey proteins in vivo after 
adding biotin to cell culture media (Roux et al., 2012). The biotin-ligase is then able to add 
biotin to lysine residues on neighboring proteins which can then be isolated and analyzed 
by mass spectrometry. This technique is best suited for cell culture work rather than tissue. 
 
Crosslinking methods 
Crosslinking approaches are now common in high-throughput RNP isolation 
techniques. However, this approach is also adaptable to the study of protein-protein 
interactions. Crosslinking methods can also be applied to Co-IPs though this technique has 
not yet been fully optimized or tested (Sutherland et al., 2008). The analysis of oligo(dT)-
purified mRNA ribonucleoproteins (mRNPs) method combines a protein and RNA 
approach to allow for the identification of RNPs as well as the mRNAs they are bound to. 
First, RNA is labeled with photoreactive nucleoside analogs of uridine and guanosine, 
allowing selective identification of RNA over DNA and increased crosslinking efficiency. 
Next, the protein-RNA complexes are crosslinked and oligo(dT)s are affinity purified and 
the protein and RNA can then be separately identified by mass spectrometry and RNA 
sequencing respectively (Baltz et al., 2012). Though application of this technique will be 
useful for the study of mRNPs, it will miss nonpolyadeylated RNAs such as microRNAs 
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whose importance in learning and memory is very recently being understood (Wang et al., 
2012b).  
 
In vitro binding methods to determine protein-protein or RNA-protein interactions 
An alternative strategy for discovering protein-protein interactions was developed 
by Sblaterro and colleagues that utilizes phage display, an in vitro method similar to yeast 
two hybrid (Di Niro et al., 2010). First, polyadenylated RNA is fragmented and reverse 
transcribed into cDNA. Next, the cDNA is cloned into bacteria and an ampicillin-based 
selection method is used to remove nonfunctional clones that do not encode ORFs. The 
vectors are ligated into a bacteriophage minor coat protein gene allowing the phage to 
“display” the protein on its outer surface. Now, a purified protein of interest can be 
introduced to see if they can bind to any of the proteins displayed by the phages. The cDNA 
from the phages recovered from this process is then sequenced to determine which phage-
displayed proteins interacted with the protein of interest. Additionally, an interesting 
technique has been developed that allows for the identification of putative RBPs (Butter et 
al., 2009). This technique works in reverse of a RIP, instead using the RNA as the bait to 
determine potential RBP binding partners. An RNA bait sequence of interest is coupled to 
an S1 aptamer. These labeled RNA fragments are then introduced to a cell population. 
RNA-protein complexes are then pulled-down and analyzed by quantitative mass 
spectrometry. This procedure is a powerful technique to complement RNA-based 
procedures. Lastly, a size-exclusion chromatography approach combined with quantitative 
proteomics useful for predicting protein-protein interactions (Kirkwood et al., 2013). First 
lysates are sonicated in PBS followed by size-exclusion chromatography which separates 
on the basis of both size and shape while maintaining cellular protein-protein interactions. 
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This results in 40 different fractions where the larger fractions represent larger interacting 
protein complexes down to the smallest fractions which have less interacting partners. The 
fractions are then evaluated by mass spectrometry to determine interacting partners of 
every protein in the lysate. Each protein will have a specific elution profile across all the 
fractions to demonstrate fraction behavior for each protein. Proteins showing similar 
coincidence in their elution profile for different fractions are thus considered to be 
associated. Like many in vitro-based methods, these techniques may capture some 
interactions that do not occur in vivo. Nevertheless, it may serve as a useful tool for filtering 
false positives in other techniques and determining possible interaction partners for a 
protein for further study. The size-exclusion and quantitative analysis approach may be 
especially useful as a validation tool for Co-IPs which have a tendency to pick up non-
physiological interactions. Such approaches may be able to filter out these cases by 
demonstrating that such interactions are unlikely to occur in biological systems. 
 
De novo protein synthesis assays 
The separation of established protein from de novo protein synthesis has been 
challenging. Methods such as BONCAT (bioorthogonal non-canonical amino acid tagging) 
were recently developed as a means of selectively isolating newly synthesized proteins 
from a larger population (Dieterich et al., 2006; Dieterich et al., 2007). Utilizing click 
chemistry, newly-synthesized proteins incorporate a non-canonical amino acid using the 
cell’s own translational machinery which can be conjugated to biotin. One of the great 
advantages of this method is that endogenous proteins are labeled as opposed to introducing 
exogenous reporter proteins. These proteins can then be isolated from the rest of the 
population using affinity chromatography and analyzed by mass spectrometry. Instead of 
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non-canonical amino acids, SILAC (stable isotope labeling by amino acids in cell culture) 
uses heavy or light isotopes of arginine and lysine (Ong et al., 2002). One population of 
cell culture will be grown with media containing the heavy isotope and a second population 
will use the light isotope. The proteins from both populations are then combined and 
analyzed by mass spectrometry. A protein of interest can then be compared between the 
two different cell cultures – one will be heavier due to incorporation of the heavy isotope 
and its abundance levels can be compared to the same protein in the other cell culture thus 
demonstrating a change in expression between two cellular conditions.  
Though both BONCAT and SILAC address different kinds of questions, there have 
been a number of recent developments of SILAC such as pulsed SILAC (pSILAC) that 
allows for the determination of newly synthesized proteins (Chen et al., 2015). There have 
also been a few recent attempts to combine BONCAT and SILAC together (Genheden et 
al., 2015; Kenney et al., 2016). Kenny et al. applied this technique to cell culture by first 
introducing medium or heavy arginine to the cells (SILAC) followed by the addition of a 
non-canonical amino acid to isolate newly synthesized proteins (BONCAT)(Kenney et al., 
2016). This combined approach allowed for the comparison of specific newly synthesized 
proteins rather than the entire population. Furthermore, another approach called BONLAC 
combines the two methods and optimizes BONCAT conditions so that it may be performed 
in intact brain slices (Bowling et al., 2016). In addition to labeling with a non-canonical 
amino acid (AHA, a methionine analog) as in BONCAT, Bowling et al., also labelled with 
medium or heavy arginine thus allowing them to selectively isolate de novo synthesized 
proteins within a short time window. An in vivo BONCAT approach was also developed 
by Liu and Cline which allowed them to assess the effect of an FMRP knockdown on 
protein synthesis-dependent behavioral plasticity in the Xenopus visual system (Liu and 
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Cline, 2016). The evolution of this method has greatly expanded our knowledge as it now 
allows the detection of activity-dependent de novo protein synthesis in vivo. 
 
FROM STATISTICAL MODELS TO SCIENTIFIC MODELS: EXPERIMENTAL VALIDATION AND 
VISUALIZATION OF IDENTIFIED PROTEINS AND RNA 
One of the greatest advantages of performing unbiased screens such as RNAseq 
and mass spectrometry is the identification of novel interactions between mRNAs and/or 
proteins. The wealth of data generated from such high-throughput experiments can be used 
to build general models to guide the direction of future scientific research. For example, 
constructing protein-protein interaction (PPI) networks from proteomics data can be used 
to guide experimental research leading to new target identification in animal models of 
disease (for further explanation of PPI network construction and analysis see (Raman, 
2010)). For example, this technique was recently used by Niere et al., with the reasoning 
that many individuals who have neurological disorders with dysregulated protein synthesis 
due to overactive mTOR signaling also suffer from epilepsy (Crino, 2008; Pun et al., 2012; 
Brewster et al., 2013; Wong, 2014; Sosanya et al., 2015b; Niere et al., 2016). To identify 
common proteins associated with epilepsy, Alzheimer’s disease, and Autism Spectrum 
Disorders, all disorders with overactive mTOR signaling, a PPI network was established 
that identified 5 “hub proteins” based on its high level of connectivity with other proteins 
in the network. One hub protein was Parkinson Protein 7 (Park7 or DJ-1), a protein that 
has many functions but most recently has been identified as an RBP (van der Brug et al., 
2008).  Importantly, the investigators went on to show that Park7 protein synthesis was 
regulated by mTOR and that it is overexpressed at synapses in a mouse model of Tuberous 
Sclerosis Complex, a form of ASD with overactive mTOR. Below we review techniques 
that may be used to visualize the localization and relative quantity of protein and/or RNA 
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to validate models generated from high-throughput methodologies (Table 1.4, Figure 1.5). 
While most of these techniques suffer from the single protein/RNA approach, they do 
provide a powerful means of validating findings that may lead to new target identification 
of diseases with dysregulated protein synthesis. 
 
Visualization and quantification of RNA localization 
In situ hybridization 
The first requirement for a protein to be synthesized in dendrites is that the mRNA 
coding for that protein is either targeted to the dendrites in response to activity or 
constitutively resides in dendrites. Some of the earliest work in this field utilized various 
methods such as in situ hybridization (ISH) and microarrays in conjunction with 
subcellular fractionation to catalog the RNAs present at the dendrite. One of the greatest 
advantages ISH is that it does not rely on subcellular fractionation – the transcript can be 
identified in fully intact tissue or cell culture. Thus, ISH and its related methods are very 
useful for confirming results obtained from subcellular fraction preparations. ISH has been 
used to characterize the localization and distribution of the RNA transcripts for the 
calcium/calmodulin-dependent protein kinase II alpha (CaMKII), microtubule-associated 
protein 2 (MAP2) and fragile X mental retardation protein (FMRP), some of the earliest 
localized transcripts discovered in the field (Hinds et al., 1993; Paradies and Steward, 1997; 
Miyashiro et al., 2003). The development of fluorescence in situ hybridization (FISH) has 
allowed researchers to visualize distribution patterns and quantify the amount of 
localization at a much higher resolution. There have been significant technical 
improvements made to FISH over the years which provide greater resolution and better 
quantification (Swanger et al., 2011). The best example of how technical improvements in
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 Table 1.4: Visualization and detection techniques for RNA and protein downsream of high-throughput experiments 
Detection of a reporter or 
endogenous RNA/protein 
Technique Detection Chemistry Detection Type Selected References 
Endogenous (RNA) 
(F)ISH 
Hybridization probe; fluorescent 
antibody 
RNA localization 
(Lecuyer et al., 2007; Swanger et al., 
2011; Cajigas et al., 2012) 
Single RNA tracking Fluorescent dyes RNA localization and translation (Katz et al., 2016) 
qRT-PCR Fluorescent DNA intercolator Relative RNA quantitation (Raymaekers et al., 2009) 
NanoString Hybridization probe Relative RNA quantitation 
(Kulkarni, 2011; Cajigas et al., 
2012) 
Endogenous (Protein) 
BONCAT Biotin De novo synthesis 
(Dieterich et al., 2006; Dieterich et 
al., 2007) 
SILAC 
Heavy/light chain amino acid 
isotopes 
De novo synthesis (Ong et al., 2002) 
BONLAC 
Biotin + heavy/light chain amino 
acid isotopes 
De novo synthesis (Bowling et al., 2016) 
FUNCAT Biotin, fluorescent antibodies De novo synthesis 
(Dieterich et al., 2010; Tom Dieck et 
al., 2012; Kos et al., 2016; Liu and 
Cline, 2016) 
BONCAT/FUNCAT-PLA Biotin, fluorescent antibodies De novo synthesis 
(tom Dieck et al., 2015; Workman et 
al., 2015; Niere et al., 2016) 
SUnSET Fluorescent antibody De novo synthesis 
(Schmidt et al., 2009; Batista et al., 
2016) 
Reporter construct (Protein) 
Destabilized GFP (dGFP) 
Fluorescent protein (fusion 
construct) 
De novo localized synthesis (Li et al., 1998; Aakalu et al., 2001) 
Kaede 
Photoactivatible GFP-like 
fluorescent protein (PAFPs) 
De novo localized synthesis 
(Ando et al., 2002; Lukyanov et al., 
2005; Raab-Graham et al., 2006; 
Workman et al., 2015) 
Dendra2 
Photoactivatible GFP-like 
fluorescent protein (PAFPs) 
De novo localized synthesis 
(Gurskaya et al., 2006; Chudakov et 
al., 2007; Wang et al., 2009; Lee et 
al., 2011) 
Venus fluorescent reporter 
Fluorescent protein (fusion 
construct) 
De novo localized synthesis 
(Tatavarty et al., 2012; Ifrim et al., 
2015) 
Biarsenical probes (FlAsH, ReAsH) Fluorescent dyes De novo localized synthesis 
(Ju et al., 2004; Martin et al., 2005; 
Rodriguez et al., 2006) 
TimeSTAMP Epitope tag De novo localized synthesis 
(Lin et al., 2008; Lin and Tsien, 
2010) 
MiniSOG 
Fluorescent protein (fusion 
construct) 
De novo localized synthesis (Shu et al., 2011) 
Luciferase Flash Kinetics Luciferase (fusion construct) De novo localized synthesis (Na et al., 2016) 
SINAPS 
Fluorescent protein (fusion 
construct) 
Real-time translation dynamics (Wu et al., 2016) 
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FISH have changed dogma was first described by Krause and colleagues using mRNA 
localization in the Drosophila embryo as a model. Prior to this study the estimated number 
of mRNAs that had distinct subcellular localizations in the embryo was ~1 -10%.  Lecuyer 
et al., screened roughly 25% of the genome and found ~ 71% of mRNAs screened had 
unique subcellular distribution patterns. The authors went on to suggest that since most of 
the transcribed mRNAs have a distinct subcellular localization these data imply that most 
cellular processes are mediated through mRNA localization (Lecuyer et al., 2007). 
Importantly, a similar finding was suggested by Schuman and colleagues in neuronal 
dendrites. They also employed FISH to verify high-throughput RNA sequencing data 
(Cajigas et al., 2012). Herein they identified 8,379 transcripts. By subtracting transcripts 
related to glial cells, interneurons, nuclei, blood vessels, and mitochondria, they suggest 
that 2,550 transcripts are localized in axons or dendrites. High-sensitivity FISH was then 
used to validate the localization of 50 of these transcripts. This work identified many 
known synaptic transcripts as well as newly discovered transcripts that had not been 
previously detected. In light of these findings synapse remodeling of synapses during 
synaptic plasticity is due to dendritic over somatic mRNA translation (Cajigas et al., 2012).  
Finally, the a more recently modification to FISH allows for the visualization of single 
RNA molecules at high resolution. Singer and colleagues have developed a method that 
allows the tracking of single RNA molecules during translation. Thus, the researchers 
labeled ribosomes and mRNA molecules and correlated their signals to determine if the 
mRNA was undergoing active translation (Katz et al., 2016). Thus, collectively RNA 
sequencing data combined with high resolution FISH, for the first time, is allowing 
investigators to catalog mRNAs localized to site specific dendritic compartments leading 
to new testable hypothesis regarding memory allocation for information storage. 
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Quantification of mRNA 
While FISH by itself provides subcellular localization of specific mRNAs, 
quantification of mRNAs in the soma versus dendritic compartments has been challenging. 
The development of the NanoString nCounter Gene Expression Assay has helped resolve 
that issue (Kulkarni, 2011). NanoString enables the detection and quantification of up to 
800 mRNA molecules (without any conversion to cDNA or PCR amplification) using 
colored probe pairs. Cajigas et al. used NanoString technology to answer the long-standing 
question of whether select mRNAs segregate, with some enriched in the soma and some 
enriched in dendrites and axons (Cajigas et al., 2012). While this finding had been 
suggested by quantitative RT-PCR comparing hippocampal synaptosomal mRNA to total 
lysate mRNA (Raab-Graham et al., 2006) the concern of somatic contamination in the 
synaptosomal fraction tempered the interpretation of this finding. Still, in cases when 
mRNA levels are low-abundance or quick validation is a necessity, qRT-PCR is remains a 
valid method for confirming RNAseq or microarray data, or quantifying relative abundance 
levels of a specific transcript between samples (Raymaekers et al., 2009). 
 
Visualization of protein localization and new translation 
SUnSET, FUNCAT, and FUNCAT/BONCAT-PLA 
Labeling newly synthesized proteins has been used to validate high-throughput 
studies investigating local translation (Buxbaum et al., 2015a; Buxbaum et al., 2015b). 
Since many of these techniques rely on fluorescent microscopy, it is possible to visualize 
and distinguish new and old proteins within a particular neuronal compartment. Surface 
sensing of translation (SUnSET) utilizes puromycin, a ribosome elongation inhibitor and 
aminoacyl-tRNA synthetase analog, to monitor the translation of de novo protein synthesis 
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(Schmidt et al., 2009). SUnSET uses monoclonal antibodies to detect the incorporation of 
puromycin into the polypeptide chain during translation. Subsequent detection and 
visualization by either flow cytometry or fluorescent microscopy thus indicates new protein 
synthesis. 
Single-molecule imaging of nascent peptides (SINAPS) is another alternative 
approach for monitoring localized transcripts in vivo which allows one to observe the real-
time translation of nascent mRNA molecules at different translational stages (Wu et al., 
2016). In order to strengthen the relatively weak signal of the nascent peptide and to 
distinguish it from background, SINAPS draws upon SunTag, another recent method that 
allows for the amplification of fluorescent intensity by recruiting multiple copies of GFP 
to a target protein (Tanenbaum et al., 2014).  
The FUNCAT (fluorescent non-canonical amino acid tagging) assay is similar to 
the BONCAT technique described earlier which labels newly synthesized proteins using 
noncanonical amino acids and click chemistry to conjugate biotin. FUNCAT, however, 
uses fluorescently-tagged amino acids to allow for the identification of newly synthesized 
proteins in situ by fluorescence microscopy (Dieterich et al., 2010; Tom Dieck et al., 2012; 
Kos et al., 2016). The drawback to FUNCAT is the fact that while it can identify whole 
populations of de novo synthesized proteins, it cannot identify specific ones. To overcome 
this difficulty, a modification was developed using a proximity ligation assay (PLA). The 
use of FUNCAT in tandem with PLA allows for the identification of a newly synthesized 
protein of interest (tom Dieck et al., 2015). FUNCAT-PLA – also called BONCAT-PLA 
in (Niere et al., 2016) – utilizes a biotin antibody to identify a protein of interest that has 
incorporated a non-canonical amino acid, signifying new protein synthesis. Another 
antibody is used to identify the protein of interest itself. When the secondary antibodies 















Figure 1.5: Workflow for experimental follow-up 
Following the completion of high-throughput methodologies, researchers can perform a variety of 
different types of experiments to follow-up predictions seen in the data. Representative assays are 
depicted in cartoon form (A.-D., left panel) and alternative approaches (A.-D., right panel) or 
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in close enough proximity, they are ligated together and undergo rolling circle replication 
in the presence of fluorescent nucleotides to produce a signal. Alternatively, the Puro-PLA 
assay utilizes puromycin, a molecule that disrupts translation resulting in the release of the 
newly-synthesized protein which can then be identified with an anti-puromycin antibody 
(Buhr et al., 2015; tom Dieck et al., 2015).  
Recently, FUNCAT/BONCAT-PLA has been used to assess the role of mTOR 
complex 1 (mTORC1) in synapse modification in vivo. mTORC1 is a protein complex that 
regulates local dendritic translation (Tang et al., 2002; Cammalleri et al., 2003; Stoica et 
al., 2011). In a recent study, Niere et al. performed mass spectrometry on different 
subcellular fractions of neurons derived from rat cortices after an intraperitoneal injection 
with rapamycin, an inhibitor of mTORC1. Notably, the mass spectrometry reports changes 













references can be found in Table 1.4 or the text. A. RNA detection and visualization using 
fluorescence in situ hybridization (FISH) in neurons. An RNA probe complementary to an RNA 
of interest is designed. A fluorescent tag is added to the probe for detection downstream. The 
probe is introduced to a neuron population. Once the RNA enters the neuron, it binds to the RNA 
of interest. Cells can then be fixed and visualized by fluorescence microscopy to visualize the 
location of the RNA within a tissue or cell culture system. B. Detection of endogenous proteins 
using bioorthogonal non-canonical amino acid tagging (BONCAT). An azide-labeled non-
canonical amino acid is introduced to a cell population. During translation, this amino acid is 
conjugated to alkyne-modified biotin using click chemistry, thus tagging a newly-synthesized 
protein. Affinity chromatography is used to isolate these biotin-labeled de novo synthesized 
proteins from the greater protein population. The isolated proteins can be identified using mass 
spectrometry. C. The photoconvertible fluorescent protein Kaede can be used to visualize local 
translation/new protein synthesis of a protein of interest. A vector containing Kaede-cDNA is 
introduced to a cell culture population. Prior to photoconversion, Kaede fluoresces green revealing 
the current population of a protein of interest. After application of UV light, Kaede fluoresces red. 
Any further green signal that appears later is indicative of new translation of the protein of interest. 
D. Options for non-chemical tag-based detection include time-specific tagging for the age 
measurement of proteins (TimeSTAMP). A fusion construct is generated between the protein of 
interest and an epitope tag flanked by a cassette for the hepatitis C virus protease. After translation, 
the protease cleaves itself and the epitope tag away from the protein of interest. The protease 
inhibitor BILN-2061 may be added to the cells at any time to inhibit the proteolytic cleavage. 
Thus, the protein of interest can retain its tag. Using this system, researchers can separate new and 
old protein synthesis after a specific time point.   
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stability. To differentiate between these two cellular mechanisms, they used 
FUNCAT/BONCAT-PLA to determine if new protein synthesis of select candidates 
identified by mass spectrometry (Niere et al., 2016). Indeed, FUNCAT/BONCAT-PLA 
demonstrated that new protein synthesis levels of Snap25 and Gap43 altered in response to 
treatment with the mTOR inhibitor rapamycin, and were consistent with the observed 
changes in protein expression indicated by mass spectrometry. Thus, new protein assays 
such as FUNCAT/BONCAT-PLA can detect new protein synthesis, providing mechanistic 
detail that mass spectrometry hints at but does not confirm. 
 
Destabilized GFP (dGFP) 
While FUNCAT/BONCAT-PLA is useful to detect new protein synthesis it does 
not provide direct evidence for new protein synthesis in dendrites. For this reason, 
fluorescent translation reporters fused to dendritic targeting sequences of the proteins of 
interest still remains the best way to visualize new protein synthesis in dendrites. This 
approach was first developed by Schuman and colleagues (Aakalu et al., 2001). 
Destabilized-GFP (dGFP) was developed to address experiments that required a 
fluorescent reporter for proteins with transient expression (Li et al., 1998). Schuman and 
colleagues capitalized on the rapid turnover properties of dGFP and created a reporter 
consisting of cDNA coding for a myristoylated dGFP fused between the 5’ and 3’UTRs of 
CaMKIIα mRNA. They reasoned that the inclusion of the UTR sequences in their reporter 
construct would ensure that the mRNA targets the dendrite, the addition of a myristoylation 
sequence (myr) tethers the reporter to the membrane and thus prevents diffusion, and after 
photobleaching the neuron, new GFP signal detected in the dendrite is due to mRNA 
translation. To ensure this was the case, they continuously photobleached the soma so that 
any new protein synthesized in the soma would not be detected in the dendrites. One caveat 
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that may hinder this assay is if the protein dGFP is fused to has a higher stability than 
dGFP, thus preventing the rapid turnover of GFP. In spite of this limitation, myrdGFP 
fused to the appropriate targeting sequences can be used to investigate compartment-
specific translation (Aakalu et al., 2001). 
 
Kaede, Dendra2, Venus, and Biarsenical probes 
An alternative approach is the usage of photoactivatable GFP-like fluorescent 
proteins (PAFPs) (Lukyanov et al., 2005) which overcomes the limitation of variability in 
mRNA stability. Kaede is a protein that allows the separation of new and old translation 
on the basis of UV-induced photoconversion (Ando et al., 2002). Kaede can be fused to 
specific proteins with the appropriate dendritic targeting sequences and used to report new 
translation by comparing mean puncta intensity before and after photoconversion (Leung 
et al., 2006; Raab-Graham et al., 2006; Leung and Holt, 2008; Banerjee et al., 2009; 
Workman et al., 2015). Kaede’s tetrameric structure has a distinct advantage when it comes 
to the tagging of ion channels which are typically tetramers (Raab-Graham et al., 2006). 
For example, Kaede has been used to monitor the local translation of Kv1.1, an ion channel 
whose translation is regulated by a microRNA, demonstrating its use and application as a 
detector of new protein synthesis (Sosanya et al., 2013). The Dendra2 reporter is another 
photoconvertible fusion protein that functions similarly to Kaede (Gurskaya et al., 2006; 
Chudakov et al., 2007; Wang et al., 2009; Lee et al., 2011). Dendra2 has a monomeric 
structure which increases functional capabilities since it can be used in protein fusion 
constructs. For example, Wang and colleagues fused the Dendra2 coding sequence to the 
5’ and 3’UTRs of sensorin mRNA to study local translation at the sensory neuron-motor 
neuron junction of an Aplysia cell culture system (Wang et al., 2009). Sensorin is a peptide 
neurotransmitter whose UTR sequences drive the mRNA to be concentrated at synapses, 
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thus allowing the researchers to visualize local translation specifically at the synapse. One 
advantage of using Dendra2 over Kaede and other similar PAFPs is that it is activated in 
the 488-nm laser range, well clear of the UV-activation range and thus allowing less chance 
of cellular toxicity. The Venus fluorescent reporter has recently been adapted to visualize 
the activity-dependent dendritic localization of PSD-95 (Tatavarty et al., 2012; Ifrim et al., 
2015). Ifrim et al. developed a unique fusion construct in which the Venus reporter was 
inserted after the 5’UTR of the PSD95 mRNA sequence. Used in this way, the Venus 
reporter (1) fluoresces just prior to and during translation of the PSD95 open reading frame 
in real-time and (2) visualizes de novo protein synthesis of PSD95 specifically in the 
dendritic spine (Ifrim et al., 2015). Finally, another approach to monitoring local translation 
is the use of biarsenical fluorescent dyes such as FlAsH and ReAsH (Ju et al., 2004; Martin 
et al., 2005; Rodriguez et al., 2006). 
 
TimeSTAMP, Luciferase flash kinetics and, MiniSOG 
TimeSTAMP is another method that can be used to monitor new protein synthesis 
that does not rely on either photoconversion or chemical tags (Lin et al., 2008; Lin and 
Tsien, 2010). An epitope tag is attached to a protein of interest which can be removed in 
the presence of a specific protease. Introduction of a drug prevents this process from 
occurring thus allowing newly synthesized proteins to retain their tags. TimeSTAMP 
allows the surveying of the whole brain in living animals.  
Recently, a luciferase-based approach that utilizes flash kinetics has also been 
developed (Na et al., 2016). This approach uses a small luciferase protein derived from G. 
princeps whose signal is dependent on the presence of coelenteraizine. Luciferase is fused 
to the protein of interest so that, upon translation, luciferase will react with coelenteraizine 
to produce a light signal. The signal decays rapidly (< 9s for the tested Arc-luciferase 
 61 
construct) so translating RNAs can be unambiguously detected even if coelenteraizine is 
still present. Thus, flashes of light signal indicate de novo protein synthesis of the protein 
of interest. Importantly, this technique utilizes wide-field microscopy, whereas other 
reporter systems usually require confocal or 2-photon imaging to detect signals above 
photobleaching (Na et al., 2016), making this assay accessible to a greater number of labs. 
Moreover, the authors who developed this assay suggest that estimation of the number of 
proteins synthesized in a local translation hot spot is within reach if combined with 
SUnSET; however, this is yet to be verified. 
There are a growing number of electron microscopy (EM) studies detecting 
polyribosomes near spine bases that relocate in the spine head upon memory consolidation 
(Ostroff et al., 2010; Ostroff et al., 2014; Ostroff et al., 2017). However, new protein 
detection at the EM level has been difficult due to a lack of electron dense tags useful for 
specific protein visualization. Shu et al. has developed a small fluorescent protein, 
MiniSOG (mini singlet oxygen generator), that can be fused to a protein of interest and 
expressed in cells, tissue, and living organisms and detected both at the light level and by 
EM (Shu et al., 2011). Fluorescence photooxidation of DAB can be achieved using 
fluorescence and 1O2 from MiniSOG. It’s been suggested that spatiotemporal control of 
local photogeneration of 1O2 will rapidly inactivate proteins of interest (Shu et al., 2011), 
perhaps allowing one to detect site specific translation at the light and subsequently at the 
EM level. Although, techniques like miniSOG hold promise, detection of specific 
translation at the EM level is still lacking.  
 
Ensuring that synthesis of the protein of interest occurs in dendrites and not the soma 
An additional requirement for local protein synthesis assays is to demonstrate that 
the synthesis occurs in the dendrites and not in the soma. In a perfect world, researchers 
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would sever dendrites and test for the appearance of newly synthesized proteins within 
isolated dendritic compartments. While Martin et al., have successfully demonstrated local 
synthesis in processes in the absence of a soma in cultured Aplysia neurons, it has proven 
far more difficult in mammalian neurons (Martin et al., 1997). Several labs have introduced 
microlesions to separate the dendrite and the soma in acute hippocampal slices (Kang and 
Schuman, 1996; Ouyang et al., 1999; Waung et al., 2008). Kang and Schuman used this 
approach to show the local synthesis of BDNF occurred in the dendrites with BDNF-
mediated potentiation (Kang and Schuman, 1996). While this approach appears optimal, it 
does have its caveats. We have noted that severing dendrites in this way can induce local 
protein synthesis of some proteins, often confounding the results when assessing activity-
dependent local protein synthesis (unpublished observation). Thus, methods have evolved 
that have adapted time-lapse imaging of fluorescent proteins fused to specific dendritic 
targeting sequences to measure de novo protein synthesis. Such measures as continuously 
photobleaching the soma have been used to avoid signal from the soma confounding 
dendritically translated fluorescent proteins (Aakalu et al., 2001). While a significant 
improvement over previous methods, continuous photobleaching can be toxic to the cell.  
The use of photoactivated fluorescent reporters, such as Kaede, does not require 
constant photoconversion, in most cases, to specifically detect protein synthesis in 
dendrites. However, these experiments require careful controls to be able to draw this 
conclusion. As observed by many laboratories, locally synthesized protein synthesis occurs 
in hot spots of the dendrites (Aakalu et al., 2001; Job and Eberwine, 2001; Kim et al., 
2013b; Sosanya et al., 2015b). Therefore, measuring the rate of diffusion of the protein of 
interest by photoconverting part of the dendrite and measuring diffusion over time (i.e. 
does the photoconverted protein diffuse into the unconverted dendrite) allows one to 
measure diffusion rates. For example, Raab-Graham and colleagues used such an approach 
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by fusing Kaede to the mRNA of Kv1.1 plus its 3’UTR. It was found that Kaede-Kv1.1 
did not diffuse, and stayed localized to hot spots within the dendrite (Raab-Graham et al., 
2006). Thus, proteins presumably function close to the site of synthesis and are easily 
detected in dendrites when fused to photoactivatable proteins. 
Additional approaches include only activating specific synapses and measuring the 
increase in protein expression within the activated part of the dendrite. For example, Huber 
and colleagues measured Arc expression after local perfusion of the mGluR agonist DHPG 
in distal dendrites (Waung et al., 2008). This technique relies on the fact that Arc expression 
occurred only in the region of mGluR activation and that protein made in the soma cannot 
traffic to the distal dendrites within the limited time that new Arc protein expression was 
detected.  
Finally, one of the more thorough experimental approaches that allows one to test 
for function of dendritically localized mRNAs is the generation of a mouse where the 
dendritic targeting sequence of the protein of interest is knocked out. Mayford and 
colleagues created a specific knockout deleting only the dendritic targeting sequence in the 
3’UTR of CaMKIIα. Importantly, ISH demonstrated that CaMKIIα mRNA was absent 
from the dendritic fields while still present in the soma of the CA1 hippocampal neurons 
in the knockout mouse relative to the wildtype litter mate. Moreover, knockout mice 
showed deficits in late long-term potentiation (L-LTP), a cellular model for learning and 
memory and at the behavioral level during a memory consolidation test (Miller et al., 
2002). While these data are impressive and striking, recent data suggesting that RNA-
binding proteins that compete for mRNAs may confound the interpretation of these results 
(Sosanya et al., 2013). The removal of a dendritic targeting sequence within the 3’UTR 
containing RBP motifs could possibly free up RBPs to bind to lower affinity target mRNAs 
which may affect synaptic plasticity and/or behavior. Still, with the development of tools 
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like CRISPR, where making knockouts are quicker and more cost effective, site-specific 
knockout of proteins will facilitate the physiological relevance of localized translation of 
specific targets. 
HOW HIGH THROUGHPUT ASSAYS MAY ANSWER LONG-STANDING QUESTIONS IN THE 
FIELD OF LEARNING AND MEMORY BY IDENTIFYING NOVEL PROTEINS INVOLVED IN 
SYNAPTIC PLASTICITY  
The usage of high-throughput experiments has the potential to point researchers 
into new directions to answer many long-standing questions in the field of learning and 
memory. As mentioned above, Niere et al., recently showed that 75% of the PSD changes 
in protein expression within an hour of mTOR inhibition in vivo (Niere et al., 2016). 
Although this data represents the overall population of dynamic protein changes, individual 
proteins from this data can be assayed to determine site-specific localization of their 
mRNAs or local synthesis. Moreover, predictions can be made to identify putative 
translation regulatory factors such as microRNAs and RBPs based on their mRNA 
sequences. Figure 1.6 outlines a few recent publications that address important questions 
in neuroscience. Here we provide examples of how others address these questions to assist 
in RNAseq and proteomic follow up studies.  
 
Synaptic tagging and capture 
The synaptic tagging and capture hypothesis (Frey and Morris, 1997; Redondo and 
Morris, 2011) proposes that synapses undergoing long-term changes to synaptic efficacy 
are somehow “tagged” in a way that allows localized proteins in one synapse to be 
“captured” from a protein pool to activate nearby synapses. Sosanya et al. has shown that 
mTOR may serve as one such tag (Sosanya et al., 2015b). They demonstrated that dendritic 
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Figure 1.6: Approaches to functional validation of high-throughput experiments 
A. Example of characterization of locally translated mRNAs involved in synaptic tagging and 
capture hypothesis. RNA sequencing of RNA-binding protein targets may show site specific 
expression based on the localized trafficking of the RNA-binding protein. (Top) For example, HuD 
target CaMKIIα mRNA selectively targets one dendritic branch over the other requiring HuD 
binding, as identified by the translational reporter construct where the coding sequence of dEGFP 
is fused to the 3’UTR of CaMKIIα mRNA. Deletion of the HuD binding site in the 3’UTR prevents 
CaMKIIα from entering into the branches and accumulates at the branch point as indicated in the 
branches pseudo-colored as a measure of intensity. Figure from Sosanya et al., 2015. (Bottom) 
From these data the working model of HuD’s role in the synaptic tagging and capture hypothesis 
is illustrated. Panels represent different states of a neuron and dendritic branch point. Protrusions 
from top branches indicate dendritic spines. Green shapes adjacent to the spines represent 
presynaptic neurons. Dendritic spines of interest (red) are shown in further detail below each image 
of the neuron within a panel. (mTOR OFF) With no signal, CaMKIIα translocation does not exhibit 
branch preference. (mTOR ON) When mTOR is active, HuD targets its mRNAs into the tagged 
synapse. Presynaptic signals (blue lightning bolts) trigger translocation of CaMKIIα mRNA to an 
active synapse. (mTOR ON or no HuD) In the absence of HuD or mTOR, CaMKIIα does not show 
branch preference. B. Model of transsynaptic signaling based on data from (Henry et al., 2012). 
CNQX-mediated inhibition of AMPA receptors resulting in mTOR activation. mTOR-activation-
dependent BDNF synthesis then results in BDNF secretion and binding to presynaptic terminals.   
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branch-specific expression of the CaMKIIα mRNA is mediated by the RNA binding 
protein HuD. mTOR stabilizes the mRNA and prevents degradation. Thus, mTOR serves 
as the tag while HuD captures CaMKIIα mRNA to promote its branch specific expression 
(Figure 1.6A). Data provided by high-throughput experiments that map RNA binding sites 
such as CLIP-SEQ used in concert with protein visualization techniques may reveal other 
HuD target mRNAs that have branch specific expression.  
 
Trans-synaptic Signaling 
An important but often overlooked feature involved in neuronal homeostasis is 
trans-synaptic signaling, the process by which proteins secreted from the postsynaptic 
spine can trigger retrograde activation of presynaptic neurons. Recently, it was shown that 
mTORC1 activation leads to the expression of BDNF which acts as a retrograde messenger 
to stimulate further neurotransmitter release from the presynaptic terminal (Henry et al., 
2012) (Figure 1.6B). A more thorough construction of pre- and postsynaptic 
signaling/regulatory networks through high-throughput experiments will be invaluable in 
determining the nature of this postsynaptic engagement. 
 
MOTIVATION FOR STUDIES 
The basis of many diseases and neuronal dysfunctionalities arise from defects in 
synaptic plasticity. The molecular substructure that underlies synaptic plasticity, in part 
mediated by the protein kinase mTOR, forms the basis of learning and memory systems 
within the brain. While numerous strides have been made in recent decades with regards 
to the molecular composition of learning and memory systems, the application of high-
throughput technologies has the potential to expand the field further and give researchers 
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a dynamic look at the complex web of interactions on the levels of both the proteome and 
the transcriptome. To this end, we have undertaken separate approaches at the level of 
protein and RNA that apply such high-throughput methodologies to better understand the 
basis of neuronal diseases. The pivotal role that mTOR plays in these processes cannot be 
overstated. The research in the following chapters apply many of the principles reviewed 
in this introduction to better understand the mechanisms by which mTORC1 dysregulation 
leads to disease states associated with learning and memory processes at the synapse. 
mTOR lies at the intersection of numerous signaling pathways at the synapse and 
controls local dendritic translation processes leading many researchers to speculate that it 
plays a key role in the basis of neuronal dysfunction (Dazert and Hall, 2011; Wang and 
Proud, 2011; Laplante and Sabatini, 2012; Betz and Hall, 2013; Costa-Mattioli and 
Monteggia, 2013; Kaeberlein, 2013; Wang et al., 2013; Abelaira et al., 2014; Lipton and 
Sahin, 2014; Wong, 2014; Crino, 2015; Lan et al., 2016; Sato, 2016). Furthermore, the 
long-standing belief in the field is that disease of overactive mTORC1 activity are a result 
of excessive protein synthesis (Hoeffer and Klann, 2010). The discovery that mTOR 
inhibition with rapamycin leads to the increase in the expression of Kv1.1 (Raab-Graham 
et al., 2006) and subsequent elucidation of the mechanism by which this occurs (Sosanya 
et al., 2013) has raised the question of whether other proteins increase in expression as well 
and the contribution of these proteins to neuronal disease. Thus, Chapter 2 focuses on the 
application of an unbiased mass spectrometry approach to detail the wide spectrum of 
proteins under active suppression or activation by mTORC1 and dysregulation of these 
proteins in diseases such Alzheimer’s disease, epilepsy, and autism spectrum disorders.  
Numerous bioinformatic approaches exist that may be useful to characterize the 
interaction between proteins, determining potential binding targets of RNA-binding 
proteins, and for drug discovery. In Chapter 3, we begin with the observations that 1) 
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seizures are commonly observed between epilepsy, AD, and ASD (Zeng et al., 2009; 
Noebels, 2011; Wong, 2014; Lee et al., 2015) and 2) that these three disorders are known 
to be a result of overactive mTOR. We then investigate if a common phenotype underlies 
these disorders through the generation of a protein-protein interaction network that 
identifies PARK7 as a unique hub connecting these diseases. We use the results of this 
analysis to explore the role of RBPs in neuronal dysfunction through bioinformatics and 
biologically validate some of our results using the tuberous sclerosis complex (TSC) mouse 
model which exhibits epileptic and autistic phenotypes. These findings underscore the 
potential for high-throughput methodologies and bioinformatics analysis to reveal 
underlying connections between proteins involved in neuronal disease. 
Fragile-X Mental Retardation Protein (FMRP) is an RBP that regulates translation 
of dendritically-localized mRNAs. Mutations in the Fmr1 gene that encodes FMRP lead to 
various cognitive defects such as intellectual disability and autistic phenotypes (Bassell 
and Warren, 2008; De Rubeis et al., 2012). Previously, our lab has identified a connection 
between FMRP activity and mTOR activity in animals upon pharmacological treatment 
with a rapidly acting antidepressant (Workman et al., 2013; Workman et al., 2015; Wolfe 
et al., 2016). Chapter 4 focuses on the usage of RNA immunoprecipitation and RNA 
sequencing to determine the targets bound to fragile-X mental retardation protein (FMRP) 
in the context of a rapidly acting antidepressant dependent on mTOR activity. Traditionally 
prescribed antidepressants are well-known for their low response rates and poor 
effectiveness (Turner et al., 2008; Fournier et al., 2010; Undurraga and Baldessarini, 2012; 
Greenberg et al., 2015). Furthermore, there the symptoms used to characterize depression 
are numerous and show little overlap in descriptive categories (Lohoff, 2010; Lux and 
Kendler, 2010; Goldberg, 2011; Hybels et al., 2011; de Vos et al., 2015; Lieblich et al., 
2015; Fried, 2017). Here, we attempt to “reverse engineer” depression using a new class 
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of rapidly acting antidepressants to determine the RNA populations controlled by FMRP 
they affect upon administration. 
Collectively, the results of these studies demonstrate that high-throughput assays, 
bioinformatics analysis, and experimental follow-up have great potential in unraveling the 
details of the molecular pathways underlying neuronal dysfunction in learning and 
memory. The data will inform future studies in drug discovery for the creation of more 
















Chapter 2: Rapid repression of mTORC1 shifts the regional expression 
of disease-related protein ensembles3,4 
INTRODUCTION 
The mechanistic/mammalian target of rapamycin complex 1 (mTORC1) is a 
serine/threonine protein kinase that is highly expressed in many cell types (Kim et al., 
2002). In the brain, mTORC1 tightly coordinates different synaptic plasticities—long-term 
potentiation (LTP) and long-term depression (LTD)—the molecular correlates of learning 
and memory (Tang et al., 2002; Hay and Sonenberg, 2004; Hou and Klann, 2004; Bove et 
al., 2011). Because mTORC1 is at the core of many synaptic signaling pathways 
downstream of glutamate and neurotrophin receptors, many hypothesize that dysregulated 
mTORC1 signaling underlies cognitive deficits observed in several neurodegenerative 
diseases (Hou and Klann, 2004; Kelleher et al., 2004; Takei et al., 2004; Tsokas et al., 
2005; Gong et al., 2006; Antion et al., 2008b; Pei and Hugon, 2008; Swiech et al., 2008; 
Hoeffer and Klann, 2010; Sharma et al., 2010; Ricciardi et al., 2011; Santini and Klann, 
2011; Costa-Mattioli and Monteggia, 2013). For example, mTORC1 and its downstream 
targets are hyperactive in human brains diagnosed with Alzheimer’s disease (AD) (An et 
al., 2003; Li et al., 2005; Yates et al., 2013). Additionally, in animal models of autism 
spectrum disorder (ASD), altered mTORC1 signaling contributes to the observed synaptic 
dysfunction and aberrant network connectivity (Zhou et al., 2009a; Sharma et al., 2010; 
Bateup et al., 2011; Luikart et al., 2011; Ricciardi et al., 2011; Zoghbi and Bear, 2012; 
Bateup et al., 2013; Gkogkas et al., 2013; Weston et al., 2014). Furthermore, epilepsy, 
                                                 
3 Parts of this chapter originally published in Niere, F., Namjoshi, S., Song E., Dilly, G.A., Schoenhard, G., 
Zemelman, B.V., Mechref, Y., Raab-Graham, K.F. (2016). Analysis of Proteins That Rapidly Change 
Upon Mechanistic/Mammalian Target of Rapamycin Complex 1 (mTORC1) Repression Identifies 
Parkinson Protein 7 (PARK7) as a Novel Protein Aberrantly Expressed in Tuberous Sclerosis Complex 
(TSC). Mol Cell Proteomics 15(2): 426-44. doi: 10.1074/mcp.M115.055079. I wrote half of the 
manuscript, performed bioinformatics analysis, prepared all tables, and prepared figures 2.1-2.3. 
4 Some tables and figures available online only from Molecular Cellular Proteomics.  
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which is common in AD and ASD, has enhanced mTORC1 activity (Crino, 2008; Pun et 
al., 2012; Brewster et al., 2013; Wong, 2014; Sosanya et al., 2015a).  
Phosphorylation of mTORC1, considered the active form, is generally regarded to 
promote protein synthesis (Laplante and Sabatini, 2012). Thus, many theorize that diseases 
with overactive mTORC1 arise from excessive protein synthesis (Hoeffer and Klann, 
2010). Emerging data, however, are demonstrating that suppressing mTORC1 activation 
can trigger local translation in neurons (Raab-Graham et al., 2006; Sosanya et al., 2013). 
Pharmacological antagonism of N-methyl-D-aspartate (NMDA) receptors, a subtype of 
glutamate receptors that lies upstream of mTOR activation, promotes the synthesis of the 
voltage-gated potassium channel, Kv1.1, in dendrites (Raab-Graham et al., 2006; Sosanya 
et al., 2013). Consistent with these results, in models of temporal lobe epilepsy there is a 
reduction in the expression of voltage-gated ion channels including Kv1.1 (Poolos and 
Johnston, 2012; Brewster et al., 2013; Sosanya et al., 2015a). 
Interestingly in a model of focal neocortical epilepsy, overexpression of Kv1.1 
blocked seizure activity (Wykes et al., 2012). Since both active and inactive mTORC1 
permit protein synthesis, we sought to determine the proteins whose expression is altered 
when mTORC1 phosphorylation is reduced in vivo. 
Rapamycin is an FDA-approved, immunosuppressive drug that inhibits mTORC1 
activity (Seto, 2012). We capitalized on the ability of rapamycin to reduce mTORC1 
activity in vivo and the unbiased approach of mass spectrometry to identify changes in 
protein expression. Herein, we provide evidence that mTORC1 activation bidirectionally 
regulates protein expression, especially in the PSD where roughly an equal distribution of 
proteins dynamically appear and disappear.  
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EXPERIMENTAL PROCEDURES  
Sample preparation 
We used three sets of paired sibling male Sprague Dawley rats (seven to nine weeks 
old) that were housed together. Within each pair, one received rapamycin (10 mg/kg) and 
the other received an equal volume of DMSO (carrier, control) via intraperitoneal (i.p.) 
injection. After one hour the animals were sacrificed. Cortices were homogenized, nuclei 
were pelleted by low speed centrifugation (100 x g) and the resulting supernatant was 
analyzed as cell lysates (L). To obtain synaptoneurosomes, homogenized cortices were 
processed as described (Workman et al., 2013). An aliquot of the synaptoneurosome 
fraction from each animal was solubilized in 1% triton X-100 (10 min) and centrifuged 
(12000 x g) to yield a triton X-100-soluble fraction (soluble, S) and a triton X-100-
insoluble fraction (pellet, PSD). To prepare protein for LC-MS/MS, lysates, soluble, and 
PSD fractions were further solubilized in SDS-sample buffer. SDS-solubilized fractions 
were run on a 10% SDS-polyacrylamide gel (4 min). The migration was stopped as the 
ladder began to separate. Gel plugs containing the sample were sectioned and sent for mass 
spectrometry analysis. Animal experiments were performed according to the National 
Institutes of Health’s Guide for the Care and Use of Laboratory Animals and approved by 
the UT-Austin Institutional Care and Usage Committee. 
 
Western blot analysis 
Proteins were separated by SDS-polyacrylamide gel electrophoresis (PAGE). To 
visualize the proteins, we used the following antibodies: rabbit anti-phospho-mTOR 
Ser2448 (1:2,000; Cell Signaling), mouse anti-mTOR (1:5,000; Life Technologies), mouse 
anti-PSD-95 (1:10,000; NeuroMab), mouse anti-synapsin 1 (1:10,000; Synaptic Systems), 
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rabbit polyclonal anti-α tubulin (1:50,000; Abcam), mouse ribosomal S6 (1:1000, Cell 
Signaling) and rabbit anti-phospho-S6 (1:1000, Cell Signaling). Membranes were 
subsequently incubated in fluorescence-conjugated secondary antibodies (AF680, Life 
Technologies; AF800, LiCor; 1:5000). Using the Odyssey CLx infrared imaging system, 
we obtained fluorescent images of the membranes. ImageJ (National Institutes of Health) 
software was used for densitometry analyses of proteins. 
 
In-gel tryptic digestion 
The gels were cut into 1mm cubes after washing gels with water for 15min. Gel 
pieces were transferred to a clean Eppendorf tube followed by adding 100 μl of water and 
incubating for 15 min. All the water was removed. This washing step was repeated with 
50% acetonitrile (ACN) and 100% ACN two times. A 100 μl of 100 mM ammonium 
bicarbonate buffer was added followed by a 5min incubation. All the liquid was removed 
and the samples were subjected to drying in speed-vacuum until they were completely 
dried. For reduction/alkylation, 100 μl of 10 mM dithiothreitol (DTT) suspended in 100 
mM ammonium bicarbonate buffer was added to the dried samples. This was followed by 
incubation in a water bath at 55°C for 45 min. After removing the alkylation solution, 100 
μl of 55 mM iodoacetamide (IAA) suspended in 100 mM ammonium bicarbonate buffer 
was added into the reduced samples followed by incubating at 37.5°C for 30 min. The 
alkylated samples were then washed with 100 μl of 100 mM ammonium bicarbonate buffer 
and incubated for 5min. A 100 μl of acetonitrile was added to make one to one ratio of 
solutions with incubation for 15min. All the solutions were removed. The samples were 
then dried before digestion. Trypsin digestion solution was prepared with 4 μl trypsin in 
96 μl of 100 mM ammonium bicarbonate buffer. The amount of trypsin was determined 
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using enzyme/protein ratio of 1:50 w/w since 200 μg of proteins were loaded into the gel. 
A 100 μl of trypsin digestion solution was added to the alkylated samples and then 
incubated for 45 min on ice. This allows the gels to absorb the trypsin digestion solution. 
The solution was removed if it was excessive. The samples were incubated at 37.5°C 
overnight. The addition of 2% trifluoroacetic acid (TFA) acidified the digestion. The 
tryptic digests were extracted from the gel by adding 0.1% TFA and incubating in ice water 
bath with sonication. The solutions were then collected in a separate clean Eppendorf tube. 
This extraction step was repeated with 30% ACN/0.1% TFA and 60% ACN/0.1% TFA 
three times. The collected peptides were then dried in a speed-vacuum and re-suspended 
in 0.1% formic acid prior to LC-MS/MS analysis. 
 
Mass spectrometry 
LC-MS/MS. Trypsin digested samples were subjected to LC-MS/MS analysis 
using Dionex 3000 Ultimate nano-LC system (Dionex, Sunnyvale, CA) interfaced to LTQ 
Orbitrap Velos mass spectrometer (Thermo Scientific, San Jose, CA) equipped with a 
nano-ESI source. The samples were initially online-purified using a PepMap 100 C18 
cartridge (3 μm, 100Å, Dionex). The purified peptides were then separated using a PepMap 
100 C18 capillary column (75 μm id x 150 mm, 2 μm, 100Å, Dionex). The separation of 
peptides was achieved at 350 nl/min flow rate, using the following gradient: 0-10 min 5% 
solvent B (98% ACN with 0.1% formic acid), 10-65 min ramping solvent B 5-20%, 55-90 
min ramping solvent B 20-30%, 90-105 min ramping solvent B 30-50%, 105-110min 
maintaining solvent B at 80%, 110-111 min decreasing solvent B 80-5%, and 111-120 min 
sustaining solvent B at 5%. Solvent A was a 2% ACN aqueous solution containing 0.1 % 
formic acid. The separation and scan time was set to 120 min. The LTQ Orbitrap Velos 
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mass spectrometer was operated with three scan events. The first scan event was a full MS 
scan of 380-2000 m/z at a mass resolution of 15,000. The second scan event was CID 
MS/MS of parent ions selected from the first scan event with an isolation width of 3.0 m/z, 
a normalized collision energy (CE) of 35%, and an activation Q value of 0.250. The third 
scan event was set to acquire HCD MS/MS of the parent ions selected from the first scan 
event. The isolation width of HCD experiment was set to 3.0 m/z while the normalized CE 
was set to 45% with an activation time of 0.1 ms. The CID and HCD MS/MS were 
performed on the 5 most intense ions observed in the MS scan event. 
 
Data processing 
Quantitation was attained employing normalized spectral counts that were 
calculated by Scaffold Q+ (Proteome Software, Inc., Portland, OR). The identification of 
proteins/peptides was achieved using MASCOT database (Brosch et al., 2009). Proteome 
Discoverer version 1.2 software (Thermo Scientific, San Jose, CA) was used to generate a 
mascot generic format file (*.mgf) which was subsequently employed for database 
searching using MASCOT version 2.3.2 (Matrix Science Inc., Boston, MA) Parent ions 
were selected from a mass range of 350-10000Da with a minimum peak count of 1. The 
parameters from Mascot Daemon were set to search against the UniProt Rattus database 
(UniProt release 2013_11). Oxidation of methionine was set as a variable modification 
while carbamidomethylation of cysteine was as a fixed modification. The formation of 
propionamide adducts on cysteine, N-terminus and C-terminus of peptides was added as 
variable modification due to the use of polyacrylamide gels. Trypsin was selected with 
missed cleavages up to two. Peptides were searched with a precursor ion mass tolerance of 
6ppm or better and fragment ion mass tolerance of 1.5 Da. The MASCOT results were 
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imported to Scaffold version 3.6.3 (Searle, 2010) (Proteome Software, Inc., Portland, OR). 
Scaffold probabilistically validates the identification of peptides and proteins assigned by 
MASCOT using PeptideProphet (Keller et al., 2002) and ProteinProphet (Nesvizhskii et 
al., 2003) algorithms, respectively. Peptide identifications were accepted with a MASCOT 
ion score greater than 20, while protein identifications were accepted with a probability 
greater than 99%. The accepted proteins contain at least two identified peptides. The 
number of entries in the database (or subset of databases) searched was 7875 entries. The 
false discovery rate (FDR) was 0.2% for identification of peptides and proteins. 
Quantitation of identified proteins was then achieved based on spectral counts after 
normalization (Table S1A-D, available online). The mass spectrometry proteomics data 
have been deposited to the ProteomeXchange Consortium 
(http://proteomecentral.proteomexchange.org) via the PRIDE partner repository (Vizcaino 




From the three biological replicates that were generated for each condition or 
treatment, namely DMSO (control) and rapamycin (Table S1A, available online), we 
thresholded the identified peptides by removing proteins that returned zero spectral counts 
in two biological replicates from each condition. We then averaged each protein across 
replicates for each condition, excluding zero values from the average. The thresholded 
protein list for each condition was used for gene ontology classification as detailed below. 
The data were further processed by dividing the averaged rapamycin spectral count data 
by the averaged DMSO spectral count data for each subcellular fraction. This produced 
 77 
three lists of rapamycin fold-change over control for each of the subcellular fractions. 
Finally, we applied a log2 transformation to the fold-change data allowing us to easily 
compare difference in protein abundance for each protein found in its respective fraction. 
Mitochondrial proteins were filtered from fractions based on the MitoMiner database for 
R. Norvegicus mitochondrial proteins (Smith et al., 2012). 
 
Gene ontology clustering 
The unique protein lists for each condition described above were loaded into 
DAVID—an online tool for functional annotation and gene ontology clustering (Huang da 
et al., 2009a; 2009b). Data were analyzed in DAVID using the biological process 
(BP_FAT) ontology as well as the KEGG pathway database (KEGG_PATHWAY). We 
utilized the DAVID Functional Annotation Chart and Functional Annotation Clustering 
using the default settings (EASE score threshold = 0.1). DAVID EASE score is a modified 
version of the Fischer Exact p-value that allows for comparison of cluster enrichment. 
 
Network analysis 
Gene ontology clustering was first performed in DAVID to produce a Functional 
Annotation Chart. This chart was then loaded into the Cytoscape plugin Enrichment Map 
which performed further enrichment to identify clusters of high overlap and visualization 
in the form of an undirected network (Merico et al., 2010). We used the following 
Enrichment Map tuning parameters to enrich DAVID results: p-value cut-off = 0.001, Q-
value cut-off = 0.05, overlap coefficient cut-off = 0.6. We utilized both Cytoscape 2.8.3 
and Cytoscape 3.1.0 for our analysis (Shannon et al., 2003). Network statistics, random 
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network generation, and network merge analysis (to identify unique GO terms in each 
treatment) were performed in Cytoscape 2.8.3 using the base plugins.  
 
Gene disease databases 
For all gene lists, we matched genes in the database overlapping with our own 
protein list. The ASD gene list was obtained from SFARI (Simons Foundation Autism 
Research Initiative) (Abrahams et al., 2013). The epilepsy gene list was obtained from the 
CarpeDB online epilepsy gene database (http://www.carpedb.ua.edu/). The Alzheimer’s 
disease gene list was obtained from the AlzGene database top 10 list in combination with 
the Alzheimer’s disease pathway from the KEGG Pathway database (hsa05010) (Bertram 
et al., 2007; Kanehisa et al., 2014). 
 
Statistics, data analysis, and image processing 
Data processing and preparation were performed in Microsoft Excel 2010 and the 
R programming language (http://www.r-project.org/). Statistics and visualization was 
performed with the R programming language and GraphPad Prism 6. The following R 
packages were used for analysis: equivalence (http://cran.r-
project.org/web/packages/equivalence/index.html), ggplot2, gplots (http://cran.r-
project.org/web/packages/gplots/index.html), moments (http://cran.r-
project.org/web/packages/moments/index.html), plyr, and reshape2 (Wickham, 2007; 
2009; 2011; RC, 2014). R Scripts for generating figures and statistical analysis deposited 
at: https://github.com/snamjoshi/MCP2015_Niere_Namjoshi_etal. See also, Appendix C. 
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Bioorthogonal non-canonical amino acid tagging and Proximity ligation assay 
tandem (BONCAT-PLA) 
Visualization of new proteins was conducted similar to (Workman et al., 2015). 
Following incubation of 21 DIV hippocampal neurons in 500 μL methionine-free media 
for 30 minutes at 37°C, azidohomoalanine (AHA, Life Technologies) and equal volume of 
rapamycin (final concentration = 200 nM) or DMSO were added to the media. 1 hour after 
treatment, cells were fixed as described by (tom Dieck et al., 2015; Workman et al., 2015). 
Click-it metabolic labeling was then performed according to manufacturer’s instructions 
(Life Technologies). Biotin-alkyne was used to detect new proteins. PLA was subsequently 
conducted according to manufacturer’s directions (Duolink, Sigma). Mouse, anti-biotin 
(1:500, Abcam), rabbit anti-GAP-43 (1:500, Abcam), rabbit anti-SNAP-25 (1:100, 
Abcam), rabbit anti-biotin (1:500, Sigma), and chicken anti-MAP2 (1:2000, Abcam) 
antibodies were used. 
 
Immunocytochemistry (ICC) 
Dissociated hippocampal neurons, 18-25 days in vitro (DIV), were prepared from 
embryonic rat pups (E17-18) similar to (Sosanya et al., 2013). For Tsc1 cultures, neurons 
were prepared from postnatal (0 to 3 days) Tsc1 conditional knockout pups similar to 
(Niere et al., 2012). Cre-2A-GFP (Puro), CMV-lentivirus (GenTarget, Inc.) was used to 
reduce TSC1 expression. GFP (CMV)-Puro lentiviral particles was used as a control. Virus 
was added to cultures at 7-9 DIV and allowed to express for 9-14 days. GFP 
immunofluorescence was used to identify infected pyramidal neurons. Cells were fixed in 
4% paraformaldehyde for 10 minutes at 37°C and permeabilized in 0.2% Triton X-100 for 
10 minutes similar to (Niere et al., 2012). Fixed cells were incubated in primary rabbit anti-
GAP43 (1:500, Abcam), rabbit anti-SNAP25 (1:100, Abcam), and chicken anti-MAP2 
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(1:2000, Abcam). Goat anti-Synapsin (1:500, Santa Cruz) and guinea pig anti-PSD95 
(1:500, Synaptic Systems) were used to visualize the pre- and postsynaptic structures 
respectively. Following overnight primary antibody incubation in 4°C, appropriate 
secondary antibodies (1:500, Life Technologies) were applied: AlexaFluor488 (AF488), 
AF647, AF405, and Cy3 (Jackson ImmunoResearch). Note, chicken anti-MAP2 used in 
conjunction with AF405 produces a granular appearance when imaged. In any given cell 
culture experiment, image acquisition across all conditions was performed on the same day 
using similar duration and intensity of excitation light. All fluorescence images were 
acquired on a Leica SP5 disk confocal microscope (Wetzlar, Germany) using an oil-
immersion, 63X lens, sampled at 1024 X 1024. 
 
Image analysis 
For PSD-95 and synapsin colocalization analysis, Z-stacks of 9 planes at 0.5 
μm/plane for each dendrite were imaged. Only one plane that had the strongest signal from 
the protein of interest was analyzed. The Pearson’s correlation coefficient (PCC) was 
determined using the ImageJ plugin JACoP. The same threshold value was applied across 
all conditions using the threshold function in ImageJ. For BONCAT-PLA, Z-stacks of 8-9 
planes at 0.5 μm/plane were imaged. For BONCAT/PLA analysis, 2 planes, for a total of 
1 μm thickness that had the brightest MAP2 signals were max projected using ImageJ. The 
projected images were analyzed for PLA and MAP2 immunofluorescence (IF). PLA and 
MAP2 signals were thresholded to at least thrice above background that remained constant 
within an experiment. To determine the background for each signal in Metamorph, the 
average fluorescence intensity in a circular region of ~90 μm adjacent to the region of 
interest was obtained. The dendritic PLA value for each protein was normalized to the 
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corresponding MAP2 IF as a volume control. For BONCAT-PLA measurements, the 
product of the total area, intensity, and puncta number of BONCAT-PLA in each dendrite 
was quantified. Dendritic MAP2 IF was determined by multiplying the total area and 
average intensity of MAP2. The BONCAT-PLA/MAP2 values were normalized to the 
average BONCAT-PLA/MAP2 of control (DMSO) dendrites to reflect the total change in 
protein with treatment. Secondary dendrites (50 μm long and 1 μm thick) were used for 
analysis to minimize variability in dendritic caliber.  
 
RESULTS 
Rapid mTORC1 suppression in vivo affects synaptic processes 
Having previously demonstrated that repressing mTORC1 in dissociated 
hippocampal neurons induced Kv1.1 mRNA translation in dendrites, we sought to identify 
in vivo the effects of briefly reducing mTORC1 activity on the proteomic expression of the 
cortex (Raab-Graham et al., 2006; Sosanya et al., 2013). We used naïve rats since our goal 
was to identify proteins that may be common across all diseases where mTORC1 activity 
is aberrantly regulated without biasing our data toward any one disease. We also took 
advantage of tandem mass spectrometry (LC-MS/MS) which can identify numerous 
proteins in a mixture and is not dependent upon access to antibody epitopes (Aebersold et 
al., 2013). Since local translation is rapid, we used a single intraperitoneal (i.p.) injection 
of rapamycin. (10 mg/kg) and harvested cortices within one hour to detect changes in 
protein expression that may be due to new protein synthesis (Weiler et al., 1997; Steward 
and Schuman, 2001; Raab-Graham et al., 2006; Waung et al., 2008; Donnelly et al., 2010; 
Niere et al., 2012; Ainsley et al., 2014). To verify the effectiveness of i.p. injection of 
rapamycin in reducing mTORC1 activity in vivo, we compared cortical lysates (Lysates) 
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isolated from rats injected with carrier (control/DMSO) to those injected with rapamycin 
by Western blotting for the active form of mTORC1 (P-mTORC1) and its downstream 
target ribosomal S6 (P-S6). Indeed, one hour after systemic administration, rapamycin 
effectively reduced the activities of mTORC1 (0.50 ± 0.14 of control) and ribosomal S6 
(S6) (0.21 ± 0.08 of control), as indicated by the ratio of the phosphorylated protein over 
the total protein (i.e. P-mTORC1/mTORC1 and P-S6/S6; Figure 2.1A) (Sosanya et al., 
2015a).  
Next, we performed LC-MS/MS analyses on cortical lysates from carrier and 
rapamycin treated rats. To assess the consistency of spectral count measurements among 
replicates (i.e. 3 independent rats/treatment), we measured the average standard errors 
across all proteins for each treatment (Figure 2.6A; DMSO = 0.169 ± 0.006, RAPA = 0.157 
± 0.006). We also calculated spectral count correlations across all proteins for each 
replicate within a treatment (Figure 2.6B; r2 > 0.93 (DMSO), r2 > 0.94 (RAPA), average r2 
across replicates). The small variability in standard error and tight correlation among all 
replicates across all proteins in each treatment denote consistent sample preparation and 
spectral count measurements. 
We first ascertained the global influence of rapidly suppressing mTORC1 by 
constructing biological networks using the gene ontology (GO) of each protein identified 
in the lysates fraction. Normalized spectral counts were averaged for each of the three 
biological replicates across all treatments. To find the most highly enriched biological 
processes, proteins were filtered into unique lists that were loaded into DAVID (Huang da 
et al., 2009a; 2009b). DAVID uses a modified version of Fisher’s Exact Test to produce 
an “EASE” score that measures the significance of clustering enrichment among the 
proteins under consideration. Due to the high number of biological processes that resulted 
from DAVID clustering data, we utilized the DAVID functional annotation chart in  
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Figure 2.1: Rapamycin reduces mTORC1 activity and rapidly alters translation and 
synaptic function 
A. One hour, systemic administration of rapamycin (10 mg/kg body weight) reduced mTORC1 
activity as measured by densitometric analyses of phosphorylated mTORC1 (P-mTORC1, 
Ser2448) and its downstream target, phosphorylated ribosomal S6 (P-S6). To obtain fold-changes 
in activity, ratios of P-mTORC1 to mTORC1 and P-S6 to S6 were normalized to DMSO values. In 
DMSO, P-mTORC1 and P-S6 values equal 1 (dashed line, home cage control). Rapamycin, P-
mTORC1 = 0.50 ± 0.14; Rapamycin, P-S6 = 0.21 ± 0.08 (Mean ± SEM). N = 3 animals per 
condition. Statistics: *, p < 0.05; Student’s t test. B. Enrichment network comparing differences in 
proteins GO clustering between DMSO and rapamycin treatments for the lysate fraction. Network 
generated from the GO biological process database by output from the DAVID Functional 
Annotation Chart and further enrichment with Enrichment Map (see Experimental Procedures). 
Tuning parameters used to enrich DAVID results: p-value cut-off = 0.001, Q-value cut-off = 0.05, 
overlap coefficient cut-off = 0.6. A node represents a GO biological process containing genes from  
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conjunction with the Cytoscape plugin Enrichment Map to visualize gene/protein clusters 
with the highest overlap (Shannon et al., 2003; Merico et al., 2010; Merico et al., 2011). 
This approach allowed us to create biological networks organized into highly enriched 
functional units (Figure 2.1B). Each node in this network is a GO biological process 
containing a statistically significant cluster of proteins from either rapamycin or 
control/DMSO treatment (based on DAVID EASE score). The edge connecting the nodes 
illustrates the relatedness of the biological processes, such that a shorter edge indicates a 
greater overlap of proteins between processes. GO biological processes that contain a high 
overlap in common proteins were circled and given a label that generally describes the 
processes it contains. 
To differentiate rapamycin-dependent biological processes in lysates, we 
overlapped control/DMSO and rapamycin networks and colored unique edges between the 
two fractions in red (Figure 2.1B). This approach revealed a high level of overlap between 
the GO biological process cluster for the DMSO (gray) and RAPA (blue) networks (Figure 
2.1B). We further characterized the networks by mean closeness centrality, mean clustering 
coefficient, and mean neighborhood connectivity (Table 2.1) (Yu et al., 2004; Nikiforova 
and Willmitzer, 2007). This evaluation also indicated a stark similarity between DMSO 
and rapamycin networks, suggesting that acute attenuation of mTORC1 activity does not 






the experimental treatments. An edge indicates proteins shared between nodes. Edge thickness 
corresponds to the number of proteins shared between nodes and edge length corresponds to 
enrichment overlap between nodes. Light blue lines indicate DMSO treatment and dark blue 
indicates rapamycin treatments. Two edges of different colors connecting the same nodes indicate 
proteins shared between processes for both treatments. Red lines indicate unique differences in 
biological processes between treatments. Annotations based on general description of processes 
contained in the cluster. Network statistics listed in Table 2.S1. 
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inhibition of mTORC1 significantly affected GO biological processes observed at the 
synapse—ion homeostasis, metal ion transport, regulation of membrane potential, and 
regulation of secretion—in addition to the expected changes in translation, as indicated by 
the red connections (see Table 2.2 for unique GO terms between treatments). Furthermore, 
synaptic vesicle maturation particularly stood out with its high level of unique connections 
between vesicle trafficking, neuron projection and morphogenesis, and protein transport 
(Figure 2.1B, green arrow, lower right corner). These results suggest that acute alterations 
in mTORC1 activity greatly impact synaptic function. 
 
PSD proteome is labile during brief rapamycin exposure and contains more 
mTORC1-responsive proteins 
Because network analysis of lysates revealed stark changes in synaptic processes after one 
hour of mTORC1 inhibition, we isolated synaptoneurosomes from cortices of control and 
rapamycin-treated rats. Through a series of filtration steps and detergent solubilization, we 
isolated fractions of synaptoneurosomes that were soluble (supernatant, S, containing 
neuronal processes void of the PSD) and insoluble (pellet, P, PSD) in the detergent, triton 
X-100 (TX-100) (Figure 2.2A, illustration of biochemical isolation) (Fiszer and Robertis, 
1967; Cohen et al., 1977). We used this modified approach for enriching PSD to allow us 
to identify promising proteins that directly interact with resident proteins of PSD (see 
Experimental Procedures). To verify the purity of the fractionation we assayed for well-
characterized resident proteins of each fraction. As indicated by Western blot analysis, the 
pellet is enriched for PSD-95—a postsynaptic marker—and the supernatant is enriched for 
tubulin and synaptophysin 1—a presynaptic marker (Figure 2.2B) (Arancio et al., 1996; 
Biederer et al., 2002; Villasana et al., 2006).  
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Figure 2.2: Proteins in postsynaptic region rapidly and bidirectionally respond to 
mTORC1 repression 
A. Schematic diagram indicating the steps and reagents used to generate the PSD-enriched (P), and 
triton X-100-soluble (S) portions of the cortices. To isolate P and S, synaptoneurosomes were 
solubilized in triton-X 100 (TX-100, 1%). B. By Western blot analysis, TX-100-insoluble pellet 
(P) was enriched in postsynaptic density-95 (PSD-95, postsynaptic marker) while TX-100-soluble 
supernatant (S) was enriched for synapsin 1 (SYN1, presynaptic marker) and tubulin. C. In PSD, 
rapamycin reduces P-S6 level (DMSO = 1.00 ± 0.31; RAPA = 0.12 ± 0.05; N = 3 animals per 
condition). Actin was used as loading control since PSD fraction is void of tubulin, as shown in B. 
Statistics: *, p < 0.05; Student’s t test. D. Histogram showing log2 transformed fold-change levels 
across the PSD (Figure 2.7, and Tables S4-S5, available online). Central grey box represents 
proteins that changed by 0-10% compared to control conditions. For PSD fraction: n = 401 proteins, 
nlog2 fold-change > 0 = 210, nlog2 fold-change < 0 = 191. Descriptive statistics: mean ± S.D. = -0.006 ± 0.5; 
variance = 0.25 CI [0.224, 0.281]; skewness = 0.40; kurtosis = 4.14. CI for variance calculated 
from Χ2 statistic. Bartlett’s Test shows variances of lysates, PSD, and soluble fold-change 
distributions are unequal (p < 0.0002). E. Number of proteins in PSD where computing log2 fold-
change (RAPA/DMSO) was not possible because the average spectral counts for either rapamycin 
or DMSO treatments was 0. These proteins are described as “out-of-range”. DMSO column 
represents 50 proteins whose average spectral counts for the rapamycin treatment condition was 0. 
RAPA column represents 39 proteins whose average spectral counts for DMSO treatment condition 
was 0. (Table S6, available online). 
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Furthermore, phospho-S6 (P-S6)—a downstream marker of mTORC1 activity—
was reduced in the PSD, indicating that mTORC1 was successfully inhibited by rapamycin 
in this fraction (DMSO = 1.00 ± 0.31; RAPA= 0.12 ± 0.05) (Figure 2.2C). Next, we 
subjected soluble and PSD fractions to LC-MS/MS to determine the proteins that were up- 
or downregulated during acute reduction of mTORC1 activity. Again, to assess consistency 
between replicates we measured the average standard errors and spectral count correlations 
across all proteins (Figure 2.7A; PSD/DMSO = 0.222 ± 0.007, PSD/RAPA = 0.198 ± 
0.006; SOL/DMSO = 0.184 ± 0.005, SOL/RAPA = 0.179 ± 0.005; Figure 2.7B; r2 > 0.85 
(PSD/DMSO), r2 > 0.88 (PSD/RAPA); r2 > 0.90 (SOL/DMSO), r2 > 0.90 (SOL/RAPA)). 
To determine how acute mTORC1 repression affects the subcellular distribution of 
proteins, we examined changes in expression. The average value of each protein that was 
detected in rapamycin was normalized to the average value of the corresponding protein in 
DMSO and thus reported as the fold change of RAPA/DMSO. We found that the majority 
of the proteins (~73 – 75%) in PSD changed their expression profiles within one hour after 
reducing mTORC1 activity as determined by variance (PSD: 0.25 CI[0.224, 0.281]) and 
fold-changes in protein expression (see Table S4, online for PSD proteins that are 
insensitive to mTORC1 activity and Table S5, online for PSD proteins whose expression 
changes, both tables available online). Furthermore, the direction of change as indicated 
by the histogram is approximately equal between the expected reduction with mTORC1 
inhibition (negative fold-change) and the unexpected increase (positive fold-change) in 
expression (Figure 2.2D). More interestingly, we discovered out-of-range proteins that 
could only be detected in either DMSO or rapamycin (Figure 2.2E; Table S6, available 
online). In PSD, 50 proteins could no longer be detected, while 39 new proteins were 
identified upon inhibiting mTORC1. The dynamic disappearance and emergence of out-
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of-range proteins in PSD suggest that mTORC1 not only regulates the expression of 
proteins but also regulates them in a site-specific fashion. 
 
Brief rapamycin exposure alters localization and expression of proteins associated 
with mTORC1-related disorders 
Dysregulated mTORC1 signaling is implicated in many neurological disorders 
such as epilepsy, Alzheimer’s disease (AD), and autism spectrum disorder (ASD) (Pei and 
Hugon, 2008; Swiech et al., 2008). We thus examined our data for disease-related proteins 
whose expressions were upregulated in a region-specific fashion during a brief reduction 
in mTORC1 activity. Like Kv1.1, these newly identified proteins that are upregulated with 
mTORC1 inhibition could potentially serve as novel therapeutic targets (Wykes et al., 
2012). Using available databases, we compiled a list of proteins associated with epilepsy 
(from CarpeDB), Alzheimer’s disease (AlzGene and KEGG Alzheimer’s disease pathway 
(hsa05010)) and ASD (SFARIgene) (Table S7A, available online). We then determined 
which of these candidate genes appeared in our MS/MS datasets (Table S7B, available 
online). This list was then filtered to remove all mitochondrial genes. Proteins that were 
detected in two out of three samples per treatment or absent in all samples were considered 
for fold-expression and spatial distribution analyses as indicated on the heat maps (Figure 
2.3). Notably, ~11% of the disease-related proteins showed changes where mTORC1 
activity had a different impact depending on the subcellular fraction. Our analyses suggest 
that proteins associated with aberrant mTORC1 disorders are differentially regulated at the 
subcellular level by mTORC1 activity. 
We detected 38 epilepsy-associated proteins (Figure 2.3, Table S8). A brief 1 hour 
reduction of mTORC1 signaling was sufficient to alter the expression of select proteins 
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Figure 2.3: mTORC1 inhibition swiftly alters the expression of epilepsy, Alzheimer’s 
disease (AD) and autism spectrum disorder (ASD) proteomes in a region-
specific fashion 
Epilepsy genes were obtained from the CarpeDB epilepsy gene database. AD genes were obtained 
from the AlzGene (top 10 list) and the KEGG Pathway Database for AD (KEGG hsa05010). ASD 
genes were obtained from the Simons Foundation Autism Research Initiative (Table S7-S8, 
available online). For heat maps, textured icons indicate out-of-range proteins with fold-changes of 
0/Control (red textured) or Rapa/0 (yellow textured). Grey indicates that the protein was not 
detected in the fraction. Textured grey indicates that the fold-change was not quantifiable because 
only 1 of the 3 biological replicates for that treatment condition produced a non-zero spectral count 
value. A. Heatmap showing the log2 fold-change for the epilepsy proteins. B. Heatmap showing 
the log2 fold-change for the AD proteins. C. Heatmap showing the log2 fold-change for the ASD 
proteins. 
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bidirectionally with ~23% (red) and ~17% (yellow) increasing their expression when 
mTORC1 is active and inhibited, respectively (beyond ± 0.5 log2 fold change; Table S8 
online). Cyclin-dependent kinase 5 (CDK5), a molecule that regulates synaptic activity and 
neurological pathology, was present in Lysates and Soluble under control conditions 
 (Figure 2.3, Table S8 online) (Barnett and Bibb, 2011; Su and Tsai, 2011).  Upon 
repression of mTORC1, CDK5 was no longer detected in Lysates, but its expression was 
increased (139% of control) in Soluble. As expected, Kv1.1 protein (KCNA1) was only 
detected in the soluble fraction when mTORC1 was repressed, confirming our previous 
findings (Raab-Graham et al., 2006; Sosanya et al., 2013; Sosanya et al., 2015a). Of 
particular interest were the highly prominent epilepsy-associated protein leucine-rich 
glioma inactivated-1 (LG1) (Anderson, 2010; Yokoi et al., 2012; Kegel et al., 2013; 
Ohkawa et al., 2013) and the plasma membrane fusion protein synaptosomal-associated 25 
kDa (SNAP-25) (Rizo and Sudhof, 2002; Catterall and Few, 2008; Selak et al., 2009; Lau 
et al., 2010; Ovsepian and Dolly, 2011; Tomasoni et al., 2013).  Rapamycin increased the 
expression of LGI1 (L=159%, P=129% of control) and SNAP-25 (L=145%, P=171% of 
control) in Lysates (L) and PSD (P) while reducing them in Soluble (LGI1=65%, 
SNAP25=57% of control). These findings are very promising as LGI1, a putative tumor 
suppressor protein, is viewed as an antiepileptogenic protein that modulates presynaptic 
release probability and postsynaptic glutamate receptor function (Chernova et al., 1998; 
Fukata et al., 2006; Schulte et al., 2006; Zhou et al., 2009b; Fukata et al., 2010). SNAP25 
mRNA is present in the dendrites and may be subject to local translation (Cajigas et al., 
2012).  Postsynaptically, SNAP25 regulates the trafficking of glutamate receptors to and 
from the membrane (Selak et al., 2009; Lau et al., 2010; Ovsepian and Dolly, 2011; 
Tomasoni et al., 2013).  These findings are intriguing as they suggest that mTORC1 
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selectively and dynamically regulates regional protein expression perhaps through 
transport or localized translation or degradation. 
We identified 15 AD-related proteins (Figure 2.3, Table S8 online).  With mTOR 
activity, 12 proteins were similarly detected among Lysates, Soluble and PSD. 
Apolipoprotein E (ApoE) and α-synuclein (SNCA), hallmark proteins associated with AD 
and other neurodegenerative disorders, were present in Lysates and Soluble (Figure 2.3, 
Table S8) (Verghese et al., 2011; Korff et al., 2013). Interestingly, rapamycin shifted the 
spatial distribution of ApoE to PSD. We constructed a heat map to quantify in a region-
specific manner the effects of mTORC1 repression on AD-related proteins (Figure 2.3, 
Table S8 online).  We discovered that mTORC1 repression oppositely regulated the 
calcium-binding protein calmodulin (CALM1) in PSD and Soluble.  CALM1 is 
hypothesized to be the central integrator of synaptic plasticity (Xia and Storm, 2005).  
Since it is widely held that disrupted mTORC1 signaling strongly contributes to 
ASD, we examined the expression of ASD-associated proteins in our data (Kelleher and 
Bear, 2008; Bourgeron, 2009; Hoeffer and Klann, 2010; Sawicka and Zukin, 2012; Wang 
and Doering, 2013). We detected 18 proteins in control and rapamycin samples (Figure 
2.3, Table S8 online).  Of interest were the growth-associated protein 43 (GAP43) and 
Homer1b/c that reside in the PSD (Tu et al., 1999; Xiao et al., 2000; Han et al., 2013).  A 
brief suppression of mTORC1 robustly upregulated the long Homers – Homer 1b/c – 
(163% of control) while downregulating GAP-43 (63% of control) (Figure 2.3, Table S8 
online). We have previously shown that the mRNAs for GAP-43 and the activity-induced, 
short Homer, Homer1a, degrade upon mTORC1 inhibition (Workman et al., 2013).  
Homer1a and the long Homers 1b/c compete for the same targets (e.g. mGlu1/5 and 
GluN2B) within the PSD complex (Xiao et al., 1998; Shiraishi et al., 2003; Hayashi et al., 
2006; Shiraishi-Yamaguchi and Furuichi, 2007). We suspect that an increase in Homer 
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1b/c within PSD during acute mTORC1 inhibition reduces the downstream signaling of 
activated receptors (e.g. mGlu1/5 and GluN2B).  On the other hand, GAP-43 is closely 
linked to learning and memory (Benowitz and Routtenberg, 1997; Holahan et al., 2007). A 
report recently demonstrated that cleavage of postsynaptic Gap43 is required for NMDA-
induced internalization of the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
(AMPA)-subtype glutamate receptor (Han et al., 2013). Additionally, induction of seizures 
by kainic acid elevated GAP-43 mRNA (McNamara and Routtenberg, 1995). Thus, 
disruption of GAP-43 and Homer 1b/c may serve as the initial molecular events that usher 
in behavioral seizures.  Conversely, reducing GAP-43 and increasing Homer 1b/c may 
mitigate the induction or perpetuation of seizures. 
 
Rapid mTORC1 inhibition bidirectionally regulates protein syntheses of GAP-43 
and SNAP-25 
A few proteins appeared to be upregulated in the PSD at one hour after mTORC1 
inhibition (Figure 2.3). We focused our attention on SNAP-25 as reduction of SNAP-25 
has been observed in age-related dementia including AD (Greber et al., 1999; Honer, 2003; 
Honer et al., 2012). This reduction has been largely attributed to a loss of synapses or 
dysfunction of presynaptic vesicular release (Greber et al., 1999; Washbourne et al., 2002; 
Honer, 2003; Honer et al., 2012). Unexpectedly, we found SNAP-25 to be upregulated in 
the PSD with rapamycin treatment, arguing that SNAP-25 may be important 
postsynaptically as well. To determine if the increase in SNAP-25 in the PSD with 
mTORC1 inhibition was due to new protein synthesis we used bio-orthogonal non-
canonical amino acid tagging (BONCAT) and proximity ligation assay (PLA) in tandem, 
after repressing mTORC1 for one hour in cultured hippocampal neurons (Figure 2.4) (tom 
Dieck et al., 2015; Workman et al., 2015). BONCAT identifies newly synthesized proteins
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Figure 2.4: mTORC1 suppression oppositely alters the appearance of new SNAP-25 and 
GAP-43 
A. Representative merged images of newly synthesized SNAP-25 protein (green) as determined by 
BONCAT-PLA when mTORC1 is active (left) or repressed (right) in or near MAP2-positive 
dendrites (red) of hippocampal cultured neurons. Scale bar = 20 μm. B. Blown up dendrite outlined 
in A. by a dotted box. Control- (left) and rapamycin-treated (right) dendrite showing new SNAP-
25 (top), MAP2 (middle), and merged image (bottom). Arrows indicate new SNAP-25 protein. 
Scale bar = 5 μm. C. Quantification of new SNAP-25 localized within or near the dendrite. Note, 
SNAP-25 increases with rapamycin. (DMSO = 1.00 ± 0.20, n = 33 dendrites; RAPA = 2.18 ± 0.34, 
n = 37 dendrites). D. Representative merged images of newly synthesized GAP-43 protein (green) 
and MAP2-positive dendrites (red) and cell bodies treated with carrier (left) or rapamycin (right). 
Scale bar = 20 μm. E. Blown up dendrite outlined in D by a dotted box. Control- (left) and 
rapamycin-treated (right) dendrite showing new GAP-43 (top), MAP2 (middle), and merged image 
(bottom). Arrows indicate new GAP-43 protein. Scale bar 5 = μm. F. Quantification of new GAP-
43 protein in or near dendrites. Note, GAP-43 protein synthesis is reduced with rapamycin. (DMSO 
= 1.00 ± 0.12, n = 38 dendrites; RAPA = 0.39 ± 0.08, n = 30 dendrites). MAP2 signal is saturated 
for visualization purposes to clearly see all dendritic branches associated with new SNAP-25 or 
GAP-43. Statistics: **, p < 0.01; ***, p < 0.001; Student's t test.
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that incorporate an azidohomoalanine (AHA)-tagged non-canonical amino acid. Using 
alkyne-azide click chemistry, proteins that contain AHA are labeled with biotin. In 
combination with PLA, which emits a fluorescent signal only when two antibodies (anti-
biotin and anti-SNAP-25) are within 30-40 nm of each other, we are able to identify new 
SNAP-25 protein specifically. Rapamycin, as predicted, increased new SNAP-25 in 
dendrites (2.18 + 0.34 of control; Figure 2.4A-C). We selected GAP-43 protein as a control 
that is down-regulated in PSD with mTORC1 inhibition (Han et al., 2013). Consistent with 
our MS/MS analyses showing reduced GAP-43 in PSD, we previously showed that Gap-
43 mRNA decays with mTORC1 inhibition (Sosanya et al., 2013). Since our MS/MS data 
showed that GAP-43 is reduced in the PSD, we suspected that mTORC1 inhibition 
attenuates GAP-43 protein synthesis. Indeed, there was a significant reduction in new 
GAP-43 in rapamycin-treated neurons relative to control neurons (0.39 + 0.08 of control; 
Figure 2.4D-F), supporting our previous report that mTORC1 inhibition reduces Gap-43 
mRNA (Sosanya et al., 2013). We noticed that the signal for both SNAP-25 and GAP-43 
within or near dendrites was punctate—perhaps suggesting synaptic localization. We 
attempted to co-label pre- and postsynaptic sides of the synapse in combination with 
BONCAT-PLA. However, the antibodies for the presynaptic protein synapsin and the 
postsynaptic protein PSD-95 did not work after the BONCAT-PLA procedure. 
Nevertheless, these data do suggest that inhibition of mTORC1 for one hour promotes new 
synthesis of SNAP-25 protein while reducing synthesis of new GAP-43. 
 
Acute mTORC1 repression bidirectionally regulates the expression of SNAP-25 and 
GAP-43 in the PSD 
To determine if changes in expression of SNAP-25 and GAP-43 with mTORC1 inhibition 
are synaptic, we treated cultured hippocampal neurons with carrier (control) or rapamycin 
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(200 nM) for one hour. We subsequently immunostained for GAP-43 or SNAP-25, while 
co-staining for MAP2, PSD-95, and synapsin to visualize SNAP-25 and GAP-43 at the 
synapse. We then asked if the amount of SNAP-25 or GAP-43 that colocalizes with the 
pre- or postsynaptic terminals changes with mTORC1 activity. To do this we determined 
the amount of colocalized protein by plotting the fluorescence intensity of GAP-43 or 
SNAP-25 with the intensity of PSD-95 or synapsin and calculated the Pearson’s correlation 
coefficient (PCC) on a pixel-by-pixel basis. Since both SNAP-25 and GAP-43 have been 
best characterized presynaptically, we used the PCC between SNAP-25 or GAP-43 and 
synapsin to normalize between conditions (Rizo and Sudhof, 2002; Powell, 2006). We 
found that rapamycin-treated neurons expressed more SNAP-25 that colocalized with the 
postsynaptic protein PSD-95, shifting its normalized PCC from 1.6 ± 0.12 to 2.1 ± 0.07 
(Figure 2.5A-D). In contrast, rapamycin reduced the normalized PCC between GAP-43 
and PSD-95 from 1.36 ± 0.08 to 1.0 ± 0.09 (Figure 2.5E-H). Interestingly, rapamycin had 
no significant effect on the normalized PCC for either SNAP-25 or GAP-43 with the 
presynaptic protein synapsin. Consistent with the localization of Gap-43 and Snap-25 
mRNAs in the dendrites, our finding s show that GAP-43 and SNAP-25 proteins are 
present postsynaptically (Ovsepian and Dolly, 2011; Cajigas et al., 2012). Moreover, we 
demonstrate that acute mTORC1 inhibition oppositely regulates the colocalization of 
SNAP-25 and GAP-43 with the postsynaptic marker PSD-95. 
DISCUSSION 
Combined neuroproteomics approach sets a framework for new discoveries in 
mTORC1-dependent synapse remodeling 
To generate a comprehensive view of acute mTORC1 function, we have employed 
tandem mass spectrometry in concert with bioinformatics analyses. Our multi-pronged  
 96 
 
Figure 2.5: Rapid mTORC1 repression bidirectionally modifies subcellular expression of 
SNAP-25 and GAP-43 
A. Representative images of neurons showing differential expression of SNAP-25 (red) 
colocalizing with the postsynaptic density protein PSD-95 (green) and the dendritic protein MAP2  
 97 
 
approach has demonstrated that mTORC1 widely acts on protein expression by inducing 
differences in regional expression of proteins and the appearance and disappearance of 
proteins within a rapid timescale. One of the most striking findings is that ~75% of the 
proteins found within the PSD fraction change in abundance, suggesting that mTORC1’s 

















(blue) when mTORC1 is active (DMSO, left panel) or repressed (Rapamycin, right panel). Scale 
bar = 20 μm. See also supplemental Figure S3. B. Blown up dendrites, indicated by dotted box 
in A, of SNAP-25 (top), PSD-95 (middle) and merged image showing colocalization (bottom). 
White arrows indicate SNAP-25 that colocalize with PSD-95. Blue arrows indicate SNAP-25 
that colocalize with synapsin. C. Same dendrite as in B., representative staining of the presynaptic 
protein synapsin (top) colocalized with SNAP-25 (bottom, merged). Scale bar = 5 μm. D. 
Normalized PCC averaged over many dendrites for SNAP-25 and the postsynaptic marker PSD-
95 or the presynaptic marker synapsin and SNAP-25. All raw PCC values were normalized to 
the average PCC between SNAP-25 and synapsin in control condition (DMSO, D). Dotted line 
indicates the average normalized PCC between SNAP-25 and synapsin in control condition. 
Note, there was an increase in the PCC of SNAP-25 with PSD-95 in rapamycin treatment 
(DMSO, D, = 1.63 ± 0.12, n = 34 dendrites; Rapamycin, R, = 2.12 ± 0.07, n = 24 dendrites). 
There was no significant difference in PCC between treatments for SNAP-25 and synapsin 
(DMSO = 1.00 ± 0.13, n = 34 dendrites; Rapamycin = 1.16 ± 0.11, n = 24 dendrites). E. 
Representative images of neurons showing differential expression of GAP-43 (red), PSD-95 
(green), and MAP2 (blue) when mTORC1 is active (DMSO, left panel) or repressed (Rapamycin, 
right panel). Scale bar 20 μm. F. Blown up dendrites, indicated by dotted box in E., of GAP-43 
(top), PSD-95 (middle) and merged image showing colocalization (bottom). White arrows 
indicate GAP-43 that colocalize with PSD-95. Blue arrows indicate GAP-43 that colocalize with 
synapsin. See also supplemental Figure S3, available online. G. available online, Same dendrite 
as in F., representative staining of synapsin (top) colocalized with GAP-43 (bottom, merged). 
Scale bar = 5 μm. H. Normalized PCC averaged over many dendrites for GAP-43 and the 
postsynaptic marker PSD-95 or the presynaptic marker synapsin and GAP-43. All raw PCC 
values were normalized to the average PCC between GAP-43 and synapsin in control condition 
(DMSO, D). Dotted line indicates the average normalized PCC between GAP-43 and synapsin 
in control condition. Note, there was a decrease in the normalized PCC of GAP-43 with PSD-95 
in rapamycin treatment (DMSO, D, = 1.36 ± 0.08, n = 36 dendrites; Rapamycin, R, = 1.00 ± 0.09, 
n = 36 dendrites). There was no significant difference in PCC between treatments for GAP-43 
and synapsin (DMSO = 1.00 ± 0.09, n = 36 dendrites; Rapamycin = 0.92 ± 0.08, n = 36 dendrites). 
Statistics: *, significantly different by one-way ANOVA, Tukey's multiple comparison; #, 
significantly different by single t test from PCC of SNAP-25 or GAP-43 with synapsin in DMSO. 
Chicken anti-MAP2 was imaged with 405 nm laser (see “Experimental Procedures”) 
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mTORC1 signaling dynamically and bidirectionally regulates protein expression 
Numerous studies have established the positive function of mTORC1 activation on 
protein expression, but very few have examined its opposite effect (Raab-Graham et al., 
2006; Auerbach et al., 2011; Laplante and Sabatini, 2012; Sosanya et al., 2013). Having 
previously demonstrated in cultures that repression of mTORC1 by rapamycin increases 
Kv1.1 translation locally in dendrites, we present here that reduction of mTORC1 activity 
in vivo upregulates protein expression in a region-specific manner (Raab-Graham et al., 
2006). Specifically, we observe that ~30% of proteins in the PSD are elevated upon 
mTORC1 repression (Fig. 2.2D). One of these proteins is SNAP-25, which markedly 
increased in the PSD at one hour after inhibiting mTORC1. While SNAP-25, a part of the 
SNARE complex, has been best characterized for its presynaptic role in neurotransmitter 
release, reduced levels are associated with postsynaptic dysfunction. Notably, these include 
phenotypes that are associated with ASD such as reduced spine density, amplitude of 
miniature excitatory postsynaptic potentials (mEPSP), and activity induced forms of 
potentiation (Tavazoie et al., 2005; Aldinger et al., 2011; Durand et al., 2012; Antonucci 
et al., 2013; Fossati et al., 2015). Moreover, SNAP-25 has recently been shown to facilitate 
the removal of kainate receptors (KARs), which are implicated in epileptogenesis, from 
the membrane surface (Rizo and Sudhof, 2002; Catterall and Few, 2008; Selak et al., 2009; 
Vincent and Mulle, 2009; Lau et al., 2010; Ovsepian and Dolly, 2011; Tomasoni et al., 
2013). Our results may help explain why in part rapamycin reduces seizure frequency in 
mTOR-related diseases, possibly through the increased expression of SNAP-25 in the PSD 
and the removal of KARs. 
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Combined mass spectrometry and bioinformatics approaches sets a framework for 
new discoveries in mTORC-1 dependent physiology 
A great body of work has characterized the molecular hallmarks of diseases 
involving protracted mTORC1 dysregulation.  However, the early molecular changes that 
contribute to the disease phenotypes have largely remained unexplored. Biochemical, 
immunohistochemical, and functional approaches used in conjunction can definitively 
determine signaling pathways.  However, these approaches are time-consuming and 
limited to reagents available and molecules being considered. Using rapid mTORC1 
repression as a paradigm of the early onset occurring in dysregulated mTORC1 signaling, 
we have discovered dynamic changes in protein expression globally and regionally.  Our 
large scale proteomic approach demonstrates that the expressions of disease-associated 
proteins are already changing after acutely disrupting mTORC1 activity. These protein 
changes are maintained during the clinical presentation of many diseases in which 
mTORC1 is disrupted.  Therefore, proteins that we have identified that change in rapid 
repression of mTORC1 may serve as valuable markers for the early detection of 
neurodegenerative illnesses. Our large-scale approach in identifying mTORC1-responsive 
proteins offers multiple targets that can potentially restore neurological deficits. In 
addition, targeting these proteins instead of mTORC1, which influences many biological 









Figure 2.6: Quantitation of standard errors in spectral counts measurements across 
treatments for Lysates 
                                                 
5 Remaining supplemental figures may be found online as supplemental material available from Molecular 
and Cellular Proteomics in (Niere et al., 2016). See also, Appendix E. 
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Figure 2.7: Quantitation of standard errors in spectral counts measurements across 
treatments for PSD and Soluble (SOL) fractions 
A. To determine the reliability of our spectral count data, standard errors for each protein within a 
treatment were computed and then normalized by the mean spectral count for that protein. The y-
axis represents the mean standard error across all proteins within the particular treatment and the 
error bars indicate the SEM for this mean value. PSD, DMSO = 0.222 ± 0.007, PSD, RAPA = 
0.198 ± 0.006; SOL, DMSO = 0.184 ± 0.005, SOL, RAPA = 0.179 ± 0.005. B. Table showing 
correlations between spectral counts across different replicates for each treatment/fraction across 
















DMSO 605 224 1498 0.060 4.055 
0.319 ± 0.16 0.735 ± 0.16 16.458 ± 8.56 
p < 0.01b 
p < 0.01a p < 0.01a 
p < 0.01b p < 0.01b 
Rapamycin 593 211 1370 0.062 4.139 
0.325 ± 0.19 0.739 ± 0.16 15.88 ± 7.32 
p < 0.01b 
p < 0.01a p < 0.01a 
p < 0.01b p < 0.01b 
 
Table 2.1: Summary of network statistics 
Mean statistics are listed with their standard deviations. aKolmogorov-Smirnov test comparing network to randomly generated network. Random 
networks (undirected) represent randomized forms of the networks they are compared to. bTOST Equivalency test comparing one network to another 
experimental treatment network within each fraction. Wilcoxon-Mann-Whitney test was used to determine TOST p-values.
                                                 
6 Remaining supplemental tables may be found online as supplemental material available from Molecular and Cellular Proteomics in (Niere et al., 2016). See 
also Appendix E 
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METAL ION TRANSPORT GO:0030001 35 4.18 x 10-4 
RESPONSE TO METAL ION GO:0010038 15 5.78 x 10-4 
REGULATION OF PROTEIN MODIFICATION PROCESS GO:0031399 26 2.85 x 10-4 
REGULATION OF SECRETION GO:0051046 20 4.20 x 10-4 
LEARNING GO:0007612 12 1.97 x 10-5 
NUCLEOTIDE CATABOLIC PROCESS GO:0009166 9 8.06 x 10-4 
NEGATIVE REGULATION OF PROTEIN MODIFICATION PROCESS GO:0031400 16 6.92 x 10-5 
REGULATION OF CELLULAR PROTEIN METABOLIC PROCESS GO:0032268 35 5.91 x 10-4 
PROTEIN HOMOOLIGOMERIZATION GO:0051260 13 3.55 x 10-4 
HETEROCYCLE CATABOLIC PROCESS GO:0046700 11 8.71 x 10-4 
SYNAPTIC VESICLE MATURATION GO:0016188 4 5.79 x 10-4 
NEGATIVE REGULATION OF CELLULAR PROTEIN METABOLIC PROCESS GO:0032269 18 7.93 x 10-4 
ION HOMEOSTASIS GO:0050801 31 8.48 x 10-4 
PURINE NUCLEOTIDE CATABOLIC PROCESS GO:0006195 8 2.54 x 10-4 
REGULATION OF MEMBRANE POTENTIAL GO:0042391 15 8.46 x 10-4 
TRANSLATION GO:0006412 27 6.99 x 10-4 
RESPONSE TO ORGANIC CYCLIC SUBSTANCE GO:0014070 14 9.88 x 10-4 
RESPONSE TO ORGANIC NITROGEN GO:0010243 10 7.79 x 10-4 
Rapamycin 
CELL REDOX HOMEOSTASIS GO:0045454 10 7.19 x 10-4 
MICROTUBULE-BASED PROCESS GO:0007017 23 3.91 x 10-4 
GLUCONEOGENESIS GO:0006094 7 3.26 x 10-4 
CELLULAR ALDEHYDE METABOLIC PROCESS GO:0006081 8 7.77 x 10-5 
RESPONSE TO REACTIVE OXYGEN SPECIES GO:0000302 11 6.47 x 10-4 
 
Table 2.2: Unique GO Terms in Lysates by Experimental Treatment 
 
Table shows unique GO terms between DMSO and Rapa treatments. p-values (DAVID EASE score, modified Fischer exact test p-value) 
generated using the DAVID Functional Annotation Chart. Average p-values for lysate fraction: 5.67 x 10-4 (DMSO), 4.32 x 10-4 (Rapa).
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Chapter 3: Bioinformatic approaches identify PARK7 as a novel 
protein aberrantly expressed in Tuberous Sclerosis Complex7,8 
 
INTRODUCTION 
 The process of learning and memory is dependent on the expression of a wide 
variety of molecules such as ion channels that can modulate the strength or weakness of 
synaptic transmission between neighboring neurons (Zhang and Linden, 2003; Kim and 
Hoffman, 2008). Since each synaptic connection is unique, a coordinated effort on the part 
of the molecules within the synapse is required to establish and maintain the connections 
between the pre- and post-synaptic cells. These processes rely on a large number of 
proteins, such as the mechanistic/mammalian target of rapamycin serine/threonine protein 
kinase (mTOR), that can alter the molecular composition of the synapse (Dazert and Hall, 
2011; Wang and Proud, 2011; Laplante and Sabatini, 2012; Betz and Hall, 2013; Costa-
Mattioli and Monteggia, 2013; Kaeberlein, 2013; Wang et al., 2013; Abelaira et al., 2014; 
Lipton and Sahin, 2014; Wong, 2014; Crino, 2015; Lan et al., 2016; Sato, 2016). mTOR 
and other important proteins are responsible for regulating the translation of dendritically-
localized mRNA so that they can be rapid expressed in the correct temporal and spatial 
dimensions. RNA-binding proteins (RBPs) play a key role in these regulatory processes 
and disruptions result in neuronal dysfunction and disease (Giese and Mizuno, 2013; 
Lipton and Sahin, 2014).  
                                                 
7 Niere, F., Namjoshi, S., Song E., Dilly, G.A., Schoenhard, G., Zemelman, B.V., Mechref, Y., Raab-
Graham, K.F. (2016). Analysis of Proteins That Rapidly Change Upon Mechanistic/Mammalian Target of 
Rapamycin Complex 1 (mTORC1) Repression Identifies Parkinson Protein 7 (PARK7) as a Novel Protein 
Aberrantly Expressed in Tuberous Sclerosis Complex (TSC). Mol Cell Proteomics 15(2): 426-44. doi: 
10.1074/mcp.M115.055079. I wrote half of the manuscript, performed bioinformatics analysis, prepared all 
tables, and prepared figures 3.1 and 3.2. 
8 Some tables and figures available online only from Molecular Cellular Proteomics. 
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mTOR signaling is known to be dysregulated in Tuberous Sclerosis Complex 
(TSC) (Huang and Manning, 2008; Swiech et al., 2008; Zeng et al., 2009). TSC is a 
multisystem disorder which in the central nervous system manifests itself in the form of 
epilepsy, ASD, and intellectual disabilities (Inoki et al., 2003; Tavazoie et al., 2005; Inoki 
et al., 2006; Crino, 2008; Bourgeron, 2009; Bateup et al., 2011; Zeng et al., 2011; Sahin, 
2012; Bateup et al., 2013). At the cellular level, synaptic plasticity is altered in mouse 
models of TSC. TSC consists of two obligate subunits, TSC1 and TSC2. The TSC complex 
inhibits mTOR activity. Importantly, disease causing mutations in either TSC1 or TSC2 
lead to overactive mTOR signaling. However, what mRNAs are repressed in TSC and how 
their translation is regulated are still open questions. 
Parkinsonian-Associated Protein 7 (PARK7 or DJ-1) is a small 24 kDa RBP with 
a highly-conserved structure (Cookson, 2004) and has been shown to regulate translation 
of a number of RNA transcripts by direct binding (van der Brug et al., 2008). Specifically, 
PARK7 associates with GC-rich transcripts involved in mitochondrial homeostasis, the 
PTEN/Akt survival pathway, apoptosis, and glutathione synthesis. The regulatory effects 
of PARK7 are lost under oxidative stress conditions. Recently, it was demonstrated that 
yeast PARK7 homologs and TORC1 (an mTOR homolog) are co-localized in stress 
granules and in P-bodies (Miller-Fleming et al., 2014). Both of these structures form in the 
cytoplasm (in neuronal as well as other cell types) under highly stressed conditions and 
allow for the rapid, local translation of a specific set of mRNAs needed to quickly respond 
to a stressed environment or to be sequestered to prevent translation. TORC1 is also known 
to be localized to stress granules under heat shock (Takahara and Maeda, 2012). Finally, 
PARK7 binds to components of the ribosome small and large subunit as well as other 
proteins (Jin et al., 2007). 114 of these proteins showed significant changes in abundance 
upon treatment with rotenone, a pesticide that produces PD-like phenotypes in animal 
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models (Jin et al., 2007). These new findings strongly point to a connection between 
mTORC, PARK7, and translational dysfunction at the synapse. 
Although PARK7 is best known for its involvement in Parkinson’s disease, its role 
in mRNA translational regulation, synaptic plasticity, and diseases such as Autism 
Spectrum Disorders (ASD) or TSC, diseases associated with epilepsy and overactive 
mTOR signaling, is not known (Zeng et al., 2009; Noebels, 2011; Wong, 2014; Lee et al., 
2015). Here we apply multiple bioinformatics approaches to better clarify the role of 
PARK7 in these disorders including a novel role in TSC. Our results demonstrate the power 
of bioinformatics in revealing unknown connections between neuronal disease and offer 
possibilities for how these neuronal dysfunctions may be treated on a pharmacological 
level through drug discovery. 
 
EXPERIMENTAL PROCEDURES 
Western blot analysis 
Proteins were separated by SDS-polyacrylamide gel electrophoresis (PAGE). To 
visualize the proteins, we used the following antibodies: rabbit anti-phospho-mTOR 
Ser2448 (1:2,000; Cell Signaling), mouse anti-mTOR (1:5,000; Life Technologies), mouse 
anti-Park7 (1:2000; Novus Biologicals) mouse anti-PSD-95 (1:10,000; NeuroMab), mouse 
anti-synapsin 1 (1:10,000; Synaptic Systems), rabbit polyclonal anti-α tubulin (1:50,000; 
Abcam), mouse ribosomal S6 (1:1000, Cell Signaling) and rabbit anti-phospho-S6 (1:1000, 
Cell Signaling). Membranes were subsequently incubated in fluorescence-conjugated 
secondary antibodies (AF680, Life Technologies; AF800, LiCor; 1:5000). Using the 
Odyssey CLx infrared imaging system, we obtained fluorescent images of the membranes. 
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ImageJ (National Institutes of Health) software was used for densitometry analyses of 
proteins. 
 
Bioorthogonal non-canonical amino acid tagging and Proximity ligation assay 
tandem (BONCAT-PLA) 
Visualization of new proteins was conducted similar to (Workman et al., 2015). 
Following incubation of 21 DIV hippocampal neurons in 500 μL methionine-free media 
for 30 minutes at 37°C, azidohomoalanine (AHA, Life Technologies) and equal volume of 
rapamycin (final concentration = 200 nM) or DMSO were added to the media. 1 hour after 
treatment, cells were fixed as described by (tom Dieck et al., 2015; Workman et al., 2015). 
Click-it metabolic labeling was then performed according to manufacturer’s instructions 
(Life Technologies). Biotin-alkyne was used to detect new proteins. PLA was subsequently 
conducted according to manufacturer’s directions (Duolink, Sigma). Mouse, anti-biotin 
(1:500, Abcam), rabbit anti-GAP-43 (1:500, Abcam), rabbit anti-SNAP-25 (1:100, 
Abcam), mouse anti-PARK7 (1:1000, Sigma), rabbit anti-biotin (1:500, Sigma), and 
chicken anti-MAP2 (1:2000, Abcam) antibodies were used. 
 
Stereotaxic in vivo virus injection and hippocampal immunohistochemistry 
To remove TSC1 in Tsc1 conditional knockout mice (Tsc1tm1Djk/J, Jackson 
Laboratory), Cre-recombinase and GFP packaged in adeno-associated virus (AAV-Cre and 
AAV-GFP) were stereotaxically injected into the hippocampus of 7 to 8 week-old male 
mice as described (Workman et al., 2015). The following coordinates (from bregma) were 
used: −2.2 mm A/P, +/− 1.5 mm M/L; −2.5 mm A/P, and +/− 1.6 mm M/L. Two weeks 
after injection, mice were transcardially perfused with phosphate buffered saline (0.1 M) 
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and the brains were postfixed in 4% paraformaldehyde. 50 μm thick hippocampal slices 
were prepared and checked for GFP expression. Slices that expressed GFP were processed 
from immunohistochemistry as described (Hays et al., 2011) using the following primary 
antibodies: mouse anti- PARK7 (1:100, Sigma Aldrich), guinea pig anti-PSD95 (1:100, 
Synaptic Systems), and chicken anti-MAP2 (1:500). After overnight primary antibody 
incubation in 4°C, the following secondary antibodies were used: AF405, Cy3, and AF647. 
 
Image analysis 
For PSD-95 and synapsin colocalization analysis, Z-stacks of 9 planes at 0.5 
μm/plane for each dendrite were imaged. Only one plane that had the strongest signal from 
the protein of interest was analyzed. The Pearson’s correlation coefficient (PCC) was 
determined using the ImageJ plugin JACoP. The same threshold value was applied across 
all conditions using the threshold function in ImageJ. For BONCAT-PLA, Z-stacks of 8-9 
planes at 0.5 μm/plane were imaged. For BONCAT/PLA analysis, 2 planes, for a total of 
1 μm thickness that had the brightest MAP2 signals were max projected using ImageJ. The 
projected images were analyzed for PLA and MAP2 immunofluorescence (IF). PLA and 
MAP2 signals were thresholded to at least thrice above background that remained constant 
within an experiment. To determine the background for each signal in Metamorph, the 
average fluorescence intensity in a circular region of ~90 μm adjacent to the region of 
interest was obtained. The dendritic PLA value for each protein was normalized to the 
corresponding MAP2 IF as a volume control. For BONCAT-PLA measurements, the 
product of the total area, intensity, and puncta number of BONCAT-PLA in each dendrite 
was quantified. Dendritic MAP2 IF was determined by multiplying the total area and 
average intensity of MAP2. The BONCAT-PLA/MAP2 values were normalized to the 
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average BONCAT-PLA/MAP2 of control (DMSO) dendrites to reflect the total change in 
protein with treatment. Secondary dendrites (50 μm long and 1 μm thick) were used for 
analysis to minimize variability in dendritic caliber. To quantify dendritic PARK7 in 
hippocampal slices, Z-stacks of 12 planes were used at 1 μm/plane. Only 1 plane where 
MAP2 signal is distinct but not saturated was analyzed. For each dendrite, the product of 
the total area and intensity of PARK7 was determined and normalized to its corresponding 
MAP2 immunofluorescence as a volume control. Each dendritic PARK7/MAP2 value was 
normalized to the average PARK7/MAP2 of wildtype dendrites. To outline the dendrites 
in hippocampal slices, the MAP2 signal was saturated to define the dendrite. The “Find 
Edges” function in ImageJ was used to create an outline of the dendrite. 
 
Bioinformatics 
Gene ontology clustering 
The unique protein lists for each condition described above were loaded into 
DAVID—an online tool for functional annotation and gene ontology clustering (Huang da 
et al., 2009a; 2009b). Data were analyzed in DAVID using the biological process 
(BP_FAT) ontology as well as the KEGG pathway database (KEGG_PATHWAY). We 
utilized the DAVID Functional Annotation Chart and Functional Annotation Clustering 
using the default settings (EASE score threshold = 0.1). DAVID EASE score is a modified 
version of the Fischer Exact p-value that allows for comparison of cluster enrichment. 
 
Protein-protein interaction network analysis 
Protein-protein interaction networks were generated using the BisoGenet plugin 
(Martin et al., 2010). Inputs were mapped as protein identifiers using protein-protein 
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interaction data from the BioGRID and MINT databases. Network was built by adding 
neighbors to seed proteins up to a distance of 2. Our output network was represented in 
terms of proteins. Networks were analyzed using degree, betweenness and closeness 
centrality network statistics. Hub proteins were identified using the degree network 
statistic. 
 
Determining PARK7 binding motifs 
A CLIP study for PARK7 revealed the presence of multiple binding motifs among 
the isolated targets (van der Brug et al., 2008). The authors of this work present their data 
as a 45-nucleotide long consensus logo that collectively summarizes the most probable 
nucleotides per position for all recovered CLIP tags. Since the typical RNA-binding motif 
is of length 6 nucleotides, we constructed a list of all possible substrings of this length from 
the consensus logo. Each substring was then ranked based on the sum of its probability 
values based on the probabilities derived from the consensus logo. We found that 
sequences contained the two motifs GNGCNG or CNGCNG occurred with highest 
probability. To find the frequency of occurrences for these motifs in a given DNA alphabet, 
we used the seqinr (Charif and Lobry, 2007) and Biostrings (Pages et al., 2016) packages. 
A graphical user interface for this process was developed using the shiny package (Chang 
et al., 2016) in R along with the DT package (Xie, 2016). PSD gene data obtained from the 
BAYES-COLLINS-MOUSE-PSD-CONSENSUS (Bayes et al., 2012) available online at 
G2C: Genes to Cognition database (http://www.genes2cognition.org/). All gene sequences 
were obtained using the biomart package (Durinck et al., 2005; Durinck et al., 2009; 
Smedley et al., 2015). 
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Connectivity Map (CMap) analysis of PARK7 PSD targets 
We obtained a list of putative PSD proteins (see above) and separated the lists into 
upregulated or downregulated genes based on our prior mass spectrometry data (Niere et 
al., 2016). We imported these gene lists to the Connectivity Map software online (Lamb et 
al., 2006; Lamb, 2007). We took the top compounds that were returned and then used 
LigDig (Fuller et al., 2015) to find their pubchem IDs. The resulting IDs were then 
imported into R. We then used the chemmineR package (Cao et al., 2008) to determine the 
pubchem footprint of each compound. The similarity of these footprints can then be 
assessed by hierarchical clustering and visualized as a heatmap. We used the pheatmap 
package (Kolde, 2015) to create the clustered dendrogram and heatmap. 
 
RESULTS 
Protein-protein interaction network analysis exposes Snca and Park7 as novel 
protein hubs shared by epilepsy, AD and ASD 
Seizures are commonly observed in epilepsy, AD, and ASD. We, therefore, 
considered the possibility that the proteins linked to these disorders (Figure 3.1) interact 
with each other in some way to elicit a shared disease phenotype. Using a Venn diagram 
to determine which of the previously identified candidate proteins are common in epilepsy, 
AD and ASD, we found that few if any were shared by the three disorders (Figure 3.1A; 2 
genes from published data (left) and 0 genes from our data (right)). We next sought to 
determine potential protein-protein interactions (PPI) using epilepsy-, AD-, and ASD-
related proteins from our MS/MS data. To do this, we first created a PPI network for each 
disease by seeding each network with its relevant disease-related proteins (48 for epilepsy, 
44 for AD, and 19 in ASD). We then constructed each network by adding neighbors to the 
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Figure 3.1: Protein-protein interaction (PPI) network analysis determines Parkinson 
protein 7 (PARK7) as a candidate molecule that may give rise to pathologies 
common in epilepsy, AD and ASD 
A. Venn diagrams depicting candidate genes between epilepsy, Alzheimer’s disease (AD), and 
autism spectrum disorder (ASD). (Left, Databases) Venn diagram for genes obtained from disease 
databases (Table S7A, available online). The genes in the intersection include amyloid precursor 
protein (APP) and glutamate receptor ionotropic, N-methyl-D-aspartate 2A (Grin2A/GluN2). 
(Right, our data) Subset of left Venn diagram showing only those genes present in our dataset. B. 
Protein-protein interaction networks for epilepsy (left), AD (right), and ASD (bottom) based on  
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seed proteins up to a distance of two nodes to exact intimate protein interactions (Figure 
3.1B, left, right, bottom). Using the degree statistic, we looked for the top nodes that formed 
the largest number of connections to other nodes (Table 3.1 A1-3), thus allowing us to 
identify intermediate molecules (herein referred to as hubs) that may link proteins 
implicated in epilepsy, AD, and ASD. To identify common hubs for all three disorders, we 
created a network using all 102 proteins identified in these diseases (Fig. 3.1B, center). 
The combined network identified several candidate common hubs (Table 3.1A4, top 10 
hubs), with mitogen-activated protein kinase 3 (MAPK3), small ubiquitin-like modifier 3 
(SUMO3), α-synuclein (SNCA), and Parkinson protein 7 (PARK7/DJ-1) demonstrating 
the highest degree statistics in epilepsy, AD, and ASD (Figure 3.1B, center). To verify that 
these common hubs were specific to epilepsy, AD, and ASD, we chose 102 random 
neuronal proteins from the R. norvegicus protein database (NCBI) and created a PPI 
network under the same parameters. MAPK3, SUMO3, SNCA, and PARK7 hubs were not 
identified as top candidates by the random PPI network, suggesting that the epilepsy-, AD, 
and ASD-associated proteins that we have identified from our MS/MS data are uniquely 
interconnected. 
Because these common hubs interact with a high number of proteins, altering the 
protein abundance of a hub could strongly affect the expression of neighboring proteins, as 
indicated by their exclusive connections to a cluster of proteins (Figure 3.1B, arrow from 
each hub pointing to green clusters or terminal hub proteins; Table 3.1). Although two of 




candidate genes. The combined PPI network (center) was seeded with epilepsy, AD and ASD 
candidate proteins found in our data set (Table S7B, available online). Network seed genes are 
represented by nodes colored in red (epilepsy), magenta (AD), blue (ASD), or orange (combined PPI 
network). Light blue nodes indicate intermediate PPI interactions between seed genes. Green nodes 
indicate proteins connected to hub proteins of high degree and/or betweenness centrality (highly 
trafficked or connected nodes), referred to in the text as “terminal hub proteins”. Proteins around 
central PPI network indicate proteins connected to the terminal hub proteins including PARK7. 
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PARK7 and SNCA (Figure 3.1B; Table S10, available online), none of them are currently 
identified as common to the epilepsy, AD, and ASD databases (Table S7A, available 
online). Moreover, while SNCA has been identified in AD (Figure 3.1B), PARK7 is absent 
in all three disorders. Our collective findings highlight the advantage of constructing PPI 
networks to identify common molecules that may underlie shared pathologic phenotypes 
of mTORC1-related disorders. 
 
PARK7 levels at the synapse require active mTORC1 
Because we identified PARK7 as a novel hub common to epilepsy, AD, and ASD 
(Figure 3.1B), we performed GO functional annotation to gain insight into how changes in 
PARK7 expression may alter the expression of terminal hub proteins (Figure 3.2A; Table 
S10C, available online). Not surprisingly, PARK7 is linked to translation-related 
processes, suggesting a putative central role in diseases with elevated mTORC1 activity 
and aberrant translation, like epilepsy, AD, and ASD (Figure 3.2A). Of note, our MS/MS 
data indicate that mTORC1 activity favors an overall increase in PARK7 throughout the 
dendrite with the biggest impact at the PSD (Figure 3.2B, heat map). After performing 
Western blot analysis on cortical PSD fractions isolated from rats that were i.p. injected 
with carrier or rapamycin for one hour (Figure 3.2C), we found that PARK7 was 
significantly reduced in the PSD by ~75% when mTORC1 was inhibited (Rapamycin = 
0.24 ± 0.10, Control = 1.00 ± 0.06, p<0.002), confirming our MS/MS data. 
Next, we measured the colocalization of PARK7 with the postsynaptic protein 
PSD-95 and the presynaptic protein synapsin. Remarkably, rapamycin reduced the 
normalized PCC of PARK7 and PSD-95 as well as PARK7 and synapsin from ~1.47 to 
1.17 and ~1.00 to 0.67, respectively (Figure 3.2D-G). Thus, our MS/MS, Western blot  
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Figure 3.2: mTORC1 activity regulates PARK7 protein expression in PSD and protein 
synthesis in dendrites 
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analysis, and colocalization findings show that mTORC1 inhibition reduces PARK7 at the 
synapse. 
If active mTORC1 increases total PARK7 protein through new translation, then 
rapamycin should reduce synthesis of new PARK7 protein. Surprisingly, using BONCAT-
PLA, we found that acute inhibition of mTORC1 reduced synthesis of new PARK7 
proteins in dendrites only by ~25% (Figure 3.2H-I; RAPA = 0.76 ± 0.05, Control = 1.00 ± 
0.11). While these results demonstrate that mTORC1 positively regulates the translation of 
Park7 mRNA, the dramatic loss of PARK7 in the PSD also suggest that inhibiting 

















A. Heatmap for PARK7 in different cellular fractions (top) and DAVID clustering results for 
PARK7 terminal hub proteins (bottom) (Table S10, available online). Heatmap is shown as log2 
fold change. In PSD, PARK7 is an out-of-range protein with fold-change of 0/Control (red 
textured). B. mTORC1 inhibition by rapamycin reduces PARK7 levels in PSD-enriched 
fraction of rat cortices. Top: representative Western blots. Bottom: densitometric analysis of 
Western blots. (DMSO = 1.00 ± 0.21; RAPA = 0.11 ± 0.06; n = 3 animals per condition). C. 
Representative images of newly synthesized PARK7 protein when mTORC1 is active (left, 
top panel) or repressed (right, top) in or near MAP2 positive dendrites (middle panels). 
Overlay images of new PARK7 proteins and MAP2 (bottom\panels). Scale = 5 μm. See 
Figure S6, available online. D. Rapamycin reduces new PARK7 (DMSO = 1.00 ± 0.11, N 
= 26 dendrites; RAPA = 0.76 ± 0.05, N = 36 dendrites). Statistics: *, p < 0.05; Student’s t test. 
E. Representative images of neurons showing differential\ expression of PARK7 (red), PSD-95 
(green), and MAP2 (blue). Scale bar 20 μm. F. Blown up dendrites indicated by dotted box in 
E. of PARK7 (top), PSD-95 (middle) and merged image showing colocalization (bottom). G. 
Same dendrite as in F., representative staining of synapsin (top) colocalized with PARK7 
(bottom, merged). Scale bar = 5 μm. PCC is reported directly under merged image for relative 
comparison between control (left) and rapamycin treated neurons (right). H. PCC averaged over 
many dendrites for PARK7 and PSD-95 or PARK7 and synapsin. Dotted line indicates average 
PCC PARK7 and synapsin. Note, PCC of PARK7 with PSD-95 (DMSO = 1.47 ± 0.08, N = 
24 dendrites; RAPA = 1.17 ± 0.05, N = 24 dendrites) and synapsin (DMSO = 1.00 ± 0.08, N = 
24 dendrites; RAPA = 0.67 ± 0.06, N = 24 dendrites) decreased after rapamycin treatment. 
Statistics: * and **, significantly different by one-way ANOVA, Tukey’s multiple comparison; 
#, significantly different by single t-test from PCC of PARK7 with synapsin in DMSO. 











Figure 3.3: PARK7 protein expression is elevated in dendrites and colocalizes with the 
PSD in Tsc1 knockout neurons 
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PARK7 expression is elevated in dendrites of neurons in a mouse model of Tuberous 
Sclerosis Complex 
To test the power of our PPI network to identify new proteins that may be aberrantly 
expressed in neurological disorders, we used a mouse model of tuberous sclerosis complex 
(TSC), a disease that exhibits epilepsy and autistic behaviors. In the Tsc1 conditional 
knockout (cKO) mouse, expression of Cre recombinase virus elevates mTORC1 activity 
by knocking down the expression of TSC1 protein, an upstream repressor of mTOR. We 
prepared dissociated hippocampal neurons from Tsc1 cKO mice and infected them at 7-9 
DIV with Cre (Tsc1 KO) or GFP (control/WT) for 9-14 days. Using an 
immunohistochemical approach, we then measured dendritic PARK7 expression at 21  
DIV. We found that PARK7 protein in dendrites was markedly increased in neurons 
infected with Cre (WT = 1.00 ± 0.22, KO = 1.79 ± 0.11; Figure 3.3A-B), suggesting that 












A. Representative images of basal PARK7 protein (top panel) in wildtype (WT) and Tsc1 knockout 
(KO) neurons where mTORC1 is overactive in MAP2 positive dendrites (middle panels). Overlay 
images of new PARK7 proteins and dendrites (bottom panel). Scale bar = 5 μm. B. Quantification of 
PARK7 protein in or near dendrites. Knockout of Tsc1 increases basal PARK7 protein (WT = 1.00 ± 
0.11, N = 9 dendrites; KO = 1.79 ± 0.22, N = 18 dendrites). Statistics: *, p < 0.05; Student’s t test. C. 
Tsc1 cKO mice expressing CRE (KO) or GFP (WT) in the CA1 region of the dorsal hippocampus. 
Phospho ribosomal S6 (P-S6, left panel) staining as a downstream indicator of mTORC1 activity. Slices 
were costained with PARK7 (middle) and MAP2 (right). In merged image P-S6 is green, PARK7 is 
red, and MAP2 is blue. Note enlarged cell bodies in KO, characteristic of overactive mTORC1 
signaling. Scale bar = 20 μm. (See Figure S3, available online, for low magnification images). D. 
Merged images of WT and Tsc1 cKO hippocampal slices stained with PARK7 (red), PSD-95 (green), 
and MAP2 (blue). Scale bar = 5 μm. Right, dendrite in dotted box in merge image was blown up and 
colocalization was determined for a single plane (right). Note, there is an increase in colocalized pixels 
with PSD-95 in the KO as noted by the increase in PCC reported next to the merged image. * denotes 
cell body in WT and KO to demonstrate that blown up images are approximately at an equal distance 
from cell bodies. Scale bar = 2.5 μm. See Figure S5, available online. E. Quantification of basal 
dendritic PARK7 between WT and KO. Note ~2 fold increase in KO (WT = 1.00 ± 0.08, N = 36 
dendrites; KO = 1.97 ± 0.06, N = 36 dendrites). F. Quantification of average PCC over many dendrites 
between PARK7 and PSD-95 (WT = 0.10 ± 0.01, N = 36 dendrites; KO = 0.30 ± 0.03, N = 36 
dendrites). PCC increases in KO, consistent with overactive mTORC1 signaling. Statistics: Student’s 
t-test; ***, p<0.001. Chicken anti-MAP2 was imaged with 405 nm laser (See Experimental 
Procedures). 
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To further extend these findings we stereotaxically injected a recombinant adeno-
associated virus (rAAV) for Cre (Tsc1 KO) or EGFP (control) into the hippocampus of 
adult Tsc1 cKO mice. Immunostaining of hippocampi from these mice showed an increase 
in the downstream marker of mTORC1 activity, phospho-S6 ribosomal protein, along with 
the typical increase in cell body size relative to control (Figure 3.3C and Figure S6, 
available online) (Tavazoie et al., 2005). Of note, the increase in basal levels of dendritic 
PARK7 in Tsc1 KO mice agreed with our results in cultured neurons (WT = 1.00 ± 0.08, 
KO = 1.97 ± 0.06; Figure 3.3C, D and E). Moreover, these mice showed more PARK7 
colocalized with PSD-95 than control mice (WT = 0.10 ± 0.01, N = 36 dendrites; KO = 
0.30 ± 0.03, N = 36 dendrites; Figure 3.3D and F). As predicted by our MS/MS and 
bioinformatics analyses, our findings demonstrate that in a disease model where mTORC1 
is overactive PARK7 expression increases. 
 
Sequence analysis of PSD protein mRNA reveals putative PARK7 binding sites 
To test the role of Park7 as a translational hub, we computationally defined a 
putative PARK7 mRNA binding sequence. Previously, van der Brug et al. combined 
recovered tags from a PARK7 CLIP experiment to construct a consensus logo that lists the 
probability of a particular base at each position in the logo (van der Brug et al., 2008) 
(Figure 3.4A).  We took this data and generated all possible combinations of nucleotide 
sequences of length 6. A length of 6 was chosen since this is a typical length of an RNA-
binding motif. We then determined the 6-nucleotide sequence for each position in the 45-
nucleotide consensus logo that would have the highest mean probability. Using this 
method, we derived two motifs of high probability: GNGCNG or CNGCNG. We 
developed a graphical user interface that allows us to easily scan for the occurrence of thes
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Figure 3.4:  Identification of PARK7 binding motifs and calculation of motif frequency 
A. Nucleotide probability of PARK7 CLIP tags from van der Brug et al. (van der Brug et al., 2008). 
Data was LOESS smoothed to interpolate between each position. B.  Graphical user interface 
written with the R shiny package that allows for the retrieval of sequences containing the PARK7 
RNA-binding motif. Interface accepts gene lists or gene and sequence lists. Uploaded gene lists are 
sent to Biomart to retrieve the 5’UTR, CDS, or 3’UTR depending on the user’s choice. Data output 
as well as sequence data can be downloaded in .csv format. Interface data table shown on screen 
can be searched columns may be sorted. The table updates in real time with each of these actions.
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sequences within any given input sequence (Figure 3.4B). To test the validity of our tool, 
we determined the occurrence of the PARK7 motifs in the 5’UTR of the protein kinase Akt 
since its sequence was recovered by CLIP by van der Brug et al. (van der Brug et al., 2008). 
We found that the Akt1 5’UTR sequence ranked at the top 82.2% for frequency per 
kilobase of the PARK7 motifs of the 500 random genes we selected.  
 
Connectivity map analysis reveals potential drugs to modulate expression of mTOR-
dependent PARK7 PSD targets 
In our previous results, we identified PARK7 as a unique hub connecting together 
diseases of overactive mTOR (Figure 3.1). Furthermore, our data suggests a role for 
mTORC1 in regulating the stability of the PARK7 protein (Figure 3.2).  We have 
previously noted that PARK7 expression was highest in the PSD fraction of neuronal 
cortical tissue by mass spectrometry (Niere et al., 2016). We hypothesized that PARK7 
may control expression of PSD proteins that we identified as mTOR targets in our mass 
spectrometry data. Using PARK7 motifs we scanned mRNA sequences coding for proteins 
localized to the PSD (Bayes et al., 2012). Out of 2894 5’UTR sequences scanned 21% had 
putative PARK7 binding sites. Next, we took the list of PSD proteins and filtered them so 
that they intersected with our mTOR mass spectrometry data. We then obtained the 
sequences of these mTOR-dependent PARK7 binding targets for the 5’UTR, coding 
sequence, and 3’UTR and divided them into groups for proteins associated with epilepsy, 
AD, and ASD (Figure 3.5A). These results show that PARK7 may bind to multiple proteins 
whose expression is altered by mTOR activity and that PARK7 binds to these mRNA 
coding for these proteins along different regions of the cDNA. These data provide new 
avenues of investigation for proteins associated with diseases that may be the result of 
dysregulated translation in diseases of overactive mTOR. 
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Figure 3.5:  PARK7 binding target for disease-associated mTOR MS/MS data and CMap 
PubChem footprint clustering 
A.   Number of disease-associated mTOR-regulated proteins with PARK7 binding sites in the 
5’UTR, CDS, or 3’UTR.  PARK7 binding site data obtained using bioinformatics approach 
developed in this chapter (see “Experimental Procedures”. MS/MS data obtained from (Niere et 
al., 2016).  Sources for disease data shown in Chapter 2 (“Experimental Procedures”). B. 
Hierarchical clustering of PubChem footprints from drugs obtained from CMap. Drugs chosen were 
above the p-value cutoff of 0.05 from CMap and anti-correlated with the input expression signature.
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To further extend this analysis, we asked how pharmacology could be used to 
reverse the expression changes seen in mTOR-dependent PARK7 proteins. We capitalized 
on an online tool called ConnectivityMap (CMap) which contains genome-wide 
microarray data from various cell culture lines after the application of specific drugs (Lamb 
et al., 2006; Lamb, 2007). We reasoned if we could use the CMap query system to find 
drugs that produce expression changes anti-correlated with the expression levels we see in 
our mTOR mass spectrometry data for PARK7 targets, we could produce a potential list of 
drugs that could reverse changes associated with mTOR-mediated PARK7 dysfunction. 
We loaded the list of up- or down-regulated mTOR proteins into CMap to produce a list of 
compounds. Interestingly, rapamycin was the second most highly-ranked compound on the 
list (p < 0.0005) of targets anti-correlated with our input gene signature to CMap. This 
finding provides evidence to support the validity of our approach. Since the list in CMap 
is fairly large, we applied a p-value cutoff of 0.05. We obtained the PubChem IDs for the 
remaining drugs and used the ChemmineR package to determine structural similarities 
between compounds by applying hierarchical clustering to their PubChem footprint (Figure 
3.5B). This segregated the compounds into 13 separate clusters of structural similarity. 
This approach provides a means for focusing the list to compounds expected to act 
similarly pharmacologically. Additionally, since many drugs can have side effects, the 
ability test multiple drugs with slightly different structure provide researchers with the 




PARK7 is a putative, dysregulated translational hub in overactive mTOR-related 
diseases 
Individuals with neurological diseases that have dysregulated mTOR activity often 
suffer spontaneous seizures (Hou and Klann, 2004; Kelleher et al., 2004; Takei et al., 2004; 
Tsokas et al., 2005; Gong et al., 2006; Antion et al., 2008a; Pei and Hugon, 2008; Swiech 
et al., 2008; Hoeffer and Klann, 2010; Sharma et al., 2010; Ricciardi et al., 2011; Santini 
and Klann, 2011; Costa-Mattioli and Monteggia, 2013). We, therefore, looked for common 
proteins that are associated with epilepsy, AD, and ASD. Surprisingly, we did not detect a 
single protein shared by available databases for the three disorders that was also in our data 
set. By creating a PPI network of our disorder-associated data sets, however, we identified 
PARK7 as a putative protein shared by epilepsy, AD, and ASD. PARK7 is reported to be 
involved in transcriptional regulation and complexes with processing bodies (P-bodies) 
suggesting that it may also play a central role in translational regulation as suggested by 
our PPI network (Ariga et al., 2013; Miller-Fleming et al., 2014). We hypothesize that the 
PARK7 translational module is aberrantly regulated in diseases with overactive mTORC1. 
Supporting our hypothesis, we have found increased protein expression in the dendrites of 
Tsc1 KO neurons, in which mTOR is overactive. Thus, exploring how PARK7 affects the 
expression of other proteins may represent a previously unexplored avenue for reversing 
dysregulated protein synthesis in ASD and other mTORC1-related diseases. 
Our work, overall, provides evidence that changes in mTORC1 activity induce a 
rapid and dramatic remodeling of the synaptic proteome by increasing and decreasing 
syntheses of specific proteins and by altering the local expression of synaptic proteins. 
However, the precise subcellular targeting mechanisms remain to be determined. We also 
show that establishing PPI network hubs—common proteins and their associated 
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molecules—or interactomes sets the stage for identifying proteins, like PARK7, that may 
account for phenotypic similarities among mTORC1-related diseases. Identification of 
these common hub proteins can open new avenues to mitigate debilitating phenotypes 
shared by many neurological disorders. 
Remarkably, utilizing protein-protein interaction networks facilitated the novel 
discovery that PARK7, a protein thus far only implicated in Parkinson’s disease, (1) is 
upregulated by increased mTORC1 activity, (2) resides in the PSD only when mTORC1 is 
active, (3) is aberrantly expressed in a rodent model of TSC, an mTORC1-related disease 
that has symptoms of epilepsy and autism, (4) and has multiple putative PSD targets whose 
expression is known to be dependent on mTOR. Collectively, these data provide the first 
report of PARK7 association with TSC and its association with multiple diseases 















A1. Epilepsy PPI Network Analysis 
Protein Degree Clustering Coefficient Terminal Hub Cluster Size 
Mapk3 169 0 97 
Sumo3 123 0.02 51 
Park7 87 0.03 40 
Snca 82 0.01 23 
Ubc 78 0.01 30 
Dlg4 60 0.05 5 
Calm1 29 0.2 15 
Stx1a 26 0.12 2 
Prkca 24 0.14 0 
Rad23b 23 0.02 4 
A2. Alzheimer's PPI Network Analysis 
Protein Degree Clustering Coefficient Terminal Hub Cluster Size 
Mapk3 169 0 98 
Sumo3 123 0.02 54 
Park7 87 0.03 40 
Snca 82 0.01 22 
Ubc 78 0.01 30 
Dlg4 60 0.05 7 
Rad23b 47 0.01 19 
Slc2a4 30 0 17 
Calm1 29 0.2 14 
Prkca 24 0.14 0 
A3. ASD PPI Network Analysis 
Protein Degree Clustering Coefficient Terminal Hub Cluster Size 
Mapk3 169 0 98 
Ubc 78 0.01 30 
Dlg4 60 0.05 5 
Snca 35 0.02 5 
Sumo3 33 0.06 11 
Dlg1 26 0.18 4 
Prkca 24 0.14 2 
Park7 22 0.14 8 
Grip1 22 0.17 0 
Magi2 21 0.12 0 
A4. Combined PPI Network Analysis 
Protein Degree Clustering Coefficient Terminal Hub Cluster Size 
Mapk3 169 0 88 
Sumo3 123 0.02 46 
Park7 87 0.03 39 
Snca 82 0.01 22 
Ubc 78 0.01 21 
Dlg4 60 0.05 5 
Rad23b 47 0.01 17 
Slc2a4 30 0 15 
Calm1 29 0.2 14 
Stx1a 26 0.12 2 
Table 3.1: Network statistics for PPI networks 
A1. – A3. List of top 10 proteins with the highest degree in the PPI network for each of the three diseases. Statistics 
correspond to the networks shown in Figure 2.6B (left, right, and bottom). Terminal hub cluster size corresponds 
to the proteins highlighted in green in Figure 2.6B. These proteins have only one neighbor – the protein hub to 
which they are attached. (A4.) Network statistics for combined PPI network (figure 2.6B, center).  
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Chapter 4: mTOR mediates trans-synaptic signaling required for 
synapse formation and rapid antidepression efficacy requiring Fragile 
X Mental Retardation Protein9 
INTRODUCTION 
Major Depressive Disorder (MDD) is a chronic illness with a lifetime prevalence 
of 16.2%, affecting over 30 million US adults (Kessler et al., 2003). The estimated 
economic burden of MDD has been rising since 2000 when it was estimated at $83.1 
billion; it is now estimated to be as high as $210.5 billion with nearly 50% due to workplace 
costs. Diagnosis of MDD by clinicians typically relies on matching the patient’s symptoms 
to a list of criteria. However, recent work has called these criteria into question on account 
of the high heterogeneity of symptoms used in diagnosis, low overlap in content between 
depression scales used by clinicians, and a complex genetic heterogeneity underlying the 
disease (Lohoff, 2010; Lux and Kendler, 2010; Goldberg, 2011; Hybels et al., 2011; de 
Vos et al., 2015; Lieblich et al., 2015; Fried, 2017). Research into pharmacological 
therapies for depression have been under investigation and the most common approach is 
the usage of SSRIs (Selective Serotonin Reuptake Inhibitors) and other drugs that target 
molecular pathways of monoamineric neurotransmitters. Yet, recent data from meta-
analyses have demonstrated that SSRIs may not be effective in antidepressent therapy – 
SSRI response rates may be as low as 54% and treatment times may be as long as 12 weeks 
before a clinical response (Turner et al., 2008; Fournier et al., 2010; Undurraga and 
Baldessarini, 2012; Greenberg et al., 2015). These findings have motivated the search for 
alternative pharmacological approaches to treat MDD. 
Recently, evidence has suggested that a new class of compounds may be effective 
in the treatment of MDD. Ketamine, an FDA-approved N-methyl-D-aspartate receptor 
                                                 
9 For a more detailed introduction see Appendix A 
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(NMDAR) antagonist has been shown to produce a rapid, long-lasting clinical response in 
depressed patients thus coining a new class of compounds known as rapid antidepressants 
(Berman et al., 2000; Zarate et al., 2006). Depression is known to cause loss of dendritic 
spines and synapse reduction in the hippocampus and PFC (Warner-Schmidt and Duman, 
2006; Kang et al., 2012). Ketamine has been shown to reverse this neuronal apathy 
suggesting its clinical relevance and its potential for treatment of depression (Li et al., 
2011). The discovery of rapid antidepressants like ketamine that inhibit NMDAR receptors 
has prompted research to discover new compounds that may demonstrate similar 
effectiveness as well as determine their mechanism of action. One such compound is Ro-
25-6981 (Ro) which has been shown to have greater specificity than ketamine as it targets 
the NR2B subunit of NMDARs (Li et al., 2010; Autry et al., 2011; Nosyreva et al., 2013; 
Workman et al., 2013). 
Our recent work has demonstrated that NMDAR antagonism with Ro rapidly 
activates the serine/threonine protein kinase mTOR through gamma-Aminobutyric acid 
receptors (GABARs) (Workman et al., 2013; Workman et al., 2015). mTOR is part of the 
protein complex mTORC1 and has been previously implicated in a number of neurological 
disorders related to defects in synaptic plasticity (Lipton and Sahin, 2014). Additionally, 
mTORC1 is a master regulator of translation that controls the expression of hundreds of 
proteins (Graber et al., 2013b; Niere et al., 2016). It has been shown that mTORC1 
signaling is reduced in MDD and that an increase in mTORC1 activity results from 
treatment with rapid antidepressants (Li et al., 2010; Workman et al., 2013). Furthermore, 
rapid antidepressant injection leads to an increase in dendritic spine density and this 
increase is a result of protein synthesis downstream of mTORC1 (Li et al., 2010; Li et al., 
2011). Collectively, this work suggests that the reversal of neuronal apathy seen upon 
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treatment with rapid antidepressants may be the results of an mTOR-mediated remodeling 
of the synapse. 
RNA-binding proteins play an important role at the synapse by coordinating the 
expression of many mRNA that code for proteins involved in synaptic plasticity (Kiebler 
and Bassell, 2006; Lenzken et al., 2014; Zhou et al., 2014; Sephton and Yu, 2015). 
Recently, we have shown that GABAR activation of mTOR though rapid antidepressants 
leads to a reduction of the RNA-binding protein FMRP (Fragile X Mental Retardation 
Protein) in dendrites with Ro treatment (Wolfe et al., 2016). Mutations in FMRP result in 
Fragile X syndrome (FXS), a neurological disorder characterized by aberrant mTOR 
signaling and dysregulated translation (Sharma et al., 2010; Hoeffer et al., 2012). 
Additionally, a number of predicted FMRP targets show differential expression changes 
upon mTOR inhibition (based on data in (Niere et al., 2016)).  
To determine the targets controlled by FMRP we devised a high-throughput RNA 
immunoprecipitation experiment followed by RNASeq (RIP-seq) in mice injected with a 
rapid antidepressant, Ro-25-6981, and an inhibitor of mTOR, rapamycin. Our work shows 
that application of the rapid antidepressant is able to shift the RNA population bound to 
FMRP and furthermore, that this shift is also dependent on mTOR activity. Our work 
suggests that rapidly-acting antidepressants such as Ro act via presynaptic engagement 
through mTOR activity that leads to synaptic remodeling. Finally, this work highlights the 




Injections and experiment design 
Wild-type male (C57BL/6, Jackson Laboratory) or FMR1-KO (B.6129P2-
Fmr1tm1Cgr/J, Jackson Laboratory) mice were injected intraperitoneally (i.p.) with either 
Ro-25-6981 (10 mg/kg), rapamycin (6 mg/kg), or saline for 45 minutes. Rapamycin cannot 
be solubilized in saline so we used DMSO at < 1.7% of injection volume based on the 
animal’s mass. This is below the range of DMSO toxicity. Animals were sacrificed after 1 
minute under isoflurane. Surgeries were performed to remove the cerebellum, midbrain, 
and hippocampus.  
 
RNA Immunoprecipitations 
Cortices (left hemispheres) from 6-week old WT or FMR1-KO mice were harvested 
and flash frozen on dry ice. Tissue was homogenized and lysed with a cordless pestle motor 
and disposable pellet mixers (VWR) in polysome lysis buffer (10 mM HEPES pH 7.0, 100 
mM KCl, 25 mM EDTA, 5 mM MgCl2, 1mM DTT, 0.5% NP-40) in a 1:1 tissue-buffer 
ratio. RNaseOUT (Thermo) and protease/phosphatase inhibitors (Halt™ Protease and 
Phosphatase Cocktail, Pierce Biotechnology) were freshly added to samples. Samples were 
rotated for 10 minutes at 4°C to induce swelling and then flash frozen on dry ice. Samples 
were thawed by holding between fingers at RT to lyse and nuclei were pelleted at 3000 x 
g for 10 minutes. Lysates obtained above were pre-cleared by adding 50 μl of washed 
magnetic bead slurry (Protein A Dynabeads, Thermo) and rotating for 30 minutes at 4°C. 
To bind the antibody to the beads, 50 μl of magnetic beads slurry was washed and then 
resuspended in 8 volumes of NT-2 buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1 mM 
MgCl2, 1mM DTT, 0.05% NP-40 with RNaseOUT/protease & phosphatase inhibitors 
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added fresh) + 5% BSA. 10 μg of either FMRP (Abcam, ab17722) or IgG (Santa Cruz 
Biotechnologies, sc-2027) antibodies were added to the beads and rotated for 10 minutes 
at RT. Antibody-bound beads were washed 4 times with ice-cold NT-2 buffer. For the 
immunoprecipitation, 4.5 mg of protein from pre-cleared lysates was added to an RNase-
free microcentrifuge tube containing the antibody-bound beads. Input collected at this step 
for downstream analysis was either 1% of the final pre-cleared lysate volume in the 
immunoprecipitation reaction (for immunoblotting) or 10% of the final pre-cleared lysate 
volume (to normalize in qPCR). The antibody-bead-lysate mixture was then diluted at a 
ratio of 1:5 with NET-2 buffer (20 mM EDTA pH 8.0, and 1 mM DTT in NT-2 buffer; 
RNaseOUT and protease/phosphatase inhibitors added fresh) and rotated for 1 hour at 
room temperature. Beads were quickly washed 6 times in ice-cold NT-2 buffer and 
immediately resuspended in 350 μl TRI Reagent® Solution (Ambion) for 10 minutes at 
RT. Beads were pelleted and the supernatant was removed and resuspended in 350 μl of 
absolute ethanol. RNA was extracted by applying ethanol-resuspended samples to spin 
column from the Direct-zol RNA MiniPrep Kit (Zymogen) according to manufacturer’s 
instructions. Eluted RNA (25 μl) was DNase treated using the TURBO DNA-free kit 
(Thermo).  
 
cDNA Synthesis and Quantitative Real-Time PCR (qRT-PCR) 
15% of the eluate from DNase-treated RNA samples was reverse-transcribed to 
cDNA using the iScript cDNA Synthesis Kit (Bio-Rad) in a 20 μl volume according to 
manufacturer’s instructions. qRT-PCR was performed in 20 μl reaction volume using the 
iQ™ SYBR® Green Supermix (Bio-Rad) and primers for GABABR1, GABABR2, 
CaMKIIα, and Cacna2δ2 (GeneCopoeia). qRT-PCR was run with the following protocol: 
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95°C for 10:00, 40 cycles of 95°C for 0:15 followed by 60°C for 1:00, 95°C for 1:00, and 
55°C for 1:00. Relative fold-enrichment was determined by the equation ΔΔCt = 2-(Ct FMRP 
RNA-IP – Ct IgG RNA-IP) - (Ct FMRP input – Ct IgG input). 
 
Library preparation 
85% of the eluate from DNaseI treated samples were analyzed for quality using the 
BioAnalyzer (Agilent Genomics). The mean RIN score across all samples was 8.488 (IQR 
= 8.375 to 8.825) and the mean RNA mass recovered (ng) was 75.31 (IQR = 36.75 to 
81.50) (Table 4.2). Recovered RNA was generally lower in the knockout samples but still 
had a high RIN. Two biological replicates for the Ro knockout samples had a RIN too low 
for library preparation and sequencing (RIN = 1.0 and 1.1 respectively). Library 
preparation was performed at the Genome Sequencing and Analysis Facility (GSAF, The 
University of Texas at Austin). After sample amplification to > 1 ug by PCR, rRNA was 
depleted using the Ribo-Zero rRNA Removal Kit (Human/Mouse/Rat) (Epicentre) 
according to the manufacturer’s instructions. RNA was then purified using the RNeasy 
MinElute Cleanup Kit (Qiagen). Library preparation of the RNA was performed with the 
NEBNext Ultra Directional RNA Library Prep Kit for Illumina (NEB). Single-end 
sequencing of RNA (SE 1x50) was performed with the HiSeq4000 (Illumina). 
 
Preprocessing of RNA sequence libraries 
Quality control assessment of RNAseq libraries 
All preprocessing was performed in the R environment (RC, 2014) and terminal 
commands were sent directly to the shell from R. Code for analysis can be found in 
Appendix D. RNAseq libraries from all technical replicates were analyzed for quality using 
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FastQC 0.11.5 (Andrews, 2010) with standard parameter settings. We inspected the 
libraries for a high Q-score (at least 37) across all base-calls. All libraries showed an overall 
high Q-score as shown in the “per sequence quality scores” distribution of FastQC. 
However, multiple libraries showed a small drop in Q-score in either the first six base-calls 
or the last 2-3 base-calls. The interquartile range for these drops never exceeded a minimum 
Q-score of 32 demonstrating that overall, the sequencing was of excellent quality. In 
general, any repetitive sequences were below 1% of all sequences in a given library and 
usually even lower. A BLAST search from the NCBI website (Boratyn et al., 2013) 
revealed that they were primarily ribosomal RNA or adaptor sequences. The technical 
replicates from the Ro knockout library (RO_KO_2) showed the lowest library complexity 
as well as abnormal GC content and per base sequence content compared to other libraries. 
Duplicated sequences were shown to be as high as 2%. We analyzed the contents of this 
library for ribosomal contamination using RNA-SeQC 1.1.8 (DeLuca et al., 2012) but 
found them to be minimal (< 2% of library sequences). We therefore attribute the unusual 
sequencing results to poor starting material since these libraries showed the lowest RIN 
scores and RNA concentration. However, they still contain important sequence information 
so opted to keep these libraries for our analysis.  
 
Trimming of RNAseq libraries 
Since a few libraries showed a lower Q-score toward the beginning and end of the 
sequences, we applied a trimming tool to the libraries to remove these lower quality base-
calls. Trimming would also remove any adaptor contamination since we saw this in a few 
of the samples. We used the tool Trim Galore 0.4.1 to trim the sequencers and adaptors. 
Trim Galore utilizes Python 2.7.11 and is wrapped around cutadapt 1.10 (Marcel, 2011). 
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Trim Galore was run as follows: trim_galore –fastqc -o trimmed_fasqc *.gz. 
Since Trim Galore is pre-loaded with Illumina adaptors we did not need to specify them as 
parameters. We ran FastQC again to verify that trimming and adaptor removal was carried 
out successfully and did not alter the quality of the libraries. 
 
Alignment of RNAseq libraries and calculating counts from BAM files 
Alignment was performed using Tophat2/Bowtie2 (Langmead and Salzberg, 2012; 
Kim et al., 2013a) using samtools 0.1.19 (Li et al., 2009a) with the following settings: 
tophat2 library-type fr-firststrand -G [GTF] p 4 -o [library] 
[index] [files]. The library-type parameter was chosen to be consistent with the 
library preparation method. Gene model annotations for M. musculus (mm9) were 
downloaded directly from Ensembl (assembly version GRCm38.84, Ensembl 84; Mar 
2016) (Cunningham et al., 2015). Pre-built reference indices for Bowtie2 were downloaded 
from the Illumina website. The alignment data shows that most libraries had a relatively 
strong alignment percentage (greater than 75%). The only exception is the Ro Knockout 
replicate 2 (16%). This is not unexpected given the lower library complexity and slightly 
higher amount of ribosomal RNA contamination. A summary of all library information and 
alignment data can be found in Table 4.3.  
Rsubread 1.20.6 (Liao et al., 2013) was used to calculate counts. Strandedness was 
maintained in counting using the “strandSpecific” parameter. Additionally, we used 
the “countMultiMappingReads = TRUE” parameter option so we could count 
ambiguously mapped reads. All BAM files for all four technical replicates were combined 
so that the final output contains counts for all of our libraries. 
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Post-alignment biological replicate quality control 
Count data for each technical replicate were combined together using the 
collapseReplicates() function from DESeq2 (Love et al., 2014). A regularized log 
transformation was applied to the data before visualization. Data was inspected to see the 
correlation in count number between different biological replicates (Figure 4.2A), principal 
components analysis to see the similarity in variance among the replicates (Figure 4.2B), 
and a Euclidean distance matrix to assess hierarchical clustering of different libraries based 
on the overall Euclidean distance between each gene (Figure 4.2C). 
 
Filtration/normalization of RNA sequence libraries and differential gene expression 
analysis 
Low count filtration, factor size normalization, and overlap comparison to other FMPR 
datasets 
Combined count data (all technical replicates collapsed) was filtered using 
HTSFilter 1.14.1 (Rau et al., 2013) with the standard settings. HTSFilter removes all low 
counts from the full list of raw counts. Annotation was performed using Bioconductor 
(Huber et al., 2015) with the org.Mm.eg.db (Carlson, 2016c) and AnnotationDbi (Pages et 
al., 2017) packages. DESeq2 factor size normalization was then applied to the data. Since 
this will scale across the entire library, the counts in the knockout libraries will be inflated. 
In order to correct for this, the ratio between extracted RNA concentrations from WT and 
Fmr1 KO tissue (BioAnalyzer results) were used to scale back the KO tissue counts after 
DESeq2 normalization. WT normalized counts were unchanged. All biological replicates 
were then averaged together across treatments. 
To filter the list further, we first sorted the list by the highest counts in the saline 
treatment and then compared to other known FMRP target data sets. This includes two 
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RIP-ChIP data sets (Brown et al., 2001; Ascano et al., 2012b), HITS-CLIP data (Darnell 
et al., 2011), PAR-CLIP data (Ascano et al., 2012b), and APRA-NeuroArray (Miyashiro 
et al., 2003). Our initial analysis showed poor overlap with the Ascano et al. and Miyahsiro 
et al. data sets; poor overlap with the Miyasiro dataset was also seen in Suhl et al. (Suhl et 
al., 2014). The Ascano data also contains a large number of RNA targets (> 5000) and may 
not be as useful for determining a proper cutoff. These sets were excluded from our 
analysis, however, consensus datasets showing overlap between the Ascano RIP-ChIP (A-
RIP), Ascano PAR-CLIP (A-PAR), Brown (B), and Darnell (D) datasets from Suhl et al. 
was included in our analysis. Cutoff was determined by sorting the list by highest 
normalized saline counts and then ranking the percent of matches between the (D), (B) 
data, and consensus data (B_D_A-RIP, B_D_A-PAR, B_D, and D_A-PAR). By including 
4120 genes from our data, we will have a 95% overlap with all genes obtained in the above 
data (Figure 4.3A). Lastly, we filtered the data by removing mitochondrial and glial cells. 
These genes were derived from the Brain RNAseq database (Zhang et al., 2014) or 
MitoMiner (Smith et al., 2012). 
 
Filtering background counts by WT-to-KO fold enrichment 
Background was assessed by two methods. 1) We computed the WT-to-KO fold 
enrichment for all major treatment libraries. Next, we took a list of FMRP non-targets 
(Darnell et al., 2011) and plotted the WT-to-KO fold enrichment of these non-targets from 
our data against the WT-to-KO fold enrichment of the targets identified in the other 
datasets the overlapped in our data (Figure 4.3B). The aim here was to determine a cutoff 
between the average WT-to-KO fold enrichment for targets versus non-targets, the latter 
of which were presumed to have a higher background and thus a lower value for the WT-
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to-KO fold ratio. We then took the average of the lower quartile of the WT-to-KO fold 
enrichment across all the different data sets (Figure 4.3B, dotted red line) and used this as 
an estimation of the cutoff for background. 2) We used univariate K-means with the 
Ckmeans.1d.dp package (Wang and Song, 2011) was used to quantify the distribution of 
signal and background counts into two clusters (Figure 4.3C, D). Gaussian mixture 
modeling (GMM), a generalization of K-means, has been used previously to characterize 
signal-to-noise for RIP-SEQ/RIP-ChIP data (Erhard et al., 2013; Lu et al., 2014), however 
our data did not converge using GMM. We then averaged the cutoffs from the two methods 
used above for WT-to-KO fold enrichment ratio cutoff of ~1.112788. We applied this value 
across all treatments to filter any data that did not meet this cutoff criterion. 
 
Differential gene expression analysis 
Differential gene expression (DGE) analysis was performed using Limma/voom 
(Law et al., 2014; Ritchie et al., 2015). Raw counts were imported into R and then 
normalized via TMM/CPM. The contrast matrix was set up to compare fold changes for 
either Saline/Ro (SAL_WT – RO_WT) or Ro+Rapa/Ro (RO_RAP_WT – RO_WT). After 
running the Limma/voom pipeline, samples were thresholded with an FDR cutoff of 0.1. 
These values were then visualized using an MA plot (Figure 4.4A) and a volcano plot 
(Figure 4.4B). 
 
Motif analysis of FMRP targets 
For motif analysis, we did not use the differentially expressed genes selected by 
Limma/voom because motif frequency/number was not significantly higher than that of the 
non-targets. All sequences were obtained from BioMart (Smedley et al., 2015) using the 
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biomaRt (Durinck et al., 2005; Durinck et al., 2009) package from Bioconductor. 
Sequences were obtained from the coding region because the majority of FMRP binding 
motifs appear to cluster in these part of the gene (Anderson et al., 2016). Since some genes 
may return multiple sequences, we only used sequences of max length for our calculations. 
Motifs were counted using the count() function from the seqinr (Charif and Lobry, 2007) 
package. The QFM sequence was counted using the matchPDict() function from the 
biostrings (Pages et al., 2016) package using the following approach: the “WGGA” motif 
is composed of sequences of either “AGGA” or “TGGA”. Both sequences are searched for 
within a given sequence string. Then, the start position of either motif within the sequence 
is ordered and the difference between the start and end positions is determined by taking 
the difference across each row. Finally, the QFM motif is determined by subsetting this 
dataframe for motifs that are only separated by a span of less than 6 bases (based on the 
difference between the start and end positions). Rho is computed using the rho() function 
from seqinr. To compute multiple rho, which is necessary for motifs for which a position 
can take on more than one nucleotide value (e.g. ACUK), a function called 
multipleRho() is used which computes rho manually according to the following 
formula: 
 
Motif statistics were calculated using base R functions except for the effect size which uses 
the cohensD() function from the lsr package (Navarro, 2015). For all motif statistics 
(freq/kB, t-test, Wilcoxon-Mann-Whitney test, effect size) except rho, we followed the 
general presentation of data from Suhl et al. (Suhl et al., 2014).  
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Clustering analysis of FMRP targets 
GO clustering of unique biological processes 
For clustering analysis, except where specified, we did not use the differentially 
expressed genes selected by Limma/voom because motif frequency/number was not 
significantly higher than that of the non-targets. Database for Annotation, Visualization 
and Integrated Discovery (DAVID 6.8) (Huang da et al., 2009a; 2009b) was queried for 
gene ontology annotation using the RDAVIDWebService package (Fresno and Fernandez, 
2013). To cluster GO terms with high similarity we used an approach similar that of the 
Enrichment Map plugin (Merico et al., 2010; Merico et al., 2011) for Cytoscape 3.0 
(Shannon et al., 2003). First, we obtained DAVID output from their functional annotation 
chart service from the “GOTERM_BP_ALL” ontology. The up-regulated and down-
regulated genes were analyzed separately by DAVID. Then, we filtered these GO terms 
using a p-value cutoff of 0.001 and an FDR cutoff of 0.05. We then took the relative 
complement of either the up-regulated or down-regulated GO terms. We then use a 
clustering approach to group GO terms of high similarity (based on the number of 
overlapping genes) from each relative complement together in a dendrogram (Figure 4.10). 
To determine the degree of overlap between genes in any two ontologies we used the 
average of the Jaccard cutoff (JC) and the overlap coefficient (OC).  
 
 
A higher overlap score indicates a greater number of genes in common. We next created a 
matrix of the average JC and OC for every GO-term against all other GO-terms. The matrix 
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was filtered for a similarity cutoff of > 0.5. This matrix was then clustered to create a 
dendrogram using the factoextra package (Kassambara and Mundt, 2016). Each branch of 
the dendrogram indicates a degree of overlap between the different GO terms. Each 
clustered branch was then manually annotated for a general biological category that 
described the GO term. To determine optimal cluster number, we tried to minimize the 
within-sum-of-squares (WSS) (Figure 4.11).   
 
Univariate/bivariate K-means clustering and clustered heatmaps 
Univariate clustering was performed as described previously using WSS to 
determine optimal cluster number (Figure 4.11). GO clustering from each cluster used the 
RDAVIDWebService package. For bivariate K-means clustering we used the Kmeans() 
function from the amap package (Lucas, 2014). To create the fold-change correlation plot, 
the all genes in the interquartile range were colored grey to indicate “background” or no 
change. Trannsynaptic proteins were obtained from the gene ontology annotations (see 
“Connectivity map analysis of FMRP targets” section below). Clustered heatmaps of the 
limma-filtered data was created using the pheatmap package (Kolde, 2015). All data 
outside of the range of -2 to 2 log2 fold-change were removed before plotting. Only data 
with an adjusted p-value less than 0.1 were included. For the heatmap of the normalized 
count data, the data was log2 transformed before plotting with pheatmap. 
 
Depression GO terms chart data source 
All of the genes from the depression GO terms chart were obtained through an 
online literature search for genes that has been associated with depression (Fatemi et al., 
2001; Tadic et al., 2007; Dlugos et al., 2009; Unschuld et al., 2009; Lee et al., 2010b; Luo 
 141 
et al., 2010; Rietschel et al., 2010; Aragam et al., 2011; Galeotti and Ghelardini, 2011; 
Shyn et al., 2011; Dekker et al., 2012; Sakaida et al., 2013; Ray et al., 2014; Gatt et al., 
2015; Gray et al., 2015; Ogawa and Kunugi, 2015; Skoog et al., 2015; Wagner et al., 2015; 
Yoshimasu et al., 2015; De Vry et al., 2016; Liu et al., 2016; Stachowicz et al., 2016).  
  
Usage of other R packages for analysis 
In addition to the packages already mentioned, we utilized a number of other 
packages for our analysis. For plotting: ggplot2 (Wickham, 2009), ggthemes (Arnold, 
2016), RColorBrewer (Neuwirth, 2014), and gridExtra (Auguie, 2016). For annotation: 
mgu74a.db (Carlson, 2016a) and org.Hs.eg.db (Carlson, 2016b). For functions used in 
DGE analysis: edgeR (Robinson et al., 2010). For data import: xlsx (Dragulescu, 2014) 
and R.utils (Bengtsson, 2016). For data transformation and processing: reshape2 
(Wickham, 2007), magrittr (Bache and Wickham, 2014), dplyr (Wickham and Francois, 










Gene Ontology (GO) enrichment reveals high heterogeneity of biological processes 
for candidate depression genes 
Symptoms of patients with MDD show a high level of heterogeneity between 
diagnosis criteria. To see if this heterogeneity was represented on the molecular scale we 
performed GO biological process analysis on a list of candidate depression genes derived 
from a literature search and used the Database for Annotation, Visualization and Integrated 
Discovery (DAVID 6.8) to cluster these genes. The resulting list was then grouped by 
unsupervised hierarchical clustering into simplified categories based on the similarity of 
overlap between the genes shared in the biological processes returned by DAVID (see 
“Experimental Procedures”). Our analysis revealed over 30 major categories with little 
overlap in functional properties such as hormone secretion, circadian rhythm regulation, 
cytokine production, and regulation of cell motility consistent with previous findings 
regarding the heterogeneity of MDD symptoms (Figure 4.8A). Furthermore, the same GO 
analysis of genes from two other datasets that isolated mRNA bound to FMRP (Brown et 
al., 2001; Darnell et al., 2011) shows little overlap with the MDD GO biological process 
chart (Figure 4.8B). This suggests that if FMRP targets related to depression have been 
identified previously, they did not significantly cluster into GO categories that overlapped 
with MDD genes. Since our previous work has shown that dendritic FMRP levels drop 
significantly after administration of rapid antidepressants \\Wolfe, 2016 #332//, we 
reasoned that immunoprecipitating FMRP target mRNAs may reveal a population that 
could be utilized to develop more targeted treatments for MDD. 
 
 143 
RNA-immunoprecipitation of FMRP mRNA targets in the mouse cortex 
The large diversity in unrelated biological processes provides a great challenge for 
the proper design of pharmaceuticals to treat MDD. We reasoned that we could optimize 
strategies for antidepressant drug discovery by characterizing the molecular changes that 
occur at the synapse upon treatment with rapid antidepressants. We sought to identify the 
mRNA targets that show differential binding to FMRP upon rapid antidepressant treatment. 
We performed RIP-seq in mice injected with either Ro and the mTOR inhibitor rapamycin, 
Ro alone, or vehicle for three biological replicates (Figure 4.1). RIP-seq was performed in 
wild-type (WT) mice as well as the Fmr1-knockout (Fmr1-KO) mice. Our RIP-seq 
approach used a number of modifications that have been shown previously to significantly 
reduce background mRNA binding (Keene et al., 2006; Jain et al., 2011). We sequenced 
four technical replicates for each RNAseq library resulting in WT libraries ranging from 
16-27 million reads (mean = 22.1 million reads, s.d. = 4.3 million reads) (Table 4.3). Reads 
obtained in KO libraries were highly variable ranging from 8-35 million reads (mean = 
19.6 million reads, s.d. = 10.3 million reads). However, reads from KO libraries mapped 
lower than those of their WT counterparts (mean KO library mapping rate = 57.64% ± 
21.11% (s.d.); mean WT library mapping rate = 68.94% ± 18.59% (s.d)) (Table 4.3). In 




Figure 4.1: Workflow for RIP-seq experiment and analysis 
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We visualized the similarity between replicates after applying a regularized log 
transformation to the raw counts (Love et al., 2014). Biological replicates between libraries 
were highly correlated which demonstrates high precision in RNA sample extraction and 
preparation (Figure 4.2A). Next, we created a Euclidean distance matrix to see the 
similarity in counts across all observations for a given biological replicate (Figure 4.2B). 
Replicates within a given treatment generally clustered into the same groups, the greatest 
exception being the second and third replicates of the Saline treatment library (SAL_WT2; 
SAL_WT3). However, all saline replicates are still within the same parent branch. Next, 
we examined the sample similarity through principal components analysis (PCA) (Figure 
4.2C). Biological replicates within the same library generally group together. The most 
notable exception is the 2nd Saline KO library (SAL_KO2). Taken together, the high 
overlap of similar groups by PCA and clustering as well as the high correlation between 
replicates within a treatment group demonstrate the reliability of our data through different 
repetitions of the experiment.  
To verify the validity of our sequencing results, we first took a list of FMRP mRNA 
targets and non-targets from a previous publication from the Darnell lab and compared the 
counts for these targets obtained from the WT or Fmr1-KO mice across treatments (Figure 
4.9A) (Darnell et al., 2011). We found the normalized counts for the targets were increased 
by 333.90% (Saline WT), 369.29% (Ro WT), and 365.35% (Ro + rapamycin WT) over 
non-targets in each treatment. This supports the validity of our obtained libraries. 
Furthermore, we inspected the result of the normalization to ensure that the ratio between 
WT and KO counts for a given treatment had been maintained. Since this was performed 
prior to low-count filtering, the counts are still highly zero-inflated (Figure 4.9B). 
However, there is a clearly a higher number of zero counts in the WT compared to KO 
counts within specific treatment. Next, we performed qRT-PCR on our 
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Figure 4.2: Quality control of count data from RIP-seq libraries 
 
All counts analyzed were transformed with a regularized log transformation of raw count data for 
each library. A. Correlation of a representative RIP-seq libraries indicates high correlation 
between targets. B. Euclidean distance matrix shows high similarity between RIP-seq libraries 
using the complete linkage method for clustering. C. Principal component analysis of 
observations in the RIP-seq libraries. Color shades indicate WT (dark shade) or KO (light shade) 
libraries. 
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immunoprecipitated RNA using primers for GABABR1 and GABABR2, two FMRP targets 
we have previously characterized, under Ro or Saline treatments (Figure 4.9C). This data 
confirms the presence of GABABR1/GABABR2 mRNA in our samples and shows that 
their levels decrease with Ro treatment.  
 
Filtration of RNA-IP data results in a high-quality dataset enriched for multiple 
neuronal GO clusters and differentially expressed FMRP targets 
Candidate RNA targets of FMRP have been obtained previously by numerous 
different methodologies including RIP-ChIP, HITS-CLIP, and PAR-CLIP (Brown et al., 
2001; Miyashiro et al., 2003; Darnell et al., 2011; Ascano et al., 2012b). We leveraged the 
results from these studies to filter our data to obtain a list of FMRP targets based on a 
consensus overlap between these data sets following the work by Suhl et al. (Suhl et al., 
2014). Here, we attempted to capture 95% of the FMRP mRNA targets present in these 
overlap data sets for our candidate targets with the highest counts (Figure 4.3A). The 
Ascano et al. and Miyashiro et al. datasets by themselves were not included in this analysis 
due to insufficient overlap with our data. This finding was similar to Suhl et al. who 
excluded the Miyashiro et al. dataset as well (Suhl et al., 2014). After filtering further to 
remove any mitochondrial or glial contaminant mRNA from our data based on an online 
database (Cahoy et al., 2008) we further filtered by establishing a count cutoff for target v. 
non-targets by determining the count enrichment of FMRP WT mRNA relative to Fmr1-
KO mRNA (Figure 4.3B). Using the FMRP target mRNA from the consensus list from 
(Suhl et al., 2014) and non-target mRNA from (Darnell et al., 2011) we searched for genes 
in common with our candidate FMRP target list and determined the distribution of fold 
changes in the saline WT condition compared to saline KO condition. Taking the bottom 
quartile across all target groups yielded a WT/KO enrichment cutoff of ~1.11. We used 
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Figure 4.3: Filtration of dataset using FMRP consensus data set targets and background 
from RIP-seq KO libraries 
A. Top: Distribution of FMRP targets from other datasets across our data. Each position along the 
X-axis represents a gene found in the Saline RIP-seq library. The gene with the highest count has 
a position near the origin while the gene with the lowest count has a position at the other end of the 
axis. The Y-axis indicates a data from the Ascano PAR-CLIP data (A-PAR), Ascano RIP-seq data  
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this metric to further filter our list of FMRP mRNA targets. To provide a more rigorous, 
unbiased filter for WT/KO enrichment in our data, we used K-means clustering to find a 
sub-population for background counts within our data. This approach is similar to Gaussian 
mixture modeling which has been previously used to analysis RIP-ChIP and RIP-Seq data 
(Erhard et al., 2013; Lu et al., 2014). This analysis revealed two separate populations 
among the log2 transformed WT/KO enrichment data – one population consisting of 
background (μ = 0.985, σ = 0.109) and a second population consisting of the FMRP mRNA 
targets (μ = 1.352, σ = 0.23) (Figure 4.3C,D). The maximum WT/KO enrichment ratio 
found in the background population is less than 1 thus providing a similar cutoff to that 
obtained by comparing to targets and non-targets as described above. Using the data from 
these distributions, we visualized the separation of enrichment between target and 
background through a scatterplot (Figure 4.3C). Altogether, this approach allowed us to 
filter out any mRNA from our data that was not enriched relative to the counts obtained in 











(A-RIP), Darnell data (D), Brown data (B), or Miyashiro data. See text for data citations. 
Consensus data sets indicate overlap between the above data (e.g. B_D_A-PAR indicates the 
intersection between the Brown, Darnell, and Ascano PAR-CLIP data). These overlap sets were 
obtained from the supplemental material in Suhl et al. (Suhl et al., 2014). Dotted red line indicates 
cutoff that was used in our data. Everything to the left of the line is considered a putative FMRP 
target and everything to the right is considered a non-target.  Bottom: Line graph indicating the 
percent of consensus FMRP targets (excluding the Ascano and Miyashiro data) that overlap with 
our data for each position in the corresponding graph above. Dotted red line indicates the same as 
in A. For all putative FMRP targets (left of dotted red line), 95% of consensus FMRP targets are 
captured. B. WT-to-KO fold enrichment for genes in our data that overlap with a data set indicated 
on the X-axis. Non-targets were obtained from (Darnell et al., 2011). Dotted red line indicates the 
average bottom quartile for all FMRP target data sets. According to this cutoff, everything above 
the line is a putative target and everything below is considered background binding. Statistics: 
***, p < 0.001; Student's t-test. C. Scatterplot showing the relationship between the WT and KO 
counts in the log2 saline RIP-seq library. Cutoff between “signal” or “background” determined by 
univariate K-means. D. Univariate K-means for log2 saline counts. The two clusters generated 
(signal, green; background, red) are overlaid on a histogram of the full saline distribution (grey).  
The max value from the background cluster was chosen as the cutoff point for the distinction 
between signal and background. 
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After obtaining our filtered data set above, we performed differential expression 
analysis (DGE) using limma+voom (Law et al., 2014; Ritchie et al., 2015). Using an FDR 
cutoff of 0.1 we obtained 242 genes across either Saline/Ro or Ro+Rapamycin/Ro 
treatments (Figure 4.4A,B).  We predict that saline/Ro fold changes will identify FMRP 
targets translated with Ro induction (log2 fold-change > 1) or FMRP targets not translated 
with Ro induction (log2 fold-change < 1). Furthermore, we predict that the 
Ro+Rapamycin/Ro fold changes will identify FMRP targets that are translated when Ro 
turns mTOR on (log2 fold-change > 1) or FMRP targets that are repressed when mTOR is 
on (log2 fold-change < 1). Next, we performed hierarchical clustering to observe mRNA 
that changed together in both fold-change groups (either Saline/Ro or Ro+Rapamycin/Ro). 
(Figure 4.4C). In general, the majority of mRNA were not differentially expressed, a 
relationship that we explore in greater detail below (Figure 4.6, 4.7). The genes showing 
the greatest differential expression when the fold-change groups were compared this way 
were primarily mRNA associated with the small and large subunits of the ribosome. We 
also clustered all libraries prior to averaging by performing a regularized log 
transformation of the raw counts (Figure 4.4D). GO clustering for biological process 
revealed six enriched clusters which included processes associated with trans-synaptic 
signaling and nervous system development. Notably, we observed differential binding 
between the different treatments indicating that FMRP sequesters a separate set of targets 
upon administration of Ro (Figure 4.4E). 
Attempts to characterize FMRP binding motifs have identified multiple common 
patterns among targets including the G-quadraplex motif, U-rich sequences, and other 
common motif patterns (Schaeffer et al., 2001; Dolzhanskaya et al., 2003; Menon and 
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Figure 4.4: Differential gene expression analysis of RIP-seq libraries 
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Mihailescu, 2007; Menon et al., 2008; Darnell et al., 2011; Phan et al., 2011; Ascano et al., 
2012b; Ray et al., 2013; Suhl et al., 2014; Chen and Joseph, 2015; Anderson et al., 2016). 
Although there is no consensus on which patterns are common to all FMRP targets, Suhl 
et al. have attempted to bioinformatically determine the occurrence of all these motifs 
within known FMRP datasets. Our approach was to partially replicate their overall analysis 
strategy with our targets to see if we obtained consistent results. We characterized the 
enrichment of putative FMRP target motifs across our filtered dataset compared to genes 
that had been filtered out of our dataset in previous processing steps described above 
(Figure 4.5A; Table 4.1). We also calculated the occurrence of the motif within sequences 
that were filtered out of the list (“non-targets”). We consider a motif to be enriched in our 
FMRP targets (n = 2696) if the frequency of occurrence per kilobase (kB) was significantly 
higher than the occurrence in non-targets (n = 11222). Sequences were used specifically 
from the coding region because the majority of FMRP motifs are found here (Anderson et 
al., 2016). Additionally, we also calculated ρ which tells us if the occurrence of a DNA 
string is over- or under-represented according to what we would expect by chance (see 
“Experimental Procedures”). For example, ρ = 10 would indicate the occurrence of the 
sequence is 10 times more likely that we would expect by chance.  
Data for motif analysis is summarized in Table 4.1. The mean frequency/kB of the 






A. MA plot showing distribution of counts by fold-change for each of the log2 transformed fold-
change conditions under consideration. Significant genes are shown in red and non-significant genes 
are shown in grey according to an FDR cutoff of 0.1. B. Volcano plots for the fold-change conditions 
under consideration. Significant genes are shown in blue and non-significant genes are shown in 
red.  C. Clustered dendrogram for fold-change conditions using the average linkage method and 
Euclidean distance. D. Clustered dendrogram for each RIP-seq library after regularized log 
transformation. Scale represents rlog transformed raw counts. Clustering performed using the 
average linkage method and Euclidean distance. Colored boxed on the right side correspond to GO 
biological process clusters named below the chart. GO clustering performed with DAVID. E. 
Scatterplot visualizing the distribution of counts between different RIP-seq libraries after log2 
















ACUK 8.036 8.483 0.455 0.477 p < 0.0001 p < 0.0001 0.144 
WGGA 16.531 16.666 0.200 0.201 p = 0.222 p = 0.239 0.026 
GAC 16.787 16.066 0.955 0.936 p < 0.0001 p < 0.0001 0.162 
GACR 7.905 7.444 0.222 0.214 p < 0.0001 p < 0.0001 0.152 







     
QFM 1.170 1.074 ― ― p < 0.0001 p < 0.0001 ― 
 
Table 4.1: Statistics for motif analysis
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targets (targets = 8.036, non-targets = 8.483). High enrichment was seen for the GAC motif 
(targets = 16.787, non-targets = 16.066), GACR (targets = 7.905, non-targets = 7.444), and 
GACARG motifs (targets = 0.875, non-targets = 0.773). While the WGGA frequency 
occurred a high frequency/kB (freq./kB = 16.531) there was significant difference in motif 
frequency compared to non-targets (freq./kB = 16.666). Finally, the QFM motif showed a 
significant enriched motif frequency per gene compared to non-targets (targets = 1.170, 
non-targets = 1.074). Importantly, the effect size (Cohen’s d) is small in all cases indicating 
that although there is a significant difference in motif frequency/kB between targets (n = 
2696) and non-targets (n = 11222) for all motifs except WGGA, the relationship may have 
moderately low practical significance. However, similar effect values were reported by 
Suhl et al. (Suhl et al., 2014). Finally, ρ was relatively small for all motifs (mean ρtargets = 
0.371, mean ρnon-targets = 0.370) but in all cases where there was significant enrichment, the 
motif occurred with a greater frequency then we would expect by chance. The GAC motif 
showed the strongest motif frequency compared to chance (ρtargets = 0.955, ρnon-targets = 
0.936). Overall, the results of our analysis were similar to the those seen in the analysis of 
the FMRP consensus data sets by Suhl et al., (Suhl et al., 2014) though there was some 
variability in the exact motif frequency in our data compared to the consensus data sets. 
Taken together, these results support the validity of our methodology and confirm that the 
motif frequency in the mRNA we isolated have similar enrichment over non-targets to 
previously identified FMRP targets.  
 
Analysis of FMRP mRNA targets reveals differential binding and GO enrichment of 
trans-synaptic signaling genes between treatments 
We have already seen that the application of Ro or Ro+Rapamycin leads to 
differential binding of FMRP mRNA targets (Figure 4.4E). Next, we sought to further 
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characterize the distributions of fold-changes for the FMRP targets in the two fold-change 
distributions under consideration (either Saline/Ro or Ro+Rapa/Ro). We predicted that if 
binding or release to FMRP is mTOR dependent then the administration of rapamycin will 
cause mRNA associated with specific biological processes to change simultaneously. To 
see if the fold-changes of any mRNA changed together within each of the different 
distributions we used univariate K-means clustering and determined the most 
representative GO biological processes found in each major cluster (k = 8). In both 
distributions (Saline/Ro or Ro+Rapa/Ro) we found that the trans-synaptic signaling genes 
were the most enriched GO biological process (Figure 4.5B, red bar). 60% of the trans-
synaptic signaling genes whose fold changes clustered together in the Saline/Ro 
distribution also clustered together in the Ro+Rapa/Ro distribution. Furthermore, most of 
these mRNA had a positive fold-change value in both distributions which we would expect 
if binding or release was mTOR dependent.  
We next visualized the intersection of the distributions described above (either 
log2(Saline/Ro) or log2(Ro+Rapa/Ro)) in order to find mRNA targets in both groups that 
changed in same direction (Figure 4.5C). Remarkably, we found that different FMRP 
targets were both released and bound in an mTOR-dependent manner from the mRNA 
population of FMRP targets that are translated when Ro activates mTOR 
(log2(Ro+Rapa/Ro) > 0) or those targets that are repressed when mTOR is on 
(log2(Ro+Rapa/Ro) < 0). We next used bivariate K-means clustering on the data this data, 
dividing it into k = 11 clusters (Figure 4.5C). Interestingly, the trans-synaptic genes group 
into different clusters suggesting that mTOR activity changes alters the expression of these 
genes by more than one mechanism. 
The population of mRNA found in saline relative to those in Ro indicate either 
FMRP targets translated with Ro induction (log2(Saline/Ro) > 0) or those targets not 
 156 
 
Figure 4.5: Motif analysis and clustering analysis for RIP-seq libraries 
A. Boxplot representing data summarized in Table 4.1. B. Distribution of log2 transformed counts 
for either the Ro+Rapamycin/Ro fold-changes or Saline/Ro fold-changes. Red bar indicates cluster 
identified by univariate K-means that is significantly enriched with trans-synaptic signaling genes 
by DAVID GO biological process clustering.  C. Scatterplot showing the log2(Ro+Rapaymcin/Ro) 
fold-changes on one axis and log2(Saline/Ro fold-change) on the other axis. Colored dots indicated 
various clusters identified by bivariate K-means clustering. Distribution (top and right) are the same 
as those shown in C.
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translated with Ro induction (log2(Saline/Ro) < 0) while the population of mRNA found 
in Ro+Rapa relative to Ro indicate FMRP targets translated when Ro turns mTOR on or 
FMRP targets repressed when mTOR is on. To further characterize the distributions of 
mRNA differentially binding to FMRP between drug treatments, we performed GO 
analysis to determine the most representative biological process clusters enriched for these 
mRNA populations (either Saline/Ro or Ro+Rapa/Ro) (Figure 4.6A,B). For either 
distribution, we first used the DAVID functional annotation chart to determine enriched 
GO biological processes for genes with a log2 fold-change > 0 or a log2 fold-change < 0 
separately. We then computed the symmetric difference between these GO terms to find 
those that were uniquely expressed in either direction. Since this list was quite large, we 
utilized the same approach that we applied to the GO terms from the MDD genes 
mentioned earlier (Figure 4.8A) to condense the most enriched terms into categories via 
unsupervised hierarchical clustering. Surprisingly, the most enriched biological processes 
for targets translated with Ro induction (log2(Saline/Ro) > 0) or translated when Ro turns 
mTOR on (log2(Ro+Rapa/Ro) < 0) were those under the parent GO category of 
GO:0099537: trans-synaptic signaling (p < 0.0001 for both fold-changes) (Figure 4.6A,B). 
These trans-synaptic genes mostly fall within the top right quadrant of the intersection of 
both of these fold-change distributions (targets translated when mTOR is on) indicated the 
mRNA involved in trans-synaptic signaling may be responsible for the synaptic remodeling 
seen in rapid antidepressant treatment (Figure 4.6C). Extending this analysis further we 
also clustered the trans-synaptic signaling genes found in either the Saline/Ro fold-change 
category (Figure 4.6D) or the Ro+Rapa/Ro fold-change category (Figure 4.6E). 
Interestingly, we see that the trans-synaptic signaling genes in the Saline/Ro fold-change 
distribution are more likely to change bidirectionally than do those found in the 
Ro+Rapa/Ro condition.  
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Figure 4.6:  Identification and clustering of trans-synaptic signaling genes 
A. Uniquely enriched GO biological process clusters for where log2(Saline/Ro) > 0.  B. Uniquely 
enriched GO biological process clusters for where log2(Ro+Rapamycin/Ro) > 0. GO analysis for 
A. and B. performed with DAVID functional annotation chart. Chart processing is described in 
detailed in “Experimental Procedures”. C. Scatterplot showing either log2(Saline/Ro) or 
log2(Ro+Rapamycin/Ro). Trans-synaptic signaling genes shown in red. D. Heatmap for trans-
synaptic signaling genes found in log2(Saline/Ro). E. Heatmap for trans-synaptic signaling genes 
found in log2(Ro+Rapamycin /Ro). Raw count data was transformed using the regularized log 
function.  Clustering using the average linkage method and Euclidean distance. Scales for C. and 




Trans-synaptic signaling proteins provide a potential target for the treatment of 
MDD 
MDD is great economic burden in modern society and it is projected to be the 2nd 
cause of disability worldwide by 2020 (Lopez et al., 2006; Mathers et al., 2006). Numerous 
pharmacological interventions have been attempted but the most common approaches, 
SSRIs, have been shown to have low effectiveness and response rates (Turner et al., 2008; 
Fournier et al., 2010; Undurraga and Baldessarini, 2012; Greenberg et al., 2015). 
Furthermore, scales and criteria for diagnosing MDD suffer from a high heterogeneity of 
symptoms which is a major impediment in the design of successful drug treatments 
(Lohoff, 2010; Lux and Kendler, 2010; Goldberg, 2011; Hybels et al., 2011; de Vos et al., 
2015; Lieblich et al., 2015; Fried, 2017). Recently, alternative approaches such as rapidly-
acting antidepressants that act on NMDA receptors have proven to be a reliable approach 
to treating MDD due to their fast action and long-lasting effects (Dwyer and Duman, 2013). 
In this work, we have attempted to “reverse engineer” MDD by examining the 
transcriptome-wide changes that occur in the cortex in response to administration of the 
rapid antidepressant Ro-25-6981. The combined approach of high-throughput assays and 
bioinformatics analysis has identified numerous targets of the Fragile-X Mental 
Retardation protein that bind differentially in response to treatment with Ro. Among the 
targets of FMRP are mRNA whose protein products are involved in trans-synaptic 
signaling. Our work suggests that these proteins are responsible for the remodeling of the 
synapse seen upon administration of rapid antidepressants and provide a unique molecular 
view of both the etiology and treatment of MDD. Finally, our pharmacological approach 
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with CMap suggests a means of using drug discovery to find alternative drugs to treat 
MDD. Further investigation into the role of the trans-synaptic signaling proteins and their 
role in increasing activity of the presynaptic neuron (“presynaptic engagement”) is 
currently underway. To date, only one work has examined the role of mTORC1 in this 
process (Henry et al., 2012) and our work underscores the importance of this pathway in 
retrograde signaling and presynaptic engagement processes. 
 
A model for presynaptic engagement of mTOR-dependent FMRP targets 
Under normal conditions, NMDA receptor activity is required for the activation of mTOR 
(Figure 4.7A, left). Our previous work has shown that NMDA antagonism results in the 
production of new GABABR surface expression resulting from the de-repression of FMRP 
and the decoupling of GABABR and GIRK channels due to increased stability of 14-3-3η 
(Workman et al., 2013; Workman et al., 2015; Wolfe et al., 2016). The FMRP targets that 
we recovered in our RIP-seq experiment from this phase are induced by Ro when mTOR 
is OFF. (Figure 4.7A, center). Our previous work also demonstrates that new GABABR 
associates with L-Type Ca2+ channels to activate mTOR (Workman et al., 2013; Workman 
et al., 2015). The mRNA in this phase are induced by Ro when mTOR is ON (Figure 4.7A, 
right). The identification of trans-synaptic signaling proteins in our RIP-seq experiment 
suggests that the released FMRP targets undergo retrograde transmission to the presynaptic 
neuron to engage in processes of presynaptic formation to strengthen connectivity with the 
postsynaptic neuron (Figure 4.7A, right). 
Our RIP-seq experiment has attempted to capture mRNA targets of FMRP from 
multiple phases of this process. We had predicted that when log2(Saline/Ro) > 0 or 
log2(Ro+Rapa/Ro) > 0, we are capturing a Ro-induced population that is either mTOR  
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Figure 4.7: Model for mTOR-mediated synaptic remodeling through FMRP targets 
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independent or mTOR ON respectively (Figure 4.7B, left). Furthermore, the population 
where log2(Saline/Ro) < 0 or log2(Ro+Rapa/Ro) < 0 is predicted to capture a Ro-repressed 
population. Out data suggests that there are three separate populations of FMRP targets 
that are separately activated based on the activity state of mTOR (Figure 4.7B). mRNA 
present in the “A” phase represent the mTOR off population which corresponds to released 
FMRP targets as shown in Figure 4.7A, center. Among these targets are a basal population 
“B” whose fold-change is altered minimally by mTOR. We call these targets mTOR 
independent. Targets in “A” are predicted to include mRNA whose protein products 
activate mTOR. As mTOR activity increases (denoted by the hypothetical line graph for 
mTOR activity in Figure 4.7B, left), the mRNA in population “A” are rebound by FMRP 
and their fold-changes drop. Finally, the data suggests that there is the “C” population 














A.  Left: Under normal conditions, glutamate binding to NMDA receptors on dendritic spines leads 
to the influx of Ca2+ which leads to the downstream activation of mTOR.  Center: Under NMDA 
receptor antagonism, such as through a rapidly-acting antidepressant like Ro-25-6981, the first 
wave of FMRP target translation is initiated. Our data shows that GIRK channels are decoupled 
from GABAB receptors due to increased stability of 14-3-3η. Furthermore, this process also results 
in the de-repression of FMRP (possibly due to inhibition of PP2A) so that its target mRNAs are no 
longer bound and are thus available for translation. Among these are GABAB mRNA. Our past data 
indicates an increase in GABABR2 protein levels and surface levels of GABA receptors (Workman 
et al., 2013; Workman et al., 2015; Wolfe et al., 2016). Right: Another wave of translation is 
initiated after the newly synthesized GABAB receptors associate with L-Type Ca2+ channels. The 
influx of Ca2+ activates mTOR and translated targets no longer bound to FMRP. In this work, we 
identify some of these targets which include mRNA involved in trans-synaptic signaling. The final 
part of our model hypothesized that the protein products of these mRNA undergo retrograde 
signaling to the presynaptic cell to initiate remodeling processes that strengthen the presynapse 
(“presynaptic engagement”) and postsynapse.  B. RIP-seq experiment predicts three separate 
populations of FMRP targets involved Ro-induced mediation of depression. Left: Hypothetical 
depiction of distributions of each FMRP target population in time. Hypothetical depiction of mTOR 
activity is shown below the main plot. Right: Correlation scatterplot, derived from Figure 4.6A, 
shows the spread of our targets in the top-right and bottom-left quadrants. Colored boxes or ellipses 
correspond to populations identified in the left portion of Figure 4.6B. Additionally, a Ro-repressed 
population is show in the purple (Figure 4.6B, lower left quadrant) representing predicted FMRP 
target mRNA involved in MDD. 
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whose fold-changes can be visualized as a scatterplot of the two distributions 
log2(Saline/Ro) or log2(Ro+Rapa/Ro) where the top-right and bottom-right quadrants 
contain mRNA that are Ro-induced (Figure 4.7B, right). Visualizing the data in this way 
also suggests that there is another population of mRNA that is Ro-repressed (Figure 4.7B, 
right, bottom-left quadrant). We hypothesize that these mRNA are involved in MDD and 
must be actively repressed in for antidepressant efficacy. Finally, our data suggests that the 
trans-synaptic mRNA found in the top-right quadrant (Ro-induced and mTOR ON) is 
responsible for the remolding of the synapse. Collectively, our work provides a foundation 
for understanding the mechanistic processes behind the synaptic remodeling seen upon 
administration of rapidly-acting antidepressants. Our future work aims to investigate these 





Figure 4.8: GO enrichment of biological process terms for MDD genes and FMRP 
consensus genes 
Top GO terms for A. an MDD depression gene list derived from a literature search or B. genes 
from the Brown et al. and Darnell et al. data sets (Brown et al., 2001; Darnell et al., 2011) from the 
DAVID functional annotation chart. Terms from the chart were clustered by the degree of overlap 
of genes in each term to produce a condensed list of major biological processes. DAVID functional 
annotation charts were filtered for a p-value cutoff of 0.001 and an FDR cutoff of 0.05. p-values or 
counts shown in the chart are means for all terms within a specific named category along the y-
axis. See “Experimental Procedures” for details. 
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Figure 4.9: RIP-seq quality control 
All counts shown in plots were scaled from 0-100 to facilitate comparisons. A. Normalized counts 
for FMRP targets and non-targets (list derived from (Darnell et al., 2011)) across treatments. B. 
Normalized counts of entire RIP-seq libraries (either WT or KO). C. Relative fold-enrichment as 
determined by real-time qPCR relative to 10% input control (ΔΔCt=2−(Ct FMRP RIP−Ct IgG RIP)−(Ct FMRP 
input−Ct IgG input)). FMRP binds to GABABR1 and GABABR2 in Saline or Ro-25-6981 treated animals 





Figure 4.10: Hierarchical clustering of overlapped GO terms derived from DAVID GO 
biological process function annotation chart 
GO terms unique to either A. Saline/Ro > 1 or B. Ro+Rapamycin/Ro > 1 were derived from the 
DAVID GO biological process functional annotation chart. A p-value cutoff of 0.001 and an FDR 
cutoff of 0.05 was used to filter the table. The resulting terms were then clustered by creating a 
similarity matrix based on the number of overlapping genes in each GO term. Clustering was 
performed using the average linkage method and used Euclidean distance. These terms were then 
used to create the charts seen in Figure 4.6 A,B. See “Experimental Procedures” for details. 
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Figure 4.11: Within-sum-of-squares (WSS) estimation for number of cluster used in 
clustering algorithms 
WSS was used to determine a suggested number of clusters to divide our data wherever a clustering 
algorithm (univariate K-means, bivariate K-means, or hierarchical) was to be applied. A. WSS 
calculation of clusters for Saline/Ro clustering (Figure 4.6A). B. WSS calculation of clusters for 
Ro+Rapamycin/Ro clustering (Figure 4.6B). C. WSS calculation of clusters for univariate K-means 
of Saline/Ro distribution (Figure 4.5B, top). D. WSS calculation of clusters for univariate K-means 
of Ro+Rapamycin/Ro clustering (Figure 4.5B, bottom). E. WSS calculation of clusters for bivariate 




RNA mass recovered (ng) 
Treatment 
Wild-type (Replicate) Knockout (replicate) 
1 2 3 1 2 3 
Ro-25-6981 
36 67 48 3 5 3 
Ro-25-6981 
+ Rapamycin 56 101 75 47 48 102 
Saline 
54 326 139 29 37 35 
RNA integrity number (RIN) 
Ro-25-6981 
9.0 8.6 9.1 1.0 8.4 1.1 
Ro-25-6981 
+ Rapamycin 8.6 8.8 8.8 9.0 7.2 8.9 
Saline 
8.6 8.3 6.7 8.7 8.8 8.3 
 















Library Length (nt) Input_Reads Mapping_Rate Multiple_Alignments 
RO_KO2_T1 20-51 436,922 16.10% 15.60% 
RO_KO2_T2 20-51 399,555 16.10% 15.50% 
RO_KO2_T3 20-51 4,787,614 16.60% 15.00% 
RO_KO2_T4 20-51 3,990,679 16.40% 15.10% 
RO_RAP_KO1_T1 20-51 8,253,643 72.90% 4.40% 
RO_RAP_KO1_T2 20-51 8,140,014 73.00% 4.40% 
RO_RAP_KO1_T3 20-51 9,524,091 73.50% 4.40% 
RO_RAP_KO1_T4 20-51 8,983,390 73.20% 4.40% 
RO_RAP_KO2_T1 20-51 1,539,793 76.00% 3.60% 
RO_RAP_KO2_T2 20-51 1,447,787 76.00% 3.60% 
RO_RAP_KO2_T3 20-51 5,235,945 75.40% 3.60% 
RO_RAP_KO2_T4 20-51 4,919,303 75.30% 3.60% 
RO_RAP_KO3_T1 20-51 8,735,516 73.30% 4.00% 
RO_RAP_KO3_T2 20-51 8,640,851 73.30% 4.00% 
RO_RAP_KO3_T3 20-51 230,114 73.60% 4.00% 
RO_RAP_KO3_T4 20-51 9,691,348 73.30% 4.00% 
RO_RAP_WT1_T1 20-51 9,425,580 81.90% 3.90% 
RO_RAP_WT1_T2 20-51 9,329,940 82.00% 3.90% 
RO_RAP_WT1_T3 20-51 3,634,272 82.50% 3.90% 
RO_RAP_WT1_T4 20-51 2,678,561 82.30% 3.90% 
RO_RAP_WT2_T1 20-51 9,389,927 86.50% 4.30% 
RO_RAP_WT2_T2 20-51 9,330,571 86.60% 4.30% 
RO_RAP_WT2_T3 20-51 3,847,304 86.70% 4.30% 
RO_RAP_WT2_T4 20-51 2,873,233 86.60% 4.30% 
RO_RAP_WT3_T1 20-51 7,040,228 86.40% 4.10% 
RO_RAP_WT3_T2 20-51 7,030,839 86.50% 4.10% 
RO_RAP_WT3_T3 20-51 1,221,288 86.70% 4.10% 
RO_RAP_WT3_T4 20-51 504,767 86.70% 4.10% 
RO_WT1_T1 20-51 8,568,455 39.00% 5.10% 
RO_WT1_T2 20-51 8,499,710 39.00% 5.00% 
RO_WT1_T3 20-51 5,282,085 40.10% 5.00% 
RO_WT1_T4 20-51 4,971,366 39.90% 5.00% 
RO_WT2_T1 20-51 973,892 60.30% 5.60% 
RO_WT2_T2 20-51 915,550 60.40% 5.60% 
RO_WT2_T3 20-51 9,052,870 61.30% 5.50% 
RO_WT2_T4 20-51 8,498,721 61.00% 5.60% 
RO_WT3_T1 20-51 7,787,301 55.40% 5.00% 
RO_WT3_T2 20-51 7,826,769 55.40% 5.00% 
RO_WT3_T3 20-51 5,785,648 56.40% 4.90% 
RO_WT3_T4 20-51 4,770,198 56.10% 4.90% 
SAL_KO1_T2 20-51 3,360,188 62.30% 4.30% 
SAL_KO1_T1 20-51 3,511,776 62.20% 4.40% 
SAL_KO1_T3 20-51 975,474 63.20% 4.30% 
SAL_KO1_T4 20-51 329,254 63.00% 4.30% 
SAL_KO2_T1 20-51 7,887,843 46.10% 4.70% 
SAL_KO2_T2 20-51 7,762,342 46.00% 4.70% 
SAL_KO2_T3 20-51 6,240,194 47.10% 4.60% 
SAL_KO2_T4 20-51 5,855,520 46.90% 4.60% 
SAL_KO3_T1 20-51 141,624 55.60% 4.40% 
SAL_KO3_T2 20-51 38,776 55.70% 4.40% 
SAL_KO3_T3 20-51 8,361,756 56.10% 4.30% 
SAL_KO3_T4 20-51 7,898,366 55.70% 4.30% 
SAL_WT1_T1 20-51 7,366,745 46.40% 4.60% 
SAL_WT1_T2 20-51 7,395,787 46.50% 4.60% 
SAL_WT1_T3 20-51 4,801,547 47.60% 4.60% 
SAL_WT1_T4 20-51 3,949,727 47.20% 4.60% 
SAL_WT2_T1 20-51 7,165,746 74.50% 3.90% 
SAL_WT2_T2 20-51 7,629,193 74.40% 3.90% 
SAL_WT2_T3 20-51 961,778 74.70% 3.90% 
SAL_WT2_T4 20-51 208,678 74.50% 3.90% 
SAL_WT3_T1 20-51 6,961,446 87.40% 4.20% 
SAL_WT3_T2 20-51 6,952,007 87.50% 4.20% 
SAL_WT3_T3 20-51 3,979,856 87.70% 4.20% 
SAL_WT3_T4 20-51 2,940,141 87.60% 4.20% 
Table 4.3: RIP-seq library and alignment data
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Chapter 5: Conclusion 
In the last decade, we have seen a vast expansion in the application of high-
throughput experiments in providing models for the physiological relevance of locally 
synthesized proteins. This expansion includes the earliest microarray studies on synaptic 
fractions, where it was considered fantasy to suggest ~400 mRNAs are localized in 
dendrites, to large scale RNA sequencing data suggesting closer to 2500 mRNAs reside in 
dendrites. Collectively, these data are expanding our knowledge of how cellular processes 
of learning and memory occur. Protein synthesis-dependent synaptic plasticity has been 
described by many investigators utilizing cellular physiology and well characterized 
protein synthesis inhibitors; however mechanistic details, at the molecular level, have 
lagged behind. Currently, many of the missing details are being provided by high-
throughput experiments that analyze the changes in the proteome or transcriptome in 
response to synaptic stimuli. However, the sudden interest in these types of experiments is 
a direct result of (1) the decreased cost of high-throughput experiments, (2) the availability 
and decreased cost of high-performance computing tools for processing large amounts of 
high-dimensional data, (3) the increasing accuracy and sensitivity of high-throughput 
sequencing technologies, and (4) the widespread development of biological assays that 
allow researchers to rapidly capture the interactions and dynamics of thousands of 
molecules simultaneously. Many other fields have embraced this technological shift and 
have begun to apply high-throughput technologies to many different avenues of research. 
The field of local dendritic translation could greatly benefit from these techniques as 
neuronal functioning and connectivity is due to a very complicated and dynamic 
framework of tightly-controlled interactions between the genome, proteome, and 
transcriptome.  
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The studies outlined here (Chapters 2-4) show the potential of high-throughput 
methodologies combined with bioinformatics to transform our knowledge of the molecular 
underpinnings of processes of learning and memory as well as neuronal dysfunction. Our 
approach in Chapter 2 used mass spectrometry to reveal that mTORC1 controls the 
expression of numerous proteins bidirectionally. We then explored these results in diseases 
of overactive mTOR to demonstrate that many proteins associated with these diseases 
change bidirectionally. This provides new avenues of exploration to determine the function 
of these proteins in situations where overactive mTOR represses their expression rather 
than actives it. In Chapter 3, we continued to explore the relationship between diseases of 
overactive mTOR through a number of bioinformatics approaches. We identified PARK7 
as a unique protein hub in an interaction network perhaps linking them together under the 
common theme of dysregulated translation. We also identified a novel function for PARK7 
in TSC and provided data suggesting possible pharmacological approaches to treating 
disorders involving mTOR and PARK7 targets. Finally, in Chapter 4, we used a high-
throughput RIP-seq approach to understand the dynamics of FMRP target binding in the 
presence of a rapidly-acting antidepressant. This experiment provides the first data that 
attempts to understand the mechanism of this class of antidepressants in MDD, suggesting 
a more general mechanism by which MDD occurs in the brain. Overall, our combined 
bioinformatics and high-throughput experiment approaches illustrates the vast potential to 
answer many long-standing questions in the field of local dendritic translation.  
Firstly, though the stages of LTP and synaptic plasticity are broadly understood, 
the specific dynamics underlying each step are not known and many different models with 
slight variation are published each year (Manninen et al., 2010). Elucidation of protein 
targets and protein-RNA interactions at different stages will provide further insight into the 
regulation and dynamics of these stages. Furthermore, LTP is typically studied at a single 
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synapse when in reality memory formation likely underlies many different processes, 
including homeostatic plasticity and synaptogenesis, at multiple synapses and systems of 
neurons taken as a whole. Some attempts have been made at providing a unified model of 
LTP (Michmizos et al., 2011) and many of the missing details could be provided by high-
throughput experiments that analyze the change in the proteome or transcriptome in 
response to synaptic stimuli. Secondly, the structural and morphological changes that occur 
in response to stimulated synapses is still poorly understood. Some important questions 
include: How do locally translated transcripts contribute to spine growth and synaptic 
remodeling? How are these processes controlled? How do signals from stimulated synapses 
lead to large-scale restructuring of synaptic connectivity between neurons and neuronal 
networks? Thirdly, and important but often overlooked feature involved in long-term 
memory formation is presynaptic engagement and retrograde signaling. Finally, many 
neurological disorders may be the consequence of a mutation in a single protein but this 
can have far-reaching effects on many other networks and processes. High-throughput 
experiments provide a powerful tool to show the alteration of molecular networks that 
occur as a result of disease states.  
There have been ongoing efforts in the last decade to provide rule-based meta-
languages to accurately model biological networks including Kappa (Feret et al., 2009) and 
NFSim (Sneddon et al., 2011). Such computational modeling systems effectively represent 
complex biological networks as a rule-based system and provide powerful prediction and 
simulation capabilities. A rule-based approach has already been used to characterize the 
structural dynamics of the PSD (Sorokina et al., 2011). This approach provides a more 
accurate and representative view of interactions between proteins since it accounts for 
stoichiometric properties within the protein-protein interaction network that reflect the 
dynamic nature inherent to molecular systems. Another possibility for representation and 
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prediction in biological networks is the use of Bayesian model-inference approaches (Pe'er, 
2005; Klinke, 2009). As data continues to increase from high-throughput experiments in 
the coming years, this information will become further integrated into computational 
modeling of the signaling networks providing a more unified view of the processes that 
underlie synaptic plasticity, memory, and the coordination of these effects through local 
translation. As techniques are refined and technology improves in the coming decade we 
foresee the frequent application of high-throughput technology to provide both novel 
candidates and coordinated local expression of proteins that make individual synapses 



















Appendix A: Pushing the threshold: How NMDAR antagonists induce 
homeostasis through protein synthesis to remedy depression10 
ENGAGING HOMEOSTATIC MECHANISMS WITH PHARMACOLOGICAL INTERVENTION TO 
TREAT MAJOR DEPRESSIVE DISORDER 
The idea of using modern medicine to push “out-of-balance” or diseased neurons 
to their tipping point seems outrageous. However, basic scientists do so on a regular basis. 
Experimental paradigms that induce long-lasting changes in synaptic efficacy—in one 
direction—are used to study cellular mechanisms of learning and memory (synaptic 
plasticity). Sustained extremes in neuronal activity, inherent to synaptic plasticity, 
eventually cause neurons and neuronal circuits to become unstable (Davis and Goodman, 
1998; Turrigiano and Nelson, 2000; Pozo and Goda, 2010). To avoid this problem, healthy 
neurons adjust their synaptic strength to maintain optimal action potential firing rates. This 
process is known as homeostatic plasticity and requires dynamic molecular changes 
(Turrigiano, 2008).  
Depression, anxiety disorders, and addiction, result from imbalanced neuronal 
networks (Figure A.1) (McClung and Nestler, 2008). Such perturbations in neuronal 
signaling, while severe, may not tip the scale enough for homeostatic mechanisms to kick 
in. Can modern medicine capitalize on what basic science has taught us about homeostasis? 
In other words, can pharmacological intervention in vivo push neuronal activity to its limit 
to induce homeostatic response that will eventually cause neurons and neuronal circuits to 
self-correct? Studies on rapid antidepressant therapies (i.e. N-methyl-D-aspartate receptor 
(NMDAR) antagonists argue yes (Figure A.1B-C). 
 
                                                 
10 Originally published in ( Raab-Graham, K.F., Workman, E.R., Namjoshi, S., Niere, F. (2016). Pushing 
the threshold: How NMDAR antagonists induce homeostasis through protein synthesis to remedy 
depression. Brain Res. 1647: 94-104. doi: 10.1016/j.brainres.2016.04.020. I wrote the “Regulation of 






















Figure A.1: Model for rapid antidepressant activation of homeostatic mechanisms 
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A. MDD leads to a network that is outside of the ideal homeostatic range, as indicated by the out 
of balance scale. B. NMDAR antagonists (green circle) pushes the network further outside the ideal 
range activating homeostatic mechanisms C. that result in relief from MDD and remission D. 
Are new antidepression therapies necessary? 
Major Depressive Disorder (MDD) is a severe neuropathophysiology that will 
affect up to 17% of the population at some point during their lifetimes (Zarate et al., 2010). 
The most common pharmacological therapies, selective serotonin reuptake inhibitors 
(SSRIs), target the serotonergic system by blocking serotonin uptake. Unfortunately, only 
~37% of individuals afflicted with MDD experience relief from their depressive symptoms 
with SSRIs (Murrough, 2012). Moreover, with continued use of SSRIs, only ~ 35-50% will 
go into remission (Rush et al., 2006; Trivedi et al., 2006; Trivedi et al., 2008; Murrough 
and Charney, 2012). Thus, finding new effective treatments for MDD is imperative. New 
therapies, such as rapid antidepressants and deep brain stimulation, are hypothesized to 
work by engaging network and cellular homeostatic mechanisms. Consequently, these 
therapies that are revolutionizing depression treatment, are predicted to drive the neurons 
to self-correct. 
 
What are Rapid Antidepressants? 
Rapid antidepressants are antagonists of NMDARs (Table A.1). NMDAR is a 
ligand and voltage-gated cation channel that is best characterized for its role in shaping 
synaptic strength during synaptic plasticity (Blanke and VanDongen, 2009). Behavioral 
assessment has shown that ketamine, Ro 25-6981 and other FDA approved NMDAR 
antagonists have remarkable efficacy in reversing treatment-resistant depression 
phenotypes. Additionally, NMDAR antagonists increase synaptogenesis, suggesting that 
increased neuronal communication arises from NMDAR blockade (Li et al., 2010; Ibrahim 
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et al., 2011; Lepack et al., 2014). While Trullas and Skolnick observed 25 years ago that 
NMDAR antagonists have antidepressant properties in rodents, recent clinical studies on 
the efficacy of ketamine and other NMDAR antagonists have renewed the field’s interest 
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Induces GABABR shift from opening K channels to facilitating L-type 
calcium channel activity 
(Workman et al., 2013) 
HPC Potentiates AMPAR-mediated evoked neurotransmission at rest (Nosyreva et al., 2013) 
Ketamine 
HPC 
Low-dose ketamine promotes low-dose AMPA-induced 
synaptogenesis (synapsin) 
(Akinfiresoye and Tizabi, 
2013) 
PFC Increases of spine number (Li et al., 2010) 
PFC Increases serotonin-induced EPSC (Li et al., 2010) 
MK-801 PFC Switches HPC-induced LTD to LTP (Thomas et al., 2014) 
Ro-25-6981 
HPC Rescues LTP and gamma oscillation in LTP-deficient Tn65DN mouse (Hanson et al., 2013) 
HPC Impairs gamma oscillation in normal mouse (Hanson et al., 2013) 
Structural plasticity Ketamine PFC Promotes spine growth (Li et al., 2011) 
Intrinsic excitability 
AP5 HPC cultures 14-3-3 eta decouples GABABRs from GIRK channels (Workman et al., 2015) 
Ketamine 
Cortex Inhibits in Ih current in layer V cortical pyramidal cells (Chen et al., 2009) 
HPC 
Knockdown of HCN1 in the dorsal hippocampal produced 
antidepressant-like behaviors in the FST, similar to ketamine injected 
rats 
(Kim et al., 2012) 
Transcription 
AP5 HPC cultures Increases expression of HDAC4 mRNA and protein (de Bartolomeis et al., 2013) 
Ketamine 
IC Increases expression Homer1a mRNA (de Bartolomeis et al., 2013) 
AC, SS Increases expression of Arc mRNA (de Bartolomeis et al., 2013) 
CP Decreases expression of PSD95 mRNA (de Bartolomeis et al., 2013) 
MC Decreases expression of Homer1b mRNA (de Bartolomeis et al., 2013) 
MK-801 
CP Decreases expression of PSD95 mRNA (de Bartolomeis et al., 2013) 
HPC astrocyte cultures Increases expression of BDNF, GFAP and TrkB mRNAs (Yu et al., 2015) 
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Brain region Effect References 
Translation (eEF2-
dependent/global 
Ketamine HPC, FC Increases expression of BDNF (Autry et al., 2011) 
MK-801 
HPC Increases expression of BDNF (Autry et al., 2011) 
HPC, FC Increases expression of Arc (Autry et al., 2011) 
Translation (mTOR-
dependent) 
AP5 HPC cultures Baclofen promotes expression of BDNF (Workman et al., 2013) 




AP5 HPC cultures Increases expression of GABABR2 protein (Workman et al., 2015) 
Ro-25-6981 HPC Increases expression of GABABR2 protein (Workman et al., 2015) 
Apoptosis AP5 HPC cultures Increases expression of pro-apoptotic genes expression (Chen et al., 2009) 
Autophagy Ro-25-6981 
CTX Delays the expression of TBI-induced autophagic proteins (Bigford et al., 2009) 
Neuronal cultures Inhibits glutamate excitotoxicity-induced cell death (Bigford et al., 2009) 
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in these drugs as potential antidepressants (Zarate et al., 2006; Skolnick et al., 2009). Still, 
at the molecular level, it is uncertain as to why blocking NMDARs relieves depressive 
symptoms. This review focuses on the convergence of the clinical application of NMDAR 
antagonists and the basic science of neuronal homeostasis focusing on protein synthesis-
dependent pathways.  
 
NMDAR ANTAGONISM LEADS TO HOMEOSTATIC PLASTICITY 
A neuron employs two forms of homeostatic responses—global and local synaptic 
scaling—to deal with extreme high or low activity (Turrigiano, 2012). Global synaptic
scaling induces a slow, cell-wide compensation in excitatory and inhibitory receptors 
throughout the soma and dendritic arbor. In contrast, local synaptic scaling occurs within 
hours as a response to local activity fluctuations, allowing dendrites or groups of synapses 
to restore operation at an optimal range (Queenan et al., 2012).   
 
NMDAR subunit composition underlies the homeostatic mechanism of 
Metaplasticity 
Metaplasticity is a form of homeostasis describing how cells or circuits reset their 
baseline activity levels in response to their previous activity (Abraham et al., 2001). 
Metaplasticity has been studied mostly at the circuit level, albeit it has been reported to 
occur at a single synapse (Lee et al., 2010a). For example, in seminal studies that deprive 
rodents of light during a critical period of visual developmental, the absence of visual input 
alters the threshold for synaptic plasticity in the forms of long-term potentiation (LTP) and 
long-term depression (LTD) (Kirkwood et al., 1996; Philpot et al., 2003). At the molecular 
level, light deprivation induces cell-wide forms of synaptic scaling by upregulating 
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excitatory receptors and downregulating inhibitory receptors. Such a shift in the ratio of 
excitatory and inhibitory inputs will favor excitation and is consistent with a reduced 
threshold to induce LTP (Turrigiano, 2012). Interestingly, upon a short exposure to light, 
causing cortical activity to rise, more excitatory synaptic input is required to induce LTP 
(Philpot et al., 2003). These experiments, as well as many that have come before and after, 
serve as the basis for metaplasticity (Bear, 1995). 
At the molecular level, changes in NMDAR subunit composition that regulate 
calcium dynamics likewise support metaplasticity (Yashiro and Philpot, 2008). NMDARs 
are obligate heteromultimers consisting of an NR1 subunit in combination with NR2A-D 
and NR3A-B (Glasgow et al., 2015). NR2A and B are the most critical subunits in setting 
the membrane threshold (Yashiro and Philpot, 2008). NR2B-containing NMDARs are 
slower to deactivate and thus carry more calcium per unit current relative to NR2A-
containing receptors (Sobczyk et al., 2005; Glasgow et al., 2015). A decrease in the 
NR2A/2B ratio, an adjustment that appears to be seemingly modest in nature, significantly 
slides the threshold to favor LTP. As expected, NR2B-containing channels are upregulated 
relative to NR2A in the dark; and upon activation, allow for greater influx of calcium in 
spines (Yashiro and Philpot, 2008). Thus, one would predict that blocking NR2B activity 
under conditions of reduced cortical activity would provide the biggest push toward 
silencing synaptic activity. Furthermore, such a push may be sufficient to engage 




MAMMALIAN TARGET OF RAPAMYCIN (MTOR) SERVES AS A THERMOSTAT IN NMDAR 
ANTAGONIST-INDUCED HOMEOSTATIC RESPONSE 
mTOR senses the functional, operating range of a neuron 
How does one identify if a neuron is “out-of-range”? Is there a molecular marker 
whose activity level gauges the general health of a neuron? In MDD, it has been suggested 
that mTOR activity levels may serve as a molecular thermostat as it can gauge the efficacy 
of antidepressant drugs (Zarate et al., 2013). mTOR is a serine/threonine kinase that 
controls protein synthesis, cell growth and metabolism by sensing the levels of nutrients, 
growth factors, cellular energy, and stress. mTOR is conserved from yeast to human, 
signifying its critical importance in cellular homeostasis. mTOR consists of two 
complexes, mTORC1 and C2. mTORC1 regulates protein synthesis through 
phosphorylation of two proteins that regulate mRNA translation—eukaryotic initiation 
factor 4 binding protein (eIF4BP) and ribosomal S6 kinase (Hay and Sonenberg, 2004). In 
the brain, mTOR mediates dendritic protein synthesis, critical for synaptic plasticity and 
memory consolidation (Graber et al., 2013b).  
In many diseases, mTORC1 is often overactive or underactive, consistent with a 
neuron operating outside its optimal range. For example, in epilepsy, Alzheimer’s disease, 
and autism spectrum disorders—including Fragile X Syndrome and Tuberous Sclerosis 
Complex—mTORC1 signaling is excessive (Pei and Hugon, 2008; Zeng et al., 2009; Gross 
et al., 2010; Sharma et al., 2010; Spilman et al., 2010; Santini and Klann, 2011; Zeng et 
al., 2011; Sahin, 2012; Crino, 2015; Sosanya et al., 2015a). Furthermore, in MDD and 
Parkinson’s disease, mTORC1 signaling is reduced (Jernigan et al., 2011; Fragkouli and 
Doxakis, 2014). It is currently unknown how mTORC1 gets stuck and fails to return to 
basal levels in these diseases. What can be done to “unstick” mTOR activity, allowing it to 
return to basal levels? Insights from NMDAR antagonists used for treating MDD may offer 
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an answer. Several labs have shown that mTORC1 activity increases with a single 
treatment of NMDAR antagonists in vivo. The increase in mTORC1 is required for the 
antidepressant efficacy of NMDAR antagonists (Li et al., 2010; Workman et al., 2013). In 
the brain, where the circuitry is intact and the release of neurotransmitters is difficult to 
control, deciphering how NMDAR blockade increases mTOR activity is challenging. 
Utilizing a simplified model of cultured hippocampal neurons, where one has tight control 
over the activation of neurotransmitter receptors, blockade of NMDARs with (2R)-amino-
5-phosphonovaleric acid (AP5) reduces basal mTOR activity (Workman et al., 2013). 
These results indeed suggest that reducing NMDAR signaling pushes mTORC1 activity 
levels down and would be predicted to induce homeostasis (Figure A.1). However, as 
mTORC1 activity remains low, the trigger for the cell to push back and return mTORC1 
activity to control levels is absent in these cultures. Collectively, these data provide the 
first hint that an extrinsic factor, such as a neurotransmitter, is necessary to restore 
mTORC1 activity to normal basal levels. 
 
NMDAR activity at rest shapes the ability of metabotropic GABABR signaling to 
turn mTORC1 activity up.  
What turns mTOR activity on with NMDAR blockade? One clue came from studies 
showing that NMDARs and γ-aminobutyric acid B receptors (GABABR), that are 
metabotropic G-protein-coupled receptor, extensively interact in a feedback loop (Guetg et 
al., 2010; Terunuma et al., 2010; Workman et al., 2013). GABA is considered as the major 
inhibitory neurotransmitter in the brain (Jembrek and Vlainic, 2015). Under normal 
physiological conditions, GABABRs inhibit neuronal activity through pre- and 
postsynaptic mechanisms. Postsynaptically, GABABRs mediate the slow inhibitory 
postsynaptic potentials via the activation of postsynaptic, G-protein-regulated, inwardly 
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rectifying potassium (GIRK) channels (Padgett and Slesinger, 2010). Stimulating 
NMDARs in cultured hippocampal neurons leads to endocytosis of GABABRs (Guetg et 
al., 2010; Terunuma et al., 2010).  Likewise, blocking NMDAR signaling in vitro increases 
the dendritic surface expression of GABABRs (Workman et al., 2013). This reciprocal 
relationship between synaptic activity and GABABR surface expression, at first glance, 
would appear to provide positive feedback—less inhibition with synaptic stimulation and 
more inhibition with reduced synaptic activity. Surprisingly, NMDAR blockade causes 
GABABR function to shift from signaling that opens GIRK channels to signaling that 
increases dendritic Ca2+ requiring L-type Ca2+ channel activity (Workman et al., 2013). 
This increase in Ca2+, in turn, activates mTORC1 in primary apical dendrites that are 
enriched in GABAergic synapses (Megias et al., 2001; Workman et al., 2013). Moreover, 
GABABR signaling through mTORC1 promotes the synthesis of the brain derived 
neurotropic factor (BDNF), which is required for new synapse formation with rapid 
antidepressants (Figure A.2) (Li et al., 2010; Workman et al., 2013). These results 
emphasize that restoring neuronal communication leads to the sustained antidepressive 
efficacy of NMDAR antagonists (Li et al., 2010; Li et al., 2011; Liu et al., 2012). 
 
RAPID ANTIDEPRESSANT EFFICACY REQUIRES DISTINCT STAGES OF NEURONAL PROTEIN 
SYNTHESIS 
Evoked versus miniature NMDAR currents 
One perplexing concept regarding the effectiveness of NMDAR antagonists as 
rapid antidepressant is the requirement that the membrane be depolarized for NMDARs to 
open. NMDARs require the binding of two neurotransmitters, glutamate and glycine.  Even 
in the presence of these molecules the channel remains closed due to Mg2+ blocking the 
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Figure A.2: Cartoon describing molecular pathways triggered by NMDAR antagonists 
Left panel: Activation of GABABRs signal to open GIRK channels reducing dendritic calcium levels. Calcium entry through NMDARs 
activates the translation elongation factor kinase eEF2K that in turn phosphorylates eEF2, inhibiting global translation. Right panel: In the 
presence of NMDAR antagonists GABABR signaling shift to facilitating L-type calcium channel activity and activates mTOR-dependent 
protein synthesis. This requires the protein synthesis and insertion of new GABABRs into the dendritic membrane. What RNA binding 
protein (RBP) mediates GABABR mRNA repression (left) and or translation (right) is an open question. In addition, reduced NMDAR 
signaling to eEF2K increases the activity of eEF2 allowing for global translation. eEF2 protein expression increases when mTOR activity 
is reduced. If new eEF2 mRNA translation and the RBPs that regulate its expression is unknown.
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ion-conducting pathway. Depolarization of the membrane dislodges Mg2+, and facilitates 
the movement of cations, particularly Ca2+, in and out of the cell (Burnashev et al., 1992). 
Considering the strict biophysical properties of the channel, one would predict that 
NMDAR antagonists quiet active neurons and neuronal circuits. However, some studies 
suggest that the Mg2+ block of NMDARs is partial at the resting membrane potential (Reese 
and Kavalali, 2015). Fortunately, since NMDAR antagonists come in many flavors, 
pharmacological approaches can dissect NMDAR resting current blockade from evoked 
and total NMDAR blockade. For example, MK-801, which selectively blocks open 
NMDARs, and memantine, only blocks NMDARs when Mg2+ is dispelled from the pore 
conducting pathway, are widely used. It is generally considered that MK-801 blocks both 
evoked and resting NMDAR currents, whereas memantine only blocks NMDARs engaged 
in firing Remarkably, rodents treated with MK-801 display improvement on behavioral 
despairs, while with memantine they do not (Autry et al., 2011; Gideons et al., 2014). Thus, 
NMDAR antagonists that are used as rapid antidepressants (e.g. MK-801) are effective at 
reducing the activity of neurons engaged in firing, as well as a population of NMDARs that 
are open at rest via spontaneous activity.  
 
NMDAR blockade-induced translation initiates two phases of antidepressant 
efficacy  
Studies suggest that antidepressant efficacy requires two phases—induction and 
sustained. While it is clear that mTORC1-dependent protein synthesis is required for the 
long-lasting effects of rapid antidepressants, the molecular changes that initiate the process 
remain unclear. Does the initiation phase require protein synthesis? Work on local 
homeostatic synaptic scaling demonstrates that acute blockade of spontaneous NMDAR 
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activity increases the miniature excitatory synaptic current (mEPSC) mediated by the 
glutamate receptor that contains α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
(AMPA) 1 subtype (GluA1). Such AMPAR-mediated synaptic scaling requires de novo 
dendritic protein synthesis of GluA1 (Sutton et al., 2006).  
Notably, several groups have observed increased expression of GluA1 with 
administration of NMDAR antagonists in vivo (Li et al., 2010; Autry et al., 2011; Nosyreva 
et al., 2013; Workman et al., 2013). A separate set of studies have also demonstrated that 
blocking spontaneous NMDAR activity increases evoked AMPAR-mediated synaptic 
potentiation in the CA1 region of hippocampal slices. This form of potentiation was 
sustained and further amplified an hour after the antagonist had been washed away 
(Nosyreva et al., 2013). Interestingly in a BDNF knockout mouse, the initial synaptic 
potentiation due to NMDAR antagonists was present and similar to wildtype slices; 
however, the sustained potentiation was absent. In contrast, the inclusion of a protein 
synthesis inhibitor blocked the early and sustained potentiation induced by NMDAR 
blockade, indicating a requirement for protein synthesis in both plasticities (Nosyreva et 
al., 2013). These results confirm the necessity of BDNF for the long-lasting effects on 
synaptic potentiation due to NMDAR blockade and perhaps hint at a separate requirement 
for protein synthesis for the initial potentiation phase. 
If mTORC1 activity mediates translation of mRNAs that are required for the 
sustained antidepressant effects of NMDAR antagonists, what mediates protein synthesis 
in the initiation phase? Schuman and colleagues proposed that Ca2+ entry through open 
NMDARs promotes the kinase activity of the eukaryotic elongation factor 2 kinase 
(eEF2K), which inhibits eEF2—an elongation factor that promotes global mRNA 
translation. As they had predicted, NMDAR blockade with AP5 in the presence of 
tetrodotoxin (TTX), which inhibits action potential, reduced Ca2+ entry, inactivated 
 188 
eEF2K, and increased local protein synthesis. These results led the authors to conclude that 
NMDAR-mediated mEPSCs inhibit local protein synthesis (Sutton et al., 2004; Sutton et 
al., 2006; Sutton and Schuman, 2006). These studies, for the first time, assigned a function 
to spontaneous release and mEPSCs, as a critical regulator of homeostatic protein synthesis 
(Sutton et al., 2004). In light of MDD, do NMDAR-mediated mEPSCs occur more often 
or have a greater impact in “depressed” neurons or neuronal circuits? There is no direct 
experimental evidence that addresses this question. However, work on rapid 
antidepressants demonstrates that eEF2-dependent translation is upregulated with 
NMDAR antagonists in vivo. Furthermore, NMDAR-antagonist-induced antidepressant 
response can be bypassed completely by treating rodents with drugs that directly activate 
eEF2 (Autry et al., 2011). 
 
NMDAR ANTAGONISTS INDUCE STRUCTURAL HOMEOSTASIS THAT CORRELATES WITH 
ANTIDEPRESSANT EFFICACY 
One of the most striking effects of rapid antidepressants is increased spine density 
(Ohgi et al., 2015). Dendritic spines are the primary location of excitatory synapses in the 
adult brain. Spine shape, size, and number vary over the normal lifetime of an individual, 
and many neuropathologies display atypical spine distribution, shape, and number (Bourne 
and Harris, 2008). Structural homeostasis is defined by neuronal architecture changes in 
response to long-term fluctuations in activity (Yin and Yuan, 2014). Over the years, 
sensory paradigms that prompt homeostatic plasticity also induce morphological changes 
in spines (Butz et al., 2009; Keck et al., 2011). For example, sensory deprivation results in 
enlarged spine heads and increased postsynaptic AMPAR expression (Wallace and Bear, 
2004; Keck et al., 2013). Moreover, whisker trimming paradigms that reduce sensory 
inputs to the cortex decreased spine elimination (Zuo et al., 2005).  
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In 1999, Kirov and Harris found that blocking NMDARs in an acute hippocampal 
slice preparation significantly increased the spine density in dendrites (Kirov and Harris, 
1999). Duman and colleagues, a decade later, also reported that NMDAR antagonism 
increased dendritic spines in vivo by using mice that sparsely expressed yellow fluorescent 
protein in the prefrontal cortex (Li et al., 2010; Li et al., 2011). With new synapse formation 
one would expect increased pre- to postsynaptic signaling. As predicted, mEPSC frequency 
in layer II/III cortical neurons increased 24 hours post-rapid antidepressant injection 
(ketamine or Ro 25-6981) (Miller et al., 2014).  
 
mTOR mediates NMDAR antagonist-induced spine formation 
mTOR activity increases spine density. In neurons with hyperactive mTOR 
signaling, elevated spine number can be reduced with the mTORC1 inhibitor rapamycin 
(Tavazoie et al., 2005). It has been suggested that mTORC1-dependent protein synthesis 
is required for new spine formation and may be the key link for remission from depression 
(Li et al., 2010; Li et al., 2011). In support of this view, direct rapamycin infusion into the 
prefrontal cortex prevents the ketamine-induced increase in spine number (Li et al., 2010; 
Li et al., 2011).  Of note, BDNF, which is translated via eEF2 and mTORC1, is necessary 
for the increased expression, maturation and stability of spines (Bennett and Lagopoulos, 
2014). In light of how BDNF is translated, speculations abound that BDNF synthesis is 
required for the expression of the early and late phases of NMDAR antagonist-mediated 
antidepressant response, whereby the “early” synthesized BDNF is secreted to act upon 
postsynaptic TrkB receptors that bind BDNF with high affinity (Autry et al., 2011). Upon 
BDNF binding, TrkB signals cascade to turn mTOR on (Takei et al., 2004; Kavalali and 
Monteggia, 2012; 2015). BDNF secretion from the postsynaptic neuron is likely to require 
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L-type calcium activity, perhaps through the activation of GABABRs (Workman et al., 
2013; Lepack et al., 2014). Further work is needed to test this hypothesis and to identify 
the intermediate events that lead to new synapse formation. In spite of incomplete 
mechanistic details, these data suggest that altering neuronal activity with natural stimuli 
such as light, experimentally with whisker trimming, or pharmacologically with NMDAR 
antagonists promotes changes in spine shape, size and density to maintain homeostasis. 
 
EVIDENCE FOR ALTERNATIVE WAYS OF INDUCING HOMEOSTATIC PLASTICITY TO 
REMEDY DEPRESSION  
Intrinsic Excitability 
If NMDAR antagonists exert their action by lowering synaptic activity to engage 
homeostatic mechanisms, then directly altering ion channel function or density (intrinsic 
excitability) of the dendritic membrane may serve the same function as NMDAR 
antagonism. For example, knockdown of the HCN1 channel produces an antidepressant 
behavioral phenotype and increases mTOR and BDNF, two molecular mediators of rapid 
antidepressant efficacy (Kim et al., 2012). While ketamine is best known for its ability to 
block NMDARs, it has been shown to also block HCN channels (Chen et al., 2009). 
Moreover, as mentioned above, switches in receptor-channel signaling are involved in 
formation and reversal of depressive symptoms. Specifically, upon NMDAR antagonism, 
GABABR signaling to GIRK channels decreases while L-type channel activity increases. 
This switch in turn enhances mTOR activity and BDNF expression (Workman et al., 2013). 
Blocking the decoupling of GABABR from GIRK in the presence of NMDAR antagonists 
restores GABABR-mediated hyperpolarization and prevents rapid antidepressant efficacy 
in vivo (Workman et al., 2015). Interestingly, sleep deprivation also mediates a rapid 
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antidepressant effect (McClung, 2007). In fruit flies, a screen designed to find mutants with 
a short sleeping phenotype identified the shaker locus (Kv1) (Cirelli et al., 2005), a channel 
whose expression is repressed by mTORC1 activity (Raab-Graham et al., 2006; Sosanya 
et al., 2013; Sosanya et al., 2015a; Sosanya et al., 2015b; Niere et al., 2016). It will be 
interesting if like HCN, reduced levels of Kv1.1 feedback to increase mTORC1/BDNF 
signaling resulting in antidepressant behaviors. All in all, these findings suggest that 
changes in intrinsic excitability can regulate the mTOR/BDNF antidepressant pathway.  
 
Regulation of Autophagy 
Aberrant autophagy has been suggested to underlie depression (Abelaira et al., 
2014). Autophagy is triggered when the cell is deprived of nutrients or placed in stressed 
conditions and serves to recycle organelles, clear protein aggregates, and eliminate non-
essential macromolecules in order to aid in cell survival. In certain cases, cell signaling 
events that induce autophagy eventually lead to apoptosis (Marino et al., 2014). Tissue 
studies in human and animal models have shown that depression is characterized by the 
loss of neural and glial cells due to chronic stress (Banasr and Duman, 2008; Krishnan and 
Nestler, 2008; Pittenger and Duman, 2008). Various stress paradigms in rats have been 
shown to upregulate levels of pro-apoptotic proteins that are released through 
mitochondrial outer membrane permeablization as well as the release of caspase 3 (Bachis 
et al., 2008; Kosten et al., 2008). Furthermore, a transcriptome-wide profile of post-mortem 
human prefrontal cortex brain tissue from 14 pairs of subjects analyzed by microarray 
revealed the over-expression of apoptosis factors and inflammatory cytokines (Shelton et 
al., 2011). Notably, antidepressants have been shown to upregulate levels of anti-apoptotic 
proteins, particularly members of the Bcl-2 family involved in the suppression of 
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mitochondrial outer membrane permeabilization, a key step in the intrinsic apoptosis 
pathway (McKernan et al., 2009).  
mTOR is known to control the homeostasis between cell growth (synthesis of new 
molecules) and autophagy (breakdown of current cell structures and macromolecules). 
mTOR is a negative regulator of autophagy but its mechanism of control is poorly 
understood. mTOR phosphorylation of ULK1 prevents activation of the ULK1 complex, a 
regulator of autophagy and inducer of apoptosis (Ganley et al., 2009; Jung et al., 2009; Lee 
and Tournier, 2011; Mukhopadhyay et al., 2015). Importantly, a reduction in both 
phosphorylation and expression of components of the mTOR signaling pathway has been 
observed in a postmortem examination of prefrontal cortex tissue obtained from depressed 
subjects in a series of studies. These proteins include NR2A, NR2B, mGluR5, PSD-95 as 
well as mTOR and its downstream targets involved in the control of translation p70SK6, 
eIF4E, p-eIF4E, eIF4B, and p-eIF4B (Feyissa et al., 2009; Deschwanden et al., 2011; 
Jernigan et al., 2011). All of this suggests an important role for mTOR in the homeostatic 
balance between autophagy and protein synthesis that may be relevant in the context of 
depression.  
Finally, the NMDAR antagonists, 3-methyladenine (3-MA) and Ro-25-6981, have 
been shown to suppress the induction of autophagy and neuronal cell death (Bigford et al., 
2009; Sadasivan et al., 2010; Xin et al., 2011). Bigford and colleagues demonstrated that 
Ro-25-6981 blocked the induction of autophagy and lowered the levels of autophagic 
proteins both in vitro and in vivo. This and previously discussed work suggest the 
possibility that the Ro-25-6981-mediated repression of NR2B signaling may by 
neuroprotective through the mTOR pathway. Thus, mTOR may be uniquely positioned (1) 
to promote the growth of new spines, (2) to regenerate dendritic architecture through 
protein synthesis, and (3) to suppress autophagy-mediated apoptosis in neurons injured by 
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chronic stress (Jia and Le, 2015). Future studies will be needed to determine the manner in 
which NR2B-specific antagonists are able to trigger these effects. 
 
PERSPECTIVES AND OPEN QUESTIONS 
Insight into depression and antidepressant therapies through the identification of 
proteins synthesized when mTORC1 is inhibited 
Are there other ways to coax the compromised or diseased neuron to self-correct? Clues 
may come from recent work that examines dendritic protein synthesis in the presence of 
the mTORC1 inhibitor rapamycin in vivo (Niere et al., 2016). While the role of mTORC1 
activity to promote translation of mRNAs is grounded in its established function of 
phosphorylating eIF4BP and ribosomal S6 kinase (Hay and Sonenberg, 2004), a few 
studies suggest a separate and likely just as important role for mTORC1 activity in 
repressing mRNA translation of specific transcripts (Raab-Graham et al., 2006; Sosanya et 
al., 2013; Niere et al., 2016). Interestingly, Niere et al., using the unbiased approach of 
mass spectrometry, demonstrates that the number of proteins that increase at the synapse 
with mTORC1 inhibition is approximately equal in number to those whose expression is 
reduced (Niere et al., 2016). Is it possible that some of these mRNAs are homeostatic in 
nature, and that the proteins they encode may predispose the neuron to turn mTORC1 back 
on? Notably, some of the proteins that are synthesized with brief mTORC1 inhibition 
overlap with proteins previously associated with depression and antidepressant properties 
(Figure A.3A-C) (Fatemi et al., 2001; Tadic et al., 2007; Dlugos et al., 2009; Unschuld et 
al., 2009; Lee et al., 2010b; Luo et al., 2010; Rietschel et al., 2010; Aragam et al., 2011; 
Galeotti and Ghelardini, 2011; Shyn et al., 2011; Dekker et al., 2012; Sakaida et al., 2013; 
Ray et al., 2014; Gatt et al., 2015; Gray et al., 2015; Ogawa and Kunugi, 2015; Skoog et 
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al., 2015; Wagner et al., 2015; Yoshimasu et al., 2015; De Vry et al., 2016; Liu et al., 2016; 
Stachowicz et al., 2016). For example, Homer 1a was found to be upregulated in several 
paradigms of antidepression therapy including sleep deprivation, electroconvulsive shock, 
ketamine, imipramine, and fluoxetine (Serchov et al., 2016). Moreover, the Homer1 
knockout mouse displays phenotypes consistent with anxiety and depression (Szumlinski 
et al., 2005). To date, it is unclear as to what protein synthesis pathways and translation 
factors are utilized to translate these homeostatic mRNAs. One would predict that eEF2 is 
involved but may not be the only factor. Notably, eEF2 is a protein whose expression is 
differentially regulated by mTORC1 activity, in a subcellular specific manner (Figure 
A.3C). Is synthesis of eEF2 mRNA required to turn mTORC1 activity on with NMDAR 
blockade (Figure A.2)? Such a result would suggest that additional translational 
mechanisms upstream of eEF2 are required for antidepressant efficacy. Nevertheless, 
coordinated stages of protein synthesis utilizing different translational mechanisms such as 
eEF2 and mTORC1 are required for rapid antidepressant efficacy, and mTORC1-
dependent translation of BDNF is critical for the sustained effects of NMDAR antagonists 
(Lepack et al., 2014). 
 
The unexplored role of RNA-binding proteins in rapid antidepression therapy 
Targeting new protein synthesis pathways as a means to treat depression is a 
relatively new idea. As noted above, protein synthesis of specific proteins is orchestrated 
to mediate short- and long-term effects. Spatial accumulation of mRNAs in dendrites is 
widely believed to be a mechanism that regulates temporal gene expression. Cis-acting 









Figure A.3: Protein expression regulated by mTORC1 activity overlap with depression 
A. Venn diagram illustrating several proteins identified by mass spectrometry of synapses with 
brief in vivo mTORC1 inhibition overlap with proteins associated with depression. B. Heat map of 
16 overlapping proteins in the postsynaptic density fraction (P) and soluble fraction (S) of 
synaptoneurosomes isolated from cortices of control and rapamycin injected rats. Note, many of 
those proteins increase with mTORC1 inhibition (yellow). C. Heat map of EEF2, demonstrating 
increased expression in soluble fraction of synaptoneurosomes with brief mTORC1 inhibition. Data 
obtained from (Niere et al., 2016) and (Fatemi et al., 2001; Tadic et al., 2007; Dlugos et al., 2009; 
Unschuld et al., 2009; Lee et al., 2010b; Luo et al., 2010; Rietschel et al., 2010; Aragam et al., 
2011; Galeotti and Ghelardini, 2011; Shyn et al., 2011; Dekker et al., 2012; Sakaida et al., 2013; 
Ray et al., 2014; Gatt et al., 2015; Gray et al., 2015; Ogawa and Kunugi, 2015; Skoog et al., 2015; 
Wagner et al., 2015; Yoshimasu et al., 2015; De Vry et al., 2016; Liu et al., 2016; Stachowicz et 
al., 2016) for bioinformatics analysis. 
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mRNA and ensure that the message is made into protein only when needed (Fernandez-
Moya et al., 2014). To date, little work has been done to determine the role of RNA binding 
factors in antidepression efficacy. Considering the importance of new synaptic 
connections, RBPs that regulate synapse structure and function are likely to be important 
for long-lasting antidepressant effects with NMDAR antagonism. Here we will highlight 
some of the RBPs that are critical for new synapse formation and synaptic scaling.  
 
(i) NMDAR-mediated RNA granule formation: mRNA-silencing foci are RNA 
granules that contain silenced mRNAs and RBPs that repress translation. Distinct 
mRNA-silencing foci are formed and dispersed with different forms of synaptic 
plasticity (Thomas et al., 2014). One particular foci that forms with NMDAR 
stimulation is the synaptic XRN1 bodies (SX-bodies). While XRN1 is an RBP that 
is best known for its role in mRNA decay, SX-bodies lack decapping activity and 
therefore serve to sequester mRNAs (Luchelli et al., 2015). Since these bodies 
increase upon NMDAR stimulation, it is interesting to ask, what happens to SX-
bodies with NMDAR antagonism? Moreover, are the sequestered mRNAs needed 
for the induction of rapid antidepressant efficacy? 
 
(ii) mRNA trafficking: A network of RBPs have been implicated in dendritic and 
synapse morphology. Remarkably, there is little functional redundancy among 
them. A single knockdown or a mutation in any one RBP disrupts translational 
regulation of its target mRNAs resulting in dendritic/spine defects. Some of the 
most compelling data for the importance of RBPs in synapse formation is the 
knockdown of the RBPs that affect mRNA trafficking (Doyle and Kiebler, 2011). 
The Staufen proteins are best known for their role in mRNA trafficking into the 
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dendrites and are required for synaptic plasticity (Tang et al., 2001). Knockdown 
of Stau2 results in 40% fewer mRNAs in dendrites that are retained in the soma. 
Moreover, Stau2-knockdown neurons show a significant reduction in synapse 
number (Goetze et al., 2006). Many depression studies have examined total mRNA 
expression; however synaptic changes in mRNA levels may be obscured. To the 
best of our knowledge, none have examined synaptic mRNA levels. Future studies 
regarding RBP-mediated mRNA trafficking deficits with MDD and with rapid 
antidepressant treatment are needed. 
 
(iii) Dendrite and Spine Morphology: Neurodegenerative diseases with synaptic 
deficiencies may serve as a clue as to which RBPs may be required for new synapse 
formation with rapid antidepressants. For example, mutations in two nuclear 
proteins TAR DNA-binding protein 43 (TDP-43) and fused in sarcoma (FUS) are 
associated with frontotemporal dementia and amyotrophic lateral sclerosis (ALS). 
Newly discovered roles for TDP-43 and FUS in dendritic branching and synapse 
formation, respectively, are emerging (Lu et al., 2009; Sephton et al., 2011). For 
example, FUS accumulates in dendritic spines to regulate morphology upon 
mGluR5 stimulation (Fujii and Takumi, 2005). Mutations in FUS result in reduced 
dendritic branching and spine maturation (Sephton et al., 2014).   One might predict 
that even modest changes in the expression or subcellular localization of TDP-43 
and FUS may contribute to the observed synaptic dysfunction, synapse loss, and 
neuronal atrophy in MDD.  
 
(iv) Synaptic Scaling: Two RBPs have been implicated in homeostatic synaptic 
scaling, the retinoic acid receptor (RAR) α and fragile X mental retardation protein 
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(FMRP). Both RBPs repress translation of their target mRNAs. During synaptic 
scaling the increase in GluA1 synthesis arises from the upstream intracellular 
synthesis of retinoic acid (RA), which in turn, causes dissociation of RARα from 
GluA1 mRNA, allowing it to be translated (Aoto et al., 2008). Interestingly, Soden 
and Chen demonstrated that AMPAR-mediated synaptic scaling is absent in CA1 
hippocampal neurons of Fmr1 knockout mouse. Moreover, RA-induced mRNA 
translation of GluA1, GluA2, and eEF2 observed in hippocampal neurons isolated 
from wildtype mice does not occur in Fmr1 knockout neurons (Soden and Chen, 
2010). How FMRP regulates RA-induced synaptic scaling is still an open question. 
Furthermore, it is unknown whether FMRP- and RA-mediated mRNA translation 
is required for the rapid antidepressant efficacy induced by NMDAR antagonists.  
 
The RBPs discussed here is a representative sample of RBPs that may be essential 
to restore proper communication between neurons that will relieve depressive symptoms. 
Many more are likely to be required. Future work examining the roles of RBPs with 
NMDAR antagonists is therefore crucial. Moreover, targeting specific RBPs may be 
critical in revealing more specific therapies for MDD. 
 
CONCLUSION 
Rapid antidepressants activate local homeostatic processes. The efficacy of these 
drugs relies on their ability to engage homeostatic mechanisms that trigger protein 
synthesis pathways. Interestingly the antidepressant efficacy remains long after the drug 
has left the patient’s system (Abdallah et al., 2015). The acute dose of NMDAR antagonists 
engages numerous synaptic mechanisms that produce a sustained and lasting increase in 
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synaptic connections that require protein synthesis. Perhaps these new synapses can 
reestablish an activity state in the brain that remediates a depressed system. Utilizing native 
mechanisms of homeostasis, rapid antidepressants offer a novel treatment that may have 




















Appendix B: FMRP Regulates an Ethanol-dependent Shift in GABABR 
Function and Expression with Rapid Antidepressant Properties11,12 
 
INTRODUCTION 
The presence of major depression increases the risk of alcohol use disorders (AUD) 
by ~2 fold (and vice versa) (Boden and Fergusson, 2011). The self-medication hypothesis 
suggests AUDs may develop when the initial antidepressant actions of alcohol are shifted 
to depressant allostatic states with chronic abuse (Koob and Le Moal, 2001). The molecular 
mechanism underlying the initial anti-depressant effects of alcohol is unknown.   
A major advance in understanding and treating depression is the recognition that 
NMDA receptor (NMDAR) antagonists act as rapid and effective antidepressant drugs 
(Skolnick et al., 2009).  A single injection of an NMDAR antagonist or “rapid 
antidepressant” is effective within 2 hours and has sustained antidepressant efficacy for 2 
weeks (Abdallah et al., 2015). These long-lasting properties depend on the activity of 
mammalian target of rapamycin (mTOR), a serine/threonine kinase essential for mRNA 
translation (Li et al., 2010; Workman et al., 2013). Recently, we demonstrated that 
activation of mTOR-dependent protein synthesis by NMDA antagonists requires a shift in 
GABABR signaling from opening potassium channels to facilitating an increase in 
dendritic calcium (Workman et al., 2013; Workman et al., 2015). Interestingly, both acute 
ethanol and rapid antidepressants block NMDARs (Lovinger et al., 1989) (Abdallah et al., 
2015). In light of these data, we propose that ethanol has lasting antidepressant efficacy, 
                                                 
11 Originally published in Wolfe, S.A., Workman, E.R., Heaney, C., Niere, F., Namjoshi, S., Cacheaux, 
L.P., Farris, S.P., Drew, M.R., Zemelman, B.V., Harris, R.A., Raab-Graham, K.F. (2016). FMRP Regulates 
an Ethanol-dependent Shift in GABABR function with Rapid Antidepressant Properties. Nat. Commun. 7: 
12867. doi: 10.1038/ncomms12867. I performed FMRP immunoprecipitations and qPCR for figure B.3A. 
12 Supplemental figures available online. 
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shares the same downstream molecular signaling events as rapid antidepressants, and 
requires de novo protein synthesis (Figure B.S1). 
Studies suggest that antidepressant efficacy requires two phases— an induction 
phase and a sustained phase (Nosyreva et al., 2013). Notably, GABABR-mediated, 
mTORC1-dependent protein synthesis is required for the long-lasting sustained phase of 
rapid antidepressants. Our previous work indicates that both new protein synthesis and an 
increase in protein stability are required for the GABABR shift in function necessary to 
increase mTORC1 activity (Workman et al., 2015). However, the mechanism that initiates 
such dynamic changes in protein expression by rapid antidepressants remains unclear. 
FMRP is an RNA binding protein that has been characterized as a repressor of 
mRNA translation. Some forms of synaptic activity trigger FMRP to release its targets, 
allowing them to be translated(Huber et al., 2002). Moreover, degradation and new protein 
synthesis of FMRP creates a window for the translation of specific mRNAs, facilitating 
long-lasting changes in synaptic function (Hou et al., 2006; Nalavadi et al., 2012). 
Complete loss of FMRP results in Fragile X syndrome (FXS), the single most common 
genetic cause of autism (Bassell and Warren, 2008). Moreover, reduced levels of FMRP, 
caused by a pre-mutation, lead to a higher incidence of tremors, ataxia, memory loss, and 
neuronal neuropathy in older men (Hagerman and Hagerman, 2013). These findings argue 
that precise levels of FMRP protein and its target mRNAs are required for normal neuronal 
function. 
Drugs of abuse promote profound changes in gene expression, mRNA translation 
rates, and synaptic protein composition (Ron and Messing, 2013; Placzek et al., 2016). 
Some studies suggest that drugs and alcohol highjack the molecular mechanisms that 
underlie synaptic plasticity (Luscher and Malenka, 2011; Lovinger and Roberto, 2013). In 
agreement with this premise, FMRP has been implicated in cocaine addiction (Smith et al., 
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2014). However, little is known about the mRNA targets and the signaling mechanisms 
involved. Here we describe a critical role for FMRP in mediating GABABR synthesis and 




Cell culture  
Primary hippocampal neurons were prepared as previously described by Niere et 
al., 2012 (Niere et al., 2012). Briefly, hippocampi were extracted from postnatal day 1-3 
Sprague-Dawley rat pups, wildtype C57BL/6 mouse pups, or fmr1-knockout (Fmr1 KO) 
mouse pups on a C57BL/6 background. The tissue was dissociated and plated in neurobasal 
A medium supplemented with B27, glutamine, and 1% fetal bovine serum. Cultures were 
plated at a density of ~100,000 cell/12mm on glass coverslips that had been coated 
overnight with 50 μg/ml poly-D-lysine and 25 μg/ml laminin in borate buffer. Cultures 
were fed after 1 day in vitro (DIV), and media was replaced approximately once a week 
with either fresh rat culture media (neurobasal A supplemented with B27, glutamine, and 
3 μM AraC) or fresh mouse culture media (glial-conditioned media with 3 μM AraC) until 
cultures were used at DIV 14-21.  
 
In vitro pharmacology  
All pharmacological reagents were added to the incubation media before calcium 
imaging or immunostaining. Ethanol was added directly to HEPES-based artificial cerebral 
spinal fluid (ACSF in mM: 100 NaCl, 10 HEPES (pH 7.4), 3 KCl, 2 CaCl2, 1 MgCl2, 10 
glucose) that was adjusted to match the osmolarity of cell culture media for live-imaging, 
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or conditioned cell culture media described above for immunostaining. For pre-treated 
cultured hippocampal neurons were pre-treated with ethanol (30 mM), cycloheximide (50 
μM), or the NMDAR antagonist Ro 25-6981 (10 μM). For GABABR activation, neurons 
were treated with (R)-baclofen (50 μM).  
 
In vitro ethanol treatment 
Primary hippocampal neurons were treated in ethanol vapor chambers according to 
a method adapted from Chandler et al., 1993 (Chandler et al., 1993). Ethanol vapor 
chambers were prepared by placing a reservoir of 31.5 mM ethanol (105% of the desired 
ethanol concentration, i.e., 30 mM) in a plastic container with 24-well culture plates 
containing neuronal cultures in which 30 mM ethanol was added to the culture media. 
Chambers were filled with 95% O2/5% CO2 and cultures were incubated for 2 hours at 
37°C. Cultures treated with vehicle (H2O) were incubated in the same manner but in the 
absence of ethanol. All cultures were treated at 14-21 DIV. Following treatment, cultures 
were immediately fixed or live imaged.  
 
In vivo ethanol treatment  
Male C57BL/6 mice (Charles Rivers) or fmr1 knockout (Fmr1 KO) mice on a 
C57BL/6 background (at least 7 weeks old) were given intraperitoneal (i.p.) injections of 
either 200 μl saline or 2.5 g/kg ethanol (in a volume of 200 μl saline) (Blednov et al., 2013). 
The hippocampi were isolated 30 minutes post-injection and flash frozen. All experiments 
were carried out in accordance with the National Institutes of Health’s Guide for the Care 
and Use of Laboratory Animals and approved by the UT-Austin Institutional Animal Care 




Primary neuronal cultures on glass coverslips were fixed with 4% 
paraformaldehyde (PFA) at room temperature (RT) for 20 minutes, washed 3 times with 
phosphate buffered saline (PBS), and permeabilized in 0.25% Triton X-100 in PBS for 5 
minutes. For FMRP staining, neurons were fixed and permeabilized in 100% methanol at 
-20°C for 10 minutes. Neurons were washed 3 times in PBS and then blocked (10% normal 
goat serum in PBS) for 30 minutes at RT. Primary antibodies were incubated in blocking 
buffer at 4°C overnight. Neurons were washed 3 times for 10 minutes with PBS, and then 
incubated in secondary antibody in blocking buffer for 1 hour at RT, and washed 3 times 
for 10 minutes with PBS before mounting in Fluoromount with DAPI (SouthernBiotech, 
0100-20). Surface staining was performed similarly. Neurons were first fixed in 4% PFA 
for 10 minutes on ice, washed 3 times in PBS, blocked with 3% normal goat serum, and 
then incubated in primary surface antibody in 3% blocking buffer overnight at 4oC. 
Following primary surface antibody incubation, neurons were washed 6 times for 10 
minutes each in PBS, then permeabilized with 0.25% Triton X-100 in PBS for 5 minutes, 
followed by 3 washes for 10 minutes each in PBS, and again incubated in primary total 
antibody in 3% blocking buffer overnight at 4°C. Neurons were washed 3 times for 10 
minutes each with PBS, and then incubated in secondary antibody in 3% blocking buffer 
for 1 hour at RT, and finally washed 4 times for 10 minutes with PBS before mounting in 
Fluoromount with DAPI to slides. The primary antibodies used were: Total GABABR1 
(1/50 dilution; Santa Cruz, sc-14006), Surface GABABR1 (1/200 dilution; Abcam, 
ab55051), GABABR2 (1/100; Neuromab 75-124), FMRP (1/500 dilution; Abcam 
ab17722), MAP2 (1/2000 dilution; Abcam ab5392), GFP (1/1,000 dilution; Aves, GFP-
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1020). Secondary antibodies included: Alexa488, 555, and 647 developed in goat (1/500 
dilution; Life Technologies, A-11039, A-11017, A-31621, A-21430, A-21449, A-21240, 
A-21237).  
 
Adeno-associated viral vectors  
The FMRP and tdTomato coding sequences were cloned into separate adeno-
associated viral (AAV) vectors containing a mouse synapsin promoter, a woodchuck post-
transcriptional regulatory element (WPRE), and SV40 poly-adenylation sequence between 
flanking AAV2 inverted terminal repeats (Cajigas et al., 2012). rAAVs were assembled 
using a modified helper-free system (Stratagene) as serotype 2/1 (rep/cap genes) viruses, 
and harvested and purified over sequential cesium chloride gradients as previously 
described (Darnell et al., 2011). Viral titers were greater than 1x109 infectious particles 
per microliter. For FMRP and tdTomato co-infections, rAAV:mSYN-FMRP and 
rAAV:mSYN-tdTomato were mixed at a ratio of 4:1. One microliter of the resulting rAAV 
mix was used per coverslip of primary cultured neurons. Imaging was performed ~1 week 
after infection.  
 
Live calcium imaging 
Dissociated hippocampal cultures were prepared from wildtype (WT) and Fmr1 
KO mice as described (Niere et al., 2012). Neurons at 14-21 DIV were used for live calcium 
imaging. Before imaging, cells were incubated in ACSF with Oregon Green 488 BAPTA-
1 AM (OGB, 200 μM; 30 min; 37°C; ThermoFisher) as described (Workman et al., 2013). 
After OGB incubation, cells were transferred to fresh ACSF (37°C) for imaging (1 
frame/20 s). Baseline calcium signal was imaged (1 min), after which (R)-baclofen (50 
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μM, Tocris) or vehicle (H2O) was added. For ethanol-treated cells, the neurons were 
incubated with OGB and imaged in ACSF containing ethanol (30 mM). Neurons were 
imaged for 800 s at RT.  Quantification of the calcium signal was performed using 
Metamorph (Molecular Devices) as described (Workman et al., 2013). Briefly, dendritic 
regions of interest (ROI) that were at least 5 μm from the soma were analyzed. The mean 
intensity values for each ROI at each time were averaged as baseline (F0). The ROI 
intensity values obtained at each time point after the addition of baclofen or vehicle were 
averaged (F). The equation, ΔF/F = ((F − F0)/F0), was used to measure the change in signal 
and data were plotted as a percentage of the baseline. 
 
BONCAT-PLA  
BONCAT-PLA was performed using Click-it Metabolic Labeling AHA, Biotin-
Alkyne, and Click-iT Reaction buffer kit (Life Technologies). Proximity ligation assay 
(PLA) was performed using Duolink kit (Duolink, Sigma) (Ron and Messing, 2013). 
Briefly, primary hippocampal neuronal cultures were incubated in a methionine-free 
artificial cerebral spinal fluid (ACSF) media for 30 minutes. AHA was then added to the 
media just before neurons were treated with ethanol for 2 hours as previously described. 
Neurons were fixed in 4% PFA for 15 minutes, washed 2 times for 5 minutes with 3% 
Bovine Serum Albumin (BSA) in PBS, followed by permeabilization with 0.25% Triton 
X-100 in PBS for 15 minutes, and washed as before. Neurons were incubated for 30 
minutes at RT in Cell Buffer Additive/Click-it Cocktail according to manufacturer 
directions. Neurons were washed as before and then blocked and incubated with primary 
antibody as previously described. Next, neurons were incubated in the appropriate PLA 
probes diluted in blocking buffer and secondary antibody at 37°C for 1 hour. Neurons were 
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washed in RT Buffer A 2 times for 5 minutes, and incubated in ligation solution at 37°C 
for 30 minutes, and washed again in Buffer A. Neurons were incubated in amplification 
solution at 37°C for 2-3 hours, followed by washing in RT Buffer B 2 times for 10 minutes 
and 1% buffer B for 1 minute. Lastly, neurons were mounted to slides in Duolink mounting 
media for imaging. Primary and secondary antibodies included: GABABR1 (1/50 dilution; 
Santa Cruz, sc-14006), GABABR2 (1/100; Neuromab 75-124), MAP2 (1/2000 dilution; 
Abcam, ab5392), biotin/α-rabbit (1/500; Sigma, SAB3700857), Alexa488 (1/500; Life 
Technologies, A-11039). PLA probes used: Rabbit Minus (1/5; Duolink, 82005), Mouse 
Plus (1/5; Duolink, 82001).  
 
Microscopy and analysis 
Images were acquired with a Leica SP5 confocal microscope under a 63X oil 
immersion lens for fixed tissue or a 63X water immersion lens for live imaging. Max 
projected images were used for immunostaining analysis from 10-μm Z-stacks of 1024 x 
1024 pixels obtained using a 400-Hz scan rate. For each experiment, all microscope 
settings were held constant. Fixed images were analyzed using NIH imaging software 
ImageJ, and live imaging quantification was performed with Metamorph (Molecular 
Devices, Sunnyvale, CA). Relative signal intensity was quantified from dendritic traces. 
Background signal was subtracted from the traced ROI that lies close to the dendrite (but 
that is void of all processes) with a custom R script. Dendrites were averaged every 10 μm.  
 
Western blot analysis  
Protein was isolated from hippocampal synaptoneurosomes (SN) prepared from 
mice treated with ethanol or vehicle as previously described. SNs were prepared by 
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homogenizing hippocampal tissue in homogenization buffer (20 mM HEPES pH 7.4, 5 μM 
EDTA pH 8.0, and protease inhibitor cocktail). Homogenate was filtered through a 100-
μm nylon filter followed by a 5-μm filter, and centrifuged at 14000 x g for 20 minutes at 
4°C. The pellet was resuspended in RIPA buffer (150 mM NaCl; 10 mM Tris pH 7.4, 0.1% 
SDS, 1% Triton X-100, 1% deoxycholate, 5 mM EDTA, and protease inhibitor cocktail) 
and centrifuged for 10 minutes. The supernatant was then isolated for Western blot 
analysis. Protein was separated on a 4-20% gradient SDS-polyacrylamide gel. The gel was 
then transferred to a nitrocellulose membrane, blocked in 5% non-fat dry milk in tris-
buffered saline and 0.1% tween-20 (TBST) for 1 hour, and incubated with primary 
antibody in blocking buffer overnight at 4°C. The blot was washed in TBST 3 times for 10 
minutes each, incubated in secondary antibody for 1 hour, and washed as before. Blots 
were imaged using a LICOR Odyssey imaging system, and ImageJ was used for 
densitometry analysis. Representative images are pseudocolored with black (lowest 
intensity) to red (highest intensity) using LICOR Image Studio software. Primary 
antibodies used consisted of: GABABR1 (1/400 dilution; Santa Cruz, sc-14006), 
GABABR2 (1/800; Neuromab 75-124), alpha-Tubulin (1/2000 dilution; Sigma, T6074). 
Secondary antibodies included: anti-mouse-IR-Dye 800 (1/5000 dilution excluding tubulin 
at 1/10,000 dilution; LICOR, 96-32210) and anti-rabbit Alexa680 (1/5000 dilution; 
Invitrogen, A-21084).  
 
RNA Immunoprecipitations 
Cortices from 6-week old C57BL/6 mice were harvested and flash frozen on dry 
ice. Tissue was homogenized and lysed with a cordless pestle motor and disposable pellet 
mixers (VWR) in polysome lysis buffer (10 mM HEPES pH 7.0, 100 mM KCl, 25 mM 
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EDTA, 5 mM MgCl2, 1mM DTT, 0.5% NP-40) in a 1:1 tissue-buffer ratio. RNaseOUT 
(Thermo) and protease/phosphatase inhibitors (Halt Protease and Phosphatase Cocktail, 
Pierce Biotechnology) were freshly added to samples. Samples were rotated for 10 minutes 
at 4°C to induce swelling and then flash frozen on dry ice. Samples were thawed by holding 
between fingers at RT to lyse and nuclei were pelleted at 3000 x g for 10 minutes. Lysates 
obtained above were pre-cleared by adding 50 μl of washed magnetic bead slurry (Protein 
A Dynabeads, Thermo) and rotating for 30 minutes at 4°C. To bind the antibody to the 
beads, 50 μl of magnetic beads slurry was washed and then resuspended in 8 volumes of 
NT-2 buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1 mM MgCl2, 1mM DTT, 0.05% 
NP-40 with RNaseOUT/protease & phosphatase inhibitors added fresh) + 5% BSA. 10 μg 
of either FMRP (Abcam, ab17722) or IgG (Santa Cruz Biotechnologies, sc-2027) 
antibodies were added to the beads and rotated for 10 minutes at RT. Antibody-bound 
beads were washed 4 times with ice-cold NT-2 buffer. For the immunoprecipitation, 4.5 
mg of protein from pre-cleared lysates was added to an RNase-free microcentrifuge tube 
containing the antibody-bound beads. Input collected at this step for downstream analysis 
was either 1% of the final pre-cleared lysate volume in the immunoprecipitation reaction 
(for immunoblotting) or 10% of the final pre-cleared lysate volume (to normalize in qPCR). 
The antibody-bead-lysate mixture was then diluted at a ratio of 1:5 with NET-2 buffer (20 
mM EDTA pH 8.0, and 1 mM DTT in NT-2 buffer; RNaseOUT and protease/phosphatase 
inhibitors added fresh) and rotated for 1 hour at room temperature. Beads were quickly 
washed 6 times in ice-cold NT-2 buffer and immediately resuspended in 350 μl TRI 
Reagent Solution (Ambion) for 10 minutes at RT. Beads were pelleted and the supernatant 
was removed and resuspended in 350 μl of absolute ethanol. RNA was extracted by 
applying ethanol-resuspended samples to spin column from the Direct-zol RNA MiniPrep 
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Kit (Zymogen) according to manufacturer’s instructions. Eluted RNA (25 μl) was DNase 
treated using the TURBO DNA-free kit (Thermo).  
 
cDNA Synthesis and Quantitative Real-Time PCR (qRT-PCR) 
DNase-treated RNA samples were reverse-transcribed to cDNA using the iScript 
cDNA Synthesis Kit (Bio-Rad) in a 20 μl volume according to manufacturer’s instructions. 
qRT-PCR was performed in 20 μl reaction volume using the iQ SYBR Green Supermix 
(Bio-Rad) and primers for GABABR1, GABABR2, CaMKIIα, and Cacna2δ2 
(GeneCopoeia). qRT-PCR was run with the following protocol: 95°C for 10:00, 40 cycles 
of 95°C for 0:15 followed by 60°C for 1:00, 95°C for 1:00, and 55°C for 1:00. Relative 
fold-enrichment was determined by the equation ΔΔCt = 2-(Ct FMRP RNA-IP – Ct IgG RNA-IP) - (Ct 
FMRP input – Ct IgG input). 
 
Forced Swim Test 
Mice were tested in the forced swim test 24 hours post-injection as described 
previously 35-37. Mice were individually placed into a cylinder containing 3 L of water 
(25°C) for 6 minutes. Each session was video recorded and the last 4 minutes of the 
sessions were later scored blindly for immobility. Animals were scored for escape-directed 
behaviors. The water was replaced between animals. Experiments were repeated by 3 
independent experimenters. Data was normalized by experimenter. 
 
Open Field 
Twenty-four hours after animals were injected i.p. with either saline or ethanol, 
they were studied in the open field test. Mice were individually placed in a 40 cm x 40 cm 
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x 35 cm arena with opaque walls. Each test session lasted 30 minutes under 85 lux 
illumination. Sessions were video recorded and analyzed via ANY-Maze (Stoelting, Wood 
Dale, IL). Mice were considered to be in the center of the maze if they entered an 18.5 cm 
x 18.5 cm area in the center of the apparatus. Mice were returned to their home cage at the 
end of the test session, and the arena was wiped down with 70% ethanol before the start of 
each run.  
 
Splash Test 
Two and a half hours after open field testing, animals underwent the splash test. 
Cage mates were moved from their home cage to a holding cage, and each animal was 
individually tested in its home cage. Two hundred microliters of 10% sucrose was applied 
to the dorsal fur of the mouse. Mice were monitored and video recorded for 5 minutes and 
then moved to a different holding cage. Videos were later scored blindly for latency to 
initiate grooming and for total time spent grooming. Grooming behavior included licking, 
grooming with forepaws, and scratching.  
 
Statistical analysis  
Prism software (GraphPad) was used for all statistical analyses. Statistical 
comparisons were made using one-way ANOVA, two-way ANOVA, Student’s t-test, or 
χ2 test with Yates. Outliers were determined using Grubbs’ test (alpha=0.05). All data are 
expressed as mean ± Standard Error of the Mean (SEM). Significance is represented by: 
n.s., not significant, *p≤0.05, **p≤0.01, ***p≤0.001, ****p≤0.0001 within-genotype 




Antidepressant and anxiolytic effects of ethanol on behavior 
To determine if acute alcohol has antidepressant properties, as predicted by the self-
medication hypothesis, we first assessed the efficacy of alcohol on antidepressant- and 
anxiolytic-like effects on behavior. The forced swim test (FST) is a behavioral test of 
despair (Porsolt et al., 1979). Rodents treated with a single injection of NMDAR 
antagonists or rapid antidepressants swim longer and thus have reduced times of 
immobility relative to controls. Notably, these positive effects on behavior last long after 
the drug has been metabolized (Li et al., 2010; Autry et al., 2011; Workman et al., 2013; 
Workman et al., 2015). Therefore, we considered the possibility that ethanol, which blocks 
NMDARs (Lovinger et al., 1989), could also act like an antidepressant at 24 hours, well 
beyond the intoxication period (Blednov et al., 2013). To test this, C57BL/6 mice were 
injected with ethanol (2.5 g/kg, i.p.), a concentration that is achieved during self-
administration in mice (Rhodes et al., 2005). Twenty-four hours after injection, the 
immobility time in ethanol-treated mice was reduced by ~15% relative to controls (Figure 
B.1a), similar to our previous observation in mice that had been exposed to the rapid 
antidepressant Ro 25-6981 (Workman et al., 2013; Workman et al., 2015). These results 
demonstrate that acute ethanol elicits an antidepressant effect on behavior similar to that 
seen with rapid antidepressants (Workman et al., 2015). 
As another measure of antidepressant effect of ethanol on behavior, we assessed 
the grooming behavior of mice using the splash test after ethanol or saline administration. 
The splash test measures latency to groom and dedicated grooming time as indicators of 
self-care and motivational behavior (Surget et al., 2008; David et al., 2009). Lack of self-
care is often observed in humans with depressive disorder (Association, 2013). We have 
previously shown that mice receiving a single i.p. injection of the rapid antidepressant Ro 
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Figure B.1: Ethanol elicits a lasting antidepressant-like effect on behavior 
a. C57BL/6 male mice were subjected to the forced swim test 24 h after i.p. injection with vehicle 
(Veh; saline) or ethanol (ETOH; 2.5 g kg−1). Ethanol treatment reduced immobility, indicating 
antidepressant efficacy. Veh=100±2.5, n=10 mice; ETOH=86±7.4, n=6. b. and c. In the splash test, 
male C57BL/6 mice groomed longer and took less time to initiate grooming 24 h post ethanol 
(2.5 g kg−1, i.p.) compared with 24 h post-vehicle (saline, i.p.) treatment. Total groom time: 
Veh=11.34±4.23 s, n=6; ETOH=35.37±6.72 s, n=5. Latency to groom: Veh=225.2±34.13 s, n=6; 
ETOH=77.55±28.44 s, n=5. d.–f. Total centre time, speed and distance were measured in the open 
field test 24 h post injection. Ethanol-treated (2.5 g kg−1, i.p.) mice spent more time in the centre, 
while speed and distance were unaffected compared with vehicle-treated (saline, i.p.) mice, 
indicating an ethanol-induced anxiolytic effect without altering mobility. Total centre time: 
Veh=327.5±35.62 s, n=6; ETOH=459.2±19.13 s, n=6. Average speed: Veh=0.042±0.002 m s−1, 
n=6; ETOH=0.041±0.002 m s−1, n=6. Total distance: Veh=75.35±3.92 m, n=6; 
ETOH=73.00±3.35 m, n=6. Significance determined by one-tailed t-test. Values represent 
mean±s.e.m.
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25-6981 spend more time grooming compared to control mice (Workman et al., 2015). We 
hypothesized that ethanol would produce similar effects on grooming behavior. Indeed, 
ethanol-treated mice spent more time grooming and displayed shorter latency to initiate 
grooming relative to controls (Figure B.1b and c).  
 Ethanol is a well-known anxiolytic substance (Blednov et al., 2001). However, the 
anxiolytic effect of a single dose of ethanol 24 hours after administration has not been 
determined. We subjected ethanol- and saline-injected mice to the open-field test to assess 
the influence of ethanol on anxiety-like behaviors after 24 hours. Mice that spend more 
time in the center of the open field are scored to indicate reduced anxiety-like behavior 
relative to mice that remain close to the perimeter (Treit and Fundytus, 1988). Indeed, mice 
that received a single dose of ethanol (2.5 g/kg, i.p.) had reduced anxiety-like behavior, 
spending ~40% more time in the center relative to controls (Figure B.1d). There was no 
significant difference in total distance traveled or average speed between the groups 
(Figure B.1e-f). These data suggest that the anxiolytic effects of ethanol last up to 24 hours 
post-injection. 
 
Acute ethanol increases GABABR2 and surface GABABRs 
Both ethanol and rapid antidepressants block NMDARs in the hippocampus 
(Lovinger et al., 1989; 1990). One of the first events triggered by NMDAR antagonism is 
increased dendritic GABABR2 protein expression (Workman et al., 2015). GABABRs are 
obligate heteromultimers, consisting of GABABR1 and R2. GABABR2 is required for 
expression of receptors at the surface by masking an endoplasmic reticulum retention 
sequence on GABABR1 (Margeta-Mitrovic et al., 2000). Similarly, treatment with a rapid 
antidepressant leads to (1) increased dendritic expression of GABABR2 but not GABABR1 
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(Workman et al., 2015), and (2) a corresponding increase in surface expression of 
GABABR1 (Sosanya et al., 2015b; Workman et al., 2015).  
To determine if acute ethanol exposure in vivo rapidly increases the levels of 
GABABR1 and/or GABABR2, hippocampal synaptoneurosomes were isolated from mice 
that had been injected with a single dose of ethanol (2.5 g/kg, i.p.) or saline for Western 
blot analysis. The hippocampi were collected within the initiation phase (30 minutes post-
injection), a phase where molecular changes facilitate increased downstream mTORC1 
activity (Raab-Graham et al., 2016). Consistent with rapid antidepressants, acute ethanol 
injection increased the protein expression of GABABR2 by ~37% in the hippocampus with 
no significant change in GABABR1 (Figure B.2a-c).   
To further identify the subcellular localization of ethanol-induced increase in 
GABABR2, we examined GABABR expression in cultured hippocampal neurons.  
GABABR1 and R2 were immunostained and quantified in the dendrites. A concentration 
of 30mM ethanol was chosen, as it has been shown to reduce NMDAR activity in 
hippocampal neurons and reflects that achieved in vivo following i.p. injection (Lovinger 
et al., 1989). Acute ethanol exposure (30 mM, 2 hours) increased the dendritic levels of 
GABABR2 by ~47%, but did not affect GABABR1 levels (Figure B.2d-g). We did not 
observe a difference in the diameter of the primary dendrites between vehicle- and ethanol-
treated neurons, demonstrating that ethanol does not modify dendritic caliber (Figure 
B.S2). These in vivo and in vitro findings establish a role for ethanol in increasing 
GABABR2 protein expression.  
Since GABABR2 is required for the surface expression of the heteromultimeric 
receptor, we predicted that the ethanol-induced elevation in GABABR2 levels would 
increase expression of receptors at the surface. We measured the surface expression of 
dendritic GABABRs using an antibody directed against the extracellular domain of 
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Figure B.2: Acute ethanol increases dendritic GABABRs in hippocampus 
 217 
GABABR1 in unpermeabilized hippocampal neurons. The surface signal was normalized 
by the total dendritic GABABR1 levels after permeabilization6. As predicted, surface 
expression of GABABRs in ethanol-treated neurons was significantly higher (~66% 
increase) relative to controls (Figure B.2h-i). This ethanol effect was consistent with what 
we previously observed following rapid antidepressant treatment of cultured hippocampal 
neurons (Workman et al., 2013). Collectively, these results suggest that ethanol promotes 
the surface expression of GABABRs, and this is likely achieved by increasing GABABR2 
protein levels. 
 
FMRP regulates the protein expression of GABABR1 and GABABR2 
Next, we sought to identify the mechanism by which NMDAR antagonism 
increases GABABR2 expression. GABABR2 mRNA is present in the dendrites of 











a.–c. Western blot analyses of GABABR1 and GABABR2 in isolated hippocampal 
synaptoneurosomes from ethanol-treated (ETOH; 2.5 g kg−1 i.p.), and vehicle-treated (Veh; saline 
i.p.) C57BL/6 male mice 30 min post injection. a. Pseudocoloured representative western blots to 
show intensity with normalized optical density for each band indicated below blot (Lookup table, 
below western blot). No significant change was observed in b. GABABR1, but a significant increase 
was found in c GABABR2 with ethanol treatment. Western blots were normalized to the loading 
control, α-Tubulin. GABABR1: Veh=1.00±0.11; ETOH=1.19±0.08. Experiment was repeated five 
times. GABABR2: Veh=1.00±0.07; ETOH=1.37±0.05. d. and e. Representative immunostaining 
images of GABABR1 and GABABR2 in cultured rat hippocampal dendrites normalized to 
microtubule associated protein 2 (MAP2) as volume control. There was no change in f. GABABR1 
and a significant increase in g. GABABR2 in ethanol treated (30 mM, 2 h) compared with vehicle-
treated (H2O, 2 h) dendrites: Total GABABR1: Veh=1.00±0.03, n=46 dendrites; ETOH=1.04±0.04, 
n=51 dendrites. Total GABABR2: Veh= 1.00±0.03, n=46 dendrites; ETOH=1.47±0.05, n=51 
dendrites. h. and i. Immunofluorescence shows a significant increase in surface GABABR1 
expression in dendrites of cultured rat hippocampal neurons treated with ethanol (30 mM, 2 h); i. 
Surface expression of GABABR1 in vehicle-treated (H2O, 2 h) and ethanol-treated (30 mM, 2 h) 
dendrites. Veh=1.00±0.09, n=43 dendrites; ETOH=1.66±0.12, n=47 dendrites. Significance 
determined by Student's t-test. Values represent mean±s.e.m. Scale bars, 5 μm. Uncropped version 
of western blots, with size markers are available in Figure B.S7a 
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regulated at the translational level. Thus, we examined RNA-binding factors that may 
regulate GABABR2 mRNA expression in dendrites. Notably, both GABABR1 and 
GABABR2 mRNAs are reported targets of FMRP, an RNA binding protein that stalls 
translational elongation of its targets (Darnell et al., 2011; Graber et al., 2013a).  
To test the hypothesis that FMRP regulates GABABR mRNA translation, we first 
verified that (1) GABABR mRNAs bind to FMRP, and that (2) the absence of FMRP in 
knockout mice results in aberrant expression of GABABRs. Using a specific antibody 
against FMRP, bound mRNAs were isolated using RNA immunoprecipitation (RNA-IP). 
GABABR1 and GABABR2 binding were assessed by reverse transcription (RT) and 
quantitative PCR. Indeed, GABABR1 and GABABR2 mRNAs were detected in the 
immunoprecipitate, along with CaMKIIα, a well-known FMRP mRNA target (Figure 
B.3a-b). The calcium channel accessory subunit Cacnα2δ2 mRNA is not a reported target 
for FMRP (Darnell et al., 2011) and was used as a negative control. Cacnα2δ2 mRNA was 
not detected in the FMRP RNA-IP (Figure B.3b). In parallel, we used lysates isolated from 
brains of mice with a genetic deletion of the Fmr1 gene. We did not observe amplification 
of any of the mRNAs in Fmr1 KO brains, providing additional evidence for specific 
binding of FMRP to GABABR1 and GABABR2 mRNAs (Figure B.3a-c). 
Next, we determined if FMRP regulates GABABR1 and GABABR2 protein levels. 
Genetic deletion of Fmr1 KO leads to the constitutive translation of FMRP target mRNAs 
and the loss of activity-dependent translation (Bassell and Warren, 2008). Protein levels of 
GABABR1 and GABABR2 were compared in hippocampal synaptoneurosomes from Fmr1 
KO and wildtype (WT) mice (Figure B.3c-g). GABABR2 basal protein levels were elevated 
by ~53% in Fmr1 KO hippocampi (Figure B.3g). GABABR1 protein levels also increased, 
albeit to a lesser extent than GABABR2 (Figure B.3f). Collectively, these data suggest that 
FMRP regulates the expression of GABABR1 and GABABR2. 
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Figure B.3: GABABR1 and GABABR2 mRNAs are FMRP targets 
a. and b. RNA immunoprecipitation (RIP) for FMRP was performed using brains from wild type 
(WT) and Fmr1 KO male mice. a. Gels showing RT–qPCR amplified product of input sample, 
FMRP RIP, and IgG control for GABABR1 and GABABR2. b. Relative fold-enrichment as 
determined by real-time qPCR relative to input control (ΔΔCt=2−(Ct FMRP RIP−Ct IgG RIP)−(Ct FMRP input−Ct 
IgG input)). FMRP binds GABABR1, GABABR2, and the positive control CaMKIIα mRNA as 
detected in the RIP sample by real-time qPCR. Cacnα2δ2 served as a negative control and was not 
detected above background. WT: GABABR1=2.66±0.248, n=2; GABABR2=2.19±0.08, n=2; 
CaMKII=3.72±0.94, n=2; Cacnα2δ2=0.11±0.6, n=2. Fmr1 KO: GABABR1=0.01±0.0002, n=2; 
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Ethanol and rapid antidepressants reduce dendritic FMRP 
As an initial test to determine if FMRP-regulated translation is linked to alcohol 
exposure, we compared FMRP target mRNAs (Darnell et al., 2011) with mRNAs that are 
differentially expressed in the hippocampi of alcohol-dependent humans (Zhou et al., 
2011). Remarkably, 225 or ~25% of verified FMRP target mRNAs overlap with mRNAs 
that are altered in alcohol-dependent individuals, suggesting a role for FMRP in aberrant 
protein levels observed in humans with AUD (Figure B.4a) (Darnell et al., 2011; Zhou et 
al., 2011). We then determined if exposure to acute ethanol (30 mM, 2 hours) or Ro 25-
6981 (10 μM, 2 hours) alters FMRP expression in the dendrites of hippocampal neurons. 
Using immunofluorescence, we found that ethanol and Ro 25-6981 reduced FMRP levels 
by ~38% and 45%, respectively (ethanol: Figure B.4b-c; Ro-25-6981: Figure B.S3). These 
data suggest that ethanol and Ro 25-6981 alter protein expression in an FMRP-dependent 
manner. 
 
Ethanol-induced synthesis of GABABR2 requires FMRP 
Due to the ethanol-induced decreases in FMRP, we hypothesized that FMRP is 
required for ethanol-induced expression of GABABRs. Specifically, if expression of 






GABABR2=0.02±0.00006, n=2; CaMKII±0.04±0.01, n=2; Cacnα2δ2=0.012±0.005, n=2. c.–g. 
Western blot analysis of hippocampal synaptoneurosomes isolated from C57BL/6 WT and Fmr1 
KO mice on a C57BL/6 background indicates the absence of e. FMRP and increased protein 
expression of f. GABABR1 and g. GABABR2. Representative western blots are pseudocoloured to 
indicate intensity of bands, and the normalized optical density for each band is indicated below blot 
(Lookup table, below western blot). Western blots were normalized to the loading control, α-
Tubulin. WT: FMRP=1.00±0.10; GABABR1=1.00±0.06; GABABR2=1.00±0.08. Fmr1 KO: 
FMRP=0.03±0.01; GABABR1=1.27±0.08; GABABR2=1.54±0.17. Experiment was repeated three 
times. Significance determined by Student's t-test. Values represent mean±s.e.m. Uncropped 
versions of qPCR gel, with size markers, are available in Figure B.S7d. Uncropped version of 
western blots, with size markers are available in Figure B.S7b. 
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Figure B.4: FMRP and AUD share target mRNAs and ethanol decreases FMRP 
a. Venn diagram illustrating the significant overlap between FMRP mRNA targets and 
differentially expressed genes in the hippocampus of humans with AUDs. Significance determined 
with χ2-test. b. and c. Immunofluorescence images normalized to MAP2 as volume control and 
quantification summary shows a significant decrease in FMRP expression in dendrites of cultured 
hippocampal neurons treated with ethanol (ETOH; 30 mM, 2 h) compared with vehicle treated 
(Veh; H2O, 2 h). Veh: FMRP =1.00±0.06, n=32 dendrites; ETOH: FMRP=0.62±0.03, n=31 
dendrites. Significance determined by Student's t-test. Values represent mean±s.e.m. Scale bar, 
5 μm.
 222 
then ethanol-induced changes in GABABR expression should be absent in Fmr1 KO mice. 
Hippocampal synaptoneurosomes were isolated from WT and Fmr1 KO mice 30 minutes 
after i.p. injection of ethanol (2.5g/kg). Western blot analysis indicated that both 
GABABR1 and GABABR2 expression remained constant in vehicle- and ethanol- treated 
Fmr1 KO mice.  As observed in Figure B.2, wildtype WT hippocampal synaptoneurosomes 
showed an ~23% increase in GABABR2 but no change in GABABR1 expression (Figure 
B.5a-c). These data suggest that ethanol-induced changes in GABABR expression are 
dependent on FMRP translational regulation. 
To determine whether protein synthesis is essential for the FMRP-dependent 
changes in GABABR expression, we measured ethanol-induced GABABRs in the presence 
of cycloheximide (CHX), a protein synthesis inhibitor. As demonstrated previously, 
ethanol did not influence the dendritic expression of GABABR1; however, co-treatment 
with cycloheximide increased GABABR1 expression by ~22%. FMRP deletion did not 
affect the basal, ethanol-, or cycloheximide-induced dendritic protein expression of 
GABABR1 (Figure B.5d-e and h). For GABABR2, we again saw a significant ~28% 
increase in dendritic expression with acute ethanol treatment; however, in the presence of 
cycloheximide the ethanol-induced increase was abolished.  Notably, when the same 
treatments were applied to the Fmr1 KO cultures, no change was observed with ethanol or 
ethanol+cycloheximide (Figure B.5f-g and i). 
We next examined the requirement for protein synthesis and FMRP in ethanol-
dependent surface expression of GABABRs. Using WT and Fmr1 KO hippocampal 
neurons, we measured ethanol-induced surface expression of GABABR1 with or without 
cycloheximide. Co-assembly of GABABR1 and R2 is required to express GABABR 
heterodimers in the membrane (Margeta-Mitrovic et al., 2000). Thus, we predicted that the 
ethanol-induced increase in surface GABABRs would require FMRP-regulated synthesis 
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Figure B.5: Fmr1 KO prevents ethanol-induced altered GABABR expression 
a.–c. Western blot analysis of GABABR1 and GABABR2 in wild type (WT) and Fmr1 KO 
C57BL/6 hippocampal synaptoneurosomes after vehicle (Veh; saline i.p., 30 min) or ethanol 
(ETOH; 2.5 g kg−1 i.p., 30 min) treatment. a. Pseudocoloured representative western blots showing 
band intensity, and normalized optical densities to WT–vehicle are reported below each image 
(lookup table, below western blot). Western blots were normalized to the loading control, α-
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of GABABR2. Again, acute ethanol increased dendritic surface GABABRs by ~76%, and 
this was blocked by cycloheximide. In Fmr1 KO neurons there was no significant ethanol-
induced change in surface GABABRs, but a decrease was observed with 
ethanol+cycloheximide (Figure B.6a-c). These data suggest that GABABR2 protein 
synthesis is required for the increased surface expression of the hetermultimeric receptor 
with ethanol exposure. 
FMRP is reported to repress new protein synthesis. Considering the effects of the 
protein synthesis inhibitor, these data suggests that the ethanol-mediated reduction in 
FMRP results in the increase in dendritic GABABR2 by de novo protein synthesis. To 
provide more direct evidence, we performed bioorthogonal noncanonical amino acid 
tagging (BONCAT) in conjunction with proximity ligation assay (PLA-Duolink) 
(Dieterich et al., 2010). BONCAT+PLA can be used to detect new synthesis of proteins of 












Tubulin. No change was found in b. GABABR1 after ethanol treatment in either genotype as shown 
by ethanol/vehicle comparison. A significant increase in c GABABR2 expression was observed in 
WT mice after ethanol, but no change was observed in Fmr1 KO mice (shown as ethanol/vehicle). 
WT ETOH/Veh: GABABR1=1.15±0.21; GABABR2=1.22±0.01. Fmr1 KO ETOH/Veh: 
GABABR1=0.94±0.04; GABABR2=0.95±0.03. Experiment was repeated three times. Significance 
determined by Student's t-test. Values represent mean±s.e.m. Representative immunofluorescent 
images d.–g. and quantification summaries h. and i. of dendritic expression of GABABR1 and 
GABABR2 from WT and Fmr1 KO primary mouse hippocampal cultures normalized to MAP2. H. 
GABABR1 expression was not changed in either genotype after 2-h treatment with vehicle (Veh; 
H2O), ethanol (ETOH; 30 mM), or ethanol and cycloheximide (30 mM ETOH+50 μM CHX). WT 
GABABR1: Veh=1.00±0.04, n=44 dendrites; ETOH=1.07±0.04, n=29 dendrites; 
ETOH+CHX=1.22±0.05, n=34 dendrites. Fmr1 KO GABABR1: Veh=1.09±0.03, n=72 dendrites; 
ETOH=1.12±0.03, n=41 dendrites; ETOH+CHX=1.42±0.07, n=43 dendrites. i. GABABR2 
expression in WT neurons increased after ethanol (ETOH; 30 mM, 2 h) compared with vehicle 
(Veh; H2O, 2 h) treatment, and was rescued with co-treatment of cycloheximide (CHX; 50 μM, 2 h). 
GABABR2 expression in Fmr1 KO dendrites was not significantly altered between neurons treated 
with Veh, ETOH, or ETOH+CHX. WT GABABR2: Veh=1.00±0.03, n=41 dendrites; 
ETOH=1.28±0.06, n=40 dendrites; ETOH+CHX=0.99±0.05, n=33 dendrites. Fmr1 KO 
GABABR2: Veh=1.46±0.05, n=73 dendrites; ETOH=1.56±0.04, n=45 dendrites; 
ETOH+CHX=1.63±0.07, n=36 dendrites. Significance determined by two-way analysis of variance 
with Tukey's post test. Value represent mean±s.e.m. Scale bars, 5 μm. Uncropped version of 
western blots, with size markers are available in Figure B.S7c. 
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acids that are incorporated during mRNA translation are biotinylated. PLA, on the other 
hand, generates a fluorescent signal when two antibodies are within 30-40 nm of each other 
(i.e., anti-GABABR1 or GABABR2 and anti-biotin). By combining these methods, we 
determined that ethanol treatment increases new protein synthesis of GABABR2 by ~40%, 
but does not alter GABABR1 synthesis, similar to the GABABR changes induced by rapid 
antidepressants (Workman et al., 2015). In Fmr1 KO dendrites, basal levels of GABABR2s 
increased by ~48%, while a significant decrease was observed in GABABR1 levels. 
Additionally, ethanol-induced translation of GABABR2 was lost in Fmr1 KO dendrites 
(Figure B.6d-i). These data provide additional evidence that the ethanol-induced increase 
in GABABR2 expression is due to new protein synthesis that requires the release of 
translational repression by FMRP. 
 
Ethanol-induced GABABR plasticity requires FMRP 
We previously demonstrated that rapid antidepressants shift GABABR signaling 
from opening potassium channels to increasing dendritic calcium (Workman et al., 2013). 
To determine if ethanol (30 mM, 2 hours) causes the same plasticity in GABABR signaling, 
we performed fluorescence calcium imaging in cultured WT and Fmr1 KO hippocampal 
neurons. A transient rise or fall in calcium in dendritic compartments can be detected using 
a fluorescent indicator that exhibits changes in fluorescent properties depending on the 
amount of bound calcium (Hendel et al., 2008). We used baclofen, a GABABR agonist, to 
activate GABABRs in the presence or absence of ethanol.  After establishing a baseline 
measurement, baclofen reduced dendritic calcium fluorescence in saline-treated WT 
neurons by ~11%, a characteristic signature of GABABR signaling increasing outward 
potassium conductance (Workman et al., 2015). However, in ethanol-treated WT neurons, 
baclofen induced distinct calcium waves and an overall averaged increase in calcium signal 
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Figure B.6: New GABABR2 protein and surface expression requires FMRP 
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of ~9% (Figure B.7a-c and Figure B.S4a and c). These results recapitulate our previous 
observations with NMDAR antagonists (Workman et al., 2013). In addition, these findings 
in WT mouse neurons are consistent with what we observed in rat cultured hippocampal 
neurons treated with ethanol or the clinically relevant rapid antidepressant Ro 25-6981 
(Figure B.S5). Unexpectedly, GABABR activation in saline-treated Fmr1 KO neurons 
failed to reduce the calcium signal. Moreover, in ethanol-treated Fmr1 KO neurons, 
GABABR activation failed to increase dendritic calcium signal (Figure B.7 b-c and Figure 
B.S4b and c). These findings suggest that the loss of FMRP in Fmr1 KO dendrites 
decouples GABABRs from potassium channels. These results also suggest that the 
dynamic, ethanol-induced plasticity in GABABR signaling, which is observed with rapid 
antidepressants, requires FMRP (Workman et al., 2013).  
To further substantiate that FMRP regulates ethanol-dependent GABABR 












Immunofluorescent images and quantification summary of GABABR1 surface expression in wild 
type (WT) and Fmr1 KO primary hippocampal cultures normalized to MAP2 as volume control. 
a. and b. Representative images of immunostaining. c. Increased expression of surface GABABR1 
in WT dendrites after ethanol (ETOH: 30 mM, 2 h) compared with vehicle (Veh: H2O, 2 h) or 
ethanol–cycloheximide (30 mM ETOH+50 μM CHX, 2 h) treatment. No significant change in 
surface GABABR1 expression in Fmr1 KO cultures treated with ETOH or ETOH+CHX was 
observed. WT surface GABABR1: Veh=1.00±0.08, n=28 dendrites; ETOH=1.76±0.17, n=37 
dendrites; ETOH+CHX=1.22±0.1, n=36 dendrites. Fmr1 KO surface GABABR1: Veh=1.36±0.13, 
n=39 dendrites; ETOH=1.44±0.15, n=42 dendrites; ETOH+CHX=0.91±0.09, n=29 dendrites. d.–
i. BONCAT combined with PLA, a method to detect newly synthesized proteins. d.–g. 
Representative images for GABABR1 and GABABR2 expression. Pixels were equally dilated by 1 
using ImageJ software for enhanced visualization as described by Cajigas et al. (Cajigas et al., 
2012). In WT and Fmr1 KO primary hippocampal cultures h. GABABR1 synthesis in dendrites 
was not altered by ethanol (30 mM, 2 h) compared with vehicle (H2O, 2 h) treatment normalized 
to MAP2. WT GABABR1: Veh=1.00±0.09, n=47 dendrites; ETOH=0.82±0.08, n=39 dendrites. 
Fmr1 KO GABABR1: Veh=0.64±0.09, n=38 dendrites; ETOH=0.48±0.05, n=36 dendrites. i. In 
contrast, ethanol induced a significant increase in new GABABR2 synthesis in WT hippocampal 
dendrites but not in Fmr1 KO dendrites. WT GABABR2: Veh=1.00±0.06, n=21 dendrites; 
ETOH=1.39±0.11, n=25 dendrites. Fmr1 KO GABABR2: Veh=1.48±0.10, n=32 dendrites; 
ETOH=1.23±0.07, n=41 dendrites. Significance determined by two-way analysis of variance with 
Tukey's post test. Values represent mean±s.e.m. Scale bars, 5 μm. 
 
 228 
did not alter the GABABR activation in saline-treated neurons because baclofen reduced 
the dendritic calcium signal. However, in ethanol-treated neurons, overexpressing FMRP 
blocked the ethanol-i nduced GABABR plasticity (Figure B.7d and Figure B.S4d-e). These 
results provide additional evidence that the dynamic reduction of FMRP with ethanol 
exposure is important for the expression of GABABR plasticity. 
 
Antidepressant effect of ethanol on behavior requires FMRP 
Since FMRP is important for ethanol-induced GABABR plasticity, we examined 
antidepressant and anxiolytic-like effects of ethanol on behavior in Fmr1 KO mice. 
Interestingly, ethanol administration did not affect the behaviors of Fmr1 KO mice in the 
splash and open field tests compared to saline-treated mice (Figure B.S6a-e). Surprisingly, 
the basal state of immobility in the FST in Fmr1 KO mice is equivalent to ethanol-injected 
WT mice (Figure B.8). To explore this paradox, we examined the requirement of GABABR 
activation in ethanol-induced decreases in immobility by using CGP-35348 to inhibit 
postsynaptic GABABRs. We previously showed that GABABR antagonism blocked the 
antidepressant-like behavior produced by NMDAR antagonist in the FST (Workman et al., 
2013). GABABR inhibition alone did not affect the immobility of saline-injected WT mice 
in the FST, similar to what we observed previously (Figure B.8) (Workman et al., 2013). 
CGP-35348, however, abolished the ethanol-induced antidepressant behavior, 
demonstrating a requirement for GABABR activation in ethanol-triggered reduction of 
immobility. Neither ethanol, CGP-35348, or ethanol + CGP-35348 treatment in Fmr1 KO 
mice produced immobility scores that were significantly different from saline-treated Fmr1 
KO mice. These findings collectively demonstrate that GABABRs and FMRP are necessary 
to elicit the ethanol-mediated antidepressant response. 
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Figure B.7: GABABR plasticity and signaling is absent in Fmr1 KO mice 
a. and c. Mouse hippocampal cultured neurons were pre-treated for 2 h with either vehicle (Veh: 
H2O) or ethanol (ETOH: 30 mM). Line graphs represent the average fluorescent calcium signal in 
dendrites over time from a. wild type (WT) and b. Fmr1 KO mice. Baseline was established for 
1 min before the addition of GABABR agonist baclofen (Bac: 50 μM) in vehicle- or ethanol-
exposed neurons. Baclofen was allowed to equilibrate as indicated by the break between dotted 
lines. c. Summary graph shows significant increase in dendritic calcium signal (ΔF/F) with the 
addition of baclofen in WT neurons pre-treated with ethanol, which was not observed in Fmr1 KO 
neurons. WT: Veh+Bac= −11.82±3.55, n=8; ETOH+Bac=9.10±1.65, n=14. Fmr1 KO: 
Veh+Bac=2.81±1.48, n=12; ETOH+Bac=3.74±1.30, n=12. d. Dendritic calcium imaging was 
performed as before in hippocampal cultured neurons infected with either vector (rAAV:mSYN-
tdTomato) or FMRP overexpression (rAAV:mSYN-FMRP and rAAV:mSYN-tdTomato). Ethanol-
induced increase in dendritic calcium is prevented by FMRP overexpression. Vector: Veh+Bac: 
−6±1.6, n=17 dendrites; ETOH+Bac: 2.5±2.5, n=17 dendrites. FMRP overexpression: Veh+Bac: 
−4±2, n=11 dendrites; ETOH+Bac: −4.7±1.4, n=27 dendrites. Significance determined by two-way 
analysis of variance, followed by Tukey's multiple comparison. Values represent mean±s.e.m.
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DISCUSSION 
Emerging behavioral and molecular evidence demonstrate that NMDAR 
antagonists act as rapid antidepressants (Li et al., 2010; Autry et al., 2011; Workman et al., 
2015; Jaso et al., 2017). Because it has long been speculated that individuals with major 
depressive disorders self-medicate with alcohol, we examined whether ethanol, which 
blocks NMDARs (Lovinger et al., 1989), acts through the same synaptic pathways as 
NMDAR antagonists. Until this study, the molecular mechanisms shared by alcohol and 
antidepressants were unexplored. Here, we provide molecular and behavioral evidence that 
acute alcohol exposure elicits antidepressant-like behaviors that persist up to 24 hours after 
administration (Figure B.1), supporting the hypothesis that ethanol initiates lasting 
antidepressant activity. We have previously demonstrated that NMDAR inhibition by rapid 
antidepressants induces two key molecular changes that are responsible for the rapid 
antidepressant response, namely (1) an increase in GABABR protein synthesis and (2) a 
shift in GABABR function that increases dendritic calcium signaling (Workman et al., 
2013; Workman et al., 2015). Our current work shows that these same signature changes 
are produced by acute ethanol exposure (Figure B.5-B.7).   
Surface expression of functional GABABRs requires the dimerization of 
GABABR1 and R2 subunits. Without GABABR2, GABABR1 is retained in the 
endoplasmic reticulum (Margeta-Mitrovic et al., 2000). Our current studies show that the 
release of GABABR2 mRNA translational repression by FMRP is necessary for the 
ethanol-induced increase in surface GABABRs with NMDAR blockade (Figure 
B.4,B.6,B.8, B.S3). Reduction of FMRP, as seen in animal models of FXS, is associated 
with elevated protein synthesis of target mRNAs (Bassell and Warren, 2008). While we 















Figure B.8: Ethanol’s antidepressant effect requires GABABR activation 
Wild type (WT) C57BL/6 and Fmr1 KO male mice were subjected to the forced swim test (FST) 
24 h post injection of vehicle (Veh: saline), ethanol (ETOH: 2.5 g kg−1), CGP-35348, a GABABR 
antagonist (CGP: 100 mg kg−1) or ethanol+CGP-5348. Ethanol-induced decrease in immobility was 
absent in Fmr1 KO mice. WT: Veh=100±3.19 s, n=9 mice; ETOH=72.97±6.23 s, n=7 mice; CGP-
35348=98.38±4.2 s, n=10; ETOH+CGP-35348=94.73±3.77 s, n=7 mice. Fmr1 KO: 
Veh=58.75±10.33 s, n=9; ETOH=69.02±8.99 s, n=3; CGP-35348=88.00±9.56 s, n=3; 
ETOH+CGP-35348=77.78±16.04 s, n=3. Significance determined by two-way analysis of variance 
Tukey's multiple comparison test. Values represent mean±s.e.m.
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FMRP has a profound effect on GABABR2 protein expression in dendrites. Constitutive 
loss of FMRP, as observed in many of its targets, abrogates stimulus-dependent mRNA 
transport and translation of target mRNAs (Muddashetty et al., 2007; Dictenberg et al., 
2008; Soden and Chen, 2010; Niere et al., 2012). We show that the ethanol-induced 
increase in GABABR2 protein is also absent in Fmr1 KO mice.  
The question of why GABABR2 is uniquely affected by acute ethanol and its 
dependence on reduced FMRP levels is intriguing. Both GABABR1 and GABABR2 mRNA 
were detected in the FMRP RNA-IP (Figure B.3). Interestingly, in vivo FMRP influences 
GABABR1 expression to a lesser extent compared to GABABR2, suggesting that FMRP 
may act in concert with other repressors such as microRNAs to tightly regulate GABABR1 
expression (Muddashetty et al., 2011). Moreover, our immunostaining and protein 
synthesis assays suggest that the increased protein levels of GABABR1 are not due to new 
protein synthesis in the dendrites, even in Fmr1 KO mice (Figure B.5 and B.6). These 
results indicate that the overall increase in synaptic GABABR1 expression in Fmr1 KO 
mice may be due to an increase in presynaptic GABABR1 expression, either through 
protein synthesis or increased protein stability. Notably, FMRP has been localized to axons 
and presynaptic terminals (Antar et al., 2006; Christie et al., 2009). Further exploration into 
presynaptic and postsynaptic GABABR expression and function in AUD and FXS is 
warranted. 
The “GABA hypoinhibition theory” posits that loss of inhibition is a leading cause 
in many of the neurological symptoms observed in FXS (Gatto et al., 2014). While studies 
showing reduced inhibition in models of FXS have focused on decreased expression of 
GABABR subunit mRNA and protein (D'Hulst et al., 2006), GABABR protein expression 
and dendritic signaling has not been explored. Interestingly, the GABABR agonist baclofen 
has shown promise in treating FXS. (R)-baclofen administration in vitro corrects the 
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elevated basal protein synthesis normally seen in Fmr1 KO mice, and rescues synaptic 
abnormalities such as increased spine density (Henderson et al., 2012). Additionally, 
baclofen administration reduced symptoms related to FXS in Fmr1 KO mice (Henderson 
et al., 2012; Qin et al., 2015). Recent studies have shown that the excitatory drive to fast 
spiking inhibitory neurons is reduced in the cortex of Fmr1 KO mice (Gibson et al., 2008). 
Our data expands upon these findings by suggesting that postsynaptic GABABR coupling 
to inwardly rectifying G protein-coupled potassium channels (GIRK) is absent in Fmr1 KO 
neurons (Figure B.7). Collectively, these results may imply that the therapeutic effects of 
baclofen in the Fmr1 KO mouse may be due to activation of presynaptic GABAB receptors 
that may in turn reduce glutamate release and reduce hyperactive mGluR signaling in the 
hippocampus (Osterweil et al., 2012).  
Changes in gene expression and protein synthesis are essential for normal 
neuroplasticity, but these crucial processes are dysregulated by drug addiction (Ron and 
Messing, 2013; Kenny, 2014; Folsom et al., 2015; Fuchsova et al., 2015). Several lines of 
evidence support parallel changes in GABABR mRNA translation/signaling as a result of 
NMDAR blockade that may be critical for alcohol actions. First, NMDAR antagonists 
mimic some effects of ethanol in humans (Holmes et al., 2013), suggesting common 
biochemical/electrophysiological signaling pathway(s). Second, changes in GABABR2 
brain gene expression correlates with lifetime alcohol consumption, supporting a role for 
altered GABABR signaling in AUD (Farris et al., 2015). Third, although controversial, the 
GABABR agonist baclofen may decrease alcohol consumption in some alcoholics 
(Krishnan-Sarin et al., 2008). In summary, our data defines a common molecular paradigm 
for alcohol and rapid antidepressants and identifies a mechanism for the initial 
antidepressant effects of alcohol. A shift in GABABR signaling is observed with both rapid 
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antidepressants and acute ethanol treatment, which may provide insight into the molecular 



















Appendix C: Code for Chapters 2 and 313 
CODE FOR DATA PROCESSING 
This section includes all the code used to process the normalized spectral counts. The raw 
data (normalized spectral counts) can be found in Table S1A (available online). Copying 
the data from the cells B12:T756 will give you what you need to replicate this script exactly 
and produce the tidy data used to generate the figures seen in the paper. 
 
First, load the plyr package: 
 
library(plyr) 
Load the data from your working directory. 
raw <- read.csv("RawData.csv", header = TRUE, stringsAsFactors = FALSE) 
Cosmetic processing. Name the rows, clean up a bit, swap 0’s to NA. 
 
names(raw) <- c("Protein", "LD1", "LD2", "LD3",  
                           "LR1", "LR2", "LR3", 
                           "PD1", "PD2", "PD3", 
                           "PR1", "PR2", "PR3", 
                           "SD1", "SD2", "SD3", 
                           "SR1", "SR2", "SR3") 
 
rownames(raw) <- raw[, "Protein"] 
raw <- raw[, -1] 





                                                 
13 This code and additional files deposited at 
https://github.com/snamjoshi/MCP2015_Niere_Namjoshi_etal 
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Split the table into separate data frames for rapa/DMSO 
 
lysDMSO <- raw[, 1:3] 
lysRapa <- raw[, 4:6] 
psdDMSO <- raw[, 7:9] 
psdRapa <- raw[, 10:12] 
solDMSO <- raw[, 13:15] 
solRapa <- raw[, 16:18] 
Next, calculate the number of proteins that returned 0 spectral counts for each replicate. 
Remove the proteins from the data frame if they have 0 values for 2 or 3 of 3 replicates. 
We consider these measurements to be unreliable. 
 
lysDMSO <- lysDMSO[which(apply(lysDMSO, 1, function(x) sum(is.na(x))) <
= 1), ] 
lysRapa <- lysRapa[which(apply(lysRapa, 1, function(x) sum(is.na(x))) <
= 1), ] 
psdDMSO <- psdDMSO[which(apply(psdDMSO, 1, function(x) sum(is.na(x))) <
= 1), ] 
psdRapa <- psdRapa[which(apply(psdRapa, 1, function(x) sum(is.na(x))) <
= 1), ] 
solDMSO <- solDMSO[which(apply(solDMSO, 1, function(x) sum(is.na(x))) <
= 1), ] 
solRapa <- solRapa[which(apply(solRapa, 1, function(x) sum(is.na(x))) <
= 1), ] 
We now have a filtered list of proteins by fraction and treatment. Looking at all the proteins, 
we see that these numbers correspond to what we reported in the publication. 
 
##   Fraction Proteins 
## 1  lysDMSO      506 
## 2  lysRapa      504 
## 3  psdDMSO      459 
## 4  psdRapa      449 
## 5  solDMSO      548 
## 6  solRapa      552 
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Now find the row means for all fractions/treatments (to average the replicates) 
 
meanLysDMSO <- rowMeans(lysDMSO, na.rm = TRUE) 
meanLysRapa <- rowMeans(lysRapa, na.rm = TRUE) 
meanPsdDMSO <- rowMeans(psdDMSO, na.rm = TRUE) 
meanPsdRapa <- rowMeans(psdRapa, na.rm = TRUE) 
meanSolDMSO <- rowMeans(solDMSO, na.rm = TRUE) 
meanSolRapa <- rowMeans(solRapa, na.rm = TRUE) 
Next we want to combine rapa and DMSO into one data frame where NA indicates that 
proteins was not found in that fraction/treatment. To do this we need to create a function 
that takes the DMSO data frame and the rapa data frame and combines them together. 
The mergeVec function below will accomplish this. 
 
mergeVec <- function(x, y) { 
    require(plyr) 
     
    input <- list(as.data.frame(t(x)), as.data.frame(t(y))) 
    input <- t(do.call(rbind.fill, input)) 
     
    return(input) 
} 
Now apply the mergeVec function to the data. We will add column names and change 
NA values back to 0. 
 
lysate <- mergeVec(meanLysDMSO, meanLysRapa) 
psd <- mergeVec(meanPsdDMSO, meanPsdRapa) 
soluble <- mergeVec(meanSolDMSO, meanSolRapa) 
 
colnames(lysate) <- c("DMSO", "Rapa") 
colnames(psd) <- c("DMSO", "Rapa") 
colnames(soluble) <- c("DMSO", "Rapa") 
 
lysate[is.na(lysate)] <- 0 
psd[is.na(psd)] <- 0 
soluble[is.na(soluble)] <- 0 
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Next we want to compute the fold changes for each fraction. This will require a function 
that divides the Rapa value by the DMSO value and then transforms the data using log2. If 
the output returns Inf (divide by zero) or -Inf (log2(0)), then the output will be assigned the 
characters “HIGH” or “LOW” respectively. 
The foldChange function below will accomplish this. 
 
foldChange <- function(fraction) { 
    output <- as.data.frame(fraction[, 2] / fraction[, 1]) 
    output <- log2(output) 
     
    output[output == Inf, ] <- "HIGH" 
    output[output == -Inf, ] <- "LOW" 
     
    return(output) 
} 
Apply the foldChange function to the data. 
 
lysateFC <- foldChange(lysate) 
psdFC <- foldChange(psd) 
solubleFC <- foldChange(soluble) 
Now merge all the lists together for each fraction using the mergeVec function. We do this 
in two steps: first for lysate and PSD and finally adding in the soluble column. 
 
fullList <- as.data.frame(mergeVec(lysateFC, psdFC)) 
fullList <- as.data.frame(mergeVec(fullList, solubleFC)) 
Last bit of ordering and cosmetic changes to get the data frame into a neat format. 
 
fullList <- fullList[ order(row.names(fullList)), ] 
fullList <- cbind(row.names(fullList), fullList) 
row.names(fullList) <- 1:length(fullList[, 1]) 
colnames(fullList) <- c("Gene", "Lysate", "PSD", "Soluble") 
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This produces the full list of proteins, our processed data. The final data frame here (or in 
some cases the precursor data frames above) will be used downstream for other analysis 
found in the paper. 
 
CODE FOR FIGURE 2.2 
To use this script you need the data generated from DataProcessing.R. In that document 
this data was assigned to the variable “fullList”. 








fullList <- read.csv("fullList.csv", header = TRUE) 
Cosmetic changes and get data into long form. “HIGH” and “LOW” are changed to NA. 
 
fullList <- fullList[, -1] 
fullList[fullList == "HIGH"] <- NA 
fullList[fullList == "LOW"] <- NA 
fullList <- apply(fullList, 2, as.numeric) 
fullList <- melt(fullList) 
fullList <- fullList[, -1] 
colnames(fullList) <- c("Fraction", "Expression") 
Subset the PSD fraction and generate the graph. 
 
histLongPSD <- subset(fullList, Fraction == "PSD") 
 
binsize <- diff(range(na.omit(histLongPSD$Expression)))/50 
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a <- ggplot(histLongPSD, aes(x = Expression, fill = Fraction)) + 
    geom_histogram(position = "identity", binwidth = binsize) + 
    geom_vline(xintercept = 0, linetype = "dashed", color = "black", si
ze = 0.3) + 
    geom_vline(xintercept = 0.1375, linetype = "solid", color = "red", 
size = 0.3) + 
    geom_vline(xintercept = -0.1375, linetype = "solid", color = "red", 
size = 0.3) + 
    scale_fill_manual(values = c("black")) + 
    scale_x_continuous(limits = c(-1.75, 1.75), breaks = seq(-2, 2, by 
= 0.5)) + 
    xlab("Log2 Fold Change") + 
    ylab("Number of Proteins") + 
    theme_bw() + 
    theme(panel.grid.major = element_blank(), panel.grid.minor = elemen
t_blank(),  
                panel.background = element_blank(), axis.line = element
_line(color = "black")) 
 
a +  
    theme(text = element_text(size = 15)) + 
    theme(legend.position = "none") + 
    annotate("rect", xmin = -0.136, xmax = 0.1375, ymin = 0, ymax = Inf
, fill = "grey99", alpha = 0.9) 
 
Statistics in Figure 2D Legend 
Import the data sets needed. 
 
fullList <- read.csv("fullList.csv", header = TRUE) 
fullListPSD <- fullList[ ,c(1,3)] 
fullListPSD$PSD <- as.numeric(as.character(fullListPSD$PSD)) 
## Warning: NAs introduced by coercion 
Number of proteins calculations (excludes out-of-range proteins): 
 
sum(fullListPSD$PSD > 0, na.rm = TRUE)  
## [1] 210 
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sum(fullListPSD$PSD < 0, na.rm = TRUE)  
## [1] 191 
sum(complete.cases(fullListPSD$PSD))  
## [1] 401 
This yields 210 PSD proteins with fold changes greater than 0, 191 PSD proteins with fold 
changes less than 0 and 401 total PSD proteins as reported. 
 
Descriptive statistics reported in figure legend: 
 
mean(fullListPSD$PSD, na.rm = TRUE) # Mean 
## [1] -0.006047828 
sd(fullListPSD$PSD, na.rm = TRUE) # Standard deviation 
## [1] 0.4950849 
var(fullListPSD$PSD, na.rm = TRUE) # Variance (CI calculated in GraphPa
d) 
## [1] 0.2451091 
skewness(fullListPSD$PSD, na.rm = TRUE) # Skewness 
## [1] -0.39867 
kurtosis(fullListPSD$PSD, na.rm = TRUE) # Kurtosis 
## [1] 4.136472 
Bartlett’s test for comparison of variance in fold-change across fractions. 
 
# Import Data and process 
fullList <- read.csv("fullList.csv", header = TRUE) 
fullList <- fullList[, -1] 
fullList[fullList == "HIGH"] <- NA 
fullList[fullList == "LOW"] <- NA 
fullList <- apply(fullList, 2, as.numeric) 
fullList <- melt(fullList) 
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fullList <- fullList[, -1]  
colnames(fullList) <- c("Fraction", "Expression") 
fullList <- fullList[complete.cases(fullList), ] 
 
# Compute Bartlett's Test 
bartlett.test(Expression~Fraction, fullList) # p < 0.0002 | Variances a
re different 
##  
##  Bartlett test of homogeneity of variances 
##  
## data:  Expression by Fraction 
## Bartlett's K-squared = 17.1834, df = 2, p-value = 0.0001856 
Figure 2.2E 
Import the data. 
 
fullList <- read.csv("fullList.csv", header = TRUE, stringsAsFactors = 
FALSE) 
 
nrow(subset(fullList, fullList$PSD == "HIGH", select = c("Gene", "PSD")
)) 
## [1] 48 
nrow(subset(fullList, fullList$PSD == "LOW", select = c("Gene", "PSD"))
) 
## [1] 58 
However, note that for the out-of-range genes we used an even more stringent 
classification. If either treatment had 2 zero values, we would not classify it as out-of-range 
because we could not reliably compute the fold-change. These were manually removed 
after the script was written and thus shortens the list. The graph shown in figure 2E was 





CODE FOR FIGURE 2.3 
To use this code you will need the proteins in Table S7A (online) (cells A12:C615) and 
“fullList.csv” which was generated in DataProcessing.R. You will also need the list of 
mitchondrial genes in “mito.csv”. 




# Disease lists 
disease <- read.csv("diseaseCandidates.csv", header = TRUE, stringsAsFa
ctors = FALSE, na.strings = "") 
 
diseaseList <- list(Epilepsy = disease$Epilepsy, 
                                        Alzheimers = disease$Alzheimers
, 
                                        ASD = disease$ASD) 
 
diseaseList <- lapply(diseaseList, na.omit) 
diseaseList <- lapply(diseaseList, as.data.frame) # Removes na.action a
ttributes 
 
# Mass spec list 
fullList <- read.csv("fullList.csv", header = TRUE) 
fullList$Gene <- toupper(fullList$Gene)  # Supp table is in uppercase, 
easier comparison 
 
# Mitochondrial gene list 
mito <- read.csv("mito.csv", header = FALSE, stringsAsFactors = FALSE) 
mito <- toupper(mito[ ,1]) 
Figure 2.3A 
Process data and generate heatmap for epilepsy genes. 
 
epilepsy <- diseaseList$'Epilepsy' 
epilepsy <- fullList[fullList$Gene %in% epilepsy[ ,1], ] # Filter to is
olate genes in our dataset 
epilepsy <- epilepsy[!epilepsy$Gene %in% mito, ] 
epilepsy <- sapply(epilepsy[ ,2:4], function(x) as.numeric(as.character
(x))) 
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epilepsyMatrix <- data.matrix (epilepsy) 
 
# Labels and out-of-range gene textured boxes added manually in Inkscap
e later 
heatmap.2( 
    as.matrix(epilepsyMatrix[ ,c(2,3)]), 
    dendrogram = "none", 
    Rowv = NULL, 
    Colv = NULL, 
    col = "heat.colors", 
    trace = "none",  
    na.color = "grey", 
    density.info = "none", 
    #key = TRUE, 
    #keysize = 0.5, 
    labCol = FALSE 
) 
Figure 2.3B 
Process data and generate heatmap for Alzheimer’s genes 
 
alz <- diseaseList$'Alzheimers' 
alz <- fullList[fullList$Gene %in% alz[ ,1], ] # Filter to isolate gene
s in our dataset 
alz <- alz[!alz$Gene %in% mito, ] 
alz <- sapply(alz[ ,2:4], function(x) as.numeric(as.character(x))) 
alzMatrix <- data.matrix(alz) 
 
# Labels and out-of-range gene textured boxes added manually in Inkscap
e later 
heatmap.2( 
    as.matrix(alzMatrix[ ,c(2,3)]), 
    dendrogram = "none", 
    Rowv = NULL, 
    Colv = NULL, 
    col = "heat.colors", 
    trace = "none",  
    na.color = "grey", 
    density.info = "none", 
    #key = TRUE, 
    #keysize = 0.5, 




Process data and generate heatmap for ASD genes 
 
asd <- diseaseList$'ASD' 
asd <- fullList[fullList$Gene %in% asd[ ,1], ] # Filter to isolate gene
s in our dataset 
asd <- asd[!asd$Gene %in% mito, ] 
asd <- sapply(asd[ ,2:4], function(x) as.numeric(as.character(x))) 
asdMatrix <- data.matrix(asd) 
 
# Labels and out-of-range gene textured boxes added manually in Inkscap
e later 
heatmap.2( 
    as.matrix(asdMatrix[ ,c(2,3)]), 
    dendrogram = "none", 
    Rowv = NULL, 
    Colv = NULL, 
    col = "heat.colors", 
    trace = "none",  
    na.color = "grey", 
    density.info = "none", 
    #key = TRUE, 
    #keysize = 0.5, 
    labCol = FALSE 
)    
 
CODE FOR FIGURE 3.6 
This code utilizes material from various disease databases (collected in 
diseaseCandidates.csv), the fullList.csv file generated in the data processing step, and a 







Load libraries and process data 
 
library(VennDiagram) 
Import data sets and process: 
 
# Disease lists 
disease <- read.csv("diseaseCandidates.csv", header = TRUE, stringsAsFa
ctors = FALSE, na.strings = "") 
 
diseaseList <- list(Epilepsy = disease$Epilepsy, 
                                        Alzheimers = disease$Alzheimers
, 
                                        ASD = disease$ASD) 
 
diseaseList <- lapply(diseaseList, na.omit) 
 
# Mass spec list 
fullList <- read.csv("fullList.csv", header = TRUE) 
fullList$Gene <- toupper(fullList$Gene)  # Supp table is in uppercase, 
easier comparison 
 
# Epilepsy List 
epilepsy <- diseaseList$'Epilepsy' 
epilepsy <- fullList[fullList$Gene %in% epilepsy, ] # Filter to isolate 
genes in our dataset 
 
# Alzheimer's List 
alz <- diseaseList$'Alzheimers' 
alz <- fullList[fullList$Gene %in% alz, ] # Filter to isolate genes in 
our dataset 
 
# ASD List 
asd <- diseaseList$'ASD' 
asd <- fullList[fullList$Gene %in% asd, ] # Filter to isolate genes in 
our dataset 
The VennSet function returns a list of each element of a 3-way Venn diagram. I am not the 
original author of this function; I believe I found this function in a StackExchange post. 
Please notify me if you come across the original source so I can give credit to the author. 
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VennSet <- function(A, B, C) 
{ 
    unionAB <- union(A, B) 
    unionAC <- union(A, C) 
    unionBC <- union(B, C) 
    uniqueA <- setdiff(A, unionBC) 
    uniqueB <- setdiff(B, unionAC) 
    uniqueC <- setdiff(C, unionAB) 
    intersAB <- setdiff(intersect(A, B), C) 
    intersAC <- setdiff(intersect(A, C), B) 
    intersBC <- setdiff(intersect(B, C), A) 
    intersABC <- intersect(intersect(A, B), intersect(B, C)) 
    items <- list(A=uniqueA, B=uniqueB, C=uniqueC, AB=intersAB , AC=int
ersAC , BC=intersBC , ABC=intersABC) 
    return(items) 
} 
Figure 3.6A (left) 
Find the different intersections and determine the number of elements in each. This is 
what will be fed into the Venn diagram. 




## [1] 319 
##  
## $B 
## [1] 184 
##  
## $C 
## [1] 532 
##  
## $AB 
## [1] 11 
##  
## $AC 
## [1] 57 
##  
## $BC 
## [1] 12 
##  
## $ABC 
## [1] 2 
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Draw the Venn diagram. In the paper the numbers and shapes for the Venn diagram were 
entered manually. I have reproduced them here with R code. 
 
grid.newpage() 
draw.triple.venn(area1 = 389, area2 = 209, area3 = 603, n12 = 13, n23 = 
14, n13 = 59,  
                                 n123 = 2, category = c("Epilepsy", "AD
", "ASD"), lty = "blank",  
                                 fill = c("brown1", "darkorchid2", "lig
htslateblue")) 
 
Figure 3.6B (right) 
First we need to import the list of disease candidates found in our mass spec data 
 
OurDiseaseList <- read.csv("Diseases.csv", header = TRUE) 
OurDiseaseList.list <- list(A = OurDiseaseList[,1], B = OurDiseaseList[
,2], C = OurDiseaseList[,3]) 
Find the intersections and determine the number of elements in each. 
 




## [1] 40 
##  
## $B 
## [1] 40 
##  
## $C 
## [1] 13 
##  
## $AB 
## [1] 3 
##  
## $AC 




## [1] 1 
##  
## $ABC 
## [1] 1 
Draw the Venn diagram. 
 
grid.newpage() 
draw.triple.venn(area1 = 48, area2 = 44, area3 = 19, n12 = 3, n23 = 1, 
n13 = 5,  
                                 n123 = 0, category = c("Epilepsy", "AD
", "ASD"), lty = "blank",  
                                 fill = c("rosybrown2", "plum", "skyblu
e1")) 
 
CODE FOR SUPPLEMENTAL FIGURES 
This document includes the code needed to calculate the coefficient of determination 
between samples of fractions and the measurement of error between the fractions. A 
correlation matrix is also included though this was not reported in the publication. 
Data processing and package loading 




Load the data and get into tidy format. RawData.csv is the data in Supplemental Table 1A 





raw <- read.csv("RawData.csv", header = TRUE, stringsAsFactors = FALSE) 
 
names(raw) <- c("Protein", "LD1", "LD2", "LD3",  
                                "LR1", "LR2", "LR3", 
                                "PD1", "PD2", "PD3", 
                                "PR1", "PR2", "PR3", 
                                "SD1", "SD2", "SD3", 
                                "SR1", "SR2", "SR3") 
 
rownames(raw) <- raw[, "Protein"] 
raw <- raw[, -1] 
The prop() function will be used to determine the variance across the different proteins 
(reliability of spectral counts). The function first calculates the standard error among the 
proteins by treatment. These standard errors are then normalized by the mean spectral count 
for the protein. This gives the mean standard error for all proteins by treatment. 
 
prop <- function(cols){ 
    x <- raw[, cols] 
    x <- x[rowSums(x == 0) <= 1, ] 
    x[x == 0] <- NA 
     
    x.var <- apply(x, 1, function(r) { 
        sd(r, na.rm = TRUE) / sqrt(sum(!is.na(r))) 
    }) 
     
    x.prop <- x.var / rowMeans(x, na.rm = TRUE) 
    return(x.prop) 
} 
The prop() function is then applied to all fractions. 
 
totals <- list(LD = prop(1:3), 
                             LR = prop(4:6), 
                             PD = prop(7:9), 
                             PR = prop(10:12), 
                             SD = prop(13:15), 
                             SR = prop(16:18)) 
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Bar Charts for figures 2.6 and 2.7 
A standard error function for use below. 
 
se <- function(x) sqrt(var(x)/length(x)) 
Arrange the data for graphing by calculating the mean and standard deviation and putting 
them into a data frame. 
 
totals.mean <- sapply(totals, mean) 
totals.se <- sapply(totals, se) 
totals.bar <- data.frame(Mean = totals.mean, SE = totals.se) 
For the publication, we put these values into GraphPad. The graph can be replicated in R 
with the following code: 
 
ggplot(totals.bar, aes(x = rownames(totals.bar), y = Mean, fill = rowna
mes(totals.bar), color = rownames(totals.bar))) + 
    geom_bar(stat = "identity", color = "black", fill = "grey") + 
    geom_errorbar(aes(ymin = Mean + 0, ymax = Mean + SE), width = 0.2, 
color = "black") + 
    xlab("Fraction") + 
    ylab("Normalized Mean S.E.M.") + 
    coord_cartesian(ylim = c(0,0.25)) + 
    theme_bw() 
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Figure C.1: Average S.E.M. of the normalized spectral counts across all genes within 
each fraction 
The following is not included in the paper but may be useful. We can plot the probability 
density functions for each of the fractions and see how the distribution of standard errors 
compares. 
 
totals.long <- melt(totals) 
 
ggplot(totals.long, aes(x = value, color = L1)) + 
    geom_density() + 
    xlab("Distribution of S.E.M.") + 
    ylab("Density") + 
    theme_bw() 
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Figure C.2: Probability distribution of standard errors across all genes within each 
fraction 
Correlations for figures 2.6 and 2.7 
Here we use the coefficient of determination to see the correlation of the triplicate 
measurements among all normalized spectral counts by treatment and fraction. We will 
still use the raw data loaded above for the analysis (stored in the variable raw). 
The correlations need to be done in sets of three. We can create the pattern sequence we 
need for each set with the code displayed below. We will store the pattern key-index in the 
variable m.  
 
v1 <- c(1:18)  
v2 <- v1+1L  
v3 <- c(0,0,3L)  
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v2 <- v2-v3 
m <- cbind(v1,v2) 
We apply the lm() function to the raw data and extracted r.squared in sets of three. The 
key specifies the pattern in which the correlations are to be computed. We assign the 
correlations to the variable fit. 
 
fit <- lapply(1:length(raw),function(x) summary(lm(raw[,m[x,1]]~raw[,m[
x,2]]))$r.squared) 
Now we just have to make some cosmetic adjustments to make fit look tidy. 
 
data.frame(Fraction = c(rep("Lysate", 6), rep("PSD", 6), rep("Soluble", 
6)), 
                     Treatment = rep(c("DMSO","RAPA"), 3, each = 3), 
                     Replicate = rep(c("1 vs 2", "2 vs 3", "3 vs 1"), 6
), 
                     R2 = round(unlist(fit), 3)) 
##    Fraction Treatment Replicate    R2 
## 1    Lysate      DMSO    1 vs 2 0.922 
## 2    Lysate      DMSO    2 vs 3 0.959 
## 3    Lysate      DMSO    3 vs 1 0.900 
## 4    Lysate      RAPA    1 vs 2 0.943 
## 5    Lysate      RAPA    2 vs 3 0.949 
## 6    Lysate      RAPA    3 vs 1 0.931 
## 7       PSD      DMSO    1 vs 2 0.794 
## 8       PSD      DMSO    2 vs 3 0.898 
## 9       PSD      DMSO    3 vs 1 0.856 
## 10      PSD      RAPA    1 vs 2 0.855 
## 11      PSD      RAPA    2 vs 3 0.905 
## 12      PSD      RAPA    3 vs 1 0.867 
## 13  Soluble      DMSO    1 vs 2 0.832 
## 14  Soluble      DMSO    2 vs 3 0.900 
## 15  Soluble      DMSO    3 vs 1 0.907 
## 16  Soluble      RAPA    1 vs 2 0.900 
## 17  Soluble      RAPA    2 vs 3 0.941 
## 18  Soluble      RAPA    3 vs 1 0.843 
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Additionally, we can also look at a correlation matrix. This does not appear in the 
publication but may also be useful. 
 
Find correlations across the entire data. 
 
corDat <- cor(raw) 
corDatMelt <- melt(corDat) 
To make the graph more readable we have scaled the colors in the correlation matrix across 
the range of R squared values (rather than scaled over 0 to 1). This makes the color shading 
much more readable visually. First we create a midpoint function. Then we find the 
midpoint of the correlations and set it to mdpt. This is then set as the midpoint of the color 
gradient in the scale_fill_gradient2() function call. 
 
# Function to calculate midpoint for use in color scale 
midpoint <- function(x) { 
    ((max(x) - min(x))/2) + min(x) 
} 
 
# Set midpoint of data to variable mdpt 
mdpt <- midpoint(corDatMelt$value) 
 
# Plot correlation matrix 
ggplot(corDatMelt, aes(x = Var1, y = Var2, fill = value)) + 
    geom_tile() + 
    scale_fill_gradient2(low = "red", mid = "orange", high = "white", m
idpoint = mdpt) + 
    theme(axis.text.x = element_text(angle = 75, hjust = 1, vjust = 1)) 
+ 
    xlab("") + 
    ylab("") 
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Figure C.3: Correlation matrix of all replicates in all fractions 
CODE FOR SUPPLEMENTAL TABLES 
This section includes all of the code and data files needed to replicate some of the results 
obtained from the online supplemental tables. 
Table S2 
First, let’s create the read.csv.list function which reads a CSV file with uneven 
columns and converts it to a list instead of a dataframe. This is pretty common when 
uploading gene lists and this is an easy fix for it. 
 
# Function reads a CSV file with uneven columns and coverts to a list i
nstead of a dataframe 
 
read.csv.list <- function(file, header) { 
    outputList <- apply(read.csv(file, header = header), 2, list) 
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    outputList <- lapply(outputList, function(x) lapply(x, '[', which(c
omplete.cases(x)))) 
     
    return(outputList) 
} 
Load the data. This data is a network stats file that has all of the network stats calculated 
by Cytoscape for the DMSO network, the rapa network, and a randomly generated 
network.  
 
network <- read.csv.list("networkStats.csv", TRUE) 
First we need to summarize the data by mean and standard deviation as it is included in the 
table. 
 
meanLysate <- unlist(lapply(network, function(x) mean(as.numeric(unlist
(x))))) 
sdLysate <- unlist(lapply(network, function(x) sd(as.numeric(unlist(x))
))) 
 




##                                    mean   sd 
## DMSO_Closeness_Centrality         0.319 0.17 
## Rapa_Closeness_Centrality         0.326 0.19 
## Random_Closeness_Centrality       0.421 0.06 
## DMSO_Clustering_Coefficient       0.735 0.16 
## Rapa_Clustering_Coefficient       0.739 0.16 
## Random_Clustering_Coefficient     0.127 0.02 
## DMSO_Neighborhood_Connectivity   16.458 8.56 
## Rapa_Neighborhood_Connectivity   15.881 7.32 
## Random_Neighborhood_Connectivity 20.268 1.34 
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Next we perform all of the tests whose P-values are listed in the table. The DMSO network, 
rapa network, and random networks were generated in Cytoscape first and all of the 
network statistics data was exported. 
 
# DMSO Lysate Analysis 
dmsoAnalysis <- lapply(network[c(1,4,7)], function(x) wilcox.test(as.nu
meric(unlist(x)), alternative = "greater")) 
 
# Rapa Lysate Analysis 
rapaAnalysis <- lapply(network[c(2,5,8)], function(x) wilcox.test(as.nu
meric(unlist(x)), alternative = "greater")) 
 
# Random Clustering Coefficent DMSO 
randDmsoCC <- ks.test(as.numeric(unlist(network[[4]])), as.numeric(unli
st(network[[6]])), alternative = "two.sided") 
 
# Random Clustering Coefficent Rapa 
randRapaCC <- ks.test(as.numeric(unlist(network[[5]])), as.numeric(unli
st(network[[6]])), alternative = "two.sided") 
 
# Random Neighborhood Connectivity DMSO 
randDmsoNC <- ks.test(as.numeric(unlist(network[[7]])), as.numeric(unli
st(network[[9]])), alternative = "two.sided") 
 
# Random Neighborhood Connectivity Rapa 
randRapaNC <- ks.test(as.numeric(unlist(network[[8]])), as.numeric(unli
st(network[[9]])), alternative = "two.sided") 
Next, we put it all into a table. 
 
summary <- data.frame(P.value = c(unname(unlist(sapply(dmsoAnalysis, "[
", 3))), unname(unlist(sapply(rapaAnalysis, "[", 3))), randDmsoCC$p.val
ue, randRapaCC$p.value, randDmsoNC$p.value, randRapaNC$p.value), 
                                            row.names = c("DMSO Closene
ss Centrality", "DMSO Clustering Coefficient", "DMSO Neighborhood Conne
ctivity", "Rapa Closeness Centrality", "Rapa Clustering Coefficient", "
Rapa Neighborhood Connectivity", "Random DMSO Clustering Coefficent", "
Random Rapa Clustering Coefficient", "Random DMSO Neighborhood Connecti
vity", "Random Rapa Neighborhood Connectivity")) 
 




##                                            P.value LessThan0.001 
## DMSO Closeness Centrality             1.768067e-38          TRUE 
## DMSO Clustering Coefficient           1.862645e-09          TRUE 
## DMSO Neighborhood Connectivity        9.313226e-10          TRUE 
## Rapa Closeness Centrality             5.078745e-36          TRUE 
## Rapa Clustering Coefficient           2.000189e-06          TRUE 
## Rapa Neighborhood Connectivity        1.862645e-09          TRUE 
## Random DMSO Clustering Coefficent     5.087042e-13          TRUE 
## Random Rapa Clustering Coefficient    8.461010e-13          TRUE 
## Random DMSO Neighborhood Connectivity 1.275006e-06          TRUE 
## Random Rapa Neighborhood Connectivity 3.169569e-07          TRUE 
The number of proteins, can be found in the Data Processing file. Characteristic path 
length, network density, nodes, and edges calculated from Cytoscape built-in statistics. 
Table S4 
This data file is the same one that is generated by the data processing file. It is included in 
the same GitHub repo as this markdown file. 
 
fullList <- read.csv("fullList.csv", header = TRUE, stringsAsFactors = 
FALSE) 
First get data into correct form. The oorToNa() function changes out-of-range genes to 
NAs that way numeric calculations can be performed. 
 
oorToNa <- function(geneList) { 
    geneList[geneList == "LOW"] <- NA 
    geneList[geneList == "HIGH"] <- NA 
    geneList[geneList == "<NA>"] <- NA 
     
    return(geneList) 
} 
 
fullListNumeric <- oorToNa(fullList) 
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Now we can output the PSD proteins seen in table S4 (available online). The comment here 
indicates there are 76 proteins as reported in the paper. 
 
subset(fullListNumeric, as.numeric(PSD) > -0.1 & as.numeric(PSD) < 0.1, 
c("Gene", "PSD"))   # 76 proteins 
Table S5 
Output of the PSD proteins seen in table S5 (available online). The comments here indicate 
that there were either 159 or 166 proteins in each of the two directions for the PSD. 
 
subset(fullListNumeric, as.numeric(PSD) < -0.1, c("Gene", "PSD"))  # 15
9 proteins 
subset(fullListNumeric, as.numeric(PSD) > 0.1, c("Gene", "PSD"))   # 16
6 proteins 
Table S6 
Output of the out-of-range proteins in the PSD. Note that we went back and manually 
removed proteins where the fold-change calculation may have been unreliable - in cases 
where there was either high variability between samples or where both genes only had data 
for 1 out of 3 spectral counts for the replicates in the numerator or denominator. 
 
as.vector(na.omit(fullList[fullList$PSD == "HIGH", "Gene"])) 
##  [1] "Actr2"    "Aldh2"    "Aldh6a1"  "Anxa6"    "Apoe"     "Arpc5l"   
##  [7] "Atp5j"    "Cadm4"    "Cct4"     "Clasp2"   "Col1a1"   "Dctn2"    
## [13] "Ddost"    "Dync1li1" "Eef1d"    "Efhd2"    "Eif5a"    "Erp29"    
## [19] "Fahd2"    "Glo1"     "Gpd1"     "Gpr158"   "Grin1"    "H2AFR"    
## [25] "Hsd11b1"  "L1cam"    "Lap3"     "Lin7c"    "Macf1"    "Maoa"     
## [31] "Mapk10"   "Marcks"   "Nckap1"   "Nf1"      "Ngef"     "Oat"      
## [37] "Pcmt1"    "Pdzd2"    "Ppib"     "Prkca"    "Prkcb"    "Qdpr"     
## [43] "Rph3a"    "Rplp0"    "Slc32a1"  "Slc9a3r1" "Suclg1"   "TSH2B" 
as.vector(na.omit(fullList[fullList$PSD == "LOW", "Gene"])) 
##  [1] "Acsf2"     "Aifm1"     "Ap2s1"     "Atad3"     "Atl1"      
##  [6] "Atp1b3"    "Cct5"      "Copg1"     "Crebbp"    "Ctbp1"     
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## [11] "Cyb5r1"    "Dctn1"     "Dlg2"      "Dlg3"      "Dpysl5"    
## [16] "Eef2"      "Eif4a2"    "Epb41l1"   "Gja1"      "Gphn"      
## [21] "Hivep2"    "Hsd17b10"  "Hsph1"     "Idh2"      "Impact"    
## [26] "Kidins220" "Kif2a"     "Map2"      "Map6"      "Mtnd4"     
## [31] "Myo5a"     "Nap1l1"    "Ndufa11"   "P4hb"      "Park7"     
## [36] "Pclo"      "Pde2a"     "Pgm1"      "Pik3cb"    "Plcb1"     
## [41] "Plec"      "Ppp1r9b"   "Pygm"      "Rpn2"      "Rtn3"      
## [46] "Rtn4"      "Rufy3"     "Ryr1"      "Slc30a3"   "Slc8a2"    
## [51] "Snd1"      "Syt12"     "Thop1"     "Tkt"       "Tmem39a"   
## [56] "Vat1"      "Wdr1"      "Zc3h18" 
Table S7 
See the figure 6 markdown file to generate these lists. 
Table S8 
See the figure 6 markdown file to generate these lists. 
 
All other figures generated through either Cytoscape or DAVID or the output of the mass 





















Appendix D: Code for Chapter 4 
UBUNTU INSTALL SHELL SCRIPT 
This section contains the shell commands followed on a fresh Ubuntu install to add all 
software used during RNAseq analysis. This is provided for reproducibility. Note that the 
shell commands here do not form a complete shell script so they should not be run directly. 
Please modify as needed. 
# Install Zshell 
sudo apt-get install zsh 
sudo apt-get install git-core 
sudo wget https://github.com/robbyrussell/oh-my-zsh/raw/master/tools/in
stall.sh -O - | zsh 
chsh -s `which zsh` 
sudo shutdown -r 0 
 
# Install R Base 
sudo echo "deb http://cran.rstudio.com/bin/linux/ubuntu xenial/" | sudo 
tee -a /etc/apt/sources.list 
gpg --keyserver keyserver.ubuntu.com --recv-key E084DAB9 
gpg -a --export E084DAB9 | sudo apt-key add - 
sudo apt-get update 
sudo apt-get install r-base r-base-dev 
 
# Install R Studio 0.99.903 
sudo apt-get install gdebi-core 
wget https://download1.rstudio.org/rstudio-0.99.903-amd64.deb 
sudo gdebi -n rstudio-0.99.903-amd64.deb 
rm rstudio-0.99.903-amd64.deb 
 
# Install dropbox 
sudo apt-get install nautilus-dropbox 
 
# Run dropbox to initiate download 
 
# Install Java/Oracle 8 
sudo apt-get update 
sudo apt-get install default-jre 
sudo apt-get install default-jdk 
sudo add-apt-repository ppa:webupd8team/java 
sudo apt-get update 
sudo apt-get install oracle-java8-installer 
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# Install FastQC 0.11.5 
cd /usr/src 
sudo curl -O http://www.bioinformatics.babraham.ac.uk/projects/fastqc/f
astqc_v0.11.5.zip 
sudo unzip fastqc_v0.11.5.zip 
sudo ln -sf /usr/src/FastQC/fastqc /usr/bin/fastqc 
sudo chmod +x /usr/bin/fastqc 
 
# Install pip 
sudo apt-get update 
sudo apt-get upgrade 
sudo apt-get install python-pip 
 
# Install python 2.7.10 
sudo apt-get install build-essential checkinstall 
sudo apt-get install libreadline-gplv2-dev libncursesw5-dev libssl-dev 
libsqlite3-dev tk-dev libgdbm-dev libc6-dev libbz2-dev 
cd /usr/src 
sudo wget https://www.python.org/ftp/python/2.7.10/Python-2.7.10.tgz 
sudo tar xzf Python-2.7.10.tgz 
cd Python-2.7.10 
sudo ./configure 
sudo make altinstall 
sudo apt-get install python-dev 
 
# Install cutadapt 1.11 
sudo -H pip install cutadapt 
 
# Install Trim Galore 0.4.1 
cd /usr/src 
sudo curl -O http://www.bioinformatics.babraham.ac.uk/projects/trim_gal
ore/trim_galore_v0.4.1.zip 
sudo unzip trim_galore_v0.4.1.zipsudo ln -sf /usr/src/trim_galore_zip/t
rim_galore /usr/bin/trim_galore 
 
# Install Tophat 2.1.1 
cd /usr/src 
sudo curl -O https://ccb.jhu.edu/software/tophat/downloads/tophat-2.1.1
.Linux_x86_64.tar.gz 
sudo tar xzvf tophat-2.1.1.Linux_x86_64.tar.gz 
 
# Install Bowtie 2.2.9 
cd /usr/src     
sudo curl -OL http://sourceforge.net/projects/bowtie-bio/files/bowtie2/
2.2.9/bowtie2-2.2.9-linux-x86_64.zip 
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sudo unzip bowtie2-2.2.9-linux-x86_64.zip 
 
# Install samtools 0.1.19 
cd /usr/src 
sudo curl -OL https://sourceforge.net/projects/samtools/files/samtools/
0.1.19/samtools-0.1.19.tar.bz2 
sudo tar jxvf samtools-0.1.19.tar.bz2 




# Install RSeQC 2.6.4 
sudo -H pip install RSeQC 
 





## The following contains all shell commands for NGS analysis tools 
# Install Piranha 1.2.1 
cd /usr/src 
sudo curl -O http://smithlabresearch.org/downloads/piranha-1.2.1.tar.gz 
sudo tar xzvf piranha-1.2.1.tar.gz 
cd piranha-1.2.1 
sudo ./configure --with-bam_tools_headers="/usr/src/BAMTools/include/" 
\ 
      --with-bam_tools_library="/usr/src/BAMTools/lib/" 
sudo make all 
sudo make install 
 
# Install CMake 3.6.2 
cd /usr/src 
sudo curl -O https://cmake.org/files/v3.6/cmake-3.6.2.tar.gz 
sudo tar xzvf cmake-3.6.2.tar.gz 
cd cmake-3.6.2 
sudo chmod u+x bootstrap 
sudo ./bootstrap 
sudo make 
sudo make install 
 
# Install BAMtools 2.4.1 
cd /usr/src 
sudo git clone git://github.com/pezmaster31/bamtools.git 
cd bamtools 
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sudo mkdir build 
cd build 
cd cmake ..  
sudo make 
 
# Install GSL-2.2.1 
cd /usr/src 
sudo curl -O http://gnu.mirrors.pair.com/gnu/gsl/gsl-2.2.1.tar.gz 
sudo tar xzvf gsl-2.2.1.tar.gz 
sudo ./configure 
sudo make 
sudo make install 
sudo apt-get install libgsl0-dev 
 
# Install BEDtools 2.25.0-1 
sudo apt-get install bedtools 
 
# Prepare to install R/Bioconductor packages 
sudo chown $USER -R /usr/lib/R 
sudo chown $USER -R /usr/share/R 
sudo apt-get update 
sudo apt-get install r-base-html r-base-latex r-cran-rgtk2 r-cran-rggob
i r-cran-rgl libxml2-dev libcurl4-gnutls-dev 
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QC, TRIMMING, ALIGNMENT, AND COUNTS 
There are two different sets of technical replicates reflecting the runs from July 2016 (two 
replicates) and August 2016 (two replicates). QC and trimming was performed separately 







QC was performed with FastQC (version 0.11.5) in the terminal. Then, all FASTQ files 
were moved to a new directory. 
system("fastqc *.gz") 
dir.create("fastqc") 
system("mv *.zip *.html fastqc") 
The QC files show high-quality Q-scores across all sequences. There is minor adaptor 
contamination. Repetitive sequences are generally below 1% of all sequences in a given 
library and consist primarily of ribosomal RNA or adaptors. The replicates from the Ro 
knockout show low library complexity and unusual GC content (compared to the other 
libraries). This is likely because of the small amount of starting material. We were only 
able to obtain one replicate for the Ro knockout because the other replicates had too little 
material to sequence. Overall, the QC shows that the data is of high quality. 
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Trimming 
Command: trim_galore --fastqc -o trimmed_fastqc *.gz 
Adaptor/quality trimming was performed with Trim Galore (version 0.4.1) using Python 
2.7.11. Trim Galore is wrapped around cutadapt 1.10 and has many known adaptors pre-
loaded so they do not need to be specified in advance. The basic options for trim galore do 
not perform any aggressive trimming and in general, a high amount of trimming was not 
needed. 
dir.create("trimmed_fastqc") 
system("trim_galore --fastqc -o trimmed_fastqc *.gz") 
Alignment 
Command: tophat2 library-type fr-firststrand -G [GTF] -p 4 -o 
[library][index][files] 
For alignment, we first created a metatable to help organize all the different libraries which 
aids in downstream processing steps. The following code chunk also creates a new 
alignment directory: 
metaTable <- data.frame(LibraryName = c("DMSO1_T1", "DMSO1_T2", "DMSO2_
T1", "DMSO2_T2", 
                                        "RO_KO2_T1", "RO_KO2_T2", 
                                        "RO_RAP_KO1_T1", "RO_RAP_KO1_T2
", "RO_RAP_KO2_T1", "RO_RAP_KO2_T2", "RO_RAP_KO3_T1", "RO_RAP_KO3_T2", 
                                        "RO_RAP_WT1_T1", "RO_RAP_WT1_T2
", "RO_RAP_WT2_T1", "RO_RAP_WT2_T2", "RO_RAP_WT3_T1", "RO_RAP_WT3_T2", 
                                        "RO_WT1_T1", "RO_WT1_T2", "RO_W
T2_T1", "RO_WT2_T2", "RO_WT3_T1", "RO_WT3_T2", 
                                        "SAL_KO1_T1", "SAL_KO1_T2", "SA
L_KO2_T1", "SAL_KO2_T2", "SAL_KO3_T1", "SAL_KO3_T2", 
                                        "SAL_WT1_T1", "SAL_WT1_T2", "SA
L_WT2_T1", "SAL_WT2_T2", "SAL_WT3_T1", "SAL_WT3_T2", 
                                        "TOT1_T1", "TOT1_T2", "TOT2_T1"
, "TOT2_T2", "TOT3_T1", "TOT3_T2"), 
                        LibraryLayout = rep("SINGLE", 42), 
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                        fastq = grep("fq.gz", list.files(getwd()), valu
e = T), 
                        condition = c(rep("CTL", 4), rep("KO", 8), rep(
"WT", 12), rep("KO", 6), rep("WT", 6), rep("TOT", 6)), 
                        technical = rep(1:2, 21)) 
 




Gene model annotations (mm9) were downloaded from Ensembl.org and pre-built 
reference indices were downloaded from the Illumina website. 












To align reads to genome, we used Tophat 2.1.1, Bowtie 2.2.9, and samtools 0.1.19. The 
gtf and index variables are strings leading to the directory where these files are stored. The 
library type was specified as fr-firststrand in accordance with the library prep protocol. 
### Move all trimmed FASTQ data files to the alignment directory 
setwd("..") 










### Create a vector that stores the tophat terminal commands for each f
ile 
tophat <- with(metaTable, paste("tophat2 --library-type fr-firststrand 
-G ", gtf, "-p 4 -o", LibraryName, index, fastq)) 
 
### This loop runs all the tophat commands in the terminal 
for(i in 1:length(tophat)) { 
  system(tophat[i]) 
} 
We created a table from the alignment results file found in each Tophat alignment file. 
These data can be found in the full_alignment_summary.csv file. 
output = data.frame() 
 
for(i in 1:length(metaTable$LibraryName)) { 
  dat <- read.table(paste(metaTable[i,1], "/align_summary.txt", sep = "
"), header = FALSE, sep = "\t", fill = TRUE, stringsAsFactors = FALSE) 
  input <- substr(dat[2,1],25,nchar(dat[2,1])) 
  mapped <- substr(dat[3,1],25,nchar(dat[3,1])) 
  multiple <- substr(dat[4,1],26,nchar(dat[4,1])) 
  rate <- substr(dat[5,1], 1, nchar(dat[5,1])-1) 
   
  summary <- data.frame(metaTable[i,1], input, mapped, multiple, rate) 
   
  output <- rbind(output, summary) 
} 
 
names(output) <- c("Library", "Input_Reads", "Mapped_Reads", "Multiple_
Alignments", "Mapping_Rate") 
 
write.csv(output, "full_alignment_summary.csv")   # Save alignment stat
s to working dir 
The alignment data shows that most libraries had relative strong alignment percentages 
(greater than 75%). The only exception to this is the Ro KO replicate 2. As mentioned 
previously, there was very low starting material for this library and low library complexity. 
While some of this can be explaining through ribosomal sequence contamination, there are 
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also further sequences in this sample that may be useful in differential gene expression 
analysis. Thus, we have opted not to remove this library. 
Calculate counts from BAM files 
We used Rsubread 1.20.6 to calculate counts. The strandSpecific = 2 option was chosen in 
accordance with the library prep protocol. We used the countMultiMappingReads = TRUE 
option specifically for the purpose of counting ambiguously mapped reads. At this point, 
all BAM files from both runs (July 2016 and August 2016) were combined into one 
directory so that the the final output includes counts for four technical replicates. 
### Create an extry column for counts and a new vector that contains th
e directory for all the BAM files from Tophat output 
metaTable$Counts <- paste(metaTable$LibraryName, "count", sep = ".") 





gtfDir <- file.path(path, "Mus_musculus.GRCm38.84.gtf") 
 
### Run Rsubread on all BAM files 
for(i in 1:length(metaTable$LibraryName)) { 
  assign(paste0(metaTable[i,1],"_Count"), featureCounts(alignmentFilesD
ir[i],  
                                                        annot.ext = gtf
Dir,  
                                                        isGTFAnnotation
File = T,  
                                                        isPairedEnd = F
ALSE, 
                                                        countMultiMappi
ngReads = TRUE, 
                                                        strandSpecific 
= 2, 
                                                        nthreads = 4)) 
} 
 
### Bind columns together into one dataframe and export 
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listObjects <- lapply(grep("*Count",ls(), value = T), get) 
countData <- as.data.frame(lapply(listObjects, function(x) x$counts)) 
names(countData) <- metaTable$LibraryName 
write.csv(countData, "countData.csv")    
Session info 
## R version 3.3.2 (2016-10-31) 
## Platform: x86_64-pc-linux-gnu (64-bit) 
## Running under: Ubuntu 16.04.1 LTS 
##  
## locale: 
##  [1] LC_CTYPE=en_US.UTF-8       LC_NUMERIC=C               
##  [3] LC_TIME=en_US.UTF-8        LC_COLLATE=en_US.UTF-8     
##  [5] LC_MONETARY=en_US.UTF-8    LC_MESSAGES=en_US.UTF-8    
##  [7] LC_PAPER=en_US.UTF-8       LC_NAME=C                  
##  [9] LC_ADDRESS=C               LC_TELEPHONE=C             
## [11] LC_MEASUREMENT=en_US.UTF-8 LC_IDENTIFICATION=C        
##  
## attached base packages: 
## [1] stats     graphics  grDevices utils     datasets  methods   base      
##  
## loaded via a namespace (and not attached): 
##  [1] backports_1.0.4 magrittr_1.5    rprojroot_1.1   tools_3.3.2     
##  [5] htmltools_0.3.5 yaml_2.1.14     Rcpp_0.12.8     stringi_1.1.2   
##  [9] rmarkdown_1.2   knitr_1.15.1    stringr_1.1.0   digest_0.6.10   
## [13] evaluate_0.10 
 
POST-PROCESSING QC 
Here we perform some exploratory data analysis in order to confirm the quality of our data. 
This includes PCA, hierarchical clustering between the different groups, and correlation of 









Load data and process 
The count data from the different sequencing runs are loaded and combined together into 
one unit. Next, a metatable is created for easier downstream processing. Then, technical 
replicates are collapsed by DESeq2 to create the final dataset used for the QC analysis. We 
apply the regularized log transformation to the data so that it is more Gaussian, a 
requirement for the QC methods. 
### Load count data 
countData1 <- read.csv("countData_july.csv", header = TRUE) 
rownames(countData1) <- countData1[ ,1] 
countData1[ ,1] <- NULL 
 
countData2 <- read.csv("countData_aug.csv", header = TRUE) 
countData2[ ,1] <- NULL 
names(countData2) <- gsub("_T1", "_T3", names(countData2)) 
names(countData2) <- gsub("_T2", "_T4", names(countData2)) 
 
countData <- cbind(countData1, countData2) %>% as.data.frame() 
 
### Create metatable 
metaTable <- data.frame(LibraryName = names(countData), 
                        technical = c(rep(1:2, 21), rep(3:4, 21))) 
 
metaTable$LibraryName <- as.factor(metaTable$LibraryName) 
metaTable$technical <- as.factor(metaTable$technical) 
metaTable$Counts <- paste(metaTable$LibraryName, "count", sep = ".") 
 
rownames(metaTable) <- metaTable[ ,1]   # Set first column to row names 
metaTable[ ,1] <- NULL 
 
### Collapse technical replicates 
dd <- DESeqDataSetFromMatrix(countData = countData, 
                             colData = metaTable, 
                             design = ~ technical) 
 
dd$technical <- gsub("_T1|_T2|_T3|_T4", "", row.names(metaTable)) 
ddRep <- collapseReplicates(dd, groupby = dd$technical) 
ddRep$technical <- as.factor(ddRep$technical) 
 
### rlog transformation of data 
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rd <- rlog(ddRep) 
ddRep <- estimateSizeFactors(ddRep) 
rdCounts <- assay(rd) %>% as.data.frame() 
Count correlations 
A simple way to visualize the precision of our independent biological replicates is simply 
by graphing their counts against each other. We expect a high correlation between all 
different groups. The data shows a high amount of correlation between log-transformed 
counts among the different groups. 
### Saline WT scatterplots 
p2 <- ggplot(rdCounts, aes(SAL_WT1, SAL_WT2)) + 
  geom_point(size = 0.5, alpha = 0.3) + 
  theme_bw() 
 
p3 <- ggplot(rdCounts, aes(SAL_WT2, SAL_WT3)) + 
  geom_point(size = 0.5, alpha = 0.3) + 
  theme_bw() 
 
p4 <- ggplot(rdCounts, aes(SAL_WT1, SAL_WT3)) + 
  geom_point(size = 0.5, alpha = 0.3) + 
  theme_bw() 
 
### Saline KO scatterplots 
p5 <- ggplot(rdCounts, aes(SAL_KO1, SAL_KO2)) + 
  geom_point(size = 0.5, alpha = 0.3) + 
  theme_bw() 
 
p6 <- ggplot(rdCounts, aes(SAL_KO2, SAL_KO3)) + 
  geom_point(size = 0.5, alpha = 0.3) + 
  theme_bw() 
 
p7 <- ggplot(rdCounts, aes(SAL_KO1, SAL_KO3)) + 
  geom_point(size = 0.5, alpha = 0.3) + 
  theme_bw() 
 
### Ro WT scatterplots 
p8 <- ggplot(rdCounts, aes(RO_WT1, RO_WT2)) + 
  geom_point(size = 0.5, alpha = 0.3) + 
  theme_bw() 
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p9 <- ggplot(rdCounts, aes(RO_WT2, RO_WT3)) + 
  geom_point(size = 0.5, alpha = 0.3) + 
  theme_bw() 
 
p10 <- ggplot(rdCounts, aes(RO_WT1, RO_WT3)) + 
  geom_point(size = 0.5, alpha = 0.3) + 
  theme_bw() 
 
### Ro KO histogram 
p11 <- ggplot(rdCounts, aes(RO_KO2, RO_KO2)) + 
  geom_point(size = 0.5, alpha = 0.3) + 
  theme_bw() 
 
### Ro Rap WT scatterplots 
p12 <- ggplot(rdCounts, aes(RO_RAP_WT1, RO_RAP_WT2)) + 
  geom_point(size = 0.5, alpha = 0.3) + 
  theme_bw() 
 
p13 <- ggplot(rdCounts, aes(RO_RAP_WT2, RO_RAP_WT3)) + 
  geom_point(size = 0.5, alpha = 0.3) + 
  theme_bw() 
 
p14 <- ggplot(rdCounts, aes(RO_RAP_WT1, RO_RAP_WT3)) + 
  geom_point(size = 0.5, alpha = 0.3) + 
  theme_bw() 
 
### Ro Rap KO scatterplots 
p15 <- ggplot(rdCounts, aes(RO_RAP_KO1, RO_RAP_KO2)) + 
  geom_point(size = 0.5, alpha = 0.3) + 
  theme_bw() 
 
p16 <- ggplot(rdCounts, aes(RO_RAP_KO2, RO_RAP_KO3)) + 
  geom_point(size = 0.5, alpha = 0.3) + 
  theme_bw() 
 
p17 <- ggplot(rdCounts, aes(RO_RAP_KO1, RO_RAP_KO3)) + 
  geom_point(size = 0.5, alpha = 0.3) + 
  theme_bw() 
 
### Fully arranged (766 x 673) 
grid.arrange(p2, p3, p4, p5, 
             p6, p7, p8, p9, 
             p10, p11, p12, p13, 
             p14, p15, p16, p17, 
             ncol = 4, 




Figure D.1: Count correlations between RIP-seq libraries 
Principal component analysis (PCA) 
Principal component analysis is another means of visualizing the similarity in count 
measurements between the different groups. The adjusted axes allow us to see whether or 
not the different groups cluster together. The data shows that each replicate for WT and 
KO cluster together due to similarity in variance. The only notable exception is the saline 
KO replicate 2 which is slightly off compared to the others. Similarly, the Ro KO replicate 
2 is also quite far off from the others. This is not completely unexpected however, since 
we did note a poor alignment rate and unusual QC from the FastQC files. 
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# Arrange variables for plotting with ggplot2 
rdNoTotal <- rd[ ,rd$technical %in% colData(rd)[3:18, 1]] 
pcaDatNoTotal <- plotPCA(rdNoTotal, intgroup = "technical", returnData 
= TRUE) 
percentVar <- round(100 * attr(pcaDatNoTotal, "percentVar")) 
 
ggplot(pcaDatNoTotal, aes(PC1, PC2, color = technical, label = name)) + 
  geom_point(size = 3) + 
  geom_text(aes(label = name), size = 3, hjust = 0.3, vjust = -0.5) + 
  xlab(paste0("PC1: ",percentVar[1],"% variance")) + 
  ylab(paste0("PC2: ",percentVar[2],"% variance")) + 
  geom_hline(aes(yintercept = 0)) + 
  geom_vline(aes(xintercept = 0)) + 
  scale_color_manual(values = c(rep("darkolivegreen3", 1), rep("cadetbl
ue3", 3), rep("dodgerblue3", 3), rep("chartreuse4", 3), rep("lightcoral
", 3), rep("firebrick", 3))) + 
  theme_bw() + 
  theme(legend.position = "none") 
 
Euclidean distance matrix 
Finally, we used a clustered heatmap to visualize the similarity between the different 
samples. Overall, many groups clustered together though some replicates, particularly the 
Saline KO replicate 2, clustered better with other libraries than it did its own replicates. It 
is contained in a branch on its own which is a parent branch to two other libraries Ro+Rapa 
KO replicate 2 and Saline KO replicate 3 which are also off on their own. In general, since 
the KO libraries are constructed from null-antibody tissue we expect their to be some level 
of background binding that will be inconsistant among the different samples. Since the 
wild-type material clusters together properly, we have kept all libraries in going forward. 
sampleDists <- dist(t(assay(rdNoTotal))) 
 
sampleDistMatrix <- as.matrix(sampleDists) 
rownames(sampleDistMatrix) <- colnames(rdNoTotal) 
colnames(sampleDistMatrix) <- NULL 
colors <- colorRampPalette(rev(brewer.pal(9, "Blues")))(255) 
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pheatmap(sampleDistMatrix, 
         clustering_distance_rows = sampleDists, 
         clustering_distance_cols = sampleDists, 
         col = colors) 
Session info 
sessionInfo() 
## R version 3.3.2 (2016-10-31) 
## Platform: x86_64-pc-linux-gnu (64-bit) 
## Running under: Ubuntu 16.04.1 LTS 
##  
## locale: 
##  [1] LC_CTYPE=en_US.UTF-8       LC_NUMERIC=C               
##  [3] LC_TIME=en_US.UTF-8        LC_COLLATE=en_US.UTF-8     
##  [5] LC_MONETARY=en_US.UTF-8    LC_MESSAGES=en_US.UTF-8    
##  [7] LC_PAPER=en_US.UTF-8       LC_NAME=C                  
##  [9] LC_ADDRESS=C               LC_TELEPHONE=C             
## [11] LC_MEASUREMENT=en_US.UTF-8 LC_IDENTIFICATION=C        
##  
## attached base packages: 
## [1] parallel  stats4    stats     graphics  grDevices utils     data
sets  
## [8] methods   base      
##  
## other attached packages: 
##  [1] RColorBrewer_1.1-2         pheatmap_1.0.8             
##  [3] gridExtra_2.2.1            ggplot2_2.2.0              
##  [5] magrittr_1.5               DESeq2_1.14.0              
##  [7] SummarizedExperiment_1.4.0 Biobase_2.34.0             
##  [9] GenomicRanges_1.26.1       GenomeInfoDb_1.10.1        
## [11] IRanges_2.8.1              S4Vectors_0.12.0           
## [13] BiocGenerics_0.20.0        
##  
## loaded via a namespace (and not attached): 
##  [1] genefilter_1.56.0    locfit_1.5-9.1       splines_3.3.2        
##  [4] lattice_0.20-34      colorspace_1.3-1     htmltools_0.3.5      
##  [7] yaml_2.1.14          survival_2.40-1      XML_3.98-1.5         
## [10] foreign_0.8-67       DBI_0.5-1            BiocParallel_1.8.1   
## [13] plyr_1.8.4           stringr_1.1.0        zlibbioc_1.20.0      
## [16] munsell_0.4.3        gtable_0.2.0         evaluate_0.10        
## [19] memoise_1.0.0        labeling_0.3         latticeExtra_0.6-28  
## [22] knitr_1.15.1         geneplotter_1.52.0   AnnotationDbi_1.36.0 
## [25] htmlTable_1.7        Rcpp_0.12.8          acepack_1.4.1        
## [28] xtable_1.8-2         scales_0.4.1         backports_1.0.4      
## [31] Hmisc_4.0-0          annotate_1.52.0      XVector_0.14.0       
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## [34] digest_0.6.10        stringi_1.1.2        grid_3.3.2           
## [37] rprojroot_1.1        tools_3.3.2          bitops_1.0-6         
## [40] lazyeval_0.2.0       RCurl_1.95-4.8       tibble_1.2           
## [43] RSQLite_1.1          Formula_1.2-1        cluster_2.0.5        
## [46] Matrix_1.2-7.1       data.table_1.9.8     assertthat_0.1       
## [49] rmarkdown_1.2        rpart_4.1-10         nnet_7.3-12 
COUNT NORMALIZATION 
Here we annotate our data in official gene symbol format and apply DESeq2 factor size 
normalization across all our libraries. We also perform filtering and some visualization of 











The squash() function simply scales any data between 0-100 for easier visualization and 
comparison. 
squash <- function(x) { 
  output <- ((x - min(x)) / (max(x) - min(x))) * 100 
  return(output) 
} 
The percentChange() function calculates the percent a measure changes from its baseline. 
percentChange <- function(new, old) { 




We used HTSFilter 1.14.1 to filter the data using the standard settings. 
countData <- read.csv(file = "combinedCounts.csv", header = TRUE) 
rownames(countData) <- countData[ ,1] 
countData[ ,1] <- NULL 
 
countData$RO_KO1 <- countData$RO_KO2 
countData$RO_KO3 <- countData$RO_KO2 
 
cdMain <- subset(countData, select = c(16:18, 13:15, 10:12, 3, 22, 23, 
7:9, 4:6)) 
conds <- sapply(names(cdMain), function(x) substr(x, 1, nchar(x)-1)) %>
% unname 
 
filter <- HTSFilter(x = cdMain,  
                    conds = conds, 
                    normalization = "none") 
 
Figure D.2: Global Jaccard index for low count filter 
 280 
cdFilter <- as.data.frame(filter$filteredData) 
cdFilter[ ,c(11, 12)] <- NULL   # Remove duplicated Ro KO columns 
Annotation (official gene symbol)  
Annotation weas performed with the Bioconductor packages org.Mm.eg.db and 
AnnotationDbi. Any sequences that did not map to a gene qualifier were filtered out of 
the dataset. 
cdFilter$symbol <- mapIds(org.Mm.eg.db, 
                      keys = row.names(cdFilter), 
                      column = "SYMBOL", 
                      keytype = "ENSEMBL", 
                      multiVals = "first") 
 
### Remove rows with no gene mapping 
cdFilter <- subset(cdFilter, select = c(17, 1:16)) 
cdFilter <- cdFilter[complete.cases(cdFilter), ] 
rownames(cdFilter) <- make.names(cdFilter$symbol, unique = TRUE) 
cdFilter[ ,1] <- NULL 
Count normalization (DESeq2 factor size) 
First, we create a metatable to organize the data. Next, the data is loaded into DESeq2. 
Since DESeq2 scaling applies across the entire library, it inflates the counts from our KO 
libraries. To fix this, we scale back the KO counts using ratios between WT and KO counts 
obtained from the BioAnalyzer results prior to sequencing. Then, all counts were collapsed 
by averaging across rows. 
### Create metatable 
metaTable <- data.frame(LibraryName = names(cdFilter), 
                        LibraryLayout = rep("SINGLE", 16), 
                        condition = c(rep("WT", 3), rep("KO", 3), rep("
WT", 3), "KO", rep("WT", 3), rep("KO", 3))) 
rownames(metaTable) <- metaTable[ ,1]   # Set first column to row names 
metaTable[ ,1] <- NULL 
 
### Get normalized counts 
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dd <- DESeqDataSetFromMatrix(countData = cdFilter, 
                               colData = metaTable, 
                               design = ~ 1) 
dd <- estimateSizeFactors(dd) 
nc <- as.data.frame(counts(dd, normalize = TRUE)) 
 
### Scale by BioAnalyzer values 
BA <- read.csv("BA_values.csv", header = TRUE, stringsAsFactors = FALSE
) 
BA$mean <- rowMeans(BA[ ,2:4], na.rm = TRUE) 
 
scale <- c(RO = BA$mean[2] / BA$mean[5], 
           RO_RAP = BA$mean[3] / BA$mean[4], 
           SAL = BA$mean[6] / BA$mean[7]) 
 
cdFilterScaled <- nc 
 
cdFilterScaled[ ,10] <- cdFilterScaled[ ,10] / (scale[1] + 1)         # 
Scale Ro 
cdFilterScaled[ ,14:16] <- cdFilterScaled[ ,14:16] / (scale[2] + 1)   # 
Scale Ro Rap 
cdFilterScaled[ ,4:6] <- cdFilterScaled[ ,4:6] / (scale[3] + 1)       # 
Scale Sal 
 
### Average across rows 
nscMean <- data.frame(row.names = row.names(cdFilterScaled), 
                     SAL_WT = rowMeans(cdFilterScaled[ ,1:3]), 
                     SAL_KO = rowMeans(cdFilterScaled[ ,4:6]), 
                     RO_WT = rowMeans(cdFilterScaled[ ,7:9]), 
                     RO_KO = cdFilterScaled[ ,10], 
                     RO_RAP_WT = rowMeans(cdFilterScaled[ ,11:13]), 
                     RO_RAP_KO = rowMeans(cdFilterScaled[ ,14:16])) %>% 
squash() 
Visualize normalized counts 
For count visualization, we first plotted the WT and KO counts be each treatment 
### Create variables for plotting with ggplot2 
nscMean.m <- melt(nscMean) 
nscMean.m$Genotype <- c(rep("WT", 14543), rep("KO", 14543), rep("WT", 1
4543), rep("KO", 14543), rep("WT", 14543), rep("KO", 14543)) 
nscMean.m$variable <- c(rep("Saline", 29086), rep("Ro-25-6981", 29086), 
rep("Ro-25-6981 + Rapamycin", 29086)) 
nscMean.m$varOrder <- factor(nscMean.m$variable, levels = c("Saline", "
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Ro-25-6981", "Ro-25-6981 + Rapamycin")) 
 
### Plot WT v. KO by treatment 
ggplot(nscMean.m, aes(x = Genotype, y = value, color = Genotype)) + 
  geom_point(position = position_jitter(width = 0.2, height = 0.2)) + 
  facet_grid(~ varOrder) + 
  xlab("") + 
  ylab("Scaled Counts") + 
  theme_few() + 
  theme(axis.ticks.x = element_blank(), 
        axis.text.x = element_blank()) 
 
Next, we plotted WT and KO counts with known FMRP targets and non-targets (Darnell 
et al., 2011) 
### Load targets and non-targets 
targets <- c("Gabbr1", "Gabbr2","Nisch", "Prrc2a", "Kif1a", "Grin2a", "
Adgrb2", "Cyfip2", "Map1b", "Bsn", "Adcy1", "Pde2a", "Lingo1", "Grin2b"
) 
nontargets <- c("Pabpc1", "Tmem65", "Hprt1", "St8sia3", "Sae1", "Glrb", 
"Gria2", "Tcerg1", "Eif3a", "Slc35f1", "Atp6ap2", "Vldlr") 
 
### Prepare variables for plotting 
nscRawTargets <- nscMean[row.names(nscMean) %in% c(targets, nontargets)
, ] %>% squash() 
nscRawTargets$targets <- ifelse(row.names(nscRawTargets) %in% targets, 
"Target", "Non-target") 
nscRawTargets.m <- melt(nscRawTargets) 
nscRawTargets.m$Genotype <- c(rep("WT", 25), rep("KO", 25), rep("WT", 2
5), rep("KO", 25), rep("WT", 25), rep("KO", 25)) 
nscRawTargets.m$variable <- c(rep("Saline", 50), rep("Ro-25-6981", 50), 
rep("Ro-25-6981 + Rapamycin", 50)) 
nscRawTargets.m$group <- rep(1:25, 6) 
nscRawTargets.m$varOrder <- factor(nscRawTargets.m$variable, levels = c
("Saline", "Ro-25-6981", "Ro-25-6981 + Rapamycin")) 
nscRawTargets.m$GenotypeOrder <- factor(nscRawTargets.m$Genotype, level
s = c("WT", "KO")) 
 
### Plot WT v. KO for FMRP targets and non-targets 
ggplot(nscRawTargets.m, aes(x = GenotypeOrder, y = value, group = group
, color = targets)) + 
  geom_point() + 
  geom_line() + 
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  facet_grid(~ varOrder) + 
  xlab("") + 
  ylab("Scaled Counts") + 
  theme_few() + 
  scale_color_discrete(name = "FMRP Targets") 
 
Finally, for the percent changes between targets and non-targets reported in the paper, we 
simply calculated the percent changes across all the dataframe for the mean normalized 
(scaled) counts. 
new <- nscRawTargets[nscRawTargets$targets == "Target", 1:6] %>% colMea
ns() 
old <- nscRawTargets[nscRawTargets$targets == "Non-target", 1:6] %>% co
lMeans() 
 
percentChange(new[1], old[1]) %>% round(2) 
## SAL_WT  
##  333.9 
percentChange(new[3], old[3]) %>% round(2) 
##  RO_WT  
## 369.29 
percentChange(new[5], old[5]) %>% round(2) 
## RO_RAP_WT  
##    365.35 
Session info 
sessionInfo() 
## R version 3.3.2 (2016-10-31) 
## Platform: x86_64-pc-linux-gnu (64-bit) 
## Running under: Ubuntu 16.04.1 LTS 
##  
## locale: 
##  [1] LC_CTYPE=en_US.UTF-8       LC_NUMERIC=C               
##  [3] LC_TIME=en_US.UTF-8        LC_COLLATE=en_US.UTF-8     
##  [5] LC_MONETARY=en_US.UTF-8    LC_MESSAGES=en_US.UTF-8    
##  [7] LC_PAPER=en_US.UTF-8       LC_NAME=C                  
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##  [9] LC_ADDRESS=C               LC_TELEPHONE=C             
## [11] LC_MEASUREMENT=en_US.UTF-8 LC_IDENTIFICATION=C        
##  
## attached base packages: 
## [1] parallel  stats4    stats     graphics  grDevices utils     data
sets  
## [8] methods   base      
##  
## other attached packages: 
##  [1] ggthemes_3.3.0             reshape2_1.4.2             
##  [3] ggplot2_2.2.0              magrittr_1.5               
##  [5] HTSFilter_1.14.1           org.Mm.eg.db_3.4.0         
##  [7] AnnotationDbi_1.36.0       DESeq2_1.14.0              
##  [9] SummarizedExperiment_1.4.0 Biobase_2.34.0             
## [11] GenomicRanges_1.26.1       GenomeInfoDb_1.10.1        
## [13] IRanges_2.8.1              S4Vectors_0.12.0           
## [15] BiocGenerics_0.20.0        
##  
## loaded via a namespace (and not attached): 
##  [1] genefilter_1.56.0   locfit_1.5-9.1      splines_3.3.2       
##  [4] lattice_0.20-34     colorspace_1.3-1    htmltools_0.3.5     
##  [7] yaml_2.1.14         survival_2.40-1     XML_3.98-1.5        
## [10] foreign_0.8-67      DBI_0.5-1           BiocParallel_1.8.1  
## [13] RColorBrewer_1.1-2  plyr_1.8.4          stringr_1.1.0       
## [16] zlibbioc_1.20.0     munsell_0.4.3       gtable_0.2.0        
## [19] evaluate_0.10       memoise_1.0.0       labeling_0.3        
## [22] latticeExtra_0.6-28 knitr_1.15.1        geneplotter_1.52.0  
## [25] htmlTable_1.7       Rcpp_0.12.8         edgeR_3.16.4        
## [28] acepack_1.4.1       xtable_1.8-2        scales_0.4.1        
## [31] backports_1.0.4     limma_3.30.5        Hmisc_4.0-0         
## [34] annotate_1.52.0     XVector_0.14.0      gridExtra_2.2.1     
## [37] digest_0.6.10       DESeq_1.26.0        stringi_1.1.2       
## [40] grid_3.3.2          rprojroot_1.1       tools_3.3.2         
## [43] bitops_1.0-6        lazyeval_0.2.0      RCurl_1.95-4.8      
## [46] tibble_1.2          RSQLite_1.1         Formula_1.2-1       
## [49] cluster_2.0.5       Matrix_1.2-7.1      data.table_1.9.8    
## [52] assertthat_0.1      rmarkdown_1.2       rpart_4.1-10        
## [55] nnet_7.3-12 
DATA FILTERING 
This section contains all the code needed to generate the cutoff and filtration used for the 




















The cutoff() function is designed to create and above and below cutoff line using the 
consensus data sets. For every row in the data, it indicates the percentage of genes that are 
now included in the cutoff point. 
cutoff <- function(range) { 
   
  above <- table(fullDist[range,"B_D_A_RipDist"]) + 
    table(fullDist[range,"B_D_A_ParDist"]) + 
    table(fullDist[range,"B_DDist"]) + 
    table(fullDist[range,"D_A_ParDist"]) 
   
   
  below <- table(fullDist[length(range):nrow(ncAvg),"B_D_A_RipDist"]) + 
    table(fullDist[length(range):nrow(ncAvg),"B_D_A_ParDist"]) + 
    table(fullDist[length(range):nrow(ncAvg),"B_DDist"]) + 
    table(fullDist[length(range):nrow(ncAvg),"D_A_ParDist"]) 
   
  return((above / (above + below)))  
} 
The annotation function anno() is used as a quick way to annotate the columns of the count 
data returned from Tophat (they are normally in Enterez format). 
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anno <- function(x) { 
  require(AnnotationDbi) 
  require(org.Mm.eg.db) 
   
  ### Annotate 
  x$symbol <- mapIds(org.Mm.eg.db, 
                     keys = row.names(x), 
                     column = "SYMBOL", 
                     keytype = "ENSEMBL", 
                     multiVals = "first") 
   
  ### Remove rows with no gene mapping 
  x <- subset(x, select = c(17,1:16)) 
  x <- x[complete.cases(x), ] 
  rownames(x) <- make.names(x$symbol, unique = TRUE) 
  x[ ,1] <- NULL 
   
  return(x) 
} 
Load data 
The count data (filtered for low counts) is loaded here. Replicates are averaged at the saline 
list is ordered by highest counts. 
nc <- read.csv("finalCountData.csv", header = TRUE) 
rownames(nc) <- nc[ ,1] 
nc <- nc[ ,-1] 
 
ncAvg <- data.frame(SAL_WT = rowMeans(nc[ ,1:3]), 
                    SAL_KO = rowMeans(nc[ ,4:6]), 
                    RO_WT = rowMeans(nc[ ,7:9]), 
                    RO_KO = nc[ ,10], 
                    RO_RAP_WT = rowMeans(nc[ ,11:13]), 
                    RO_RAP_KO = rowMeans(nc[ ,14:16])) 
 
ncAvg <- ncAvg[order(ncAvg$SAL_WT, decreasing = TRUE), ] 
Determining initial cutoff by comparison to other data 
We will first be loading all targets from previous data into R. The Miyashiro and Ascano 
data will be excluded from the final plotting because it does not have much in common 
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with our list (similar to what was found by Suhl et al. (Suhl et al., 2014)). However, we are 
still providing their data in the code below. The consensus overlap lists from Suhl et al. are 
also included below. 
### Brown data 
brownDat <- read.xlsx("brown_list.xls", sheetIndex = 1, header = TRUE, 
startRow = 2) 
brownProbes <- brownDat[ ,"Probe.Set"] %>% as.vector() 
probes <- as.list(mgu74aALIAS2PROBE) 
brownGenes <- probes[probes %in% brownProbes] %>% unlist() %>% names() 
 
### Darnell data 
darnellDat <- read.xlsx("darnell_list.xls", sheetIndex = 1, header = TR
UE, startRow = 2) 
darnellGenes <- darnellDat[ ,"Symbol.from.mm9"] %>% as.vector() 
 
### Ascano PAR-CLIP data 
ascanoParDat <- read.xlsx("ascano_par.xlsx", sheetIndex = 1, header = T
RUE, startRow = 3, colIndex = 1:4) 
ascanoParGenes <- ascanoParDat[ascanoParDat$Total.mRNA.binding.sites > 
0, "Gene"] %>% as.vector() 
 
### Ascano RIP-CHIP data 
ascanoRipDat <- read.csv("ascano_rip.csv", header = TRUE, na.strings = 
"") 
ascanoRipDat <- ascanoRipDat[ ,c(1,3)] 
ascanoRipDat <- split(ascanoRipDat, ascanoRipDat$Target.bin) 
ascanoRipDat <- ascanoRipDat$Target 
ascanoRipGenes <- ascanoRipDat[ ,1] %>% as.vector() 
 
### Miyashiro data 
miyashiroDat <- read.csv("miyashiro.csv", header = TRUE) 
miyashiroDat <- miyashiroDat[-c(1,1153:1159), ] 
miyashiroDat <- miyashiroDat[ ,"UniGene"] %>% as.data.frame() 
names(miyashiroDat) <- "unigene" 
miyashiroDat$unigene <- as.character(miyashiroDat$unigene) 
miyashiroDat$symbol <- mapIds(org.Hs.eg.db, 
                            keys = miyashiroDat$unigene, 
                            column = "SYMBOL", 
                            keytype = "UNIGENE", 
                            multiVals = "first") 
miyashiroGenes <- miyashiroDat$symbol %>% na.omit() %>% as.vector() 
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### Consensus data 
BDARIP <- read.xlsx("consensus_FMRP.xlsx", sheetIndex = 2, header = FAL
SE, startRow = 2, stringsAsFactors = FALSE)$X1 
BDAPAR <- read.xlsx("consensus_FMRP.xlsx", sheetIndex = 3, header = FAL
SE, startRow = 2, stringsAsFactors = FALSE)$X1 
BD <- read.xlsx("consensus_FMRP.xlsx", sheetIndex = 4, header = FALSE, 
startRow = 2, stringsAsFactors = FALSE)$X1 
DAPAR <- read.xlsx("consensus_FMRP.xlsx", sheetIndex = 5, header = FALS
E, startRow = 2, stringsAsFactors = FALSE)$X1 
Using the above data, we can now construct a large table that includes all the genes in long 
format for plotting with ggplot2. The code below also has a few extra details to get the 
factor levels in the correct order. 
### Distributions across ranked saline genes for full data sets 
fullDist <- data.frame(row.names = row.names(ncAvg) %>% toupper(), 
                       order = 1:nrow(ncAvg), 
                       brownDist = ifelse((row.names(ncAvg) %>% toupper
()) %in% (brownGenes %>% toupper()), "Brown", NA), 
                       darnellDist = ifelse((row.names(ncAvg) %>% toupp
er()) %in% (darnellGenes %>% toupper()), "Darnell", NA), 
                       ascanoParDist = ifelse((row.names(ncAvg) %>% tou
pper()) %in% (ascanoParGenes %>% toupper()), "Ascano PAR-CLIP", NA), 
                       ascanoRipDist = ifelse((row.names(ncAvg) %>% tou
pper()) %in% (ascanoRipGenes %>% toupper()), "Ascano RIP-CHIP", NA), 
                       miyashiroRipDist = ifelse((row.names(ncAvg) %>% 
toupper()) %in% (miyashiroGenes %>% toupper()), "Miyashiro", NA), 
                       B_D_A_RipDist = ifelse((row.names(ncAvg) %>% tou
pper()) %in% (BDARIP %>% toupper()), "B_D_A-RIP", NA), 
                       B_D_A_ParDist = ifelse((row.names(ncAvg) %>% tou
pper()) %in% (BDAPAR %>% toupper()), "B_D_A-PAR", NA), 
                       B_DDist = ifelse((row.names(ncAvg) %>% toupper()
) %in% (BD %>% toupper()), "B_D", NA), 
                       D_A_ParDist = ifelse((row.names(ncAvg) %>% toupp
er()) %in% (DAPAR %>% toupper()), "D_A-PAR", NA)) 
 
fullDist.m <- melt(fullDist, id.vars = "order") 
 
fullDist.m$value <- factor(fullDist.m$value, levels = rev(c("Darnell", 
"Brown", "B_D_A-RIP", "B_D_A-PAR", "B_D", "D_A-PAR", "Ascano PAR-CLIP", 
"Ascano RIP-CHIP", "Miyashiro"))) 
fullDist.m$variable <- factor(fullDist.m$variable, levels = rev(c("darn
ellDist", "brownDist", "B_D_A_RipDist", "B_D_A_ParDist", "B_DDist", "D_
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A_ParDist", "ascanoParDist", "ascanoRipDist", "miyashiroRipDist"))) 
 
fullDist.m <- fullDist.m[complete.cases(fullDist.m), ] 
Next, we constructed a cutoff line that was able to capture 95% of the genes within the 
consensus data list. To do this, we use the cutoff() function described above. For each gene 
in the data that is included it reports the overlap percentage with the consesus list once the 
for loop is run. Note that the for loop could be better optimized as it takes quite a while to 
run. The final data frame orderedCoverage contains all the info as a percentage. 
### Above/below cutoff line 
coverage = NULL 
for(i in 1:nrow(ncAvg)) { 
  coverage[i] <- cutoff(1:i) 
} 
 
orderedCoverage <- data.frame(order = 1:nrow(ncAvg), 
                              coverage = coverage * 100) 
Finally, the data is filtered by including 95% of the genes that overlap with the other data 
sets. There are two graphs show below. One shows each gene found in our data with the 
other data sets and shows the cutoff line (shown in red). The bottom graph then shows the 
percentage of genes that overlap within each row of our ordered data set using the 
information from orderedCoverage(). The filtered list (4120 genes in total) will now be used 
moving forward for the next filtration steps. 
consensusCutoff <- orderedCoverage[orderedCoverage$coverage < 95, ] %>% 
nrow() 
 
### Consensus percentage graph 
a <- ggplot(orderedCoverage, aes(x = order, y = coverage)) + 
  geom_line() + 
  geom_vline(xintercept = consensusCutoff, color = "red", linetype = "d
ashed") + 
  xlab("Ranked Saline Genes") + 
 290 
  ylab("Percent Consensus Lists in Cutoff") + 
  theme_bw() 
 
### Consensus overlap graph 
b <- ggplot(fullDist.m, aes(x = order, y = value)) + 
  geom_point(alpha = 0.75, color = "dodgerblue") + 
  geom_vline(xintercept = consensusCutoff, color = "red", linetype = "d
ashed") + 
  xlab("") + 
  ylab("") + 
  theme_bw() 
 
### Fully arranged graphs 
gA <- ggplotGrob(a) 




Determining KO cutoff by comparison to other data 
We have taken two approaches to removing high background counts. The first approach is 
show here. We know potential targets and non-targets from previous data (Darnell et al., 
2011). By determining the enrichment ratio between WT and KO for a given treatment, we 
can see where distributions of enrichment ratios for the targets or non-targets fall for all 
the consensus data sets. Using this, we can calibrate and approximate acceptable range of 
background for our cutoff. 
### Create enrichment ratios of WT over KO for each treatment 
ncAvgDif <- data.frame(row.names = row.names(ncAvg), 
                       SAL = ncAvg$SAL_WT / ncAvg$SAL_KO, 
                       RO = ncAvg$RO_WT / ncAvg$RO_KO, 
                       RO_RAP = ncAvg$RO_RAP_WT / ncAvg$RO_RAP_KO) 
 
### Load targets and non-targets 
targets <- c("Gabbr1", "Gabbr2", "Nisch", "Prrc2a", "Kif1a", "Grin2a", 
"Adgrb2", "Cyfip2", "Map1b", "Bsn", "Adcy1", "Pde2a", "Lingo1", "Grin2b
") 
nontargets <- c("Pabpc1", "Tmem65", "Hprt1", "St8sia3", "Sae1", "Glrb", 
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"Gria2", "Tcerg1", "Eif3a", "Slc35f1", "Atp6ap2", "Vldlr") 
 
### Create a data frame that includes the overlap of genes with our dat
a set for each consensus gene list as well as the full Brown and Darnel
l lists 
foldRange <- rbind(data.frame(group = "Brown", value = ncAvgDif[row.nam
es(ncAvgDif) %in% brownGenes, ]$SAL), 
                   data.frame(group = "Darnell", value = ncAvgDif[row.n
ames(ncAvgDif) %in% darnellGenes, ]$SAL), 
                   data.frame(group = "B_D_A-RIP", value = ncAvgDif[(ro
w.names(ncAvgDif) %>% toupper()) %in% BDARIP, ]$SAL), 
                   data.frame(group = "B_D_A-PAR", value = ncAvgDif[(ro
w.names(ncAvgDif) %>% toupper()) %in% BDAPAR, ]$SAL), 
                   data.frame(group = "B_D", value = ncAvgDif[(row.name
s(ncAvgDif) %>% toupper()) %in% BD, ]$SAL), 
                   data.frame(group = "D_A-PAR", value = ncAvgDif[(row.
names(ncAvgDif) %>% toupper()) %in% DAPAR, ]$SAL), 
                   data.frame(group = "Non-Targets", value = ncAvgDif[r
ow.names(ncAvgDif) %in% nontargets, ]$SAL)) 
 
### Determine average enrichment ratio range between WT and KO for all 
groups 
foldRange.s <- split(foldRange, foldRange$group) 
 
### Take the mean of the lower quartile of the ranges for all groups (i
ndicated by the dotted line) 
cutoff <- sapply(foldRange.s, function(x) quantile(x$value, prob = 0.25
))[1:6] %>% mean() 
This gives us a cutoff of 1.112788. In other words, a fold enrichment of this value is believed 
to be the acceptable threshold for where background counts occur. Finally, the data is 
graphed. We also performed t-tests on all data for the significance bars. 
### T-tests to show each cutoff is different from non-targets 
data.frame(row.names = c("Brown", "Darnell", "B_D_A-RIP", "B_D_A-PAR", 
"B_D", "D_A-PAR"), 
           p.value = c(t.test(foldRange[foldRange$group == "Brown", "va
lue"], foldRange[foldRange$group == "Non-Targets", "value"])$p.value, 
                       t.test(foldRange[foldRange$group == "Darnell", "
value"], foldRange[foldRange$group == "Non-Targets", "value"])$p.value, 
                       t.test(foldRange[foldRange$group == "B_D_A-RIP", 
"value"], foldRange[foldRange$group == "Non-Targets", "value"])$p.value
, 
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                       t.test(foldRange[foldRange$group == "B_D_A-PAR", 
"value"], foldRange[foldRange$group == "Non-Targets", "value"])$p.value
, 
                       t.test(foldRange[foldRange$group == "B_D", "valu
e"], foldRange[foldRange$group == "Non-Targets", "value"])$p.value, 
                       t.test(foldRange[foldRange$group == "D_A-PAR", "
value"], foldRange[foldRange$group == "Non-Targets", "value"])$p.value)
) 
##                p.value 
## Brown     6.945032e-06 
## Darnell   7.145567e-04 
## B_D_A-RIP 2.446077e-04 
## B_D_A-PAR 7.041381e-06 
## B_D       7.660948e-06 
## D_A-PAR   4.259868e-04 
### Data for signficance bars locations 
sig1 <- data.frame(a = c(1, 1:7, 7), b = c(3.4, 3.5, 3.5, 3.5, 3.5, 3.5
, 3.5, 3.5, 3.4)) 
sig2 <- data.frame(a = c(2, 2:7, 7), b = c(3.2, 3.3, 3.3, 3.3, 3.3, 3.3
, 3.3, 3.2)) 
sig3 <- data.frame(a = c(3, 3:7, 7), b = c(3.0, 3.1, 3.1, 3.1, 3.1, 3.1
, 3.0)) 
sig4 <- data.frame(a = c(4, 4:7, 7), b = c(2.8, 2.9, 2.9, 2.9, 2.9, 2.8
)) 
sig5 <- data.frame(a = c(5, 5:7, 7), b = c(2.6, 2.7, 2.7, 2.7, 2.6)) 
sig6 <- data.frame(a = c(6, 6:7, 7), b = c(2.4, 2.5, 2.5, 2.4)) 
 
### Graph data 
c <- ggplot(foldRange, aes(x = group, y = value, fill = group)) + 
  geom_boxplot() + 
  geom_hline(yintercept = cutoff, color = "red", linetype = "dashed") + 
  xlab("") + 
  #ylab("WT-to-KO Fold Ratio") + 
  ylab("") + 
  scale_y_continuous(breaks = c(seq(0,5, by = 0.5))) + 
  theme_bw() + 
  theme(legend.position = "none") 
 
### Draw signifiance bar lines 
c + geom_line(data = sig1, aes(x = a, y = b, fill = NULL)) + annotate("
text", x = 4.0, y = 3.55, label = "***", size = 4) + 
  geom_line(data = sig2, aes(x = a, y = b, fill = NULL)) + annotate("te
xt", x = 4.5, y = 3.35, label = "***", size = 4) + 
  geom_line(data = sig3, aes(x = a, y = b, fill = NULL)) + annotate("te
xt", x = 5.0, y = 3.15, label = "***", size = 4) + 
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  geom_line(data = sig4, aes(x = a, y = b, fill = NULL)) + annotate("te
xt", x = 5.5, y = 2.95, label = "***", size = 4) + 
  geom_line(data = sig5, aes(x = a, y = b, fill = NULL)) + annotate("te
xt", x = 6.0, y = 2.75, label = "***", size = 4) + 
  geom_line(data = sig6, aes(x = a, y = b, fill = NULL)) + annotate("te
xt", x = 6.5, y = 2.55, label = "***", size = 4) 
 
Determining KO cutoff by univariate K-means 
We sought to find a more unbiased, quantitative means of assigning a threshold to the 
background counts. To do this, we used univariate K-means to attempt to separate out a 
pattern of background WT/KO enrichment from signal from the filtered data set (4120 
genes). 
ncAvgCut <- ncAvg[1:consensusCutoff, ] 
ncAvgCut$"Saline" <- ncAvg[1:consensusCutoff, "SAL_WT"] / ncAvg[1:conse
nsusCutoff, "SAL_KO"] 
ncAvgCut$"Ro" <- ncAvg[1:consensusCutoff, "RO_WT"] / ncAvg[1:consensusC
utoff, "RO_KO"] 
ncAvgCut$"Ro+Rapa" <- ncAvg[1:consensusCutoff, "RO_RAP_WT"] / ncAvg[1:c
onsensusCutoff, "RO_RAP_KO"] 
 
### Univariate k-means clustering. Arrange output in data frame 
clustDat <- data.frame(row.names = row.names(ncAvgCut), 
                       enriched = ncAvgCut$Saline, 
                       cluster = Ckmeans.1d.dp(ncAvgCut$Saline, 2)$clus
ter) 
 
### Define a second cutoff by taking the max in the "background" cluste
r 
cutoff2 <- split(clustDat, clustDat$cluster)[[1]]$enriched %>% max() 
cutoff2 
## [1] 1.289769 
Visualize WT/KO enrichment ratio with cutoff established 
We are now in a position to examine the final KO cutoff using our two separate methods. 
Here we simply take the average of the two cutoffs for a final cutoff assigned in the variable 
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KOcutoff. This cutoff will be applied to the data by applying it to the saline fraction only. 
The resulting gene list will be our filtered targets. 
### Define knockout cutoff 
KOcutoff <- mean(cutoff, cutoff2) 
KOcutoff 
## [1] 1.112788 
### Filter data to obtain this cutoff 
filteredTargets <- ncAvgCut[ncAvgCut$Saline > KOcutoff, 1:6] 
We now look at the distributions of points that fall above and below the cutoff line. 
### Create a filter variable that specifies signal or background 
ncAvgCut$filter <- ifelse(ncAvgCut$Saline > KOcutoff, "Signal", "Backgr
ound") 
 
### Graph with ggplot2 and arrange together 
  ggplot(ncAvgCut, aes(x = SAL_KO %>% log2(), y = SAL_WT %>% log2(), co
lor = filter)) + 
    geom_point() + 
    scale_color_manual(values = c("grey60", "blue2")) + 
    xlab("log2(Knockout)") + 
    ylab("log2(Saline)") + 
    theme_bw() + 
    theme(legend.position = "none") 
 
We can also look at the distributions of genes that were removed by the filter compared to 
the total distribution: 
ncLog <- ncAvgCut[ ,7:9] 
ncLog <- apply(ncLog, 2, log2) %>% as.data.frame() 
names(ncLog) <- c("Saline", "Ro", "RoRapa") 
ncLog$filter <- ncAvgCut$filter 
 
g1 <- ncLog[ncLog$filter == "Signal", ] 
g2 <- ncLog[ncLog$filter == "Background", ] 
 
  ggplot(ncLog, aes(x = Saline)) + 
  geom_histogram(data = ncLog[which(ncLog$filter %in% "Signal"), ], aes 
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(y = ..density..), fill = "grey60", bins = 100) + 
  geom_histogram(data = ncLog[which(ncLog$filter %in% "Background"), ], 
aes(y = ..density..), fill = "grey60", bins = 100) + 
  geom_density(data = ncLog[which(ncLog$filter %in% "Signal"), ], aes(y 
= ..density..), fill = "chartreuse3", alpha = 0.5) + 
  geom_density(data = ncLog[which(ncLog$filter %in% "Background"), ], a
es(y = ..density..), fill = "firebrick2", alpha = 0.5) + 
  theme_bw() 
 
Filtering mitochondrial and glial cells 
To remove mitchondrial and glial cells, we searched the MitoMiner (Smith et al., 2012) 
database and the Brain RNA-seq database for cell types (Zhang et al., 2014) 
mito <- read.csv("mito.csv", header = FALSE, stringsAsFactors = FALSE)$
V1 
glia <- read.csv("glial.csv", header = FALSE, stringsAsFactors = FALSE)
$V1 
 
filteredTargets <- filteredTargets[!(row.names(filteredTargets) %in% c(
mito, glia) ), ] 
 
finalCountData <- nc[row.names(nc) %in% row.names(filteredTargets), ] 
Final filtration with limma 
Finally, we take our filtered list and apply limma+voom for differential expression 
analysis. 
### Preprocess data columns 
countData <- read.csv(file = "combinedCounts.csv", header = TRUE, strin
gsAsFactors = FALSE) 
rownames(countData) <- countData[ ,1] 
countData[ ,1] <- NULL 
cdMain <- subset(countData, select = c(7:12, 16:18, 3:6, 13:15)) %>% an
no() 
cdMain <- cdMain[ ,1:9] 
cdMain <- cdMain[row.names(cdMain) %in% row.names(finalCountData), ] 
 
### Analyze with limma+voom 
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dge <- DGEList(counts = cdMain) 
dge <- calcNormFactors(dge) 
dge <- cpm(dge, log = TRUE, prior.count = 3) 
design <- model.matrix(~ 0+factor(c(1,1,1,2,2,2,3,3,3))) 
colnames(design) <- c("RO_RAP_WT", "RO_WT", "SAL_WT") 
 
contrast.matrix <- makeContrasts(SAL_WT-RO_WT, RO_RAP_WT-RO_WT, levels 
= design) 
 
v <- voom(cdMain, design, plot = FALSE) 
fit <- lmFit(v, design) 
fit2 <- contrasts.fit(fit, contrast.matrix) 
fit2 <- eBayes(fit2) 
resultsRo <- topTable(fit2, coef = 1, number = 25000) 
resultsRoRap <- topTable(fit2, coef = 2, number = 25000) 
 
resultsRo$Threshold <- ifelse(resultsRo$adj.P.Val < 0.1, "Significant", 
"Non-Significant") 
resultsRoRap$Threshold <- ifelse(resultsRo$adj.P.Val < 0.1, "Significan
t", "Non-Significant") 
Visualization of final dataset 




  ggplot(resultsRo, aes(x = AveExpr, y = logFC, color = Threshold)) + 
  geom_point(alpha = 0.4, size = 0.8) + 
  geom_hline(aes(yintercept = 0), color = "blue", size = 1.2) + 
  scale_color_manual(values = c("grey40", "red")) + 
  ylim(-1.5,1.5) + 
  xlim(6.5,14) + 
  xlab("Mean of Normalized Counts") + 
  ylab("Log2 Fold-Change") + 
  ggtitle("Saline/Ro") + 
  theme_bw() + 
  theme(legend.position = "none") 
 
ma2 <- 
  ggplot(resultsRoRap, aes(x = AveExpr, y = logFC, color = Threshold)) 
+ 
  geom_point(alpha = 0.4, size = 0.8) + 
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  geom_hline(aes(yintercept = 0), color = "blue", size = 1.2) + 
  scale_color_manual(values = c("grey40", "red")) + 
  ylim(-1.5,1.5) + 
  xlim(6.5,14) + 
  xlab("Mean of Normalized Counts") + 
  ylab("Log2 Fold-Change") + 
  ggtitle("Ro+Rapa/Ro") + 
  theme_bw() + 
  theme(legend.position = "none") 
 
grid.arrange(ma1, ma2, 
            ncol = 2, 




  ggplot(resultsRo, aes(x = logFC, y = -log10(adj.P.Val), color = Thres
hold)) + 
  geom_point(alpha = 0.4, size = 1.75) + 
  xlim(-1,1) + 
  ylim(0,2) + 
  xlab("Log2 Fold-Change") + 
  ylab("-log10 FDR Cutoff") + 
  ggtitle("Saline/Ro") + 
  theme_bw() + 
  theme(legend.position = "none") 
 
vp2 <- 
  ggplot(resultsRoRap, aes(x = logFC, y = -log10(adj.P.Val), color = Th
reshold)) + 
  geom_point(alpha = 0.4, size = 1.75) + 
  xlim(-1.3,1.3) + 
  ylim(0,2) + 
  xlab("Log2 Fold-Change") + 
  ylab("-log10 FDR Cutoff") + 
  ggtitle("Ro+Rap/Ro") + 
  theme_bw() + 
  theme(legend.position = "none") 
 
grid.arrange(vp1, vp2, 
             ncol = 2, 




### Heatmap for fold-change data 
heatmap <- merge(resultsRo, resultsRoRap, by = 0) 
heatmap <- heatmap[heatmap$adj.P.Val.x < 0.1 & heatmap$adj.P.Val.y < 0.
1, ] 
heatmap <- heatmap[(heatmap$logFC.x > -2 & heatmap$logFC.x < 2) & (heat
map$logFC.y > -2 & heatmap$logFC.y < 2), ] 
 
heatmap <- data.frame(row.names = heatmap$Row.names, 
                  Ro = heatmap$logFC.x, 
                  RoRap = heatmap$logFC.y) 
 
pheatmap(heatmap,  
         color = brewer.pal(11, "RdYlBu"), fontsize = 7, 
         clustering_method = "average", 
         clustering_distance_rows = "euclidean", 
         clustering_distance_cols = "euclidean",  
         show_rownames = FALSE) 
 
### Heatmap for raw count data 
finalCountData.log <- apply(finalCountData, 2, log2) 
finalCountData.log <- finalCountData.log[row.names(finalCountData.log) 
%in% row.names(heatmap), c("SAL_WT1", "SAL_WT2", "SAL_WT3", "RO_WT1", "
RO_WT2", "RO_WT3", "RO_RAP_WT1", "RO_RAP_WT2", "RO_RAP_WT3")] 
 
pheatmap(finalCountData.log, 
         color = brewer.pal(11, "RdYlBu"), fontsize = 7, 
         clustering_method = "average", 
         clustering_distance_rows = "euclidean", 
         clustering_distance_cols = "euclidean", 
         show_rownames = FALSE) 
 
Session info 
## R version 3.3.2 (2016-10-31) 
## Platform: x86_64-pc-linux-gnu (64-bit) 
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The getMaxLengthSequences() function is used to find the sequence of maximum length 
from the list returned from BioMart. 
getMaxLengthSequences <- function(x) { 
  salSeqMax <- split(x, factor(x$mgi_symbol)) 
  salSeqMax <- lapply(salSeqMax, function(x) max(x$length)) %>% unlist(
) %>% as.data.frame() 
  salSeqMax$mgi_symbol <- row.names(salSeqMax) 
  row.names(salSeqMax) <- NULL 
  names(salSeqMax) <- c("length", "mgi_symbol") 
  salSeqUnique <- merge(salSeqMax, x) 
  salSeqUnique <- salSeqUnique[order(salSeqUnique$mgi_symbol), ] 
   
  return(salSeqUnique) 
} 
The getmotifs() sequence calculates the occurance of various motifs believed to be present 
within FMRP target mRNA sequences. For the majority of motifs, they are simply searched 
using the matchPDict() function from the seqinr package. However, the qfm motif needs its 
own special function because of its usual properties. 
The approach taken here is to first find the two sequences that make up the QFM motif 
(WGGA = AGGA or AGGT). All instances where they occur are then converted into a 
dataframe. Next, the occurances of the WGGA motif (start and stop positions) are arranged 
into a vector and the difference is taken between these start and stop values in order to find 
the number of nucleotides that are between each occurance of a WGGA. Finally, all 
occurances less than 6 long (i.e. at least 5 bases between each WGGA) are then returned. 
getmotifs <- function(x) { 
  require(seqinr) 
   
  seq <- x %>% tolower() %>% s2c() 
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  qfm <- matchPDict(PDict(c("AGGA", "TGGA")), DNAString(x)) %>% unlist(
) %>% data.frame() 
  qfm <- qfm[order(qfm$start), 1:2] %>% as.matrix() %>% t() %>% c() %>% 
diff() %>% unique() 
  qfm <- sum(qfm[-1] < 6) 
   
  output <- c("ACUK" = count(seq, 4)[c("actg", "actt")] %>% sum(), 
              "WGGA" = count(seq, 4)[c("agga", "tgga")] %>% sum(), 
              "GAC" = count(seq, 3)["gac"] %>% sum(), 
              "GACR" = count(seq, 4)[c("gaca", "gacg")] %>% sum(), 
              "GACARG" = count(seq,6)[c("gacaag", "gacagg")] %>% sum(), 
              "QFM" = qfm) 
   
  return(output) 
} 
The rho() function in the seqinr package is unable to compute probabilities for multiple 
motifs at the same time. This function gets around this by manually computing rho for 
multiple values. This is needed for nearly every motif. 
multipleRho <- function(sequ, motif1, motif2) { 
  require(seqinr) 
   
  freq1 <- count(sequ, nchar(motif1), freq = TRUE)[motif1] 
  freq2 <- count(sequ, nchar(motif2), freq = TRUE)[motif2] 
  expected1 <- sapply(s2c(motif1), function(x) count(sequ, 1, freq = TR
UE)[unique(x)]) %>% unique() %>% prod() 
  expected2 <- sapply(s2c(motif2), function(x) count(sequ, 1, freq = TR
UE)[unique(x)]) %>% unique() %>% prod() 
   
  output <- (freq1 + freq2) / (expected1 + expected2) 
  names(output) <- NULL 
  return(output) 
} 
The getRho() function calculates rho for all motifs. This function depends on the 
multipleRho() function described above. 
getRho <- function(x) { 
  require(seqinr) 
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  seq <- x %>% tolower() %>% s2c() 
   
  output <- c(ACUK = multipleRho(seq, "actg", "actt"), 
              WGGA = multipleRho(seq, "agga", "tgga"), 
              GAC = rho(seq, 3)["gac"], 
              GACR = multipleRho(seq, "gaca", "gacg"), 
              GACARG = multipleRho(seq, "gacaag", "gacagg")) 
   
  names(output) <- c("ACUK", "WGGA", "GAC", "GACR", "GACARG") 
  return(output) 
} 
Obtain coding sequences from BioMart 
Our analysis consists only of the coding region of FMRP. We have chosen this due to the 
fact the majority of FMRP binding motifs appear to be clustered in this part of the gene 
(Anderson et al., 2016). First, we load the data files and obtain the coding sequences: 
### Load gene list 
genes <- read.csv("finalData.csv", header = TRUE, stringsAsFactors = FA
LSE)$Row.names 
 
filteredCounts <- read.csv("finalCountData.csv", header = TRUE, strings
AsFactors = FALSE, row.names = 1) %>% row.names() 
 
### Get all sequences for the filtered list 
ensembl <- useMart("ensembl", dataset = "mmusculus_gene_ensembl") 
 
sequ <- biomaRt::getSequence(id = filteredCounts, 
                                type = "mgi_symbol", 
                                seqType = "coding", 
                                mart = ensembl) 
Next, we filter the sequence list into two categories: either "target" which consists of the 
final filtered limma list and "non-target" which represent those that are not in that list. 
### Remove unavailable sequences 
sequ <- sequ[!grepl("Sequence unavailable", sequ$'coding', fixed = TRUE
), ] 
 
### Find the length of each sequence then pick the max length sequence 
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if there are multiple sequences returned from BioMart 
sequ <- sequ[order(sequ$mgi_symbol), ] 
sequ$length <- sapply(sequ$coding, nchar) 
sequ <- getMaxLengthSequences(sequ) 
 
### Filter into either "targets" or "non-targets" 
targets <- sequ[sequ$mgi_symbol %in% genes, ] 
nonTargets <- sequ[!(sequ$mgi_symbol %in% genes), ] 
Analyze coding sequences for motifs 
Warning! Running the first line of code is a very computationally intensive process. A 
matrix is generated that calculates all motifs for every sequence string in the data set. 
### Targets 
targetMotifs <- matrix(sapply(targets[ ,"coding"], getmotifs), nrow = n
row(targets), ncol = 6, byrow = TRUE) 
targetMotifTable <- data.frame(Length = targets$length) 
rownames(targetMotifTable) <- make.names(targets$mgi_symbol, unique = T
RUE) 
targetMotifTable <- cbind(targetMotifTable, targetMotifs) %>% as.data.f
rame() 
names(targetMotifTable) <- c("Length", "ACUK", "WGGA", "GAC", "GACR", "
GACARG", "QFM") 
 
targetMotifTable$ACUK.freq <- round((targetMotifTable$ACUK * 1000) / ta
rgetMotifTable$Length, 2) 
targetMotifTable$WGGA.freq <- round((targetMotifTable$WGGA * 1000) / ta
rgetMotifTable$Length, 2) 
targetMotifTable$GAC.freq <- round((targetMotifTable$GAC * 1000) / targ
etMotifTable$Length, 2) 
targetMotifTable$GACR.freq <- round((targetMotifTable$GACR * 1000) / ta
rgetMotifTable$Length, 2) 
targetMotifTable$GACARG.freq <- round((targetMotifTable$GACARG * 1000) 
/ targetMotifTable$Length, 2) 
targetMotifTable$QFM.freq <- round((targetMotifTable$QFM * 1000) / targ
etMotifTable$Length, 2) 
 
rhoMotifs <- matrix(sapply(targets[, "coding"], getRho), nrow = nrow(ta
rgets), ncol = 5, byrow = TRUE) 
 
### Non-targets 
nonTargetMotifs <- matrix(sapply(nonTargets[ ,"coding"], getmotifs), nr
ow = nrow(nonTargets), ncol = 6, byrow = TRUE) 
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nonTargetMotifTable <- data.frame(Length = nonTargets$length) 
row.names(nonTargetMotifTable) <- make.names(nonTargets$mgi_symbol, uni
que = TRUE) 
nonTargetMotifTable <- cbind(nonTargetMotifTable, nonTargetMotifs) %>% 
as.data.frame() 
names(nonTargetMotifTable) <- c("Length", "ACUK", "WGGA", "GAC", "GACR"
, "GACARG", "QFM") 
 
nonTargetMotifTable$ACUK.freq <- round((nonTargetMotifTable$ACUK * 1000
) / nonTargetMotifTable$Length, 2) 
nonTargetMotifTable$WGGA.freq <- round((nonTargetMotifTable$WGGA * 1000
) / nonTargetMotifTable$Length, 2) 
nonTargetMotifTable$GAC.freq <- round((nonTargetMotifTable$GAC * 1000) 
/ nonTargetMotifTable$Length, 2) 
nonTargetMotifTable$GACR.freq <- round((nonTargetMotifTable$GACR * 1000
) / nonTargetMotifTable$Length, 2) 
nonTargetMotifTable$GACARG.freq <- round((nonTargetMotifTable$GACARG * 
1000) / nonTargetMotifTable$Length, 2) 
nonTargetMotifTable$QFM.freq <- round((nonTargetMotifTable$QFM * 1000) 
/ nonTargetMotifTable$Length, 2) 
 
rhoMotifsNonTarget <- matrix(sapply(nonTargets[, "coding"], getRho), nr
ow = nrow(nonTargets), ncol = 5, byrow = TRUE) 
Calculate statistics 
### T-tests 
tt <- c(t.test(targetMotifTable$ACUK.freq, nonTargetMotifTable$ACUK.fre
q)$p.value, 
        t.test(targetMotifTable$WGGA.freq, nonTargetMotifTable$WGGA.fre
q)$p.value, 
        t.test(targetMotifTable$GAC.freq, nonTargetMotifTable$GAC.freq)
$p.value, 
        t.test(targetMotifTable$GACR.freq, nonTargetMotifTable$GACR.fre
q)$p.value, 
        t.test(targetMotifTable$GACARG.freq, nonTargetMotifTable$GACARG
.freq)$p.value, 
        t.test(targetMotifTable$QFM, nonTargetMotifTable$QFM)$p.value) 
 
### Wilcox-Mann_Whitley tests 
wmw <- c(wilcox.test(targetMotifTable$ACUK.freq, nonTargetMotifTable$AC
UK.freq, correct = FALSE)$p.value, 
         wilcox.test(targetMotifTable$WGGA.freq, nonTargetMotifTable$WG
GA.freq, correct = FALSE)$p.value, 
         wilcox.test(targetMotifTable$GAC.freq, nonTargetMotifTable$GAC
.freq, correct = FALSE)$p.value, 
         wilcox.test(targetMotifTable$GACR.freq, nonTargetMotifTable$GA
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CR.freq, correct = FALSE)$p.value, 
         wilcox.test(targetMotifTable$GACARG.freq, nonTargetMotifTable$
GACARG.freq, correct = FALSE)$p.value, 
         wilcox.test(targetMotifTable$QFM, nonTargetMotifTable$QFM, cor
rect = FALSE)$p.value) 
 
### Effect size 
cd <- c(cohensD(targetMotifTable$ACUK.freq, nonTargetMotifTable$ACUK.fr
eq), 
        cohensD(targetMotifTable$WGGA.freq, nonTargetMotifTable$WGGA.fr
eq), 
        cohensD(targetMotifTable$GAC.freq, nonTargetMotifTable$GAC.freq
), 
        cohensD(targetMotifTable$GACR.freq, nonTargetMotifTable$GACR.fr
eq), 
        cohensD(targetMotifTable$GACARG.freq, nonTargetMotifTable$GACAR
G.freq), 
        cohensD(targetMotifTable$QFM, nonTargetMotifTable$QFM)) 
Assemble final motif table 
motifSummary <- data.frame("Mean Frequency per kB (Cutoff)" = colMeans(
targetMotifTable)[8:13], 
                           "Mean Frequency per kB (Non-Cutoff)" = colMe
ans(nonTargetMotifTable)[8:13], 
                           "Rho (Cutoff)" = c(colMeans(rhoMotifs), NA), 
                           "Rho (Non-Cutoff)" = c(colMeans(rhoMotifsNon
Target), NA), 
                           "t-test" = round(tt, 3), 
                           "Wilcoxon-Mann-Whitney Test" = round(wmw, 3)
, 
                           "Cohen's d" = round(cd, 3)) 
 
motifSummary 
##             Mean.Frequency.per.kB..Cutoff. 
## ACUK.freq                        8.0357233 
## WGGA.freq                       16.5308086 
## GAC.freq                        16.7872366 
## GACR.freq                        7.9048368 
## GACARG.freq                      0.8750705 
## QFM.freq                         0.6477374 
##             Mean.Frequency.per.kB..Non.Cutoff. Rho..Cutoff. 
## ACUK.freq                            8.4833728    0.4547952 
## WGGA.freq                           16.6661166    0.1999265 
## GAC.freq                            16.0662057    0.9553620 
## GACR.freq                            7.4436598    0.2222723 
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## GACARG.freq                          0.7731510    0.0243765 
## QFM.freq                             0.6544778           NA 
##             Rho..Non.Cutoff. t.test Wilcoxon.Mann.Whitney.Test Cohen
.s.d 
## ACUK.freq         0.47667503  0.000                      0.000     0
.144 
## WGGA.freq         0.20053122  0.222                      0.239     0
.026 
## GAC.freq          0.93583759  0.000                      0.000     0
.162 
## GACR.freq         0.21408773  0.000                      0.000     0
.152 
## GACARG.freq       0.02209649  0.000                      0.000     0
.115 
## QFM.freq                  NA  0.000                      0.000     0
.088 
Visualize motifs 
Visualization was performed similar to (Suhl et al., 2014). This is simply the visualization 
of the table produced above. 
Motif frequency 
motifFreq.m <- rbind(melt(targetMotifTable[ ,8:12]), 
                 melt(nonTargetMotifTable[ ,8:12])) %>% as.data.frame() 
motifFreq.m$type <- c(rep("Target", nrow(melt(targetMotifTable[ ,8:12])
)), 
                  rep("Non-Target", nrow(melt(nonTargetMotifTable[ ,8:1
2])))) 
levels(motifFreq.m$variable) <- c("ACUK", "WGGA", "GAC", "GACR", "GACAR
G") 
motifFreq.m$type <- factor(motifFreq.m$type, levels = c("Target", "Non-
Target")) 
 
  ggplot(motifFreq.m, aes(x = type, y = value, fill = type)) + 
  geom_boxplot() + 
  facet_grid(. ~ variable) + 
  xlab("") + 
  ylab("") + 
  labs(fill = "") + 
  scale_fill_manual(values = c("dodgerblue4", "darkgoldenrod2")) + 




qfmCount.m <- rbind(melt(targetMotifTable[ ,7]), 
                     melt(nonTargetMotifTable[ ,7])) %>% as.data.frame(
) 
qfmCount.m$type <- c(rep("Target", nrow(melt(targetMotifTable[ ,7]))), 
                      rep("Non-Target", nrow(melt(nonTargetMotifTable[ 
,7])))) 
qfmCount.m$type <- factor(qfmCount.m$type, levels = c("Target", "Non-Ta
rget")) 
 
  ggplot(qfmCount.m, aes(x = type, y = value, fill = type)) + 
  geom_boxplot() + 
  scale_fill_manual(values = c("dodgerblue4", "darkgoldenrod2")) + 
  xlab("") + 
  ylab("") + 
  theme_bw() 
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The functionalAnnotationChart() function a list of genes, and ontology (term), and an output 
file name. It returns the Functional Annotation Chart from DAVID. 
functionalAnnotationChart <- function(genes, term, filename) { 
   
  require(RDAVIDWebService) 
  require(org.Mm.eg.db) 
   
  david <- DAVIDWebService$new(email = "snamjoshi87@utexas.edu", url = 
"https://david.ncifcrf.gov/webservice/services/DAVIDWebService.DAVIDWeb
ServiceHttpSoap12Endpoint/") 
  egenes <- select(org.Mm.eg.db, genes, "ENTREZID", "SYMBOL")[,2] 
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  chart <- addList(david, egenes, 
                   idType = "ENTREZ_GENE_ID", 
                   listName = "Functional Annotation Chart", 
                   listType = "Gene") 
   
  setAnnotationCategories(david, term) 
  getFunctionalAnnotationChartFile(david, fileName = filename) 
   
  return(paste("Ouput DAVID analysis file:", filename)) 
} 
The uniqueFilteredGoTerms() function a list of downregulated genes and a list of upregulated 
genes from DAVID results, and a desired PValue and FDR cutoff. It first applies these 
cutoffs to both data sets. Then, it finds the unique GO terms between the remaining terms. 
uniqueFilteredGoTerms <- function(downfileName, upfileName, PValue, FDR
) { 
  downBP <- read.table(downfileName, sep = "\t", header = TRUE, strings
AsFactors = FALSE, quote = "") 
  downBP <- downBP[ ,c("Term", "PValue", "FDR")] 
  downBP <- downBP[downBP$PValue < PValue | downBP$FDR < FDR, ] 
   
  upBP <- read.table(upfileName, sep = "\t", header = TRUE, stringsAsFa
ctors = FALSE, quote = "") 
  upBP <- upBP[ , c("Term", "PValue", "FDR")] 
  upBP <- upBP[upBP$PValue < PValue | upBP$FDR < FDR, ] 
   
  sharedBP <- intersect(downBP$Term, upBP$Term) 
  downOnlyBP <- setdiff(downBP$Term, upBP$Term) 
  upOnlyBP <- setdiff(upBP$Term, downBP$Term) 
   
  downOnlyTableBP <- downBP[downBP$Term %in% downOnlyBP, c("Term", "PVa
lue", "FDR")]  
  upOnlyTableBP <- upBP[upBP$Term %in% upOnlyBP, c("Term", "PValue", "F
DR")] 
   
  downOnlyTableBP <- downOnlyTableBP[order(downOnlyTableBP$PValue), "Te
rm"] 
  upOnlyTableBP <- upOnlyTableBP[order(upOnlyTableBP$PValue), "Term"] 
   
  return(list(downTable = downOnlyTableBP, upTable = upOnlyTableBP)) 
} 
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The simplifyGo() function takes a DAVID functional annotation chart and creates a 
similarity matrix for each GO term with every other GO term by using two different 







. This approach is based off of (Merico et al., 2010; Merico et al., 
2011). The similarity metrics are calculated within the subfunction called similarity(). These 
metrics are two different ways of assessing the degree of overlap between two gene lists. 
The average score of JC and OC for each set of genes associated with a GO term is 
computed in a giant similarity matrix for all GO terms. Note that this procedure is very 
computational intensive. Finally, the matrix is filtered for a similarity cutoff of > 0.5. The 
function then returns this matrix. 
simplifyGo <- function(david_chart) { 
   
  ### Similarity function for overlap coefficient and jaccard cutoff 
  similarity <- function(list) { 
     
    A <- list[[1]] 
    B <- list[[2]] 
     
    JC <- function(A, B) { 
      output <- (intersect(A, B) %>% length()) / (union(A, B) %>% lengt
h()) 
      return(output) 
    } 
     
    OC <- function(A, B) { 
      output <- (intersect(A, B) %>% length()) / (min(length(A), length
(B))) 
      return(output) 
    } 
     
    similarity <- mean(c(OC(A, B), JC(A, B))) 
    return(similarity) 
 311 
  } 
   
  ### Create similarity matrix 
  list1 <- david_chart[ ,"Genes"] %>% strsplit(split  = ",") %>% lapply
(FUN = as.numeric) 
  list2 <- list1 
   
  computeSimilarity <- Vectorize(function(x, y) { 
    vec1 <- list1[[x]] 
    vec2 <- list2[[y]] 
     
    similarity(list(vec1, vec2)) 
  }) 
   
  filterMatrix <- outer(1:length(list1), 1:length(list2), computeSimila
rity) 
  rownames(filterMatrix) <- david_chart[ ,"Term"] 
  colnames(filterMatrix) <- david_chart[ ,"Term"] 
  filterMatrix[filterMatrix < 0.5] <- 0 
   
  return(filterMatrix) 
} 
The getDendrogramClusters() function is used to extract the cluster data from the hcut() 
function. 
getDendrogramClusters <- function(hcut_output) { 
  clusters <- data.frame(Cluster = hcut_output$cluster %>% unname(), 
                         Term = hcut_output$labels) 
   
  labels <- merge(data.frame(Term = labels(hcut_output %>% as.dendrogra
m()),  
                             Order = 1:nrow(clusters)), clusters, "Term
") 
   
  output <- labels[order(labels$Order), ] 
  return(output) 
} 
The determineClusterNumbers() function utilizes the within sum of squares (WSS) to 
estimate cluster number for hierachical clustering of the GO terms (based on their similarity 
index). The function returns a plot which is used to approximate the clusters. 
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determineClusterNumbers <- function(x, n) { 
  require(ggplot2) 
   
  wss <- (nrow(x) - 1) * sum(apply(x, 2, var)) 
   
  for(i in 2:n) { 
    wss[i] <- sum(kmeans(x, centers = i)$withinss) 
  } 
   
  wss <- as.data.frame(cbind(wss, clusters = 1:n)) 
   
  plot <- ggplot(wss, aes(clusters, wss)) + 
    geom_line() + 
    geom_point() + 
    theme_bw() 
   
  return(plot) 
} 
The determineClusterNumbers1D() function operates simarilary to the above function but 
instead provides WSS for a univariate distribution with K-means. 
determineClusterNumbers1D <- function(x, n) { 
  require(ggplot2) 
  require(Ckmeans.1d.dp) 
   
  wss <- (length(x) - 1) * var(x) 
   
  for(i in 2:n) { 
    wss[i] <- sum(Ckmeans.1d.dp(x, i)$withinss) 
  } 
   
  wss <- as.data.frame(cbind(wss, clusters = 1:n)) 
   
  plot <- ggplot(wss, aes(clusters, wss)) + 
    geom_line() + 
    geom_point() + 
    theme_bw() 
   
  return(plot) 
} 
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The kMeanPlot() function takes a two column data frame (x) and the number of cluster (n), 
clusters the data, and graphs it. 
require(amap) 
 
colorFunc <- colorRampPalette(c("lightblue", "blue")) 
 
kMeansPlot <- function(x, n) { 
  clustDat <- as.matrix(x) 
  clustDat[is.na(clustDat)] <- 0 
  kClust <- Kmeans(clustDat, centers = n, method = "pearson", iter.max 
= 50) 
   
  clustDat <- as.data.frame(cbind(clustDat, clusters = kClust$cluster)) 
  clustDat$clusters <- as.factor(clustDat$clusters) 
  centers <- as.data.frame(kClust$centers) 
   
  clustPlot <- ggplot(clustDat, aes(RO, RO_RAP, color = clusters, fill 
= clusters)) + 
    geom_point() + 
    geom_vline(xintercept = 0, color = "black") + 
    geom_hline(yintercept = 0, color = "black") + 
    xlab("Ro Fold Change") + 
    ylab("Ro+Rapamycin Fold Change") + 
    xlim(-1.5,1.5) + 
    ylim(-1.5,1.5) + 
    ggtitle("K Means Clustering for Ro or Ro+Rapa Fold Changes") + 
    theme_bw() 
   
  clustPlot 
} 
Load data and filter 
fc <- read.csv("finalData.csv", header = TRUE, stringsAsFactors = FALSE
) 
row.names(fc) <- fc$Row.names 
fc[ ,1] <- NULL 
fc <- fc[ ,c("logFC.x", "logFC.y")] 
names(fc) <- c("RO", "RO_RAP") 
 
counts <- read.csv("finalCountData.csv", header = TRUE, stringsAsFactor
s = FALSE, row.names = 1) 
countsAvg <- data.frame(row.names = row.names(counts), 
                        SAL_WT = rowMeans(counts[ ,1:3]), 
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                        RO_WT = rowMeans(counts[ ,7:9]), 
                        RO_RAP_WT = rowMeans(counts[ ,11:13])) 
countsAvg.log <- apply(countsAvg, 2, log2) %>% as.data.frame() 
 
### Here we apply a fold-change filter 
roDownGenes <- fc[fc$RO < quantile(fc$RO, 0.25), ]  
roUpGenes <- fc[fc$RO > quantile(fc$RO, 0.75), ] 
 
roRapDownGenes <- fc[fc$RO_RAP < quantile(fc$RO_RAP, 0.25), ] 
roRapUpGenes <- fc[fc$RO_RAP > quantile(fc$RO_RAP, 0.75), ] 
Differential binding 
This graph is just to illustrate the differential binding effects seen in different fold-change 
conditions. 
p1 <- 
  ggplot(countsAvg.log, aes(x = SAL_WT, y = RO_WT)) + 
  geom_point(color = "dodgerblue3") + 
  xlab("Normalized Saline Counts") + 
  ylab("Normalized Ro Counts") + 
  theme_bw() 
 
p2 <- 
  ggplot(countsAvg.log, aes(x = SAL_WT, y = RO_RAP_WT)) + 
  geom_point(color = "dodgerblue3") + 
  xlab("Normalized Saline Counts") + 
  ylab("Normalized Ro + Rapamycin Counts") + 
  theme_bw() 
 
p3 <- 
  ggplot(countsAvg.log, aes(x = RO_RAP_WT, y = RO_WT)) + 
  geom_point(color = "dodgerblue3") + 
  xlab("Normalized Ro + Rapamycin Counts") + 
  ylab("Normalized Ro Counts") + 
  theme_bw() 
 
grid.arrange(p1, p2, p3, 
             ncol = 3, 
             nrow = 1) 
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Unique GO clustering by fold-change group 
Code to generate DAVID Functional Annotation Charts for Ro and RoRap. For all DAVID 
charts, we used a p-value cutoff of 0.001 and FDR cutoff of 0.05. The strategy here is to 
use the GO cutoffs from early to cluster on the basis of similarity. This will group like GO-
terms together in a branch on the dendrogram. This unbiased approach allows us to give 
our own names manually to each major cluster family. Then, we can take the average p-
value within each branch, the average number of genes per GO term, and plot this with 
ggplot2. To determine cluster number, the within sum of squares (WSS) is graphed for n 
clusters. The chosen cluster number attempts to minimize the WSS of squares by visually 
seeing where the overall shape of the plot begins to flatten out on the y-axis. 
### Query DAVID for Ro and get unique GO terms 
functionalAnnotationChart(roDownGenes,  
                          term = "GOTERM_BP_ALL",  




                          term = "GOTERM_BP_ALL",  
                          filename = "david_ro_up_1000_biological_proce
ss.txt") 
 
uniqueBpRo <- uniqueFilteredGoTerms(downfileName = "david_ro_down_1000_
biological_process.txt", 
                                    upfileName = "david_ro_up_1000_biol
ogical_process.txt", 
                                    PValue = 0.001, 
                                    FDR = 0.05) 
 
### Query DAVID for Ro+Rap and get unique GO terms 
functionalAnnotationChart(roRapDownGenes,  
                          term = "GOTERM_BP_ALL",  





                          term = "GOTERM_BP_ALL",  
                          filename = "david_roRap_up_1000_biological_pr
ocess.txt") 
 
uniqueBpRoRap <- uniqueFilteredGoTerms(downfileName = "david_roRap_down
_1000_biological_process.txt", 
                                       upfileName = "david_roRap_up_100
0_biological_process.txt", 
                                       PValue = 0.001, 
                                       FDR = 0.05) 
 
### Query DAVID for candidate depression genes 
dep <- read.csv("depression_gene_candidates.csv", header = FALSE, strin
gsAsFactors = FALSE)$V1 
 
dep <- sapply(dep, function(x) { 
  y <- tolower(x) 
  y <- paste0(toupper(substr(y, 1, 1)), substr(y, 2, nchar(y))) 
  return(y) 
  })  
 
names(dep) <- NULL 
 
functionalAnnotationChart(dep,  
                          term = "GOTERM_BP_ALL",  
                          filename = "david_depression_1000_biological_
process.txt") 
 
### Query DAVID for consensus FMRP genes 
BD <- read.xlsx("consensus_FMRP.xlsx", sheetIndex = 4, header = FALSE, 
startRow = 2, stringsAsFactors = FALSE)$X1 
 
BD <- sapply(BD, function(x) { 
  y <- tolower(x) 
  y <- paste0(toupper(substr(y, 1, 1)), substr(y, 2, nchar(y))) 
  return(y) 
})  
 
names(BD) <- NULL 
 
functionalAnnotationChart(BD,  
                          term = "GOTERM_BP_ALL",  
                          filename = "david_BD_1000_biological_process.
txt") 
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Ro top GO chart 
### Load DAVID data and filter 
roUp <- read.table("david_ro_up_1000_biological_process.txt", header = 
TRUE, sep = "\t", stringsAsFactors = FALSE) 
roUp <- roUp[roUp$PValue < 0.001 | roUp$FDR < 0.05, c("Term", "PValue", 
"Genes", "Count")] 
roDown <- read.table("david_ro_down_1000_biological_process.txt", heade
r = TRUE, sep = "\t", stringsAsFactors = FALSE, quote = "") 
roDown <- roDown[roDown$PValue < 0.001 | roDown$FDR < 0.05, c("Term", "
PValue", "Genes", "Count")] 
 
roUp <- roUp[!(roUp$Term %in% roDown$Term), ] 
roDown <- roDown[!(roDown$Term %in% roUp$Term), ] 
 
### Determine optimal cluster number 
roUpMatrix <- simplifyGo(roUp) 
determineClusterNumbers(roUpMatrix, 30) 
 
### Create dendrogram and get clusters 
roUpDendrogram <- hcut(roUpMatrix, k = 30, stand = TRUE) 
fviz_dend(roUpDendrogram, rect = TRUE, cex = 0.5, show_labels = TRUE) 
 
roUpClusters <- getDendrogramClusters(roUpDendrogram)  
 
### Merge clusters with original DAVID data 
roUpClusters.mg <- merge(roUpClusters, roUp, "Term")[ ,c("Term", "PValu
e", "Count", "Cluster", "Order")] 
roUpClusters.mg$NegLogPValue <- -log10(roUpClusters.mg$PValue) 
roUpClusters.mg$Direction <- rep("Up", nrow(roUpClusters.mg)) 
roUpClusters.mg <- roUpClusters.mg[order(roUpClusters.mg$Order), ] 
 
# write.csv to export file 
Now, the dendrogram data is manually annotated and re-imported to R. 
roUpChart <- read.csv("roUpClusters_network_data.csv", header = TRUE, s
tringsAsFactors = FALSE) 
### Create Ro Chart 
roUpChart.s <- split(roUpChart, roUpChart$Category) 
roUpSummary <- data.frame(Term = names(roUpChart.s), 
                          NegLogPValue = lapply(roUpChart.s, function(x
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) mean(x$NegLogPValue)) %>% unlist() %>% unname(), 
                          Count = lapply(roUpChart.s, function(x) mean(
x$Count)) %>% unlist() %>% unname(), 
                          stringsAsFactors = FALSE) 
roUpSummary <- roUpSummary[roUpSummary$NegLogPValue > -log(0.01), ] 
roUpSummary$Term <- factor(roUpSummary$Term, levels = roUpSummary[order
(roUpSummary$NegLogPValue, decreasing = FALSE), "Term"]) 
 
ggplot(roUpSummary, aes(x = NegLogPValue, y = Term, size = Count)) + 
  geom_segment(aes(yend = Term), xend = 0, color = "black", size = 0.5) 
+ 
  geom_point(shape = 21, color = "black", fill = "dodgerblue3") + 
  scale_size_area(max_size = 5.5) + 
  scale_size_continuous(limits = c(1, 160), breaks = c(40, 80, 120, 160
)) + 
  scale_x_continuous(limits = c(4, 16), breaks = seq(4, 16, by = 2)) + 
  ylab("") + 
  xlab("-log(p-value)") + 
  theme_bw() + 
  theme(axis.text.x = element_text(color = "grey30", size = 12), 
        axis.text.y = element_text(color = "grey30", size = 12), 
        axis.title.x = element_text(size = 17)) 
 
Ro+Rap top GO chart 
### Load DAVID data and filter 
roRapUp <- read.table("david_roRap_up_1000_biological_process.txt", hea
der = TRUE, sep = "\t", stringsAsFactors = FALSE) 
roRapUp <- roRapUp[roRapUp$PValue < 0.001 | roRapUp$FDR < 0.05, c("Term
", "PValue", "Genes", "Count")] 
roRapDown <- read.table("david_roRap_down_1000_biological_process.txt", 
header = TRUE, sep = "\t", stringsAsFactors = FALSE) 
roRapDown <- roRapDown[roRapDown$PValue < 0.001 | roRapDown$FDR < 0.05, 
c("Term", "PValue", "Genes", "Count")] 
 
roRapUp <- roRapUp[!(roRapUp$Term %in% roRapDown$Term), ] 
 
### Determine optimal cluster number 
roRapUpMatrix <- simplifyGo(roRapUp) 
determineClusterNumbers(roRapUpMatrix, 30) 
 
### Create dendrogram and get clusters 
roRapUpDendrogram <- hcut(roRapUpMatrix, k = 30, stand = TRUE) 
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fviz_dend(roRapUpDendrogram, rect = TRUE, cex = 0.5, show_labels = TRUE
) # 803 x 469 
 
roRapUpClusters <- getDendrogramClusters(roRapUpDendrogram)  
 
### Merge clusters with original DAVID data 
roRapUpClusters.mg <- merge(roRapUpClusters, roRapUp, "Term")[ ,c("Term
", "PValue", "Count", "Cluster", "Order")] 
roRapUpClusters.mg$NegLogPValue <- -log10(roRapUpClusters.mg$PValue) 




# write.csv to export file 
Now, the dendrogram data is manually annotated and re-imported to R. 
### Create RoRap Chart 
roRapUpChart <- read.csv("roRapUpClusters_network_data.csv", header = T
RUE, stringsAsFactors = FALSE) 
roRapUpChart.s <- split(roRapUpChart, roRapUpChart$Category) 
roRapUpSummary <- data.frame(Term = names(roRapUpChart.s), 
                          NegLogPValue = lapply(roRapUpChart.s, functio
n(x) mean(x$NegLogPValue)) %>% unlist() %>% unname(), 
                          Count = lapply(roRapUpChart.s, function(x) me
an(x$Count)) %>% unlist() %>% unname(), 
                          stringsAsFactors = FALSE) 
roRapUpSummary <- roRapUpSummary[roRapUpSummary$NegLogPValue > -log(0.0
1), ] 
roRapUpSummary$Term <- factor(roRapUpSummary$Term, levels = roRapUpSumm
ary[order(roRapUpSummary$NegLogPValue, decreasing = FALSE), "Term"]) 
 
ggplot(roRapUpSummary, aes(x = NegLogPValue, y = Term, size = Count)) + 
  geom_segment(aes(yend = Term), xend = 0, color = "black", size = 0.5) 
+ 
  geom_point(shape = 21, color = "black", fill = "dodgerblue3") + 
  scale_size_area(max_size = 5.5) + 
  scale_size_continuous(limits = c(1, 300), breaks = c(50, 100, 150, 20
0, 250, 300)) + 
  scale_x_continuous(limits = c(4, 24), breaks = seq(4, 24, by = 4)) + 
  ylab("") + 
  xlab("-log(p-value)") + 
  theme_bw() + 
  theme(axis.text.x = element_text(color = "grey30", size = 12), 
 320 
        axis.text.y = element_text(color = "grey30", size = 12), 
        axis.title.x = element_text(size = 17)) 
 
Depression top GO chart 
depChart <- read.csv("depression_network_data.csv", header = TRUE, stri
ngsAsFactors = FALSE) 
depChart.s <- split(depChart, depChart$Category) 
depChartSummary <- data.frame(Term = names(depChart.s), 
                                NegLogPValue = lapply(depChart.s, funct
ion(x) mean(x$NegLogPValue)) %>% unlist() %>% unname(), 
                                Count = lapply(depChart.s, function(x) 
mean(x$Count)) %>% unlist() %>% unname(), 
                                stringsAsFactors = FALSE) 
 
depChartSummary$Term <- factor(depChartSummary$Term, levels = depChartS
ummary[order(depChartSummary$NegLogPValue, decreasing = FALSE), "Term"]
) 
 
ggplot(depChartSummary[-34, ], aes(x = NegLogPValue, y = Term, size = C
ount)) + 
  geom_segment(aes(yend = Term), xend = 0, color = "black", size = 0.5) 
+ 
  geom_point(shape = 21, color = "black", fill = "grey50") + 
  scale_size_area(max_size = 4) + 
  ggtitle("Enriched GO Biological Process Terms") + 
  ylab("") + 
  xlab("-log(p-value") + 
  theme_bw() 
 
FMRP consensus top GO chart 
bdChart <- read.csv("BD_network_data.csv", header = TRUE, stringsAsFact
ors = FALSE) 
bdChart.s <- split(bdChart, bdChart$Category) 
bdChartSummary <- data.frame(Term = names(bdChart.s), 
                              NegLogPValue = lapply(bdChart.s, function
(x) mean(x$NegLogPValue)) %>% unlist() %>% unname(), 
                              Count = lapply(bdChart.s, function(x) mea
n(x$Count)) %>% unlist() %>% unname(), 
                              stringsAsFactors = FALSE) 
 
bdChartSummary$Term <- factor(bdChartSummary$Term, levels = bdChartSumm
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ary[order(bdChartSummary$NegLogPValue, decreasing = FALSE), "Term"]) 
 
ggplot(bdChartSummary, aes(x = NegLogPValue, y = Term, size = Count)) + 
  geom_segment(aes(yend = Term), xend = 0, color = "black", size = 0.5) 
+ 
  geom_point(shape = 21, color = "black", fill = "#FF66FF") + 
  scale_size_area(max_size = 4) + 
  ggtitle("Enriched GO Biological Process Terms") + 
  ylab("") + 
  xlab("-log(p-value") + 
  theme_bw() 
 
Univariate K-means clustering and GO ontology 
Ro fold-changes 
determineClusterNumbers1D(fc$RO, 15)  
roClust <- Ckmeans.1d.dp(fc$RO, 8) 
roClusters <- data.frame(row.names = row.names(fc), 
                         foldChange = fc$RO, 
                         cluster = roClust$cluster)   ### Gather cluste
ring data 
 
### Remove tails of distribution 
roClusters <- roClusters[roClusters$foldChange < 1.5, ] 
roClusters <- roClusters[roClusters$foldChange > -1.6, ] 
For GO clustering, we took the genes from each cluster and sent them to DAVID. For 
example, in the first cluster we would use the following code: 
roClusters.s <- split(roClusters, roClusters$cluster) 
functionalAnnotationChart(roClusters.s[[1]] %>% row.names(),  
                          term = "GOTERM_BP_ALL",  
                          filename = "DAVID_BP_KM1D_CLUST1.txt") 
The GO clustering reveals that for 1-D clustering across the entire distribution by fold-
change, the fifth cluster contains genes enriched for trans-synaptic signaling that change 
together (average p-value = 6.00 ∗ 10−8). 
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### For loop to set boundaries of clusters within distribution during p
lotting 
roBoundaries = NULL 
 
for(i in 1:(roClusters$cluster %>% max())) { 
  roBoundaries <- rbind(roBoundaries, split(roClusters, roClusters$clus
ter)[[i]]$foldChange %>% range()) 
} 
 
### Plot data 
p <-  
  ggplot(roClusters, aes(x = foldChange)) + 
    geom_density() + 
    theme_bw() 
 
d <- ggplot_build(p)$data[[1]] 
 
p + 
  geom_area(data = subset(d, x < roBoundaries[7,2]), aes(x = x, y = y), 
fill = "grey92") + 
  geom_area(data = subset(d, x < roBoundaries[6,2]), aes(x = x, y = y), 
fill = "grey92") + 
  geom_area(data = subset(d, x < roBoundaries[5,2]), aes(x = x, y = y), 
fill = "red") + 
  geom_area(data = subset(d, x < roBoundaries[4,2]), aes(x = x, y = y), 
fill = "grey92") + 
  geom_area(data = subset(d, x < roBoundaries[3,2]), aes(x = x, y = y), 
fill = "grey92") + 
  geom_area(data = subset(d, x < roBoundaries[2,2]), aes(x = x, y = y), 
fill = "grey92") + 
  geom_area(data = subset(d, x < roBoundaries[1,2]), aes(x = x, y = y), 
fill = "grey92") 
 
Ro+Rap fold-changes 
determineClusterNumbers1D(fc$RO_RAP, 15)  
 
roRapClust <- Ckmeans.1d.dp(fc$RO_RAP, 8) 
roRapClusters <- data.frame(row.names = row.names(fc), 
                         foldChange = fc$RO_RAP, 




### Remove tails of distribution 
roRapClusters <- roRapClusters[roRapClusters$foldChange < 1.5, ] 
roRapClusters <- roRapClusters[roRapClusters$foldChange > -1.6, ] 
### For loop to set boundaries of clusters within distribution during p
lotting 
roRapBoundaries = NULL 
 
for(i in 1:(roRapClusters$cluster %>% max())) { 
  roRapBoundaries <- rbind(roRapBoundaries, split(roRapClusters, roRapC
lusters$cluster)[[i]]$foldChange %>% range()) 
} 
 
### Plot data 
p1 <-  
  ggplot(roRapClusters, aes(x = foldChange)) + 
    geom_density() + 
    theme_bw() 
 
d1 <- ggplot_build(p1)$data[[1]] 
 
p1 + 
  geom_area(data = subset(d1, x < roRapBoundaries[7,2]), aes(x = x, y = 
y), fill = "grey92") + 
  geom_area(data = subset(d1, x < roRapBoundaries[6,2]), aes(x = x, y = 
y), fill = "grey92") + 
  geom_area(data = subset(d1, x < roRapBoundaries[5,2]), aes(x = x, y = 
y), fill = "red") + 
  geom_area(data = subset(d1, x < roRapBoundaries[4,2]), aes(x = x, y = 
y), fill = "grey92") + 
  geom_area(data = subset(d1, x < roRapBoundaries[3,2]), aes(x = x, y = 
y), fill = "grey92") + 
  geom_area(data = subset(d1, x < roRapBoundaries[2,2]), aes(x = x, y = 
y), fill = "grey92") + 
  geom_area(data = subset(d1, x < roRapBoundaries[1,2]), aes(x = x, y = 
y), fill = "grey92") 
 
Fold-Change Correlation 
The purpose of this plot is to see gene that changed in the same direction between the two 
calculated fold-change categories (Saline/Ro or Ro+Rap/Ro). 
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### Load data for trans-synaptic genes so they can be uniquely colored 
on the plot. 
transRo <- read.csv("roTranssynaptic.csv", stringsAsFactors = FALSE) 
transRo[ ,1] <- NULL 
transRoRap <- read.csv("roRapTranssynaptic.csv", stringsAsFactors = FAL
SE) 
transRoRap[ ,1] <- NULL 
trans <- c(transRo$genes, transRoRap$genes) %>% unique() 
fc$Category <- rep("No Change", nrow(fc)) 
fc[fc$RO > quantile(fc$RO, 0.75) | fc$RO_RAP > quantile(fc$RO_RAP, 0.75
), "Category"] <- "Up" 
fc[fc$RO < quantile(fc$RO, 0.25) | fc$RO_RAP < quantile(fc$RO_RAP, 0.25
), "Category"] <- "Down" 
fc[row.names(fc) %in% trans, "Category" ] <- "Transsynaptic" 
plotOrder <- c("No Change", "Down", "Up", "Transsynaptic") 
fc$Category <- reorder.factor(fc$Category, new.order = plotOrder) 
fc <- fc %>% arrange(Category) 
 
ggplot(fc, aes(x = RO_RAP, y = RO, color = Category, fill = Category)) 
+ 
  geom_point(shape = 21) + 
  geom_hline(yintercept = 0) + 
  geom_vline(xintercept = 0) + 
  scale_x_continuous(limits = c(-1.5, 1.5)) + 
  scale_y_continuous(limits = c(-1.5, 1.5)) + 
  xlab("Log2 Fold Change (Ro+Rap / Ro)") + 
  ylab("Log2 Fold Change (Saline / Ro)") + 
  scale_fill_manual(values = c("grey50", "deepskyblue1", "deepskyblue1"
, "red2")) + 
  scale_color_manual(values = c("black", "black", "black", "black")) + 
  theme_bw() + 
  theme(axis.text.x = element_text(color = "black", size = 12), 
        axis.text.y = element_text(color = "black", size = 12), 
        axis.title.x = element_text(size = 17), 
        axis.title.y = element_text(size = 17)) 
 
Bivariate K-means clustering and GO ontology 
Finally, we will cluster the above genes using 2-D K-means. We will use the same approach 
as before by minimizing the WSS for clusters. 
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### Load data and cluster 
fc <- read.csv("finalData.csv", header = TRUE, stringsAsFactors = FALSE
) 
row.names(fc) <- fc$Row.names 
fc[ ,1] <- NULL 
fc <- fc[ ,c("logFC.x", "logFC.y")] 






### Extract clusters 
clusterID <- data.frame(gene = row.names(fc), 
                        cluster = as.integer(kMeansPlot(fc, 8)$data$clu
sters), 
                        stringsAsFactors = FALSE) 
clusterID <- split(clusterID, clusterID$cluster) 
 
### Perform GO clustering as before 
Session info 
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##  [7] class_7.3-14           gtools_3.5.0           assertthat_0.1         
## [10] rprojroot_1.1          digest_0.6.10          R6_2.2.0               
## [13] plyr_1.8.4             backports_1.0.4        RSQLite_1.1            
## [16] evaluate_0.10          diptest_0.75-7         lazyeval_0.2.0         
## [19] annotate_1.52.0        kernlab_0.9-25         whisker_0.3-2          
## [22] rmarkdown_1.2          labeling_0.3           splines_3.3.2          
## [25] stringr_1.1.0          RCurl_1.95-4.8         munsell_0.4.3          
## [28] htmltools_0.3.5        nnet_7.3-12            tibble_1.2             
## [31] dendextend_1.3.0       XML_3.98-1.5           AnnotationForge_1
.16.0 
## [34] MASS_7.3-45            bitops_1.0-6           grid_3.3.2             
## [37] RBGL_1.50.0            xtable_1.8-2           GSEABase_1.36.0        
## [40] gtable_0.2.0           DBI_0.5-1              scales_0.4.1           
## [43] stringi_1.1.2          genefilter_1.56.0      flexmix_2.3-13         
## [46] robustbase_0.92-6      tools_3.3.2            fpc_2.1-10             
## [49] trimcluster_0.1-2      DEoptimR_1.0-8         survival_2.40-1        
## [52] yaml_2.1.14            colorspace_1.3-1       cluster_2.0.5          
## [55] prabclus_2.2-6         memoise_1.0.0          knitr_1.15.1           
## [58] modeltools_0.2-21 
SHINY APP FOR PARK7 BINDING MOTIF IDENTIFICATION 
This document contains all the code needed to run the Shiny app that determines Park7 





   
  titlePanel("Determine Putative Park7 RNA Targets"), 
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  sidebarLayout( 
 
    sidebarPanel(width = 4, 
      selectInput(inputId = "dataChoice", 
                  label = "1. Select data type:", 
                  choices = c("Gene and sequence list" = "geneSeq", 
                              "Gene list only" = "gene")), 
      
      fileInput(inputId = "dat", 
                label = "2. Load data (.csv):", 
                accept = ".csv"), 
       
       
      conditionalPanel( 
        condition = "input.dataChoice == 'gene'", 
        radioButtons(inputId = "biomartType", 
                     label = "3. Retrieve sequence from Biomart:", 
                     choices = c("5utr", "cds", "3utr"), 
                     inline = TRUE) 
         
      ), 
       
      actionButton(inputId = "execute", 
                   label = "Find binding sites and view data", 
                   style = "color: #fff; background-color: #337ab7; bor
der-color: #2e6da4"), 
       
       
      tags$hr(), 
       
 
      conditionalPanel( 
        condition = "input.dataChoice == 'gene'", 
         
        tags$div(class = "header", checked = NA, 
                 tags$b("4. Download data: ")), 
         
        actionButton(inputId = "biomartDat", 
                       label = "Biomart sequence data", 
                       icon("download")), 
         
        actionButton(inputId = "bindingDat", 
                       label = "Binding site data", 
                       icon("download")) 
         
 328 
      ), 
       
      conditionalPanel( 
        condition = "input.dataChoice == 'geneSeq'", 
         
        tags$div(class = "header", checked = NA, 
                 tags$b("3. Download data: ")), 
         
        actionButton(inputId = "bindingDat2", 
                       label = "Binding site data", 
                       icon("download")) 
      ), 
       
      tags$hr(), 
       
      tags$div(class = "header", checked = NA, 
               tags$b("Instructions:")), 
       
      tags$div(class = "header", checked = NA, 
               tags$p("First select your data type. A gene list should 
be a  
                       file that contains a single column of mouse gene
s in the 
                       official gene symbol format ONLY and no column h
eader. 
                       A gene and sequence list contains a gene list in 
the first 
                       column, a list of sequences in the second column
, and no 
                       column header. All input files must be in .csv f
ormat. 
                       If your input is a gene list, the sequences 
                       will be retrieved automatically using the Ensemb
le Biomart 
                       service. The resulting table is displayed on the 
right and 
                       can be manipulated to sort by a specified column
.")), 
       
      tags$hr(), 
       
      tags$div(class = "header", checked = NA, 
               tags$p("This tool was developed by the following members 
of the  
                       Raab-Graham Lab: Sanjeev Namjoshi, Farr Niere, J
uan Penaranda,  
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                       Kimberly Raab-Graham, and Cameron Reynoldson. Co
ncept developed by 
                       S.N., F.N., and K.R.G based on Park7 CLIP data [
1]. Original code  
                       written in Python by J.P. and C.R. Code translat
ed into R and Shiny  
                       app developed by S.N. For any questions or comme
nts please email S.N.  
                       at snamjoshi87@utexas.edu. All code is available 
on GitHub.")) 
       
    ), 
    mainPanel( 
      DT::dataTableOutput("table") 
    ) 






shinyServer(function(input, output) { 
  rv <- reactiveValues() 
  rv$seq <- NULL 
  rv$bioMart <- NULL 
 
  observe({ 
    if(input$execute) { 
      indat <- input$dataChoice 
      infile <- input$dat 
 
      if(indat == "geneSeq") { 
        seq <- read.csv(infile$datapath, stringsAsFactors = FALSE, head
er = FALSE) 
        names(seq) <- c("sequence", "gene") 
         
        withProgress(message = "Finding binding sites...", 
                     value = NULL, { 
                       rv$seq <- createTableOutput(seq) 
                       incProgress(0.1) 
                     }) 
      } 
 
      if(indat == "gene") { 
        genes <- read.csv(infile$datapath, stringsAsFactors = FALSE, he
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ader = FALSE)  
        type <- input$biomartType 
         
        withProgress(message = "Contacting BioMart...", 
                     value = NULL, { 
                       seqBioMart <- get_sequences(genes, type) 
                     }) 
         
        names(seqBioMart) <- c("sequence", "gene") 
        rv$bioMart <- seqBioMart 
         
        withProgress(message = "Finding binding sites...", 
                     value = NULL, { 
                       rv$seq <- createTableOutput(seqBioMart) 
                     }) 
      } 
    } 
 
    if(input$biomartDat > 0) { 
      fname <- paste("Biomart_data_", input$biomartType, Sys.Date(), ".
csv", sep = '') 
       
      withProgress(message = "Downloading BioMart data...", 
                    value = NULL, { 
                      write.csv(rv$bioMart, fname) 
                    }) 
    } 
 
    if(input$bindingDat > 0) { 
      fname <- paste("Binding_data", Sys.Date(), ".csv", sep = '') 
      withProgress(message = "Downloading BioMart data...", 
                    value = NULL, { 
                      write.csv(rv$seq, fname) 
                    }) 
 
    } 
 
    if(input$bindingDat2 > 0) { 
      fname <- paste("Binding_data", Sys.Date(), ".csv", sep = '') 
      withProgress(message = "Downloading BioMart data...", 
                    value = NULL, { 
                      write.csv(rv$seq, fname) 
                    }) 
    } 
  }) 
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  output$table <- DT::renderDataTable(DT::datatable({ 
    rv$seq 
  })) 
}) 
Global functions 






windows <- c("CNGCNG", "GNGCNG") 
 
get_sequences <- function(genes, type) { 
 
  ensembl <- useMart("ensembl", dataset = "mmusculus_gene_ensembl") 
   
  if(type == "5utr") { 
    seq <- getSequence(id = genes, 
                       type = "mgi_symbol", 
                       seqType = "5utr", 
                       mart = ensembl) 
     
    seq <- seq[!grepl("Sequence unavailable", seq$'5utr', fixed = TRUE)
,] 
  } 
   
  if(type == "cds") { 
    seq <- getSequence(id = genes, 
                        type = "mgi_symbol", 
                        seqType = "coding", 
                        mart = ensembl) 
  } 
   
  if(type == "3utr") { 
    seq <- getSequence(id = genes, 
                       type = "mgi_symbol", 
                       seqType = "3utr", 
                       mart = ensembl) 
     
    seq <- seq[!grepl("Sequence unavailable", seq$'3utr', fixed = TRUE)
,] 
  } 
   
  return(seq) 
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}   
   
createTableOutput <- function(seq) { 
  ### Calculate Sequence length 
  seqlength <- sapply(seq$sequence, nchar) %>% unlist() %>% unname() 
   
  ### Calculate CXGCXG indices and matches 
  w1Full <- sapply(seq$sequence, function(x) matchPattern(windows[1], D
NAString(x), fixed = FALSE)) 
  w1Full <- lapply(w1Full, function(x) slot(x, "ranges") %>% as.data.fr
ame()) 
  w1Matches <- sapply(w1Full, nrow) %>% unlist() %>% unname() 
  w1Indices <- lapply(w1Full, function(x) paste(x$start, collapse = ", 
")) %>% unlist() 
   
  ### Calculate GXGCXG indices and matches 
  w2Full <- sapply(seq$sequence, function(x) matchPattern(windows[2], D
NAString(x), fixed = FALSE)) 
  w2Full <- lapply(w2Full, function(x) slot(x, "ranges") %>% as.data.fr
ame()) 
  w2Matches <- sapply(w2Full, nrow) %>% unlist() %>% unname() 
  w2Indices <- lapply(w2Full, function(x) paste(x$start, collapse = ", 
")) %>% unlist() 
   
  ### Calculate frequency per kB 
  freq <- ((1000 * (w1Matches + w2Matches)) / seqlength) %>% round(2) 
   
  ### Generate table 
  output <- data.frame("Gene" = seq$gene, 
                       "Seq.Length" = seqlength, 
                       "CXGCXG Indices" = w1Indices, 
                       "CXGCXG Matches" = w1Matches, 
                       "GXGCXG Indices" = w2Indices, 
                       "GXGCXG Matches" = w2Matches, 
                       "Total Matches" = w1Matches + w2Matches, 
                       "Freq/kB" = freq, 
                       stringsAsFactors = FALSE) 
   
} 
Session info 
## R version 3.3.2 (2016-10-31) 
## Platform: x86_64-pc-linux-gnu (64-bit) 




##  [1] LC_CTYPE=en_US.UTF-8       LC_NUMERIC=C               
##  [3] LC_TIME=en_US.UTF-8        LC_COLLATE=en_US.UTF-8     
##  [5] LC_MONETARY=en_US.UTF-8    LC_MESSAGES=en_US.UTF-8    
##  [7] LC_PAPER=en_US.UTF-8       LC_NAME=C                  
##  [9] LC_ADDRESS=C               LC_TELEPHONE=C             
## [11] LC_MEASUREMENT=en_US.UTF-8 LC_IDENTIFICATION=C        
##  
## attached base packages: 
## [1] stats     graphics  grDevices utils     datasets  methods   base      
##  
## loaded via a namespace (and not attached): 
##  [1] backports_1.0.4 magrittr_1.5    rprojroot_1.1   tools_3.3.2     
##  [5] htmltools_0.3.5 yaml_2.1.14     Rcpp_0.12.8     stringi_1.1.2   
##  [9] rmarkdown_1.2   knitr_1.15.1    stringr_1.1.0   digest_0.6.10   
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